<SEC-DOCUMENT>0001654954-25-001578.txt : 20250214
<SEC-HEADER>0001654954-25-001578.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214161555
ACCESSION NUMBER:		0001654954-25-001578
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		25628995

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cvm_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2" xmlns:cvm="http://cvm.com/20241231"><head><title>cvm_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2024-10-01to2024-12-31" id="ixv-5662">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2024-10-01to2024-12-31" format="ixt:booleanfalse" id="ixv-5663">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2024-10-01to2024-12-31" id="ixv-5664">--09-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2024-10-01to2024-12-31" id="ixv-5665">Q1</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2024-10-01to2024-12-31" id="ixv-5666">2025</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" unitRef="USDPShares" decimals="INF" id="ixv-5667">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-5668">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-5669">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-5670">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-5671">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" unitRef="USDPShares" decimals="INF" id="ixv-5672">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-5673">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-5674">74084041</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-5675">63787104</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-10-01to2023-12-31" unitRef="Shares" decimals="0" id="ixv-5676">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2024-10-01to2024-12-31" unitRef="Shares" decimals="0" id="ixv-5677">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2023-10-01to2023-12-31" unitRef="Shares" decimals="0" id="ixv-5678">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-10-01to2023-12-31" unitRef="Shares" decimals="0" id="ixv-5679">0</ix:nonFraction><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsMember" unitRef="Shares" decimals="0" id="ixv-5680">88573</ix:nonFraction><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-01-11_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5681">2300000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5682">200000.0</ix:nonFraction><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5683">700000.0</ix:nonFraction><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5684">500000.0</ix:nonFraction><ix:nonFraction name="us-gaap:DepreciationExpenseOnReclassifiedAssets" contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5685">500000.0</ix:nonFraction><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5686">200000.0</ix:nonFraction><ix:nonFraction name="cvm:LeaseExpenseUnderOperatingLeases" contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5687">100000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5688">100000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-5689">700000.0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvm-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="From2024-10-01to2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_UnvestedCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-11_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-01-11_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-12-01to2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_ChangesInEquityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_ChangesInEquityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-10-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-10-18_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_ConsultingAgreementsOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_ConsultingAgreementsOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_TopMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_BottomMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_ConsultantsOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_PreFundedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:PreFundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_TopMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_BottomMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_PreFundedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:PreFundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_IncentiveStockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_StockCompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-02-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:DocumentType" id="ixv-6312">10-Q</ix:nonNumeric></span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="ixv-6313">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <strong><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" id="ixv-6314">December 31, 2024</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="ixv-6315">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the transition period from _________ to __________.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Commission file number <strong><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityFileNumber" id="ixv-6316">1-11889</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:45%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:88%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityRegistrantName" id="ixv-6317">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="ixv-6318">Colorado</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityTaxIdentificationNumber" id="ixv-6319">84-0916344</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;State or other jurisdiction incorporation</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;(IRS) Employer Identification Number</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityAddressAddressLine1" id="ixv-6320">8229 Boone Boulevard</ix:nonNumeric>, <ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityAddressAddressLine2" id="ixv-6321">Suite 802</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span style="text-decoration:underline"><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityAddressCityOrTown" id="ixv-6322">Vienna</ix:nonNumeric>, <ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="ixv-6323">Virginia</ix:nonNumeric> <ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-6324">22182</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Address of principal executive offices</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:CityAreaCode" id="ixv-6325">703</ix:nonNumeric>) <ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:LocalPhoneNumber" id="ixv-6326">506-9460</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Registrant's telephone number, including area code</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title of Each Class</p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of Each Exchange on Which Registered</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:Security12bTitle" id="ixv-6327">Common Stock</ix:nonNumeric></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:TradingSymbol" id="ixv-6328">CVM</ix:nonNumeric></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-6329">NYSE</ix:nonNumeric> American</strong></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityCurrentReportingStatus" id="ixv-6330">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityInteractiveDataCurrent" id="ixv-6331">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large&#160;accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="ixv-6332">Non-accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746; </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="ixv-6333">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="ixv-6334">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="From2024-10-01to2024-12-31" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="ixv-6335">&#9744;</ix:nonNumeric>&#160;&#160;&#160; No &#9746;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Class of Stock</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;No. Shares Outstanding</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common </strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonFraction contextRef="AsOf2025-02-10" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-6336">77,211,541</ix:nonFraction></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>February 10, 2025</strong></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="TOC">TABLE OF CONTENTS </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PART I FINANCIAL INFORMATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#ffffff"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Item 1.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Page</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a1">Condensed Balance Sheets at December 31, 2024 (unaudited) and September 30, 2024</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a2">Condensed Statements of Operations for the three months ended December 31, 2024 and 2023 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a3">Condensed Statements of Stockholders&#8217; Equity for the three months ended December 31, 2024 and 2023 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a4">Condensed Statements of Cash Flows for the three months ended December 31, 2024 and 2023 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a5">Notes to Condensed Financial Statements<strong>&#160;</strong>(unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a6">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a6">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">18</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a7">Item 3.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a7">Quantitative and Qualitative Disclosures about Market Risks</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">28</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a8">Item 4.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a8">Controls and Procedures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">29</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><a href="#a9">PART II</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a10">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a10">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">30</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a11">Item 5.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a11">Other Information</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">30</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a12">Item 6.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a12">Exhibits</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">30</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a13">Signatures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">31</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a1">CONDENSED BALANCE SHEETS</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ASSETS</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets: </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_682" contextRef="AsOf2024-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,614,115</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_683" contextRef="AsOf2024-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,738,173</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_684" contextRef="AsOf2024-12-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,069</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_685" contextRef="AsOf2024-09-30" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,097</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Supplies used for R&amp;D and manufacturing </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_686" contextRef="AsOf2024-12-31" name="cvm:SuppliesUsedForRDAndManufacturingCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">863,104</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_687" contextRef="AsOf2024-09-30" name="cvm:SuppliesUsedForRDAndManufacturingCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,019,908</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_688" contextRef="AsOf2024-12-31" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_689" contextRef="AsOf2024-09-30" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_690" contextRef="AsOf2024-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,857,788</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_691" contextRef="AsOf2024-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,055,678</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease right-of-use assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_692" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,899,819</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_693" contextRef="AsOf2024-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,350,364</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right-of-use assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_694" contextRef="AsOf2024-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,619</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_695" contextRef="AsOf2024-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,495,937</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_696" contextRef="AsOf2024-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,592,663</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_697" contextRef="AsOf2024-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,129,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patent costs, net </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_698" contextRef="AsOf2024-12-31" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,394</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_699" contextRef="AsOf2024-09-30" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,492</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deposits </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_700" contextRef="AsOf2024-12-31" name="us-gaap:DepositsAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_701" contextRef="AsOf2024-09-30" name="us-gaap:DepositsAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_702" contextRef="AsOf2024-12-31" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438,403</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_703" contextRef="AsOf2024-09-30" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,475,441</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_704" contextRef="AsOf2024-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,698,787</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_705" contextRef="AsOf2024-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,991,766</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY&#160; </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current Liabilities: </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_708" contextRef="AsOf2024-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,999,214</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_709" contextRef="AsOf2024-09-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,448,467</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_710" contextRef="AsOf2024-12-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,601</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_711" contextRef="AsOf2024-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,042</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Due to employees </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_712" contextRef="AsOf2024-12-31" name="cvm:DueToEmployeeCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">558,103</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_713" contextRef="AsOf2024-09-30" name="cvm:DueToEmployeeCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,306</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease obligation, current portion </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_714" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,074,490</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_715" contextRef="AsOf2024-09-30" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,010,995</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease obligation, current portion </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_716" contextRef="AsOf2024-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,155</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_717" contextRef="AsOf2024-09-30" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,969</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_718" contextRef="AsOf2024-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,479,563</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_719" contextRef="AsOf2024-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,615,779</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_720" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,412,252</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_721" contextRef="AsOf2024-09-30" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,957,925</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_722" contextRef="AsOf2024-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,373,340</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_723" contextRef="AsOf2024-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,425,979</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_724" contextRef="AsOf2024-12-31" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_725" contextRef="AsOf2024-09-30" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_726" contextRef="AsOf2024-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,390,155</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_727" contextRef="AsOf2024-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,124,683</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and contingencies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">STOCKHOLDERS' EQUITY </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock, $<ix:nonFraction id="fid_743" contextRef="AsOf2024-12-31" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_746" contextRef="AsOf2024-09-30" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_747" contextRef="AsOf2024-09-30" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_731" contextRef="AsOf2024-12-31" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_732" contextRef="AsOf2024-09-30" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonFraction id="fid_751" contextRef="AsOf2024-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_753" contextRef="AsOf2024-09-30" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_755" contextRef="AsOf2024-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">74,084,041</ix:nonFraction> and <ix:nonFraction id="fid_756" contextRef="AsOf2024-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">63,787,104</ix:nonFraction> shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_733" contextRef="AsOf2024-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">730,839</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_734" contextRef="AsOf2024-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,870</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_735" contextRef="AsOf2024-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">531,662,716</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_736" contextRef="AsOf2024-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,241,074</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_737" contextRef="AsOf2024-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">521,084,923</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_738" contextRef="AsOf2024-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">514,011,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders' equity&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_739" contextRef="AsOf2024-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,308,632</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_740" contextRef="AsOf2024-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,867,083</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_741" contextRef="AsOf2024-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,698,787</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_742" contextRef="AsOf2024-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,991,766</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a2">CONDENSED STATEMENTS OF OPERATIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_784" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,430,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_785" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,352,509</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_786" contextRef="From2024-10-01to2024-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,463,355</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_787" contextRef="From2023-10-01to2023-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,378</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_788" contextRef="From2024-10-01to2024-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,893,418</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_789" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,485,887</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_790" contextRef="From2024-10-01to2024-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,893,418</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_791" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,485,887</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_792" contextRef="From2024-10-01to2024-12-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">170,103</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_793" contextRef="From2023-10-01to2023-12-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">197,696</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_794" contextRef="From2024-10-01to2024-12-31" name="us-gaap:OtherNonoperatingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,541</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">)&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_795" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OtherNonoperatingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,941</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_796" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,073,062</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_797" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_800" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,073,062</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_801" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_802" contextRef="From2024-10-01to2024-12-31" name="us-gaap:EarningsPerShareDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.11</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_803" contextRef="From2023-10-01to2023-12-31" name="us-gaap:EarningsPerShareDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.14</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_804" contextRef="From2024-10-01to2024-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">65,325,855</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_805" contextRef="From2023-10-01to2023-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">48,470,600</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="9"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a3">STATEMENT OF STOCKHOLDERS' EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td colspan="2"/><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1312" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">63,787,104</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1313" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,870</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1318" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,241,074</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1323" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">514,011,861</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1328" contextRef="AsOf2024-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,867,083</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1354" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,450,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1357" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1409" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">14,500</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1314" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1319" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">401(k) contributions paid in common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1360" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">142,822</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1363" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,428</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1410" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,706</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1334" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1426" contextRef="From2024-10-01to2024-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,134</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1366" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">154,615</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1369" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,546</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1411" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,541</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1339" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1427" contextRef="From2024-10-01to2024-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,087</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1372" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,552,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1375" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,525</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1412" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,924,775</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1388" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1428" contextRef="From2024-10-01to2024-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1436" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">3,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">)&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1390" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">)&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1415" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,411</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1399" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1431" contextRef="From2024-10-01to2024-12-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,381</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1400" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1416" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:CostIncurredInIssuanceOfStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">650,291</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1401" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1432" contextRef="From2024-10-01to2024-12-31" name="cvm:CostIncurredInIssuanceOfStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">650,291</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1402" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1403" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="cvm:CostIncurredInIssuanceOfStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1324" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,073,062</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1329" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,073,062</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, DECEMBER 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1315" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">73,084,041</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1316" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">730,839</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1321" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">531,662,716</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1326" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">521,084,923</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1331" contextRef="AsOf2024-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,308,632</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1332" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">47,422,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1333" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1338" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1343" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">487,091,396</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1348" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,214,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">401(k) contributions paid in common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1358" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,724</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1361" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1394" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,730</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1314-da2283" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1404" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,907</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1364" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">88,573</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1367" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">886</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1395" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,421</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1319-98f6cc" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1405" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,307</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1370" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,490,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1373" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,900</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1396" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,955,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1334-99eb0b" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1406" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,980,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1339-0cb39c" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1397" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1388-024463" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1407" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1424" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" name="cvm:CostIncurredInIssuanceOfStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1398" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:CostIncurredInIssuanceOfStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">470,229</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1391" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="cvm:CostIncurredInIssuanceOfStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1408" contextRef="From2023-10-01to2023-12-31" name="cvm:CostIncurredInIssuanceOfStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">470,229</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1393" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="cvm:CostIncurredInIssuanceOfStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1399-7dcbb8" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1344" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1349" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, DECEMBER 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1335" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,018,601</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1336" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,186</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1341" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,950,994</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1346" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">493,800,920</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1351" contextRef="AsOf2023-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,650,260</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a4">CONDENSED STATEMENTS OF CASH FLOWS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1112" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,073,062</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1113" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1115" contextRef="From2024-10-01to2024-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">995,192</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1116" contextRef="From2023-10-01to2023-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,004,633</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Non-cash lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1117" contextRef="From2024-10-01to2024-12-31" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1118" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,504</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1119" contextRef="From2024-10-01to2024-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,839</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1120" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,386</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Equity based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1121" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,381</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1122" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Common stock contributed to 401(k) plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1123" contextRef="From2024-10-01to2024-12-31" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,133</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1124" contextRef="From2023-10-01to2023-12-31" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,907</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Loss on patent impairment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1307" contextRef="From2024-10-01to2024-12-31" name="cvm:GainLossOnPatentImpairment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,541</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">(Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1309" contextRef="From2024-10-01to2024-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">79,724</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1126" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">100,546</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1127" contextRef="From2024-10-01to2024-12-31" name="cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,842</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1128" contextRef="From2023-10-01to2023-12-31" name="cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">98,765</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1129" contextRef="From2024-10-01to2024-12-31" name="cvm:IncreaseDecreaseInDeposit" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1130" contextRef="From2023-10-01to2023-12-31" name="cvm:IncreaseDecreaseInDeposit" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,884</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1132" contextRef="From2024-10-01to2024-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">473,514</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1133" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">765,078</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1134" contextRef="From2024-10-01to2024-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,291</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1135" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,924</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1136" contextRef="From2024-10-01to2024-12-31" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,797</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1137" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,454</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1138" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,139,973</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1139" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,887,928</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1141" contextRef="From2024-10-01to2024-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,954</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1142" contextRef="From2023-10-01to2023-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,650</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1308" contextRef="From2023-10-01to2023-12-31" name="cvm:GainLossOnPatentImpairment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1144" contextRef="From2023-10-01to2023-12-31" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,211</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1145" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">32,954</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1146" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">64,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock and pre-funded warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1148" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1149" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,980,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1150" contextRef="From2024-10-01to2024-12-31" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469,020</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1151" contextRef="From2023-10-01to2023-12-31" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504,913</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments on obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1156" contextRef="From2024-10-01to2024-12-31" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,411</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1157" contextRef="From2023-10-01to2023-12-31" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,593</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1158" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,048,869</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1159" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,048,494</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET DECREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1160" contextRef="From2024-10-01to2024-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">124,058</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1161" contextRef="From2023-10-01to2023-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">904,295</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1162" contextRef="AsOf2024-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,738,173</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1163" contextRef="AsOf2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, END OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1164" contextRef="AsOf2024-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,614,115</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1165" contextRef="AsOf2023-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,241,440</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease obligation included in accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1169" contextRef="From2024-10-01to2024-12-31" name="cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,087</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1170" contextRef="From2023-10-01to2023-12-31" name="cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">714</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consulting services paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1173" contextRef="From2024-10-01to2024-12-31" name="cvm:NonCashConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,087</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1174" contextRef="From2023-10-01to2023-12-31" name="cvm:NonCashConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,307</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Financing costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1177" contextRef="From2024-10-01to2024-12-31" name="cvm:NonCashFinancingCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,220</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1178" contextRef="From2023-10-01to2023-12-31" name="cvm:NonCashFinancingCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,019</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1179" contextRef="From2024-10-01to2024-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,735</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1180" contextRef="From2023-10-01to2023-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,659</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a5">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>THREE MONTHS ENDED DECEMBER 31, 2024 AND 2023 (UNAUDITED)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_1181" contextRef="From2024-10-01to2024-12-31" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_3314d6"><p style="font-size:10pt;font-family:times new roman;margin:0px">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of December 31, 2024 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2024 is derived from the September 30, 2024 audited financial statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1189" contextRef="From2024-10-01to2024-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1190" contextRef="From2024-10-01to2024-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1191" contextRef="From2024-10-01to2024-12-31" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at&#160;the lower of cost or&#160;net realizable value&#160;and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1192" contextRef="From2024-10-01to2024-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_3314d6" continuedAt="cont_309c48"><ix:nonNumeric id="fid_1193" contextRef="From2024-10-01to2024-12-31" name="cvm:LeasesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities, and are expensed as incurred.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1194" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1195" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1196" contextRef="From2024-10-01to2024-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1301" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $<ix:nonFraction id="fid_1221" contextRef="AsOf2024-12-31" name="us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction> at December 31, 2024 and September 30, 2024.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_309c48" continuedAt="cont_6134fa"><ix:nonNumeric id="fid_1197" contextRef="From2024-10-01to2024-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2024 and September 30, 2024.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1198" contextRef="From2024-10-01to2024-12-31" name="cvm:ImpairmentOfLongLivedAssetsPolicyTextblock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1302" contextRef="From2024-10-01to2024-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Fair Value Measurements -</em> In accordance with the provisions of ASC 820, <em>Fair Value Measurements</em>, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#8217;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#8217;s money market funds approximated their fair value at&#160;$<ix:nonFraction id="fid_1222" contextRef="AsOf2024-12-31" name="us-gaap:FinancialInstrumentsOwnedOtherAtFairValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction> and $<ix:nonFraction id="fid_1224" contextRef="AsOf2024-09-30" name="us-gaap:FinancialInstrumentsOwnedOtherAtFairValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,480,000</ix:nonFraction> as of December 31, 2024 and September 30, 2024, respectively.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_6134fa"><ix:nonNumeric id="fid_1199" contextRef="From2024-10-01to2024-12-31" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1201" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, <em>Segment Reporting</em> (Topic 280): <em>Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;),</em> which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1182" contextRef="From2024-10-01to2024-12-31" name="cvm:LiquidityDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1183" contextRef="From2024-10-01to2024-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_05a66f"><p style="font-size:10pt;font-family:times new roman;margin:0px">C.&#160;<span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2024, the Company sold <ix:nonFraction id="fid_1433" contextRef="From2024-10-01to2024-12-31" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,552,500</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1232" contextRef="AsOf2024-12-31" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction> per share and pre-funded warrants to purchase up to <ix:nonFraction id="fid_1236" contextRef="AsOf2024-12-31_cvm_PreFundedMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,577,500</ix:nonFraction> shares of common stock, at an offering price of $<ix:nonFraction id="fid_1234" contextRef="AsOf2024-12-31_cvm_PreFundedMember" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.3099</ix:nonFraction> per pre-funded warrant, for proceeds of approximately $<ix:nonFraction id="fid_377" contextRef="From2024-12-01to2024-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">4.4</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_378" contextRef="From2024-12-01to2024-12-31" name="cvm:NetofissuanceCosts" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.6</ix:nonFraction> million. As of December 31, 2024, none of the pre-funded warrants in connection with the December 2024 offering have been exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company determined that the pre-funded warrants sold in the December 2024 offering are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#8217;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the transaction in December 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $<ix:nonFraction id="fid_359" contextRef="AsOf2023-11-30" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction> per share and received proceeds of approximately $<ix:nonFraction id="fid_370" contextRef="From2023-11-01to2023-11-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">4.5</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_372" contextRef="From2023-11-01to2023-11-30" name="cvm:NetofissuanceCosts" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.5</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Other Equity Transactions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In October 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited (&#8220;Ergomed&#8221;) pursuant to which the Company issued <ix:nonFraction id="fid_1239" contextRef="AsOf2024-10-31_cvm_ErgomedMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction> shares of common stock in exchange for services. The shares are legally issued and outstanding.&#160;&#160;The Company determined the issuance of shares to a non-employee for services rendered or to be rendered is within the scope of ASC 718. In accordance with ASC 718, the shares are not issued and outstanding for accounting purposes as they are unvested and forfeitable. The shares will be recognized on the&#160;settlement date and measured at fair value when the shares are settled for services rendered by Ergomed. The Company incurred share issuance costs of approximately $<ix:nonFraction id="fid_1437" contextRef="From2024-10-01to2024-10-18_cvm_ErgomedMember" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,000</ix:nonFraction> to issue the shares from this agreement which were immediately expensed.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_05a66f" continuedAt="cont_e22023"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Underlying share information for equity compensation plans as of December 31, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1202" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:80%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_278" contextRef="AsOf2024-12-31_cvm_IncentiveStockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">138,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_275" contextRef="AsOf2024-12-31_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,787,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_276" contextRef="AsOf2024-12-31_cvm_StockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,283,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_277" contextRef="AsOf2024-12-31_us-gaap_StockCompensationPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">634,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_274" contextRef="AsOf2024-12-31_cvm_IncentiveStockBonusPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">640,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Option Activity</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1203" contextRef="From2024-10-01to2024-12-31" name="cvm:ScheduleOfStockOptionActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_284" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">502,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_285" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,833</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_281" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_286" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Share-Based Compensation Expense:</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1204" contextRef="From2024-10-01to2024-12-31" name="cvm:ScheduleOfCompensatingBalancesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_336" contextRef="From2024-10-01to2024-12-31_us-gaap_EmployeeStockMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,381</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_335" contextRef="From2023-10-01to2023-12-31_us-gaap_EmployeeStockMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_338" contextRef="From2024-10-01to2024-12-31_cvm_NonEmployeesMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,839</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_339" contextRef="From2023-10-01to2023-12-31_cvm_NonEmployeesMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,386</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at December 31, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1205" contextRef="From2024-10-01to2024-12-31" name="cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_299" contextRef="From2024-10-01to2024-12-31_cvm_SeriesNMember" name="cvm:IssueDate1">8/18/2008</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_308" contextRef="AsOf2024-12-31_cvm_SeriesNMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,339</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_316" contextRef="AsOf2024-12-31_cvm_SeriesNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_325" contextRef="From2024-10-01to2024-12-31_cvm_SeriesNMember" name="cvm:ExpirationDate">8/18/2026</ix:nonNumeric>&#160; </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_300" contextRef="From2024-10-01to2024-12-31_cvm_SeriesUUMember" name="cvm:IssueDate1">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_309" contextRef="AsOf2024-12-31_cvm_SeriesUUMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_317" contextRef="AsOf2024-12-31_cvm_SeriesUUMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_326" contextRef="From2024-10-01to2024-12-31_cvm_SeriesUUMember" name="cvm:ExpirationDate">6/30/2026</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_301" contextRef="From2024-10-01to2024-12-31_cvm_SeriesXMember" name="cvm:IssueDate1">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_310" contextRef="AsOf2024-12-31_cvm_SeriesXMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">120,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_318" contextRef="AsOf2024-12-31_cvm_SeriesXMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.25</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_327" contextRef="From2024-10-01to2024-12-31_cvm_SeriesXMember" name="cvm:ExpirationDate">7/13/2026</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_302" contextRef="From2024-10-01to2024-12-31_cvm_SeriesYMember" name="cvm:IssueDate1">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_311" contextRef="AsOf2024-12-31_cvm_SeriesYMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_319" contextRef="AsOf2024-12-31_cvm_SeriesYMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_328" contextRef="From2024-10-01to2024-12-31_cvm_SeriesYMember" name="cvm:ExpirationDate">8/15/2026</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_303" contextRef="From2024-10-01to2024-12-31_cvm_SeriesMMMember" name="cvm:IssueDate1">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_312" contextRef="AsOf2024-12-31_cvm_SeriesMMMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">333,432</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_320" contextRef="AsOf2024-12-31_cvm_SeriesMMMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_329" contextRef="From2024-10-01to2024-12-31_cvm_SeriesMMMember" name="cvm:ExpirationDate">6/22/2026</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_304" contextRef="From2024-10-01to2024-12-31_cvm_SeriesNNMember" name="cvm:IssueDate1">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_313" contextRef="AsOf2024-12-31_cvm_SeriesNNMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,087</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_321" contextRef="AsOf2024-12-31_cvm_SeriesNNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_330" contextRef="From2024-10-01to2024-12-31_cvm_SeriesNNMember" name="cvm:ExpirationDate">7/24/2026</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_305" contextRef="From2024-10-01to2024-12-31_cvm_SeriesRRMember" name="cvm:IssueDate1">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_314" contextRef="AsOf2024-12-31_cvm_SeriesRRMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">234,009</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_322" contextRef="AsOf2024-12-31_cvm_SeriesRRMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_331" contextRef="From2024-10-01to2024-12-31_cvm_SeriesRRMember" name="cvm:ExpirationDate">10/30/2026</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-Funded</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1229" contextRef="From2024-10-01to2024-12-31_cvm_PreFundedMember" name="cvm:IssueDate1">12/31/2024</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1228" contextRef="AsOf2024-12-31_cvm_PreFundedMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,577,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1227" contextRef="AsOf2024-12-31_cvm_PreFundedMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_306" contextRef="From2024-10-01to2024-12-31_cvm_BottomMember_cvm_ConsultantsMember" name="cvm:IssueDate1">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_307" contextRef="From2024-10-01to2024-12-31_cvm_TopMember_cvm_ConsultantsMember" name="cvm:IssueDate1">11/19/2024</ix:nonNumeric> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_315" contextRef="AsOf2024-12-31_cvm_ConsultantsOptionMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">610,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_323" contextRef="AsOf2024-12-31_cvm_BottomMember_cvm_ConsultantsMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.70</ix:nonFraction> - $<ix:nonFraction id="fid_1230" contextRef="AsOf2024-12-31_cvm_TopMember_cvm_ConsultantsMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_332" contextRef="From2024-10-01to2024-12-31_cvm_BottomMember_cvm_ConsultantsMember" name="cvm:ExpirationDate">7/27/2027</ix:nonNumeric> -&#160;<ix:nonNumeric id="fid_333" contextRef="From2024-10-01to2024-12-31_cvm_TopMember_cvm_ConsultantsMember" name="cvm:ExpirationDate">11/1/2034</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_e22023"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024, <ix:nonFraction id="fid_1303" contextRef="AsOf2024-12-31_cvm_ChangesInEquityWarrantsMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,577,500</ix:nonFraction> pre-funded warrants at an offering price of $<ix:nonFraction id="fid_645" contextRef="AsOf2024-12-31_cvm_ChangesInEquityWarrantsMember" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.3099</ix:nonFraction> were issued.&#160; No pre-funded warrants or warrants recorded as equity were issued during the three months ended December 31, 2023.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024, <ix:nonFraction id="fid_1304" contextRef="AsOf2023-12-31_cvm_ChangesInEquityWarrantsMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,450,000</ix:nonFraction> pre-funded warrants were exercised.&#160; No pre-funded warrants or warrants recorded as equity were exercised during the three months ended December 31, 2023.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired or were extended during the three months ended December 31, 2024 and 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024 and 2023, the Company issued <ix:nonFraction id="fid_499" contextRef="From2024-10-01to2024-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">154,615</ix:nonFraction> and <ix:nonFraction id="fid_1245" contextRef="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">88,573</ix:nonFraction> shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_501" contextRef="From2024-10-01to2024-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.85</ix:nonFraction> and $<ix:nonFraction id="fid_1248" contextRef="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.56</ix:nonFraction> during the three months ended December 31, 2024 and 2023, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024, <ix:nonFraction id="fid_1252" contextRef="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">500,000</ix:nonFraction> options with an exercise price of $<ix:nonFraction id="fid_1246" contextRef="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsMember" name="us-gaap:StockOptionExercisePriceIncrease" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.70</ix:nonFraction> were issued to a consultant.&#160; The options vest immediately and will expire on November 1, 2034.&#160; No options were issued to a consultant during the three months ended December 31, 2023.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024 and 2023, the Company recorded total expense of approximately $<ix:nonFraction id="fid_1249" contextRef="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsOtherMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">397,000</ix:nonFraction> and $<ix:nonFraction id="fid_1251" contextRef="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsOtherMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">218,000</ix:nonFraction>, respectively, relating to the share-based compensation under various consulting agreements. On December 31, 2024 and September 30, 2024, consulting fees of approximately $<ix:nonFraction id="fid_1255" contextRef="AsOf2024-12-31_cvm_ConsultingAgreementsOtherMember" name="cvm:ConsultingFeesIncluedPrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,000</ix:nonFraction> and $<ix:nonFraction id="fid_1257" contextRef="AsOf2024-09-30_cvm_ConsultingAgreementsOtherMember" name="cvm:ConsultingFeesIncluedPrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction>, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1184" contextRef="From2024-10-01to2024-12-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There were no related party transactions during the three months ended December 31, 2024 and 2023. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1185" contextRef="From2024-10-01to2024-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_612247"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"><em>Clinical Research Agreements</em>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#8217;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $<ix:nonFraction id="fid_668" contextRef="From2024-10-01to2024-12-31_cvm_ErgomedMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million as of December 31, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at <ix:nonFraction id="fid_466" contextRef="AsOf2023-12-31_us-gaap_LeaseAgreementsMember" name="cvm:AnnualIncreaseToInterestPayments" decimals="INF" unitRef="Pure" scale="-2">3</ix:nonFraction>%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_612247" continuedAt="cont_f3a6ca"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of December 31, 2024 and September 30, 2024, respectively, the net book value of the finance lease right-of-use asset is approximately $<ix:nonFraction id="fid_1269" contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">6.9</ix:nonFraction> million and $<ix:nonFraction id="fid_1271" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">7.4</ix:nonFraction> million and the balance of the finance lease liability is approximately $<ix:nonFraction id="fid_1272" contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">9.5</ix:nonFraction> million and $<ix:nonFraction id="fid_1273" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">10.0</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1274" contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.1</ix:nonFraction> million and $<ix:nonFraction id="fid_1275" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.0</ix:nonFraction> million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the three months ended December 31, 2024 and 2023, the finance right-of-use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $<ix:nonFraction id="fid_1276" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.5</ix:nonFraction> million in both periods, which is included in research and development expense on the accompanying condensed statements of operations. Total cash paid related to finance leases during the three months ended December 31, 2024 and 2023, was approximately $<ix:nonFraction id="fid_1268" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million for both periods, of which approximately $<ix:nonFraction id="fid_459" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million was for interest. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying condensed statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying condensed statements of cash flows. As of December 31, 2024, the weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_1280" contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember" name="cvm:AnnualIncreaseToInterestPayments" decimals="INF" unitRef="Pure" scale="-2">8.46</ix:nonFraction>% and the weighted average remaining lease term is <ix:nonNumeric id="fid_467" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne" format="ixt-sec:duryear">3.83</ix:nonNumeric> years. During the three months ended December 31, 2024 and 2023, total finance lease costs were approximately $<ix:nonFraction id="fid_1281" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million, consisting of approximately $<ix:nonFraction id="fid_1283" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.5</ix:nonFraction> million of lease asset amortization and approximately $<ix:nonFraction id="fid_1285" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million of interest on the finance lease liabilities for both periods. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right-of-use assets or lease liabilities but rather are expensed as incurred. During the three months ended December 31, 2024, there were approximately $<ix:nonFraction id="fid_463" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:VariableLeaseCost" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.3</ix:nonFraction> million of variable finance lease costs, which are included in research and development expense on the accompanying condensed statements of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $<ix:nonFraction id="fid_1311" contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember" name="cvm:FinancingArrangementDepositBaseRentAmount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.3</ix:nonFraction> million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of December 31, 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1207" contextRef="From2024-10-01to2024-12-31" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_432" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,065,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_433" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,838,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_434" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,929,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_435" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,021,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_436" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_437" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_439" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,108,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_440" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,622,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_441" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,486,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_442" contextRef="AsOf2024-12-31" name="cvm:FinanceLeaseLiabilityCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,074,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_443" contextRef="AsOf2024-12-31" name="cvm:FinanceLeaseLiabilityNoncurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,412,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of December 31, 2024 and September 30, 2024, respectively, the net book value of the operating lease right-of-use asset is approximately $<ix:nonFraction id="fid_1290" contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.4</ix:nonFraction> million and $<ix:nonFraction id="fid_1291" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.5</ix:nonFraction> million and the balance of the operating lease liability is approximately $<ix:nonFraction id="fid_1292" contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million and $<ix:nonFraction id="fid_1293" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.7</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1294" contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million is current in both periods. During the three months ended December 31, 2024 and 2023, the Company incurred lease expense under operating leases of approximately $<ix:nonFraction id="fid_1296" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="cvm:LeaseExpenseUnderOperatingLeases" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million in both periods, which is included in general and administrative expense on the accompanying condensed statements of operations. Total cash paid related to operating leases during the three months ended December 31, 2024 and 2023 was approximately $<ix:nonFraction id="fid_465" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="us-gaap:OperatingLeasePaymentsUse" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million for both periods. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying condensed statements of cash flows. The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_1300" contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember" name="cvm:AnnualIncreaseToInterestPaymentsOperating" decimals="INF" unitRef="Pure" scale="-2">8.98</ix:nonFraction>% and the weighted average the remaining lease term is <ix:nonNumeric id="fid_1299" contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember" name="cvm:OPeratingLeaseWeightedAverageRemainingLeaseTerm" format="ixt-sec:duryear">6.81</ix:nonNumeric> years.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_f3a6ca"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of December 31, 2024, approximate future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1208" contextRef="From2024-10-01to2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_444" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_445" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_446" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_447" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_448" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_449" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_450" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_451" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,165,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_452" contextRef="AsOf2024-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_453" contextRef="AsOf2024-12-31" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,599,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_454" contextRef="AsOf2024-12-31" name="cvm:OperatingLeaseLiabilityCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">226,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_455" contextRef="AsOf2024-12-31" name="cvm:OperatingLeaseLiabilityNoncurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,373,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1186" contextRef="From2024-10-01to2024-12-31" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024, the Company abandoned three patents which resulted in an impairment of $<ix:nonFraction id="fid_1260" contextRef="From2024-10-01to2024-12-31" name="us-gaap:AssetImpairmentCharges" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,541</ix:nonFraction> on patent costs. During the three months ended December 31, 2023, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;<ix:nonNumeric id="fid_1259" contextRef="From2024-10-01to2024-12-31" name="cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" format="ixt-sec:duryear">7</ix:nonNumeric>&#160;years. For the three months ended December 31, 2024 and 2023, amortization of patent costs totaled approximately $<ix:nonFraction id="fid_430" contextRef="From2024-10-01to2024-12-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction> and $<ix:nonFraction id="fid_431" contextRef="From2023-10-01to2023-12-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction>, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1209" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_412" contextRef="AsOf2024-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_413" contextRef="AsOf2024-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_414" contextRef="AsOf2024-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_415" contextRef="AsOf2024-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_416" contextRef="AsOf2024-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_417" contextRef="AsOf2024-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_418" contextRef="AsOf2024-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_419" contextRef="AsOf2024-12-31" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1187" contextRef="From2024-10-01to2024-12-31" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="cont_6b2105"><p style="font-size:10pt;font-family:times new roman;margin:0px">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants, unvested common stock&#160;and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The calculation of basic and diluted net loss per share includes <ix:nonFraction id="fid_1267" contextRef="AsOf2024-12-31_cvm_PreFundedMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,577,500</ix:nonFraction> of the pre-funded warrants that remain outstanding as of December 31, 2024.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_6b2105"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1210" contextRef="From2024-10-01to2024-12-31" name="cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_406" contextRef="From2024-10-01to2024-12-31" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,073,062</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_407" contextRef="From2023-10-01to2023-12-31" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_408" contextRef="From2024-10-01to2024-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">65,325,855</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_410" contextRef="From2023-10-01to2023-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">48,470,600</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_409" contextRef="From2024-10-01to2024-12-31" name="us-gaap:EarningsPerShareDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.11</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_411" contextRef="From2023-10-01to2023-12-31" name="us-gaap:EarningsPerShareDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.14</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1211" contextRef="From2024-10-01to2024-12-31" name="cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_396" contextRef="From2024-10-01to2024-12-31_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,837,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_397" contextRef="From2023-10-01to2023-12-31_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,839,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Common Stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_1439" contextRef="From2024-10-01to2024-12-31_cvm_UnvestedCommonStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_398" contextRef="From2024-10-01to2024-12-31_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">144,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_399" contextRef="From2023-10-01to2023-12-31_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_401" contextRef="From2024-10-01to2024-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">18,981,427</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_402" contextRef="From2023-10-01to2023-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,986,278</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1188" contextRef="From2024-10-01to2024-12-31" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">J. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a6">Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Company Overview</span>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. None of the Company&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS, AND PATH FORWARD</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Immunotherapy is a large, high growth market.</span></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A Bloomberg report from January 2023 asserted that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. (https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is <em><span style="text-decoration:underline">given first</span></em><span style="text-decoration:underline">, right after diagnosis, before any other treatment including surgery</span>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine has been tested in approximately 740 patients in Phase 1, 2 and 3 clinical studies conducted in the U.S., Canada, Europe, Israel and Asia. In these studies, it has been administered in multiple doses by various routes and various frequencies to determine its safety and efficacy. The data from these studies allowed CEL-SCI to determine the patient population most responsive to Multikine and most likely to benefit from it. The target population is newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET imaging) and with low PD-L1 tumor expression (determined via biopsy), two features that physicians routinely assess at baseline as part of standard practice.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&#160; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&#160; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the target patient population CEL-SCI believes Multikine significantly extended life. In the Phase III study, CEL-SCI observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">What is Multikine and who is it for?</span></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><span style="text-decoration:underline">before</span></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Multikine target population is not yet treated adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>No lymph node involvement</strong> (via PET imaging)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Low PD-L1 tumor expression</strong> (TPS&lt;10) (via biopsy)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">PD-L1 is a protein receptor on the tumor surface that helps the tumor repel cells of the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. These checkpoint inhibitors appear to act best when tumors express high levels of PD-L1 receptors (usually TPS &gt;20 to TPS &gt;50). While none of these drugs are currently approved as a first-line treatment before surgery, even if such approvals were to come in the future, CEL-SCI believes the large majority of patients having low PD-L1 would still be expected to need Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">CEL-SCI believes Multikine leads to longer survival with no safety issues.</span></strong> Clinical investigations of Multikine, presented at ESMO (Europe Society for Medical Oncology) in October 2023, have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong><em><span style="text-decoration:underline">risk of death cut in half at five years</span></em></strong><strong><em> </em></strong>versus the control;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths, no Multikine-related delays of surgery, no Multikine-related interference with post-surgical treatment, and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference on Head and Neck Oncology (ECHNO), the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and the 2023 American Head and Neck Society (AHNS). These publications can be accessed at http://www.cel-sci.com.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine</span></strong><strong><span style="text-decoration:underline"> works by inducing pre-surgical responses.</span></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;">Multikine causes pre-surgical responses;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;">Pre-surgical responses lead to longer life;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction,&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><span style="text-decoration:underline">none</span><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.&#160; These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg1.jpg" alt="cvm_10qimg1.jpg"/> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial.&#160; Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and control patients who did not receive Multikine (gray). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg2.jpg" alt="cvm_10qimg2.jpg"/> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine cut the 5-year risk of death in half in the target population.</span></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the target population. Survival increased from 45% in the control group to 73% in the Multikine group at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg3.jpg" alt="cvm_10qimg3.jpg"/> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low (log rank) p-value of 0.0015, which is very significant as a statistical matter. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg4.jpg" alt="cvm_10qimg4.jpg"/> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s physician consultants tell CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the rate of an event (chances) of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0 (which would mean parity between the compared groups). In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; (the upper limit of the 95% confidence interval &#8211; for the hazard ratio &#8211; in this case) is still below (better) than the hazard ratio required for most drug approvals. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&#160; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&#160; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg5.jpg" alt="cvm_10qimg5.jpg"/> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg6.jpg" alt="cvm_10qimg6.jpg"/> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial. CEL-SCI&#8217;s regulatory strategy going forward is to seek approval of Multikine following full enrollment of its confirmatory study wherever possible. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg7.jpg" alt="cvm_10qimg7.jpg"/> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone. CEL-SCI expects to initiate the confirmatory study in Q1/Q2 2025 and reach full enrollment in Q2 2026.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If approved as a pre-surgical treatment, CEL-SCI believes Multikine should be added to the standard of care for the target population in this unmet medical need.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study. The planned confirmatory study will be much smaller&#8212;less than a quarter the size of the prior study&#8212; and will focus on the patients who saw the greatest survival benefit when treated with Multikine.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Why Do We Believe Our Confirmatory Study Will Be Successful? </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg8.jpg" alt="cvm_10qimg8.jpg"/> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a great unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% in the target population based on the Phase III data. Chemotherapy (in addition to radiotherapy following surgery) has improved survival outcome for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicine Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug, especially if the drug has been shown to be safe. Every situation is different and depends on the specific facts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">IN CONCLUSION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Strong survival data:</strong> Multikine-treated patients in the target population had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine in the Phase III study. In addition, no safety signals or toxicities versus standard of care. The Hazard ratio is 0.35 with an upper limit (95% Confidence Interval) of 0.66.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Addressing an unmet medical need:</strong> Multikine focuses on the 70% of patients not well served by the two leading approved drugs for head and neck cancer, Keytruda and Opdivo. Multikine&#8217;s proposed indication is a pre-surgical treatment in head &amp; neck cancer, where no drug is currently approved.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Multikine&#8217;s Target Population:</strong> The confirmatory registration study will focus on newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FDA pathway:</strong> CEL-SCI aims to begin the 212-patient confirmatory registration study in Q1/Q2 2025, with full enrollment expected in Q2 2026 with the potential to seek early approval after full enrollment.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Liquidity and Capital Resources</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, the Company has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. The Company will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company&#8217;s capital requirements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, the construction and upgrade of the Company&#8217;s manufacturing and laboratory facilities and clinical trials. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all of the Company&#8217;s liquidity and capital requirements and anticipates having to do so in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The cost of the confirmatory registration study is estimated to be about $30 million. The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.&#160; However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2024, the Company&#8217;s cash decreased by approximately $0.1 million.&#160;Significant components of this decrease included net proceeds from the December 2024 financing of $4.5 million offset by cash used to fund the Company&#8217;s regular operations of approximately $4.1 million and approximately $0.5 million in payments on their finance lease obligations.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2023, the Company&#8217;s cash decreased by approximately $0.9 million.&#160; The significant component of this decrease included cash used to fund the Company&#8217;s regular operations of approximately $4.9 million, and approximately $0.4 million in payments on the Company&#8217;s finance lease obligations, offset by net proceeds from the November 2023 financing of approximately $4.5 million.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2024, 1,450,000 pre-funded warrants were exercised.&#160; No warrants were exercised during the three months ended December 31, 2023.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Results of Operations and Financial Condition</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred a net operating loss of approximately $6.9 million for the three months ended December 31, 2024. This net operating loss consists of significant non-cash expenses including approximately $1.1 million in share-based compensation to employees and non-employees, and approximately $1.0 million in depreciation and amortization expense.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2024 and 2023, there was no change in the research and development expenses as it remained constant at approximately $4.4 million. The major components of research and development expenses include an approximate $0.2 million increase over the prior period in clinical studies costs as a result of preparing the confirmatory study for enrollment, costs incurred for supplies and materials used which increased by $0.2 million compared to the prior period and an increase over the prior period in other research and development expenses of $0.1 million, offset by a decrease of $0.5 million of employee stock compensation expense compared to the prior period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2024, general and administrative expenses increased by approximately $0.3 million, or 15%, compared to the three months ended December 31, 2023. This increase is primarily due to a $0.2 million increase in non-employee stock compensation and $0.2 million increase in other costs related to public relations, offset by a decrease of approximately $0.1 million of employee stock compensation expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2024 and 2023, net interest expense remained constant at approximately $0.2 million, which is primarily due to the interest paid on the Company&#8217;s lease liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">MULTIKINE</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,409,465</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,329,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">20,598</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,257</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">TOTAL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,430,063</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,352,509</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company&#8217;s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Critical Accounting Estimates </span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI's significant accounting estimates are more fully described in Part II, Item&#160;7 of the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2024. However, certain accounting estimates are particularly important to the portrayal of CEL-SCI&#8217;s financial position and results of operations and require the application of significant judgments by management. As a result, the financial statements are subject to an inherent degree of uncertainty. In applying those estimates, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. These estimates are based on CEL-SCI's historical experience, terms of existing contracts, observance of trends in the industry and information available from outside sources, as appropriate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management believes that the following critical accounting estimates require the most significant judgments and estimates with respect to the preparation of CEL-SCI&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Lease Accounting&#160;</em>&#8211; The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate. The determination of the incremental borrowing rates for new and modified lease contracts is a critical accounting estimate. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Share-based Compensation&#160;</em>&#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718,&#160;<em>Compensation &#8211; Stock Compensation</em>&#160;(&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by CEL-SCI&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, CEL-SCI has based its assumption for stock price volatility on the variance of daily closing prices of CEL-SCI&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a7">Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not believe that it has any significant exposure to market risk.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a8">Item 4.&#160; CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the direction and with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer and Chief Financial and Operations Officer, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of December 31, 2024. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and regulations, and that such information is accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s Chief Executive Officer and Chief Financial and Operations Officer has concluded that the Company&#8217;s disclosure controls and procedures were not effective as of December 31, 2024 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no changes in the Company&#8217;s internal control over financial reporting that occurred during the three months ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a9">PART II</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a10">Item 2.&#160; Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2024, the Company issued 154,615 restricted shares of common stock to consultants for investor relations services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company&#8217;s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="a11">Item 5.&#160; Other Information</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending December 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span class="atag" style="display: inline" id="a12"><strong>Item 6.</strong> <strong>Exhibits</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Number&#160;</p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exhibit</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">31</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">32</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">Section 1350 Certifications</a></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a13">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI CORPORATION</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date:&#160; February 14, 2025</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By:&#160;&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/&#160; Geert Kersten</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal Executive Officer&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/&#160; Patricia Prichep</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal Financial Officer&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><strong></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p><strong></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">c)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">d)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">February 14, 2025</td> <td style="width:3%;">By: </td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert Kersten</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Executive Officer</td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">c)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">d)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">February 14, 2025</td> <td style="width:3%;">By: </td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Patricia Prichep</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Patricia Prichep</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Financial Officer</td> <td>&nbsp;</td></tr></table> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table></p> <p style="margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><u><strong>EXHIBIT 32</strong></u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In connection with the Quarterly Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending December 31, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Principal Executive Officer of the Company and Patricia Prichep, Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">February 14, 2025</td> <td style="width:3%;">By: </td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td>Geert Kersten</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Executive Officer</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">By: </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">/s/ Patricia Prichep</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Patricia Prichep</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Principal Financial Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cvm-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cvm="http://cvm.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20241231">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementOfStockholdersEquityUnaudited" id="StatementOfStockholdersEquityUnaudited">
        <link:definition>000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LIQUIDITY" id="LIQUIDITY">
        <link:definition>000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000009 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000010 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>000012 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShare" id="LossPerCommonShare">
        <link:definition>000013 - Disclosure - LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000014 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>000018 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareTables" id="LossPerCommonShareTables">
        <link:definition>000019 - Disclosure - LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000020 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>000021 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>000022 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>000023 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>000029 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>000030 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails" id="LossPerCommonShareDetails">
        <link:definition>000031 - Disclosure - LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails1" id="LossPerCommonShareDetails1">
        <link:definition>000032 - Disclosure - LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetailsNarrative" id="LossPerCommonShareDetailsNarrative">
        <link:definition>000033 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingCurrent" name="SuppliesUsedForRDAndManufacturingCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" name="SuppliesUsedForRDAndManufacturingNonCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DueToEmployeeCurrent" name="DueToEmployeeCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CostIncurredInIssuanceOfStock" name="CostIncurredInIssuanceOfStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" name="StockIssuedDuringPeriodValueStockWarrantsExercised" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossOnPatentImpairment" name="GainLossOnPatentImpairment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" name="IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncreaseDecreaseInDeposit" name="IncreaseDecreaseInDeposit" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" name="NonCashFinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock" name="NonCashConsultingServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" name="NonCashFinancingCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeasesPolicyTextBlock" name="LeasesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" name="ImpairmentOfLongLivedAssetsPolicyTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfStockOptionActivityTableTextBlock" name="ScheduleOfStockOptionActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfCompensatingBalancesTableTextBlock" name="ScheduleOfCompensatingBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" name="ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" name="ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" name="ScheduleOfAntiDilutiveSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssueDate1" name="IssueDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfWarrantOptions" name="SharesIssuableUponExerciseOfWarrantOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ConsultingFeesIncluedPrepaidExpenses" name="ConsultingFeesIncluedPrepaidExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetofissuanceCosts" name="NetofissuanceCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityCurrentPortion" name="FinanceLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityNoncurrentPortion" name="FinanceLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityCurrentPortion" name="OperatingLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityNoncurrentPortion" name="OperatingLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AnnualIncreaseToInterestPayments" name="AnnualIncreaseToInterestPayments" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AnnualIncreaseToInterestPaymentsOperating" name="AnnualIncreaseToInterestPaymentsOperating" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingArrangementDepositBaseRentAmount" name="FinancingArrangementDepositBaseRentAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeaseExpenseUnderOperatingLeases" name="LeaseExpenseUnderOperatingLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm" name="OPeratingLeaseWeightedAverageRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" name="FinanceLeaseWeightedAverageRemainingLeaseTermOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" name="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LIQUIDITYAbstract" name="LIQUIDITYAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="ChangesInEquityWarrantsMember" id="cvm_ChangesInEquityWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedCommonStockMember" id="cvm_UnvestedCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlanMember" id="cvm_IncentiveStockBonusPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BottomMember" id="cvm_BottomMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TopMember" id="cvm_TopMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PreFundedMember" id="cvm_PreFundedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlansMember" id="cvm_IncentiveStockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsOptionMember" id="cvm_ConsultantsOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LandlordMember" id="cvm_LandlordMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsOtherMember" id="cvm_ConsultingAgreementsOtherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonEmployeesMember" id="cvm_NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cvm-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_c536b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_c536b6" xml:lang="en-US">CONDENSED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_f54907" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_f54907" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_cb70fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_cb70fa" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_a46fd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_a46fd2" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingCurrent_lbl_4a6f52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingCurrent_lbl_4a6f52" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_0024cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_0024cf" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_46bef3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_46bef3" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_7" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_ec2c29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_ec2c29" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_a53034" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_a53034" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_4c26f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_4c26f7" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_938906" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_938906" xml:lang="en-US">Patent costs, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_ea97cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_ea97cc" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_12" xml:lang="en-US">[Deposits Assets, Noncurrent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_0f9328" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_0f9328" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_13" xml:lang="en-US">[Supplies used for R&amp;D and manufacturing]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_fb1226" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_fb1226" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_14" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_5bbf0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_5bbf0f" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_f602a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_f602a4" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_84edf4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_84edf4" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_fe9d14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_fe9d14" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_DueToEmployeeCurrent" xlink:label="cvm_DueToEmployeeCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DueToEmployeeCurrent" xlink:to="cvm_DueToEmployeeCurrent_lbl_e4dfc8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DueToEmployeeCurrent_lbl_e4dfc8" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_2982ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_2982ef" xml:lang="en-US">Finance lease obligation, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_90258f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_90258f" xml:lang="en-US">Operating lease obligation, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_5eb5a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_5eb5a8" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_22" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_8256f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_8256f1" xml:lang="en-US">Finance lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_cf01bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_cf01bf" xml:lang="en-US">Operating lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_44129a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_44129a" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_1cf3dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_1cf3dc" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_26" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_18e7f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_18e7f9" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_b1cee8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_b1cee8" xml:lang="en-US">Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_7df34a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_7df34a" xml:lang="en-US">Common stock, $0.01 par value; 600,000,000 shares authorized; 74,084,041 and 63,787,104 shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_4795d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_4795d2" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_d89606" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_d89606" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_604f48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_604f48" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_32" xml:lang="en-US">[Equity, Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_c4c480" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_c4c480" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_33" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_889d6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_889d6c" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_72e085" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_72e085" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_5cf0be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_5cf0be" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_a3667b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_a3667b" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_5530c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_5530c4" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_f459bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_f459bf" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_bfb4b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_bfb4b1" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_7d14d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_7d14d7" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_0fe851" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_0fe851" xml:lang="en-US">CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_f9e154" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_f9e154" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_94fc37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_94fc37" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_e37ae7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_e37ae7" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_1c1fac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_1c1fac" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_db4083" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_db4083" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_6" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_fc7267" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_fc7267" xml:lang="en-US">Interest expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl_99b964" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl_99b964" xml:lang="en-US">Other expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl_8" xml:lang="en-US">[Other Nonoperating Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_5b1db3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_5b1db3" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_9" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_f1b431" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_f1b431" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_10" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_da0947" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_da0947" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_1d64ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_1d64ea" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_47c156" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_47c156" xml:lang="en-US">STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_34baa4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_34baa4" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_9e84ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_9e84ca" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_0e8bae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_0e8bae" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_c27c5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_c27c5d" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_319b42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_319b42" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_8e2633" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_8e2633" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_ad9130" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_ad9130" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_fbc221" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_fbc221" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_88d721" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_88d721" xml:lang="en-US">401(k) contributions paid in common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_353d9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_353d9d" xml:lang="en-US">401(k) contributions paid in common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_340779" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_340779" xml:lang="en-US">Stock issued to nonemployees for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_f7fa69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_f7fa69" xml:lang="en-US">Stock issued to nonemployees for service, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_32d3ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_32d3ba" xml:lang="en-US">Proceeds from the sale of common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_d58971" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_d58971" xml:lang="en-US">Proceeds from the sale of common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_7e43fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_7e43fa" xml:lang="en-US">Equity based compensation - employees, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="cvm_CostIncurredInIssuanceOfStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CostIncurredInIssuanceOfStock" xlink:to="cvm_CostIncurredInIssuanceOfStock_lbl_3a2e3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CostIncurredInIssuanceOfStock_lbl_3a2e3d" xml:lang="en-US">Share issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_bbd759" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_bbd759" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl_756b51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl_756b51" xml:lang="en-US">Pre-funded warrant exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl_7c3c30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl_7c3c30" xml:lang="en-US">Pre-funded warrant exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_fa4296" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_fa4296" xml:lang="en-US">Equity based compensation - employees, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_03626c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_03626c" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_b804ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_b804ea" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_641bfb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_641bfb" xml:lang="en-US">CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_92f6c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_92f6c1" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_2" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_84103e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_84103e" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_6520b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_6520b4" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl_91eaf6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl_91eaf6" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_ddadf0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_ddadf0" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_b1e1f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_b1e1f4" xml:lang="en-US">Equity based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_58e796" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_58e796" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_GainLossOnPatentImpairment" xlink:label="cvm_GainLossOnPatentImpairment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossOnPatentImpairment" xlink:to="cvm_GainLossOnPatentImpairment_lbl_97e0d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossOnPatentImpairment_lbl_97e0d9" xml:lang="en-US">Loss on patent impairment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_d2bd38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_d2bd38" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_2571a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_2571a5" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_11" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:to="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing_lbl_960985" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing_lbl_960985" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:label="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:to="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing_lbl_12" xml:lang="en-US">[Supplies used for R&amp;D and manufacturing 1]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInDeposit" xlink:to="cvm_IncreaseDecreaseInDeposit_lbl_7bef68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_IncreaseDecreaseInDeposit_lbl_7bef68" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncreaseDecreaseInDeposit" xlink:label="cvm_IncreaseDecreaseInDeposit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInDeposit" xlink:to="cvm_IncreaseDecreaseInDeposit_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncreaseDecreaseInDeposit_lbl_13" xml:lang="en-US">[Deposits]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_d4da17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_d4da17" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_4af839" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_4af839" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_15" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_1a3f57" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_1a3f57" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_16" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_ea678f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_ea678f" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_17" xml:lang="en-US">[Increase (Decrease) in Employee Related Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_4c6c25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_4c6c25" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_18" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_725e20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_725e20" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_8c4330" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_8c4330" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_20" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_0c9114" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_0c9114" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_21" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_5f5934" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_5f5934" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_22" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_e5ef3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_e5ef3d" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_ec1b3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_ec1b3d" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_f1886b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_f1886b" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_25" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_3b2d07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_3b2d07" xml:lang="en-US">Payments on obligations under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_26" xml:lang="en-US">[Repayments of Debt and Lease Obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_6f0966" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_6f0966" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_4754c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_4754c5" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_28" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_34ca80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_34ca80" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_c5a427" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_c5a427" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_85099c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_85099c" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable_lbl_6de5a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable_lbl_6de5a7" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock_lbl_5a1c61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock_lbl_5a1c61" xml:lang="en-US">Consulting services paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" xlink:label="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" xlink:to="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities_lbl_2083f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities_lbl_2083f9" xml:lang="en-US">Financing costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_4e6545" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_4e6545" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_72f278" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_72f278" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_da3b2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_da3b2e" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_fa8d7e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_fa8d7e" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LIQUIDITYAbstract" xlink:label="cvm_LIQUIDITYAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LIQUIDITYAbstract" xlink:to="cvm_LIQUIDITYAbstract_lbl_a13c1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LIQUIDITYAbstract_lbl_a13c1b" xml:lang="en-US">LIQUIDITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_a32ec3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_a32ec3" xml:lang="en-US">LIQUIDITY</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="cvm_LiquidityDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_2" xml:lang="en-US">[LIQUIDITY]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_e447a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_e447a0" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_724be0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_724be0" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_961477" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_961477" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_302fa3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_302fa3" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="cvm_CommitmentsAndContingenciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommitmentsAndContingenciesAbstract" xlink:to="cvm_CommitmentsAndContingenciesAbstract_lbl_411999" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommitmentsAndContingenciesAbstract_lbl_411999" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_ef5be2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_ef5be2" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_790a19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_790a19" xml:lang="en-US">PATENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_dbf5a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_dbf5a8" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_ce11ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_ce11ef" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_df9322" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_df9322" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_2" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_f43547" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_f43547" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_a3d57b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_a3d57b" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_634337" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_634337" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_c1038c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_c1038c" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_631563" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_631563" xml:lang="en-US">Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_aa8dc1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_aa8dc1" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_4" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_fa6594" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_fa6594" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LeasesPolicyTextBlock" xlink:label="cvm_LeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeasesPolicyTextBlock" xlink:to="cvm_LeasesPolicyTextBlock_lbl_67368b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeasesPolicyTextBlock_lbl_67368b" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_650463" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_650463" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_1e4d02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_1e4d02" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_6abd6d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_6abd6d" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl_460f0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl_460f0e" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_cebb98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_cebb98" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:to="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_31f1f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_31f1f4" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl_0327a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl_0327a4" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_6b4067" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_6b4067" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_87120d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_87120d" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_52b7af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_52b7af" xml:lang="en-US">Schedule of equity compensation plans</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:to="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_48a136" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_48a136" xml:lang="en-US">Schedule of Stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:to="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_6dbdf9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_6dbdf9" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:to="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_343bda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_343bda" xml:lang="en-US">Schedule of warrants and non-employee options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_24832b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_24832b" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_f8f783" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_f8f783" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_c1400c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_c1400c" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:to="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_44113d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_44113d" xml:lang="en-US">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:to="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_c365b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_c365b6" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedOtherAtFairValue_lbl_a1c1c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedOtherAtFairValue_lbl_a1c1c4" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" xlink:label="us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" xlink:to="us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets_lbl_f84757" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets_lbl_f84757" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_c418bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_c418bc" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_d1fc77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_d1fc77" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="cvm_IncentiveStockBonusPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_22" xml:lang="en-US">[Incentive Stock Bonus Plan [Member]]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_b07544" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_b07544" xml:lang="en-US">Non-Qualified Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_b52c6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_b52c6c" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl_62b74f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl_62b74f" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="cvm_IncentiveStockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlansMember" xlink:to="cvm_IncentiveStockBonusPlansMember_lbl_6a248f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlansMember_lbl_6a248f" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_50e395" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_50e395" xml:lang="en-US">Remaining Options/shares Under Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_9a1488" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_9a1488" xml:lang="en-US">Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl_d74f7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl_d74f7a" xml:lang="en-US">Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_23f3e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_23f3e7" xml:lang="en-US">Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_dfa1fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_dfa1fb" xml:lang="en-US">Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_81cda9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_81cda9" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl_c802bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl_c802bb" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonEmployeesMember" xlink:label="cvm_NonEmployeesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonEmployeesMember" xlink:to="cvm_NonEmployeesMember_lbl_7f8b8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonEmployeesMember_lbl_7f8b8e" xml:lang="en-US">Non-employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_f1d3b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_f1d3b4" xml:lang="en-US">Stock Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_72d8b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_72d8b2" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_a67780" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_a67780" xml:lang="en-US">Related Party Transactions By Related Party Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_44c655" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_44c655" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_BottomMember" xlink:label="cvm_BottomMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_BottomMember" xlink:to="cvm_BottomMember_lbl_ef5cd1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_BottomMember_lbl_ef5cd1" xml:lang="en-US">Bottom [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_debf68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_debf68" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_TopMember" xlink:label="cvm_TopMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TopMember" xlink:to="cvm_TopMember_lbl_16aa72" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TopMember_lbl_16aa72" xml:lang="en-US">Top [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_PreFundedMember" xlink:label="cvm_PreFundedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PreFundedMember" xlink:to="cvm_PreFundedMember_lbl_fe828a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PreFundedMember_lbl_fe828a" xml:lang="en-US">Pre-Funded [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_0ece9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_0ece9c" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_acc87b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_acc87b" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_f97db8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_f97db8" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_2b6986" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_2b6986" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_e02abb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_e02abb" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_171c6d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_171c6d" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_09c360" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_09c360" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultantsOptionMember" xlink:label="cvm_ConsultantsOptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsOptionMember" xlink:to="cvm_ConsultantsOptionMember_lbl_3387ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsOptionMember_lbl_3387ad" xml:lang="en-US">Consultants Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IssueDate1" xlink:label="cvm_IssueDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssueDate1" xlink:to="cvm_IssueDate1_lbl_d8f47a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssueDate1_lbl_d8f47a" xml:lang="en-US">Issue Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:to="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_ff8bd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_ff8bd2" xml:lang="en-US">Shares Issuable Upon Exercise Of Warrant/options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_e0218a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_e0218a" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ExpirationDate" xlink:label="cvm_ExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate" xlink:to="cvm_ExpirationDate_lbl_599966" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate_lbl_599966" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="us-gaap_TradingActivityByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeAxis_lbl_3793c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl_3793c8" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_9dddf8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_9dddf8" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ChangesInEquityWarrantsMember" xlink:label="cvm_ChangesInEquityWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ChangesInEquityWarrantsMember" xlink:to="cvm_ChangesInEquityWarrantsMember_lbl_1b546c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ChangesInEquityWarrantsMember_lbl_1b546c" xml:lang="en-US">Changes in Equity Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_50feae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_50feae" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_c0258d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_c0258d" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_d6b4ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_d6b4ae" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_0aac22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_0aac22" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="cvm_ConsultingAgreementsOtherMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsOtherMember" xlink:to="cvm_ConsultingAgreementsOtherMember_lbl_768291" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsOtherMember_lbl_768291" xml:lang="en-US">Consulting Agreements Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_70fbb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_70fbb8" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl_468098" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl_468098" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="cvm_ConsultingFeesIncluedPrepaidExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:to="cvm_ConsultingFeesIncluedPrepaidExpenses_lbl_f170b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingFeesIncluedPrepaidExpenses_lbl_f170b1" xml:lang="en-US">Consulting fees inclued prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_27dc2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_27dc2e" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl_7915ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl_7915ae" xml:lang="en-US">Cost of shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_f8d2d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_f8d2d6" xml:lang="en-US">Shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl_32b2ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl_32b2ce" xml:lang="en-US">Common stock shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_d4265f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_d4265f" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_b1c9de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_b1c9de" xml:lang="en-US">Public offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_5fd93b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_5fd93b" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NetofissuanceCosts" xlink:label="cvm_NetofissuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetofissuanceCosts" xlink:to="cvm_NetofissuanceCosts_lbl_ec510b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetofissuanceCosts_lbl_ec510b" xml:lang="en-US">Net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_850751" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_850751" xml:lang="en-US">Nine months ending September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_e3c909" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_e3c909" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_9bf068" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_9bf068" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_428759" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_428759" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_7c16b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_7c16b8" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_217fcd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_217fcd" xml:lang="en-US">2030</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_b5ea80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_b5ea80" xml:lang="en-US">Total future minimum lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_b529d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_b529d7" xml:lang="en-US">Less imputed interest on finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xml:lang="en-US">[Finance Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_b8e573" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_b8e573" xml:lang="en-US">Net present value of financing lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_bfa640" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_bfa640" xml:lang="en-US">Less net present value of financing lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_9d0e6e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_9d0e6e" xml:lang="en-US">Net present value of financing lease obligations - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_d8f7f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_d8f7f4" xml:lang="en-US">Nine months ending September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_460a7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_460a7f" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_3c534d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_3c534d" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_0d4101" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_0d4101" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_208354" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_208354" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_315ed5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_315ed5" xml:lang="en-US">2030</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_3ce5cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_3ce5cb" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_7bafe7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_7bafe7" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_98edbe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_98edbe" xml:lang="en-US">Less Imputed Interest On Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_732b7c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_732b7c" xml:lang="en-US">Net Present Value Of Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityCurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_0a81d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_0a81d0" xml:lang="en-US">Net present value of lease finance lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_433565" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_433565" xml:lang="en-US">Net present value of lease finance lease obligations - non-current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_02b13f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_02b13f" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_bb79bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_bb79bf" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LandlordMember" xlink:label="cvm_LandlordMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LandlordMember" xlink:to="cvm_LandlordMember_lbl_fc4eb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LandlordMember_lbl_fc4eb4" xml:lang="en-US">Landlord [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl_3ec38f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl_3ec38f" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="cvm_AnnualIncreaseToInterestPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AnnualIncreaseToInterestPayments" xlink:to="cvm_AnnualIncreaseToInterestPayments_lbl_3c5f5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AnnualIncreaseToInterestPayments_lbl_3c5f5b" xml:lang="en-US">Annual increase to interest payments</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_AnnualIncreaseToInterestPaymentsOperating" xlink:label="cvm_AnnualIncreaseToInterestPaymentsOperating" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AnnualIncreaseToInterestPaymentsOperating" xlink:to="cvm_AnnualIncreaseToInterestPaymentsOperating_lbl_1a0dca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AnnualIncreaseToInterestPaymentsOperating_lbl_1a0dca" xml:lang="en-US">Annual increase to interest payments operating</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_c2050d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_c2050d" xml:lang="en-US">Finance lease right-of-use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_405325" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl_405325" xml:lang="en-US">Finance lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_2d4aec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_2d4aec" xml:lang="en-US">Finance lease liability current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl_3ec78c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl_3ec78c" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="cvm_FinancingArrangementDepositBaseRentAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingArrangementDepositBaseRentAmount" xlink:to="cvm_FinancingArrangementDepositBaseRentAmount_lbl_25dbbf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingArrangementDepositBaseRentAmount_lbl_25dbbf" xml:lang="en-US">Financing arrangement deposit base rent amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_0bb4bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_0bb4bb" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_ee9903" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_ee9903" xml:lang="en-US">Operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_ba74aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_ba74aa" xml:lang="en-US">Operating lease liability current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl_288078" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl_288078" xml:lang="en-US">Interest amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl_1385d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl_1385d8" xml:lang="en-US">Total depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_470aa1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_470aa1" xml:lang="en-US">Finance Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_d639b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_d639b9" xml:lang="en-US">Amortization of Finance Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl_e13aca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl_e13aca" xml:lang="en-US">Interest Expense on Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LeaseExpenseUnderOperatingLeases" xlink:label="cvm_LeaseExpenseUnderOperatingLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeaseExpenseUnderOperatingLeases" xlink:to="cvm_LeaseExpenseUnderOperatingLeases_lbl_af7030" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeaseExpenseUnderOperatingLeases_lbl_af7030" xml:lang="en-US">incurred lease expense under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl_2ea78d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl_2ea78d" xml:lang="en-US">Variable finance lease costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl_75622b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl_75622b" xml:lang="en-US">Total cash payment for oprating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm" xlink:to="cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm_lbl_b89007" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm_lbl_b89007" xml:lang="en-US">Weighted average time of maturity of operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:to="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne_lbl_293aae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne_lbl_293aae" xml:lang="en-US">Weighted average time of maturity of finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_f7776d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_f7776d" xml:lang="en-US">Research and development expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_18b686" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_18b686" xml:lang="en-US">Nine months ending September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_c79b50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_c79b50" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_5bcf91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_5bcf91" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_9639fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_9639fa" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_7e6503" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_7e6503" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_375c1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_375c1e" xml:lang="en-US">2030</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_345bb0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_345bb0" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xml:lang="en-US">[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_bce607" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_bce607" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xml:lang="en-US">[Other Indefinite-Lived Intangible Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl_331175" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl_331175" xml:lang="en-US">Impairment patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_754f62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_754f62" xml:lang="en-US">Amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:to="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_b1f120" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_b1f120" xml:lang="en-US">Weighted average amortization period for patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl_fa931f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl_fa931f" xml:lang="en-US">Net loss available to common shareholders - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl_7f1c99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl_7f1c99" xml:lang="en-US">Loss per share- basic and diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_86be6f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_86be6f" xml:lang="en-US">Weighted average shares outstanding - basic and diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_578c47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_578c47" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_UnvestedCommonStockMember" xlink:label="cvm_UnvestedCommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedCommonStockMember" xlink:to="cvm_UnvestedCommonStockMember_lbl_b2428e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedCommonStockMember_lbl_b2428e" xml:lang="en-US">Unvested Common Stock[Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_3ab06f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_3ab06f" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_842ddf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_842ddf" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_abcd07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_abcd07" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_582b96" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_582b96" xml:lang="en-US">Common stock shares issued</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cvm-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20241231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20241231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20241231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20241231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementOfStockholdersEquityUnaudited" xlink:href="cvm-20241231.xsd#StatementOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20241231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20241231.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20241231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20241231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20241231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20241231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20241231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20241231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20241231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20241231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetailsNarrative" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmDueToEmployeeCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_GainLossOnPatentImpairment" xlink:label="loc_cvmGainLossOnPatentImpairment" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmGainLossOnPatentImpairment" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:label="loc_cvmIncreaseDecreaseInSuppliesUsedForRDAndManufacturing" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmIncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncreaseDecreaseInDeposit" xlink:label="loc_cvmIncreaseDecreaseInDeposit" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmIncreaseDecreaseInDeposit" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000020 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000029 - Disclosure - PATENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000030 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000031 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetailsNarrative" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cvm-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20241231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20241231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20241231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20241231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementOfStockholdersEquityUnaudited" xlink:href="cvm-20241231.xsd#StatementOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20241231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20241231.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20241231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20241231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20241231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20241231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20241231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20241231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20241231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20241231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetailsNarrative" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_46cc7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapAssetsCurrentAbstract_46cc7b" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_313773" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_313773" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_767bf0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapPrepaidExpenseCurrent_767bf0" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingCurrent_de7377" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingCurrent_de7377" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_d53d7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapDepositsAssetsCurrent_d53d7b" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_0e537f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapAssetsCurrent_0e537f" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_523021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_523021" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_8b1d86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_8b1d86" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_1eb847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_1eb847" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_3ea7a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_3ea7a9" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_ea11fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_ea11fc" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_72c344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_72c344" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_82dd66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapAssets_82dd66" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_fe4988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_fe4988" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_65d0d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_65d0d4" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_b26c96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_65d0d4" xlink:to="loc_us-gaapAccountsPayableCurrent_b26c96" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_bcd1ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_65d0d4" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_bcd1ea" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent_538b2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_65d0d4" xlink:to="loc_cvmDueToEmployeeCurrent_538b2a" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_0aaab2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_65d0d4" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_0aaab2" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_8489f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_8489f7" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_f0fb2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapLiabilitiesCurrent_f0fb2c" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_f514b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_f514b5" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_f1319f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_f1319f" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_0d32f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_0d32f0" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_a438a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapLiabilities_a438a4" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_b45fa2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapStockholdersEquityAbstract_b45fa2" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_7ea8f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_b45fa2" xlink:to="loc_us-gaapPreferredStockValue_7ea8f3" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_746632" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_b45fa2" xlink:to="loc_us-gaapCommonStockValue_746632" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_e2be1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_b45fa2" xlink:to="loc_us-gaapAdditionalPaidInCapital_e2be1a" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_fa3322" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_b45fa2" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_fa3322" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_ab3729" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_b45fa2" xlink:to="loc_us-gaapStockholdersEquity_ab3729" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_288a14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c97abf" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_288a14" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_8f674c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_8f674c" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_0b61de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_0b61de" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_8267f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" xlink:to="loc_us-gaapPreferredStockSharesIssued_8267f5" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_9d0f0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_9d0f0c" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_796fa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_796fa6" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_bdeb48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" xlink:to="loc_us-gaapCommonStockSharesAuthorized_bdeb48" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_afe987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" xlink:to="loc_us-gaapCommonStockSharesIssued_afe987" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_7b9e28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5e114a" xlink:to="loc_us-gaapCommonStockSharesOutstanding_7b9e28" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_e7fe68" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_b6a1fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_e7fe68" xlink:to="loc_us-gaapOperatingExpensesAbstract_b6a1fa" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_31937f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b6a1fa" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_31937f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_b06fb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b6a1fa" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_b06fb2" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_542a71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b6a1fa" xlink:to="loc_us-gaapOperatingExpenses_542a71" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_bc9088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b6a1fa" xlink:to="loc_us-gaapOperatingIncomeLoss_bc9088" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_6e3916" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b6a1fa" xlink:to="loc_us-gaapInterestIncomeExpenseNet_6e3916" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_51c7ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b6a1fa" xlink:to="loc_us-gaapOtherNonoperatingExpense_51c7ac" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_aa4385" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_e7fe68" xlink:to="loc_us-gaapNetIncomeLoss_aa4385" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_09f3b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_e7fe68" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_09f3b6" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_46bf40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_e7fe68" xlink:to="loc_us-gaapEarningsPerShareDiluted_46bf40" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_7c3bc5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_e7fe68" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_7c3bc5" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_92bc18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_66f1c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_92bc18" xlink:to="loc_us-gaapStatementTable_66f1c2" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ef439c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_66f1c2" xlink:to="loc_us-gaapStatementLineItems_ef439c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_6a0ed8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_66f1c2" xlink:to="loc_us-gaapStatementEquityComponentsAxis_6a0ed8" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_00466e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_6a0ed8" xlink:to="loc_us-gaapEquityComponentDomain_00466e" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_1cb16b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_00466e" xlink:to="loc_us-gaapCommonStockMember_1cb16b" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_46d921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_00466e" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_46d921" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_57a13c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_00466e" xlink:to="loc_us-gaapRetainedEarningsMember_57a13c" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_54bd0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapSharesIssued_54bd0e" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_0613ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockholdersEquity_0613ca" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_afa87b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_afa87b" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_336f75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_336f75" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_7ff4f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_7ff4f6" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_e98e19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_e98e19" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_b4c976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_b4c976" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_1b38e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_1b38e2" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_fd118b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_fd118b" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="loc_cvmCostIncurredInIssuanceOfStock_aaf34d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_cvmCostIncurredInIssuanceOfStock_aaf34d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_75dc5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapNetIncomeLoss_75dc5a" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised_87df88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised_87df88" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised_1f68d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised_1f68d9" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_4dac86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_4dac86" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_60eb35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapSharesIssued_60eb35" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_808ae5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef439c" xlink:to="loc_us-gaapStockholdersEquity_808ae5" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_398e2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapProfitLoss_398e2c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_802dba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" xlink:to="loc_us-gaapDepreciationAndAmortization_802dba" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_ae45b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" xlink:to="loc_us-gaapOtherNoncashExpense_ae45b8" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_0c2ec5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_0c2ec5" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_88a376" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" xlink:to="loc_us-gaapShareBasedCompensation_88a376" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_76b4d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_76b4d1" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_GainLossOnPatentImpairment" xlink:label="loc_cvmGainLossOnPatentImpairment_bad58a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" xlink:to="loc_cvmGainLossOnPatentImpairment_bad58a" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_d43898" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92591a" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_d43898" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_07c3e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_d43898" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_07c3e6" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:label="loc_cvmIncreaseDecreaseInSuppliesUsedForRDAndManufacturing_211923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_d43898" xlink:to="loc_cvmIncreaseDecreaseInSuppliesUsedForRDAndManufacturing_211923" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncreaseDecreaseInDeposit" xlink:label="loc_cvmIncreaseDecreaseInDeposit_49c3b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_d43898" xlink:to="loc_cvmIncreaseDecreaseInDeposit_49c3b7" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_0afac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_d43898" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_0afac7" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_27a9b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_0afac7" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_27a9b8" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_d66da1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_0afac7" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_d66da1" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_748645" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_0afac7" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_748645" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_7c22fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_0afac7" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_7c22fd" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_bb2e7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_bb2e7f" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_06d799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_bb2e7f" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_06d799" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_41c5ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_bb2e7f" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_41c5ae" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_91d50d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_bb2e7f" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_91d50d" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_857360" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_857360" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_81141b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_857360" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_81141b" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_d7e2c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_857360" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_d7e2c6" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_d39d36" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_d39d36" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_4e6878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_4e6878" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8a625b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8a625b" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5bbc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5bbc2" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a11b25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a11b25" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_522bd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_522bd6" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmNonCashFinanceLeaseObligationIncludedInAccountsPayable_5ac073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_522bd6" xlink:to="loc_cvmNonCashFinanceLeaseObligationIncludedInAccountsPayable_5ac073" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmNonCashConsultingServicesPaidWithIssuanceOfCommonStock_fb35fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_522bd6" xlink:to="loc_cvmNonCashConsultingServicesPaidWithIssuanceOfCommonStock_fb35fa" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmNonCashFinancingCostsIncludedInCurrentLiabilities_23924d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_522bd6" xlink:to="loc_cvmNonCashFinancingCostsIncludedInCurrentLiabilities_23924d" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_116933" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_ee9446" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_116933" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_074999" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_116933" xlink:to="loc_us-gaapInterestPaidNet_074999" order="35" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_969fac" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_9766a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_969fac" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_9766a2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY">
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LIQUIDITYAbstract" xlink:label="loc_cvmLIQUIDITYAbstract_ceb59f" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="loc_cvmLiquidityDisclosureTextBlock_c30926" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmLIQUIDITYAbstract_ceb59f" xlink:to="loc_cvmLiquidityDisclosureTextBlock_c30926" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_33071b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_f771fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_33071b" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_f771fa" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_b42ce0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_ede3e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_b42ce0" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_ede3e2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_bb034b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_e376d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bb034b" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_e376d2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_1f5289" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_9c6c29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_1f5289" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_9c6c29" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_8fe6c2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_814d57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_8fe6c2" xlink:to="loc_us-gaapEarningsPerShareTextBlock_814d57" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_9284a6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_a92b59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_9284a6" xlink:to="loc_us-gaapSubsequentEventsTextBlock_a92b59" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_76676e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_9e33fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_9e33fd" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_e749fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_e749fc" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_7bdc18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapInventoryPolicyTextBlock_7bdc18" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_160937" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_160937" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LeasesPolicyTextBlock" xlink:label="loc_cvmLeasesPolicyTextBlock_af431c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_cvmLeasesPolicyTextBlock_af431c" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_1b74e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_1b74e9" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_3ab5eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_3ab5eb" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_48e6fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_48e6fb" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_9392ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_9392ca" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_4c3109" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_4c3109" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_1e87ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_1e87ef" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_a02f42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_a02f42" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_aa9ded" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapUseOfEstimates_aa9ded" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_71f422" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_76676e" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_71f422" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_cc1a80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_a69c01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_cc1a80" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_a69c01" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="loc_cvmScheduleOfStockOptionActivityTableTextBlock_8c42e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_cc1a80" xlink:to="loc_cvmScheduleOfStockOptionActivityTableTextBlock_8c42e7" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_949ef2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_cc1a80" xlink:to="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_949ef2" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_cfb564" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_cc1a80" xlink:to="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_cfb564" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_ad7df4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_5010b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_ad7df4" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_5010b0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_3426af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_ad7df4" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_3426af" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4bfbb9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_80cd93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4bfbb9" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_80cd93" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_20a46e" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_abc6ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_20a46e" xlink:to="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_abc6ee" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_93af12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_20a46e" xlink:to="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_93af12" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000020 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83405e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" xlink:label="loc_us-gaapFinancialInstrumentsOwnedOtherAtFairValue_097ded" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83405e" xlink:to="loc_us-gaapFinancialInstrumentsOwnedOtherAtFairValue_097ded" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" xlink:label="loc_us-gaapFairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets_490e9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83405e" xlink:to="loc_us-gaapFairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets_490e9e" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_fa11fa" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_fd5ed8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_fa11fa" xlink:to="loc_us-gaapStatementTable_fd5ed8" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_bbdcea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fd5ed8" xlink:to="loc_us-gaapStatementLineItems_bbdcea" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_c7e448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fd5ed8" xlink:to="loc_us-gaapAwardTypeAxis_c7e448" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d236e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_c7e448" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d236e3" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember_d9c56d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d236e3" xlink:to="loc_cvmIncentiveStockBonusPlanMember_d9c56d" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_b2e4f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d236e3" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_b2e4f7" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_125482" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d236e3" xlink:to="loc_cvmStockBonusPlansMember_125482" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember_cf14ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d236e3" xlink:to="loc_us-gaapStockCompensationPlanMember_cf14ac" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember_017b9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d236e3" xlink:to="loc_cvmIncentiveStockBonusPlansMember_017b9c" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_19167f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bbdcea" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_19167f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_f226fa" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8efd93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_f226fa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8efd93" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_ea4abb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_f226fa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_ea4abb" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49f39c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_f226fa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49f39c" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_de61d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_f226fa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_de61d5" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_3f934f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3f148c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_3f934f" xlink:to="loc_us-gaapStatementTable_3f148c" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_90cac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3f148c" xlink:to="loc_us-gaapStatementLineItems_90cac7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_599817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3f148c" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_599817" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_0229dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_599817" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_0229dd" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_4d0340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_0229dd" xlink:to="loc_us-gaapEmployeeStockMember_4d0340" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember_684049" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_0229dd" xlink:to="loc_cvmNonEmployeesMember_684049" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_dfea62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_90cac7" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_dfea62" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_665d28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_397383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_665d28" xlink:to="loc_us-gaapStatementTable_397383" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_daba86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_397383" xlink:to="loc_us-gaapStatementLineItems_daba86" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_237ead" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_397383" xlink:to="loc_us-gaapPlanNameAxis_237ead" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_01f510" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_237ead" xlink:to="loc_us-gaapPlanNameDomain_01f510" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_40d3d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_397383" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_40d3d5" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_0c66b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_40d3d5" xlink:to="loc_us-gaapRelatedPartyDomain_0c66b8" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_34fe90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_397383" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_34fe90" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_34fe90" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember_c34721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_01f510" xlink:to="loc_cvmBottomMember_c34721" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_4f3060" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0c66b8" xlink:to="loc_cvmConsultantsMember_4f3060" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember_741bf5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_01f510" xlink:to="loc_cvmTopMember_741bf5" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_PreFundedMember" xlink:label="loc_cvmPreFundedMember_b98985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" xlink:to="loc_cvmPreFundedMember_b98985" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_6431b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" xlink:to="loc_cvmSeriesNMember_6431b8" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_a6ef15" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" xlink:to="loc_cvmSeriesUUMember_a6ef15" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_73eb02" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" xlink:to="loc_cvmSeriesXMember_73eb02" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_a26769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" xlink:to="loc_cvmSeriesYMember_a26769" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_d41bca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" xlink:to="loc_cvmSeriesMMMember_d41bca" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_fc472f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" xlink:to="loc_cvmSeriesNNMember_fc472f" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_7d116d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_9204a8" xlink:to="loc_cvmSeriesRRMember_7d116d" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember_0a8387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0c66b8" xlink:to="loc_cvmConsultantsOptionMember_0a8387" order="72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1_12bf19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daba86" xlink:to="loc_cvmIssueDate1_12bf19" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_db21aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daba86" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_db21aa" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_0e9511" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daba86" xlink:to="loc_cvmExercisePrice_0e9511" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate_18f306" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daba86" xlink:to="loc_cvmExpirationDate_18f306" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_94a4a4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5b306f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_94a4a4" xlink:to="loc_us-gaapStatementTable_5b306f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0d8043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5b306f" xlink:to="loc_us-gaapStatementLineItems_0d8043" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis_8651c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5b306f" xlink:to="loc_us-gaapTradingActivityByTypeAxis_8651c7" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_1f5a4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeAxis_8651c7" xlink:to="loc_us-gaapTradingActivityByTypeDomain_1f5a4d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_04d8f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5b306f" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_04d8f6" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_a603a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_04d8f6" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_a603a4" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7e1f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5b306f" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7e1f8" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_8f5f92" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b7e1f8" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_8f5f92" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_73bfc9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5b306f" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_73bfc9" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_410e0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_73bfc9" xlink:to="loc_us-gaapRelatedPartyDomain_410e0c" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_4d701e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5b306f" xlink:to="loc_us-gaapPlanNameAxis_4d701e" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_53d2b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_4d701e" xlink:to="loc_us-gaapPlanNameDomain_53d2b1" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_PreFundedMember" xlink:label="loc_cvmPreFundedMember_270379" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_a603a4" xlink:to="loc_cvmPreFundedMember_270379" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ChangesInEquityWarrantsMember" xlink:label="loc_cvmChangesInEquityWarrantsMember_fc6fd9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeDomain_1f5a4d" xlink:to="loc_cvmChangesInEquityWarrantsMember_fc6fd9" order="72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_988683" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_8f5f92" xlink:to="loc_cvmRestrictedStocksMember_988683" order="73" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_3dc026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_410e0c" xlink:to="loc_cvmConsultantsMember_3dc026" order="74" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_613b0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_53d2b1" xlink:to="loc_cvmConsultingAgreementsMember_613b0c" order="75" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_286e37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_53d2b1" xlink:to="loc_cvmErgomedMember_286e37" order="76" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="loc_cvmConsultingAgreementsOtherMember_79c32f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_53d2b1" xlink:to="loc_cvmConsultingAgreementsOtherMember_79c32f" order="77" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db6587" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db6587" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease_953534" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease_953534" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="loc_cvmConsultingFeesIncluedPrepaidExpenses_1800f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_cvmConsultingFeesIncluedPrepaidExpenses_1800f2" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_b75ac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_b75ac7" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_1a15ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_1a15ec" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_2a0c7e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_2a0c7e" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued_e89f45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapExcessStockSharesIssued_e89f45" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_a18f3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapCommonStockSharesIssued_a18f3a" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_2b6cad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapSaleOfStockPricePerShare_2b6cad" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_5b7bde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_5b7bde" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NetofissuanceCosts" xlink:label="loc_cvmNetofissuanceCosts_a3a8a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0d8043" xlink:to="loc_cvmNetofissuanceCosts_a3a8a4" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_af6338" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_af6338" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7d5a20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7d5a20" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_c9f67a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_c9f67a" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_828a85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_828a85" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_3f4b20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_3f4b20" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_9254d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_9254d1" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_7ef863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_7ef863" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_f45de1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_f45de1" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_7f1b66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_us-gaapFinanceLeaseLiability_7f1b66" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityCurrentPortion_418b75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_cvmFinanceLeaseLiabilityCurrentPortion_418b75" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_c3b2d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_1f370d" xlink:to="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_c3b2d7" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9b3af7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9b3af7" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d3f68e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d3f68e" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b3372f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b3372f" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_096d82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_096d82" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_882103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_882103" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_840db1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_840db1" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ad2bdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ad2bdd" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_ed9f22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_ed9f22" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1023c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1023c0" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_ea5b35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_us-gaapOperatingLeaseLiability_ea5b35" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityCurrentPortion_71bc4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_cvmOperatingLeaseLiabilityCurrentPortion_71bc4d" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_e833ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b7e033" xlink:to="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_e833ba" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_0251c6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_07c96b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0251c6" xlink:to="loc_us-gaapStatementTable_07c96b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_fce8bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_07c96b" xlink:to="loc_us-gaapStatementLineItems_fce8bb" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_156641" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_07c96b" xlink:to="loc_us-gaapPlanNameAxis_156641" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_6a2ba8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_156641" xlink:to="loc_us-gaapPlanNameDomain_6a2ba8" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_76263b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_07c96b" xlink:to="loc_srtTitleOfIndividualAxis_76263b" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_24f507" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_76263b" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_24f507" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_917efe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_07c96b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_917efe" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_a12d3d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_917efe" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_a12d3d" order="50" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_abf8e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_6a2ba8" xlink:to="loc_cvmErgomedMember_abf8e8" order="51" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember_578fff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_24f507" xlink:to="loc_cvmLandlordMember_578fff" order="52" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember_943546" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_a12d3d" xlink:to="loc_us-gaapLeaseAgreementsMember_943546" order="53" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="loc_cvmAnnualIncreaseToInterestPayments_46e774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_cvmAnnualIncreaseToInterestPayments_46e774" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_AnnualIncreaseToInterestPaymentsOperating" xlink:label="loc_cvmAnnualIncreaseToInterestPaymentsOperating_5ad1d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_cvmAnnualIncreaseToInterestPaymentsOperating_5ad1d9" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_420b25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_420b25" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_3c2622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapFinanceLeaseLiability_3c2622" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_3e0746" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_3e0746" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_7120ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapSecurityDeposit_7120ea" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="loc_cvmFinancingArrangementDepositBaseRentAmount_3e8e40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_cvmFinancingArrangementDepositBaseRentAmount_3e8e40" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_e69534" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_e69534" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_d41e68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapOperatingLeaseLiability_d41e68" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_03651f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_03651f" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_699e5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapInterestPaid_699e5f" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="loc_us-gaapDepreciationExpenseOnReclassifiedAssets_e2b347" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapDepreciationExpenseOnReclassifiedAssets_e2b347" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_e58856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_e58856" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_63f69f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_63f69f" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_11dd21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_11dd21" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LeaseExpenseUnderOperatingLeases" xlink:label="loc_cvmLeaseExpenseUnderOperatingLeases_3a68eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_cvmLeaseExpenseUnderOperatingLeases_3a68eb" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost_08a8ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapVariableLeaseCost_08a8ed" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse_d24cb0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapOperatingLeasePaymentsUse_d24cb0" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="loc_cvmOPeratingLeaseWeightedAverageRemainingLeaseTerm_c380e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_cvmOPeratingLeaseWeightedAverageRemainingLeaseTerm_c380e6" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne_dc3834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne_dc3834" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_1c4ef0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fce8bb" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_1c4ef0" order="21" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000029 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d3779c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d3779c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_398347" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_398347" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_46bc00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_46bc00" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bb441f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bb441f" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cac0a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cac0a2" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_00c165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_00c165" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_8a0940" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_8a0940" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_a445fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_0d5753" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_a445fb" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000030 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_89dcc2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_57fab0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_89dcc2" xlink:to="loc_us-gaapAssetImpairmentCharges_57fab0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_cf4b0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_89dcc2" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_cf4b0f" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_0bd7c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_89dcc2" xlink:to="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_0bd7c0" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000031 - Disclosure - LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_0e34e5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaapUndistributedEarningsLossAvailableToCommonShareholdersBasic_3bfd24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_0e34e5" xlink:to="loc_us-gaapUndistributedEarningsLossAvailableToCommonShareholdersBasic_3bfd24" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareDilutedAbstract_8a67b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_0e34e5" xlink:to="loc_us-gaapEarningsPerShareDilutedAbstract_8a67b6" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_125b86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_0e34e5" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_125b86" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_b8c9d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_0e34e5" xlink:to="loc_us-gaapEarningsPerShareDiluted_b8c9d8" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_2e0bb7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_081392" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_2e0bb7" xlink:to="loc_us-gaapStatementTable_081392" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_2e3e3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_081392" xlink:to="loc_us-gaapStatementLineItems_2e3e3f" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_648187" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_081392" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_648187" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_60f448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_648187" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_60f448" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_UnvestedCommonStockMember" xlink:label="loc_cvmUnvestedCommonStockMember_e332de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_60f448" xlink:to="loc_cvmUnvestedCommonStockMember_e332de" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_1dbbdf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_60f448" xlink:to="loc_cvmOptionsMember_1dbbdf" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_5d2ae7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_60f448" xlink:to="loc_cvmUnvestedRestrictedStockMember_5d2ae7" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ec89ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2e3e3f" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ec89ef" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetailsNarrative" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_cd1ef1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e5e211" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_cd1ef1" xlink:to="loc_us-gaapStatementTable_e5e211" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_a0d3fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e5e211" xlink:to="loc_us-gaapStatementLineItems_a0d3fa" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_6e2591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e5e211" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_6e2591" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_f3b8a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_6e2591" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_f3b8a4" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_PreFundedMember" xlink:label="loc_cvmPreFundedMember_4432a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_f3b8a4" xlink:to="loc_cvmPreFundedMember_4432a9" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_ab21f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a0d3fa" xlink:to="loc_us-gaapCommonStockSharesIssued_ab21f0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvm-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20241231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20241231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20241231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20241231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementOfStockholdersEquityUnaudited" xlink:href="cvm-20241231.xsd#StatementOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20241231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20241231.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20241231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20241231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20241231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20241231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20241231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20241231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20241231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20241231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20241231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20241231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetailsNarrative" xlink:href="cvm-20241231.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="loc_cvmCostIncurredInIssuanceOfStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCostIncurredInIssuanceOfStock" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000020 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlanMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmStockBonusPlansMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlansMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmNonEmployeesMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmBottomMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmTopMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_PreFundedMember" xlink:label="loc_cvmPreFundedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmPreFundedMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesYMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesMMMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNNMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsOptionMember" order="72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssueDate1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTradingActivityByTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_PreFundedMember" xlink:label="loc_cvmPreFundedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmPreFundedMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ChangesInEquityWarrantsMember" xlink:label="loc_cvmChangesInEquityWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityByTypeDomain" xlink:to="loc_cvmChangesInEquityWarrantsMember" order="72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="73" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="74" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="75" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="76" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="loc_cvmConsultingAgreementsOtherMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsOtherMember" order="77" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="loc_cvmConsultingFeesIncluedPrepaidExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmConsultingFeesIncluedPrepaidExpenses" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapExcessStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_NetofissuanceCosts" xlink:label="loc_cvmNetofissuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetofissuanceCosts" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cvmLandlordMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLeaseAgreementsMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="loc_cvmAnnualIncreaseToInterestPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAnnualIncreaseToInterestPayments" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_AnnualIncreaseToInterestPaymentsOperating" xlink:label="loc_cvmAnnualIncreaseToInterestPaymentsOperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAnnualIncreaseToInterestPaymentsOperating" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="loc_cvmFinancingArrangementDepositBaseRentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinancingArrangementDepositBaseRentAmount" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPaid" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="loc_us-gaapDepreciationExpenseOnReclassifiedAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationExpenseOnReclassifiedAssets" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_LeaseExpenseUnderOperatingLeases" xlink:label="loc_cvmLeaseExpenseUnderOperatingLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmLeaseExpenseUnderOperatingLeases" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapVariableLeaseCost" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="loc_cvmOPeratingLeaseWeightedAverageRemainingLeaseTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOPeratingLeaseWeightedAverageRemainingLeaseTerm" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="21" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000029 - Disclosure - PATENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000030 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000031 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_UnvestedCommonStockMember" xlink:label="loc_cvmUnvestedCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedCommonStockMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetailsNarrative" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20241231.xsd#cvm_PreFundedMember" xlink:label="loc_cvmPreFundedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmPreFundedMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvm_10qimg6.jpg
<TEXT>
begin 644 cvm_10qimg6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &D ;P# 2(  A$! Q$!_\0
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M,<T >I45XM\4/BI=Z1HGB6R\'V=\VIZ)+:PW>J?9D>TM)))(CY;;V!=C&_\
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M*^%OC;Q9I&C^ ]'U73+>ZT?7KF\L[?4I-3EN+TR(9I=TBNGW?D*@;V.,=.E
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MXUC3.U0%&3G@5-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.^L=)MM/N$0V%LY=CL20C]RH8D!25&%'''%+'X+\"^'-+@":1:V&G:5=?VE
M"[".UE"E=Z G"\,PP..3QS6(+K[3J*0Z?J%SJ>CQ:C8-!<RN9<2EG\U%D/+
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M?_BJ-EW_ ,]X_P#OT?\ XJK%(2 ,G@4 5MEW_P ]HO\ OT?_ (JC9=]YXO\
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M<HJO]E3_ )Z3?]_6_P :/LJ?\])O^_K?XT 6**K_ &5/^>DW_?UO\:/LJ?\
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M ,]4_P"^A1YT/_/5/^^A0!+147G0_P#/5/\ OH4>=#_SU3_OH4 2T5%YT/\
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M1?O4^X/XAZ5AT-"U147G0_\ /5/^^A1YT/\ SU3_ +Z% R6BHO.A_P">J?\
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M14M% $7DP_\ /)/^^11Y,/\ SR3_ +Y%2T4 1>3#_P \D_[Y%'DP_P#/)/\
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M%B?XTO5GTE'^''T*MW##]AN/W2?ZMOX1Z4Z&&'[-%^Z3[@_A'I2WG_'C<?\
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MS4]% $'VI?\ GE-_W[-'VI?^>4W_ '[-3T4 0?:E_P">4W_?LT?:E_YY3?\
M?LU/10!!]J7_ )Y3?]^S1]J7_GE-_P!^S4]% $'VI?\ GE-_W[-'VI?^>4W_
M '[-3T4 0?:E_P">4W_?LT?:E_YY3?\ ?LU/10!XG^T!,'\%Z8-D@_T\?>0C
M_EF]?-F:^EOVA/\ D2]-_P"O\?\ HMZ^:*^_R+_=EZL^7S#^,Q<T9I**]\\T
M7-&:2B@#F]</_$Q'_7,?UK+K3US_ )"0_P!P?UK,KPZ_\1GHT_A1]J_L]3JO
MP8TY?+E.+B<<(2/OFO6OM2_\\IO^_9KRO]GC_DBFF_\ 7Q/_ .C#7K8KX7$_
MQI>K/HZ/\./H4;NY7[#<?NIO]6W_ "S/I3X;E?LT7[J;[@_Y9GTJ2\_X\;C_
M *YM_*GP_P#'I%_N#^5<_0U$^U+_ ,\IO^_9H^U+_P \IO\ OV:GHH&0?:E_
MYY3?]^S1]J7_ )Y3?]^S4]% $'VI?^>4W_?LT?:E_P">4W_?LU/10!!]J7_G
ME-_W[- N5) \N49]8S4]% !1110 4444 </KHN;_ %MK74/!C:GIL,8:&<S0
MKF3=S@LX(X X]JW]#2==&A2XMH+5E+!(+?!2)-QV+QQD+@''&<UA^(]$75M6
M0>3:7EQ;0I-!;7:G9N$H).<$ ,!M)P2..,5L>'K"33="M[26*"%D+MY5O_JX
M@SE@BG R "!G SC- &[14*RQM(T:NK.OWE!Y'UI%DC9V175F3[P!R1]: )Z*
MA66)D+K(I4'!(/ -34 %%%5I)MK>7&OF2>G8>Y/:@!TDJ1+N<X[ =R?057$+
MSG=.,1]HO_BO7Z=*EAAVMYDC>9(?XNP]@.U6J "BBB@ HHHH **** "BBB@
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M]I,<[A,1UY!S[UWZ:9IL=P+F/3[9)P<B18E#9^N,U+';6T4TDT4$:22\NZJ
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M%_\ (C:7_P!?X_\ 1;U\PYK[O)/]W7JSYK,/XS'9HS3<T9KW3SAV:,TW-&:
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M!CB_N]&;Z^@]J %:5Y&*6^,#AI#T'T]34D421 A<DGEF/)8^]3*H50J@ #@
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MT5!]DA_V_P#OXW^-'V2'_;_[^-_C0!/14'V2'_;_ ._C?XT?9(?]O_OXW^-
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M0!XG^TE_R(&E?]A%?_14E?+%?47[2$\3^!M+"2HQ_M$<!@?^63U\MU]MD_\
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MHHH **** "BBB@ HHHH **** "BF,RHI9F"J.I/:JN99SP6CA]>C-]/0?K0
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M +Z7_&CSIO\ GTD_[Z7_ !H GHJ#SIO^?23_ +Z7_&CSIO\ GTD_[Z7_ !H
MGHJ#SIO^?23_ +Z7_&CSIO\ GTD_[Z7_ !H GJI>M>"!A:1AG(XR<5)YTW_/
MI)_WTO\ C1YTW_/I)_WTO^- 'BWQ ^'/B[QO;0P--!"(IO-&YLCH1_6O/?\
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M V>6/NG&1MV=NO-:R_:8]:OI+J#4IKI3FQ1&D6W:/RAA25^0$MN!W\YQCC%
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M#LR#CY"2=^0WS9]L5=T'[;'J=U!.+RY0J6:\N!-'EMW">7)\N<'[T?''0<4
M=C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvm_10qimg8.jpg
<TEXT>
begin 644 cvm_10qimg8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $% B\# 2(  A$! Q$!_\0
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M_"_;3TTW_O[+_P#$4?V=B/Y?Q0?6J7<]TS1FO"_^%^VGIIO_ ']E_P#B*/\
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M)M=<%D;:3M< @E3@\UUDOC#1+C7DU9HKZ(P:Y_:L4:QH=Z,L092=PVL/+.,
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M$4,NJS8B=)59 J.73[C,Z@,Y7L6)Q5?4M;U35Q$NH7?FI$69$6-(U#-]YMJ
M#<<#)QDXKHI? MS%IK,XO$O%LQ>EV@ M<>7YGE>9NSOVGKC&[Y?>I(? HNOL
M7EW%]:B6]@LYS>VRQ[?-!PZA7) !4Y5L'!!]JS]I26I7+-Z'$T5K6FG:??\
MB:VTNUU-DM)G"?:[B,1\XY(4M@9(PN2.HSCFK>I^'H[*RU&Z7^T+9K+[.#;W
M]N(I"92XZAB"!L!!'7/M6O/%.Q'*SGJ*ZBX\-:;8:=<W^H:M,D4)M55(;<.\
MC3V_G<98 !>03Z=LU:T_PHT'B4VTMY$0FI1V5L[P"1+G<ADWE2<%?+V-C_;
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M6!;6UCMPQ8(.6;JQZDGW)R:O5FZ2,:=&F3B-GC7/95<@#\@*TJ&,^2?VA/\
MDH__ &ZQ?^S5XY@;=HX'3BO8_P!H3_DHX_Z]8O\ V:O'G5XV9'1D=>"K#!!]
MP:^PP?\  AZ'@5_XC-^[\575TUM.-,T^WOK184@O84D$L0BQLVY<J/NCC;CD
M^M-G\474NU8--TVR3[0+N6.WM\+/*H.UG!)X7<Q"C"@D\4_5O"E[I[Z&MI(+
M_P#MFWBDA$:X*RN%)A/N-Z'/<,#4NI^#-2MO$E]H^E$:LMF(B]U%B.-C(BLN
M"Q Y)('.6QD"K3I$-2,UM=OI-)?3Y!')O4HUPP)E9#)YI4G.#E_FSC/OBK-A
MXHO-/2Q,=E8S7%@KQVUS/$6DCC<L60?, 1EWP2,C<<&J8T/6#9W%Y_9MPMO;
M.T4SLNT1NI *'/.[+#Y>O/3K1J&AZOI422ZC826Z,QCR2K;7 R4;!.UL?PG!
M]JUM!Z$^\M2\?%5^;41K9V*72VBV"7J0D3I $$>T'.,E1C=C=@D BB#Q5?V4
M2KIEG8Z<YECFE>VA(\]D!"[E)*XPS9  !R<U:A\&7TJ6+;F=K[2Y=1@2(*[,
MR%L1X!)YV@YP.OL:S6\,Z\NH?8'TYEG\D7'S2H$\LG ??NVXSQG/7CK4KV;T
M'[Y93Q7=P3VQM--TZTM+<RG[%%$PAE,J&-R^6+$E#M'S<#IBA/%E_':K"ECI
MXD%FVGFX,),K6Y4KY>2V  &P"!NP "3BH+?PKXCN[B:W@T><R03?9Y0V$$<F
M =A+$ $Y&.><\9JG:Z9>7>HR6"1I#/%O,OVB01+$%^\7+$!<4^6FPO(T&\3W
M<@59["PGC:UCM+A'B;%TB!1&9,-]Y=JX9=I'XFJ27\$FM1WMS9K%;@@-!8'[
M/M0#&$/.#CN<DGKG-7!X6U7[9/;RO9P+!"ERUQ+=HL#1N0$99,[6#$X&/0^A
MJ6+PRTVE2SQ7:SW2NT:) 5>)F#JH3?G[S;MRX&" 3GT+TUL%I,K:I?Z8^BV6
MBZ5%<FTMII;@R7FP.[N%! 5<A5 0=SDDGVJ>QU>/3_!&JZ7'/ON-3FB4P^7Q
M#$F2S!O5_E7 [ Y[5!I^CP:AXML]"BU!6CGG2 W2)E03]XJ,_, <X/&<9XS6
MEIWA>QU[RI-"U6=XQ/Y-PMU:A9(@8WD#*J,WF9$3C:"#D#US2;@E9^H+F;NC
M+EUZ>>U5)K&RDNTB2 7[0YG"+C:,D[<@  -MW8 &:OKXSU&.ZENK>PTZWGGN
MH[Z>2. YFG1BP<Y8XR6;*C ^8\5'9:1H.HZB(K/6+W[/';7%Q<>;9JLL8BC+
MX #E6W8(^\,=ZJ:GIEE!I5KJ^F7TMU93RR0-Y\(BDBD0*Q! 9@05=2"#Z@XK
M/]VW:P_>6IGVEQ]ENDG-O!<!<YBN$WHX(P01^/U%;0\5W7E-:MIFGOIQ@6W6
MP>-VB15D,BD'=NW;F8YW?Q$=.*FA\,VL8D_M74)K>2WT[^T;F&& .\(9T6./
MEE&XJX<], @=>DB>%K)[%];35+B31%M_/,B6F;C/F^44,>[:,-R6W;<$=SBG
M*5-[@E);&;JGB/4M8BFCO1!B:2&5S%$$RT41B3 ' &T]!Z"I%\4ZL)M$EW0E
MM%7;;9C^][O_ 'C@*N?15':I;?2-"FL]2U)M9O'T^T:!$>*S7S':7?P59P!M
MV$$ACG/%4-6TM=.:UFMKL7MC>Q>=;7 0H6 8JRLISM96!!&3V()!H7(W:PGS
M;CH]?U*+0[/1XI42WL[K[7"P7YPXY )[J#E@/5B>]:$?C*_M[GS[/3=-M6:\
M6_D$<#8EF <$MEB<$2."HP.>,5S=%;NG%]">9FI8:W+IS7Z06%D]K?JJ36LL
M9:/8'#A5^;<N"!@YSQUJS)XGO)Y9EN;*RGL98HX?L#1$01I'DQ[ &#*5+-\P
M;)W-DG)K"HHY([V#F9HW.KW-S:/:&&VA@:Z^UB."((J/L"  #HNT#CKGDDFK
MLWBF\NII9K_3]/OI#<2W,1N("WV=Y#N?:,X*D\[6W#/..N<&BGR1[!S,TTUR
M^CB@B41;8+*:P7*_\LI2Y?/O^\;![<4S5M5FUFXCN;JVMHYEB6)Y(4*F;:H4
M,^206P .,#VK/HHY$G<+LZ"?QAK=Q8S6<LL)BFLTLG_=\[5)^8'L[ E6;N"1
M4(\27IL);&:VM+B"2UAM-LL9.P1;O+<$$?.-[<]#GI6+12]G'L',S4NM=OKN
M76))O*W:NZR7.U<<J^\;?3FM.W\31V'A[1+2"QL[RYL);B;-W 7$,C.I1E((
MW<#)4Y7('%<Q10Z<7H"DT6'OKZ25IGO;AI&D,S-YAY<MNW?7/.?6M:[\4W=X
M"'T[3HA+.MS=B* J+V09PTHSR/F8[5VC))Q6#13<8OH%V;:^)KY=,%G]FM#.
MML;);XQ$W"P$$&,-G&,$KG&[:<9Q2S^)[^XT^2V>VLUGFA2VGOEB(N)X5QA&
M;.,8502 "0H!)K#HI>SCV#F9T4_B"RU9K>#5]*2TM8+7[(C:5N1U7.Y0P=B'
M4'/RG'WNO JEK>I6^H3V<=G%+':6-JEG#Y[ R.JECN;' )+' ' &!SBLJBA0
M2=T#DV%%%%6(**** "BBB@ HHHH **** "BBB@ KTCX(_P#)5;3_ *]IO_0:
M\WKTCX(_\E5M/^O:;_T&L<1_"EZ%0^)'VA1117PY](%%%% !1110 4444 %%
M%% !1110 4444 %%%% %'2O^0?\ ]M9?_1C5>JCI7_(/_P"VLO\ Z,:KU#W
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MDP-TFXA2<]]K'TX.:T]F^K_JX<Z['HM_I$=IJPBT#PO:ZJL^IR6]VCP&40*
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M;N@^LT^S/K#9]*-GTKY/_P"%YZ]_T%M5_P"^;;_XU1_PO/7O^@MJO_?-M_\
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M72]G),]O-/=6QB,#+"\JL5#-E&6-L'.1@Y'3+K7PI9:@UE/IVJSW5I=0W$@
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MZBNM6@NX/E)9D1Y/G / 95=2 <=,5#HNL:9X;^RPCQ =1D%[+>BYACD M_\
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MYD.5DB<HR_0CD47%S<WEP]S=W$MQ._WI)7+LWU)YJ*BBW4 HHHH *](^"/\
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MP^O/TS6%JWA_1-<N["XU738[V339Q<VHE)*QRC!#[<X)! ()!P1D<T 0>#-
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M<7#AE,G_ "P"1;7!!&22<G&*I5NZ)]GV/.(+2ZN8[B2VMY)DMH_.F*+D1ID
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M &A/^2CC_KUB_P#9J\=QD5]Q^(OAMX-\5ZK_ &IKFE/=7>P1[Q<RQ_*.@PK
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MS_\ Q='_  H_X9_]"_)_X&S_ /Q=']JT^S#ZE4[H^,**^S_^%'_#/_H7Y/\
MP-G_ /BZ/^%'_#/_ *%^3_P-G_\ BZ/[5I]F'U*IW1\845]G_P#"C_AG_P!"
M_)_X&S__ !='_"C_ (9_]"_)_P"!L_\ \71_:M/LP^I5.Z/C"BOL_P#X4?\
M#/\ Z%^3_P #9_\ XNC_ (4?\,_^A?D_\#9__BZ/[5I]F'U*IW1\845]G_\
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I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_10qimg7.jpg
<TEXT>
begin 644 cvm_10qimg7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %  C@# 2(  A$! Q$!_\0
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MK9*Q@W<*ECF9#ACE?Y5%10U<2;1?ZC(H%16[93'I4U8O0Z$[H****!A1110
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M:]J$!GL=?2YB!V[XDC89ZXR![BM_J%3:Z(^M1[,^@.*.*\'/CKQ5_P!!5O\
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MXO\ XFG_ &/B.Z%_;-#LSZZ"( %"C Z#'2N>U;P[8ZK>QWDLUS;S+ ]JQA<
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M.(M:Z-/]:,+>_*_N1]&?+G.T9]:/EQC:,>E?.G_"P/%W_08?_OU'_P#$T?\
M"P/%W_08?_OU'_\ $U/]D5^Z+_UGPO9_@?11\LXRJD Y''2C,?\ ='Y5\[?\
M+ \7?]!IO^_4?_Q-'_"P/%W_ $&F_P"_4?\ \31_9&([H/\ 6K"_RO[D?1 6
M,$L% )ZG')IV5_NU\Y_\+ \7_P#09;_OU'_\31_PL#Q?_P!!EO\ OU'_ /$T
M?V37[H7^LV%_E?X'T:Q4]A6-I&BVFD37\EK-+(U_<M=2^:0<.0 <8 P.!Q7A
MG_"P/%W_ $&'_P"_4?\ \31_PL#Q=_T%W_[]1_\ Q-/^R*^UT+_6?"WORO\
M ^B@R#HH!]J0&,9Q&O)R>*^=O^%@>,/^@T__ 'ZC_P#B:/\ A8'C#_H-/_WZ
MC_\ B:G^Q\1W17^M6%[/[D?0I\LCE5/.>G>G[ESG;7SO_P )]XP_Z#+?]^H_
M_B:/^$^\8?\ 09;_ +]1_P#Q-/\ LJOW1/\ K/ANS^Y'T=O6G^8M?-O_  L#
MQ=_T&&_[]1__ !-'_"?>+O\ H,M_WZC_ /B:7]D5NZ+_ -;,/_*_P/I'S!1Y
M@KYO_P"$^\8?]!A_^_4?_P 31_PGWB__ *"S_P#?J/\ ^)H_LBMW0?ZV8?\
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MQ6\<5E$/(6W5278\0R-(N?J6(-#E6[%<M/N9T.G:A<B,V]C/-YAVIL0G<><
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M_@,W^%'_  B?BK_H6]2_\!F_PKZNR?6C)]:/[5J?RH/[&I_S,^4?^$4\4_\
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MTX:1I:Z:VFBQB^Q-@& Y*C'(P.V,#&.F.*+H%<H7'BFPM%D:ZM[J+RF:.0;
M2D@B,IC.#][8,^G;-(GB>"2^BMDL+H9\[SMP ,7EQI)TSSE77H:OOHNDR>9Y
MEA$_F)L?=D[QMV\\\G:2,]<<9I3HVE-*)C81&0$G=SG)0(>_]P!?H!1H'O&=
M#XJL;B".1(+J$2^4,RQ@>69<^3N .<-CMTR,XIR^(8K7PM8ZQJ2D&>W66181
MG'R[F(!.2 ,GN:OIH^EHT3)81*8HUB0@'Y57.T?ADX],\4V;0](N+*WLI].A
MDMK92L,; D1@KM('MCBC0-3.N?%MC;/.'L-0987FC+K"NUC$"9"/FR0 ,^_:
MM73M1AU*&:2*.6(PRM"Z2KA@PP>Q/!!!_&HGT/1Y$9)-/B96:1B"3R9!ASU_
MB'!JW;VMM:^9]FA6+S6WOM_B; &3[X 'X4.P*_4FHHHJ2@HHHH V=%^Y/_O#
M^507?_'W+]?Z5/HOW)_]X?RJ"[_X^Y?K_2L%\;(K? B"BBBM3D"BBB@ )"J6
M8@ <DDX J*>.*ZM);>1OW<\;(=IP2",'!^AIM[&TVG7,*+O:2)T53W)4@"N<
MCL?$,,<$*.^R)0$=C&YCS!M(&<=)/T[XIQ5^IG*5NA8_X1.V%JT"W13?;O;.
MZPKE@VWYC_M (HJRN@A-0FO4OY$DF9RX$:[<,$! !Z$%%(/\ZI0VGB%-06YF
M+E72))A',,;0TF[:#T;YHS],C)J"!O$4EW/ +IY+JT6%G4.@B;,9+*1C.2<<
M] >>G%5KW,_=[%ZU\/1Z;<&^74)'D))D\U%VR@J@(.> 28U.?4FI[;18!X>N
M-+F$D:72.C@,"T:-G" _[(( ^E8UUIGB"]@;[2LKL5D15\U, &2-EW<X) 5L
M'V%:/E>(UE9!,Q19#Y,C,I)'FY^?U!CX]<C\:EW[B37\HL7ANUP9([H'S%C!
M>.)0&99/,W]3R2,'FJ]QX=GAM%6SNWG<&WC02(G[N..;>#VW$ GKUXJ*.#7M
M.T945A:QVL2L,;755 ;S 0.I^Z1C_&BUNM5F,"+=SK</-Y<T+LA$:-&#N1AG
M=L(_\>P>U5KW%[NUBXWABQ)FA6Z=1<,)I(\ DR L0X]!ECD=/UR'PQ;RPO&U
MZ[!B,L(USQ 8<?D<_45)J]CJ,VJV]SIS/$RVTD0F5E&QBZ$;@>2N%.<5##!X
M@1RF?+3S=R$%,;?.8ON ZYC*XQWZ\TE=J]RK*]K&DUC<2:=+:2W[*6*[)(T"
ME%7'&.^<'/\ O'%9L7A:TMX#&;Q_+4QL"45=H0N>OT<C/TJ*"#Q/%Y4KRS3,
MJQEHY)8\,=KB09 ]?+Q^/O0MIXAN(S'>/,(F2?<@>,[\HOEJW7C.\?EFC5=0
M;3Z&AI^C)9P3H;U[I+B!(,LJC"JI52,=>#5-_"=O-:FWGO975B,LJ*AQY/DX
MR/;GZU!IUMXFBBL;6[/DQ0Q*CO 4;D;<  GA=H*GKSD\Y%6K&#Q#'/9/=7#R
MH2WVE)67Y>6QM*]>-O!'?J.:>JUN&CZ#E\,6Z,T@N-KNL8)6%1EDD\S=]21@
MUO=:Y^XM=936;R:V>7[-.5^[(H(Q$0-H/3#XSZCUYI]@OB**2%]0*S,N\3+&
M5"29V["G<$?-G/O[4FF]6RHM)V2-VBBBI-@HHHH <G^L7ZBNC[5SB?ZQ?J*Z
M+M6%7='7A]F+1116!UA1110 4444 -Y]*6LS5=7L=%LOMFH3^3!N";MI;D].
ME8W_  L'PK_T$_\ R$_^%4J<Y*\5<ASC%V;.LHKE/^%@>%?^@E_Y"?\ PH_X
M6!X5_P"@E_Y"?_"K]A4_E8O:P[G5T5RO_"P?"O\ T$__ ""_^%)_PL#PK_T$
MO_(3_P"%'L*G\K#VL.YU=%<I_P + \*_]!+_ ,A/_A2_\+!\*_\ 03_\@O\
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MO^@X/^_$G_Q-+ZM6_E?W!]:I?S+[SL:*X[_A:'@;_H.#_OQ)_P#$T?\ "T/
MW_0<'_?B3_XFCZM6_E?W!]:I?S+[SL:*X[_A:'@;_H.#_OQ)_P#$T'XG^!O^
M@V/^_$G_ ,31]6K?RO[@^M4/YU]YV-%<;_PM#P-_T&__ "!)_P#$T?\ "T/
MW_0;_P#($G_Q-/ZM6_E?W!]:H?SK[SLJ*XW_ (6AX&_Z#?\ Y D_^)H_X6AX
M&_Z#?_D"3_XFCZM6_E?W!]:H?SK[SLJ*XW_A:'@;_H-_^0)/_B:/^%H>!O\
MH-_^0)/_ (FCZM6_E?W!]:H?SK[SLJ*XW_A:'@;_ *#?_D"3_P")I?\ A9_@
M;_H-#_OQ)_\ $T?5JW\K^X/K5#^=?>=C17'?\+0\#?\ 0<'_ 'XD_P#B:/\
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MJ%1,< ;^>N0!SWQ6'XS_ -59?[S_ ,A7;A;\ZN>9C/X<K')4445[!\X%%%%
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MF5)12KP=I1_'R/2PMJZE1J*\9?AYG-,KH[(ZE74D,I&"".H- &:Z[X@G3/\
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M^@CJO_?Q/_B:/[7PZ[_<']E8CR^\^<**^C_^%#>$_P#H(ZK_ -_$_P#B:/\
MA0WA/_H(ZK_W\3_XFJ_MC#^?W!_96([(^<**^C_^%#>%?^@AJO\ W\3_ .)H
M_P"%#>$_^@AJO_?Q/_B:7]L4//[A?V77[(^<**^D5^ GA)CM_M+5?^_J?_$5
M)_PH'PC_ -!'5?\ OZG_ ,14O.:"[_<4LIK/HOO/G;2M+OM;UBUTC38C+=W3
MB.->WN3Z #))]!7TAJ']F_#/X?6^C:80][("JN1S+*1\\K?3_ 5K>#_AGX=\
M%ZC-J.GM<7%S+'Y8DN75C&O4[< 8SQGZ5+K_ ,/=/\0ZJ;^^O[T-M"(B.H5
M.P&WUYKR,1F%/$5HJ5^1?BSL_L^M1P\_9I<\M/1'@+L[NTDC%W8EF9CDDGDD
MTF[VKVW_ (5'H7_/Y??]]I_\32?\*CT+_G\OO^^T_P#B:]6.:X>*LK_<?(5.
M'<5-W:7WGB?X4?A7M?\ PJ+0O^?V^_[[3_XFC_A46A?\_M]_WVG_ ,36O]LT
M//[CC_U6Q79?>>*?A1^%>U_\*BT+_G]OO^^T_P#B:/\ A46A?\_M]_WVG_Q-
M/^VJ'G]P?ZK8KLOO/%/PH_"O;/\ A4>A_P#/[?\ _?:?_$T?\*CT/_G]O_\
MOM/_ (FE_;5'S^XO_5?$]E]YXG^%'X5[7_PJ71/^?Z^_[[3_ .)H_P"%2Z)_
MS_7W_?:?_$T_[9H>?W$?ZKXGLOO/%/PH_"O:_P#A4NB?\_U]_P!]I_\ $T?\
M*ET3_G^OO^^T_P#B:/[9H>?W!_JOB>R^\\4_"C\*]K_X5%H7_/\ 7W_?:?\
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MFO0+&QMM.LHK*TC$4$*A$4=@*\S'9K&K3]G3Z[GT&3\.U:%=5JUK1V6^IH
M"EHHKYL_10HHHH **** "BBB@ HHHH *,4@JG=7MI91B2\N8K>,G:&E<*"?3
MF@3=B[15*.^LY889H[J%XYN(W5P0_P!#WJO/JMA;!S<W\$ 1_+;?(%PV V.>
M^"#CT-.S%S(U/PI:H+?V3^1MO(&\\9BQ(#Y@]5]?PIYN;?[2(#/&)V7<(]PW
M$>N.N*+,.9%RFYYJBVH62QO*U[ L:-L9C( %;T)SU]JX+Q)9:O=>*Y4LKL?:
MI5A-A.+L(++!S(6AW#S,@$]#D<' &:<8<SLW8B=3E5TKGI5'S5S7]E^,/^AJ
MM?\ P6C_ ..4W^RO&7_0UVO_ (+!_P#'*7*OYE^(N=_RLZC)]:,GUKE_[+\8
M_P#0V6O_ (+!_P#'*/[+\8_]#9:_^"P?_'*.5?S+\1\[_E9U&3ZT9/K7+_V7
MXQ_Z&RU_\%@_^.4?V7XQ_P"ALM?_  6#_P".4<J_F7XASO\ E9U&3ZT9/K7+
M_P!E^,?^ALM?_!8/_CE']E^,?^ALM?\ P6#_ ..4<J_F7XASO^5G49/K1D^M
M<O\ V7XQ_P"ALM?_  6#_P".4?V7XQ_Z&RU_\%@_^.4<J_F7XASO^5G49/K2
M5S']E^,?^ALM?_!8/_CE']E^,?\ H;+7_P %@_\ CE'*OYE^(<[_ )6=1D^M
M&3ZUR_\ 9?C'_H;+7_P6#_XY1_9?C'_H;+7_ ,%@_P#CE'*OYE^(<[_E9TDX
M)C)';FJM8QTKQ@?^9JM?_!:/_CE0/I?BY6VGQ5:_^"L?_'*UBEM=?C_D93D]
M^5G045SW]F>+?^AJM?\ P6#_ ..4?V9XM_Z&JU_\%@_^.55EW_,CG_NO^OF=
M#17/?V9XM_Z&JU_\%@_^.4?V9XM_Z&JU_P#!8/\ XY19=_S#G_NO^OF=#17/
M?V9XM_Z&JU_\%@_^.4?V9XM_Z&JU_P#!8/\ XY19=_S#G?\ *_Z^9T-%<1JT
MGB32(()+CQ/!))<S+;0PQZ8NZ61NBC,F!P"22<  UE3Z_P"(K8WT4VKRB\L
MK3VL6DI(XC92PD!$N"N%;G/48QFA0OL_S(=9)V:/4X!R6_"I?^!5YGJ.KZYI
M>B6VLMXD:XL+B(3^=!HX81Q$ [W'F# PP]_;BEDUW6H]3EL4\4K-,AE1?*TD
M,)9(U5GC7][DL PZX'7G@UG[-O6_YFRK*.C7Y'I>6_N4O6O'[C4-4U@Z<]]=
MS:K#)-/;-I<8_LZ9)TX+,1(0P4@C[V,L",G KL-,TOQ8FE6L5UXB@:=(E60M
M:[SG'.6W#=]<#/6AT[*[8E7;?NQ;^X[#Y?6CY?6L#^SO$_\ T,=O_P" (_\
MBZ/[.\3_ /0QV_\ X C_ .+J.7^\OQ+YW_(_P_S-_P"7UH^7UK _L_Q1_P!#
M'!_X C_XNC^SO$__ $,=O_X C_XNCE_O+\0YW_(_P_S-_BCBL'^SO%'_ $,-
MO_X _P#V=']G>*/^ABM__ '_ .SI\B_F7XASR_D?X?YFY16%_9WBC_H8K?\
M\ 1_\71_9_BC_H8X/_ $?_%T<J_F7XA>7\K_  _S-[BCY:P?[.\4?]#%;_\
M@"/_ (NC^SO%'_0Q6_\ X C_ .+HY?[R_$.9_P C_#_,W>*.*P?[.\3_ /0Q
MP?\ @"/_ (NE_L_Q-_T,=O\ ^ (_^+HM_>7XAS?W7^!O?+1Q6!_9OB?_ *&.
M#_P!'_Q=']F^*/\ H8K?_P  1_\ %T<J_F7XBYW_ "/\#H<BC(KG?[/\4?\
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M7*AX%$JDRJ1D%1GD$ ]/2ARD^@XPBNIL4445D=(4444 %%%% !1110 4444
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M5WGAR\N-0\*Z1?W;![BYLX9I& P"S("3CMR:4I2:U*A&$7[IMT445!L%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 45BZSK%GH6EOJ%ZS",,J*J
M+N>1V(554=R20!4$6K#]Z^IV<FF(BJ1)<R1[#DD8W!B,\<CZ=:?*[7)<DG8Z
M#ZTE9IU;30Z1'4;822;=BF9<MN^[@9YSV]:I:IXEL-,GMH,BXFFNHK5XXG4M
M"9#A6<9R!1RMZ(3G%*]S?S1FLV/5-.<92_MV 4OD2J?E!P3UZ \9J!-<LY+V
M2(/&;=+<7!NA,ACQN(QUSQC.<8]Z.5AS+N;7%+BLAM:TE425M3M5CD!*,9U
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MU6T,4L:B-8/+S;.#M!'S<!O?!KM_A[;7-E\-O#MI>0W,%S!8Q12Q7:XDC=5
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M"J-*06QDGG 'K2=K:#5[ZFO1114EA1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:IW"BBB@84444 %%%% !1110 4444 )VKA=3\+:AJ"7JFZC<S/*Z-(S9=74
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MF?/=D ?"\8*'IG((QS76Z5>7%_I\5S=:?)83,6#02]5PQ&?H<9'0X(R!6&?
MFDFV^S&>Z, B$/E_N\! VX+C9P W(]#S70V%E'I]A%90O(\<0P&D(+'G/. *
M;MT$K]2S1112&%%%% !1110 H)!R#@BK44F]?]H=:J4Y'V.&[=Z35RXRL7J*
M!R**R-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*C:W]T_E0!8@;*8/4<5-5: ,KG((!%6:R>YO'8****104444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_10qimg1.jpg
<TEXT>
begin 644 cvm_10qimg1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %V 9L# 2(  A$! Q$!_\0
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M2P%E%X;LHH1<O>!(TVXF<8>0$<AF'!/?O61/_;4VFJEJNM0DV1642LWFK/\
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M=P"5<B.9#E''^T#R#7$2VVN-;23VD&HL5L=1%BTN[SU0R0&)2S<ACM;:&.[
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MDJ@$F-N_&1MR.>U9YMO$DNFW=W>2:FNIVVGV3QI#*P0W #&3"J=KDG 88(H
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M*I** (_*C_YYK^5'E1_\\U_*I** (_*C_P">:_E1Y4?_ #S7\JDHH C\J/\
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M4 %%%% "  = *6BB@ HHHH **** "BBB@ HJH9R6*Q1F7'4@@ 'TS4GFS_\
M/J?^^Q0!/14'FS_\^I_[[%'FS_\ /J?^^Q0!/14'FS_\^I_[[%'FS_\ /J?^
M^Q0!/14'FS_\^I_[[%'FS_\ /J?^^Q0!/14'FS_\^I_[[%'FS_\ /J?^^Q0!
M/14'FS_\^I_[[%'FS_\ /J?^^Q0!/14'FS_\^I_[[%'FS_\ /J?^^Q0!/14'
MFS_\^I_[[%'FS_\ /J?^^Q0!/14'FS_\^I_[[%'FS_\ /J?^^Q0!/14'FS_\
M^I_[[%'FS_\ /L?^^Q0!*>G%>1?$/XU:-X-D;3-.1-5UA2 \2OB.#_?8=_\
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M&8@$@?0$9]^.QK3KCX_#MW!KMG=1RQ-%#L9YBS"7(#[U"CC#L^X\_@<#'84
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M_)*?"O\ V"K;_P!%+7SV;_#$]K _$SK*JWG^H3_KK'_Z&*M55O/]2G_76/\
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M5\-?^24>%?\ L%6W_HI:^)S;X8GOX+XF=;56\_U"?]=8_P#T,5:JK>?ZE/\
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MFJT79$0%LX[=:CUG15BCFU*P,"V2^6P@60M+'&X_=NX/][&>#QF@#S_QA_R
MD_Z[+_(UP-=[XP_Y 2?]=E_D:X*@#Z&_9]FA30-:#RHI^T1\%@/X37M/VFV_
MY^(_^^A7C/[/8!T#6L@'_2(__037M>U?[H_*@"+[3;?\_$?_ 'T*/M-M_P _
M$?\ WT*EVK_='Y4;5_NC\J (OM-M_P _$?\ WT*!<0%@JS(2>P85+M7^Z/RH
MVK_='Y4 +1110 4444 <-J5S=V6M:I<V-YJ"6JLKWCP6T#Q6["-<D[B'8[ I
M. <#%=NI!4$'((Z^M<#K<L+ZEJMRUC&UM9A3=QMJ$D)N@$#$^4ORL-I &[[V
M"#P*[R.1)8U>-@RGH0: )**HM=6T=L]P]Q$L$>=TC. JX.#D]!@U&=1T]+:*
MY:_MU@F(6.0R+M<GH <X/X4 :5%5A)&]PT:NI=0"RYY&>F1^!JS0 4TD*"20
M .I-122K$ 7SD\!1R2?:HQ$\C![CH.5C'0?7U- #=[SYV$QQ?W^A;Z>@]ZM(
MB1H$10JCL*?10 4444 )256EFCMX7EF=8XT!9F8X  [DUYO<?'7X<VUU+;G5
M)9#&Q0O';NRMCN#CD>]53I5*GP1;,Y5(P^)V/4:K/_R$H/\ KE)_-*\S_P"%
M_?#C_H)77_@*]-/QX^&AE28ZE<[E4J/]%?H<9[>PK?ZK6_D?W$>WI?S(]6S[
MT9]Z\L_X7Y\./^@E<_\ @*]'_"_OAQ_T$KG_ ,!7H^JU_P"1_<'UBG_,CU2E
M[5Q7A#XB^&/&]Q>6^@74D[V:JTH>(IM#$@=?H:[45SSA*#Y9*S-8R4E=%2S^
M]<?]=F_I5RJ=G]ZX_P"NS?TJY0QH****0PHHHH **** $[U')_JC]*D'6HY/
M]4?I3CN1/8^"-2/_ !-KO_KLW\S53-6=2_Y"UW_UV?\ F:J9K]&P3_=(^/J_
M$QV:,TW-&:].YF.S7I?@GGPSQ_SV?^E>99KTOP'=6<&G:>NH$K9/?;9V&>$R
M-QX]J\'.W_L_S1Z67_Q?D=7IFJ:YI5O<V5K+9_9+@YD5[6-V?G(W,1DX[9Z4
MZRU?Q!:Q"W6[MTC6(P+(EM&)A&?X?,QNQ^-;MR;:349XM0AT1=D4LEA#87*1
MBXPRA5=P>/E)(S@D@TUXO"/VY[6"9)DDFNHTN/M0'EB.(.AQT(+94'OBO@SZ
M4Y6&"2S>Z:Q98/M,#6TC!06V-]X ]LXQQVJ_'JFLMI*:9>7BR6T811B-59E0
M80,P&6 SQGI6Q?W6@MIDNI+8VV(M*MYXEBNL>;,2H=2H.<KDYXR:OV*>&+?6
M=.D@N[=T:8+&\EPL@N8S 69V4_<VO@8.* /,?&'_ " D_P"NR_R-<%FN[\7G
M_B1)_P!=E_D:X$F@#Z-_9[.?#^M?]?$?_H)KVNO$OV>#GP_K?_7Q'_Z":]MH
M **** "BBB@ HHHH **** //]>LKBZU.]\O0+:6:/,ZW#V*3><BQKMBW,.6:
M0D>H4=L@UUT5K8V6G-#':Q6MJJL6BC0*H!Y;A?QKB-:B6;4;[4H+[3)K9@]M
M+=-=$R6NZ,1^4$4')W#<%!!+''7FO1D^XO)/'4]: //=/^SGPA8I;V\AL['5
M6DGA$#C;%Y[LIVD9(&4;IT&:<-'&IZ9J-\LC6EHUQ=-$KVY?=!(BJY5#@ABR
MLRGWZ'->AT4 <'97FKVFOP0-;D&\>.2:-H68E61LGS!P/+"HN._)_B%=Y110
M!6CAV,78EY#U8_R'H*LT44 %%%% #%K \1>)M$\*:1)JNN7J6UNO SRSG^ZH
MZD^U;^?6OG3]H10VN:*& 8"!\ \_Q5U82@L16C3;LF<V)K.C3<TCSKXC_%[6
M?'$SV%H7TW1%/RVRM\TWH9".O^[T'OUKS+(]:[/3M&U#6+EK;2M+FOIE7<R0
M0[RH]3CI4%U836-Y)9WMDUM<Q':\4L>UE/N#7V5&E0HKV<6E;H?-5*\ZCYY(
MY/(]:,CUKO;[PIK^F637VH^'[JTM5P#++!M49.!S[DBHI_#FL6M[:V5SHEU!
M<W?^HBDMRK3?[HQS78IT'M-&+E);Q.'R/455EN/X8_\ OJNBUF-4TN8>6JLK
M '@<<URE%9.+Y4:TO>5SZ0_97_Y"GB;_ *XV_P#Z$]?4"]*^7_V5_P#D*>)O
M^N-O_P"A/7U OW:^'S'_ 'F7R_(^EPO\)%>S^]<_]=F_I5NJ=G]ZY_Z[-_2K
ME<#.E!1112&%%%% !1110 E,D^X:?3)/NFFMR);'P'J7_(6N_P#KL_\ ,U4J
MSJ9_XF]Y_P!=G_F:J9K]%P3_ '2/D:OQ,=13<T9KT;F8ZO1?!\<<WAC9( 1Y
M[_TKSC->C>#&_P"*<'_79_Z5X6=?P/FCT<!_&^1O&QM" #&#BG?8[7_GFM/W
M4;J^%/I!@L[90<1CGBB.TMHVW)&H/K3]U&Z@#%\7M_Q(UY_Y;+_(UP)-=QXM
M;_B1K_UV7^1KA": /I#]G<Y\/:W_ -?,?_H)KV^O#_V=/^1>US_KYC_]!->X
M4 %%%% !1110 4444 %1NI>-E!VE@1GTJ2B@#@K3PIK=I>:?<K<Z0[V-L+:,
MFQ<>GS_ZS[V 1_P(^IKO1G'/6BB@ HHHH **** "BBB@ HIKND:%W8*HZDU4
M"27'WP8XO[O1F^OH/:@ ,VXD0Q^9C@MG ^F>]?/W[0#2MKNB^9&%_P!'?HV?
MXJ^B<!5"J  .@%?/_P =K&YU'Q=X;TVQC$EW=1M%$A8+N8MP,G@5Z&734<1&
M4MM?R//QZ;I-+R_,\\\ ZI8V^F^*K"[N[":>\B@6+3-1NOLD-R%?+-Y_5649
MP 1G-2?$)-/\0>(];UO2_$=@\5FML/+DFRTA.%*0D#]XJ8Y;Z]:YS4?!^N6%
MHE_J&CRQQ/+-"#C<=T1Q(2!R%&#\W3WJ2V\%:]?6?VJVTF20?OLQ8Q*HB56?
M*'GHZX'4YXKV)TZ;J2J*HO>_X%SR.:3@HN.QV/BO5+"_TK4?$&J-H0\31W5N
MVG-HVH-<K<HA7/FIG"J% ZA3[>K[3X@:+?6JZIJ5J-),NHM"$%X9YHVN2OVJ
MX' ,:+&"JC'5SSQ7$OX4U2STPZA':B6#>L;"$,S@F+S<E< X"<D]!5>\\/:C
M:FY,FGS2PVYQ+<1PN8EX!Y8J,8R.N*TC@J,H)>TU7GMY$NI-2ORFE\4+3P[:
MZ;:_V ;".9O,^T1:==&XA5!+B%MQ)PS)R1G\J\GS77:]975AI+1W-G-:;PK(
MLL93<,]1D<BN.)KTU3]DHQYN;3<4'S7=K'T;^RVTBZKXG\N,,/)M\DMC'S/7
MU!YES_S[+_W\_P#K5\P_LJ'.J^*/^N-O_P"A/7U*OW17Q^8?[Q+Y?D?087^$
MC/LY+G=<?Z.O^N;_ ):?3VJWYEU_S[+_ -_/_K5'9_>N?^NS?TJW7"SI1!YE
MU_S[+_W\_P#K4>9=?\^R_P#?S_ZU3T4AD'F77_/LO_?S_P"M1YEU_P ^R_\
M?S_ZU3T4 0>9=?\ /LO_ '\_^M1YEU_S[+_W\_\ K5/10!7\RY_Y]U_[^?\
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M4.ZC=7Q!]"3;J-U0[J-U &/XK;_B2K_UV7^1KB":[+Q4W_$F7_KLO\C7$DT
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MU%PL5M6;_B5R_5?YUS!-='JK?\2R3ZC^=<P37EXM^^=M#X3Z8_9/.=6\5_\
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M96Z;9GYQ"4P4. 00QX(/M5F'Q*9+/2+C[&%_M*R>\(\S_5[45MO3G[V,\=*
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M22?I70:?IUMIEDEI80B"!26V@DDDG)))Y)))))Y-:U% !1110 4444 %%%%
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_10qimg2.jpg
<TEXT>
begin 644 cvm_10qimg2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %% 9(# 2(  A$! Q$!_\0
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M9=7(*S36EG'$\@))()4 D9)I-#\#^"_#-V]WX=\)Z3I%Q(NQI;*SCA8KZ94
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M/V>W_P">$?\ WR*/L]O_ ,\(_P#OD5-10!#]GM_^>$?_ 'R*/L]O_P \(_\
MOD5-10!#]GM_^>$?_?(H^SV__/"/_OD5-10!"((5(98D4CN%%3444 %%%% !
M1110 4444 %%%% !1110 4454>5F8QP@%APS'HO^)]J )I)5CP,%G/11U-11
MQ,S"24Y8=%'1?\3[U-'$L8)Y9CU8]34E !12$@#).!5;<\_$1*1=W[M]/\:
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MFC"_]!.3\T_^)J_11<+%#"_]!.3\T_\ B:,+_P!!.3\T_P#B:OT47"Q0PO\
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M_A0!/14'VA?[DO\ W[;_  H^T+_<E_[]M_A0!/14'VA?[DO_ '[;_"C[0O\
M<E_[]M_A0!/14'VA?[DO_?MO\*/M"_W)?^_;?X4 3T5 LZDA0L@)]4(_I4]
M!1110 4444 %%%4+TWOV?-D]NC@Y8W )7;^!H OT5P[^)=133K"ZECM(8[L2
MN;ADE:(1J1Y;<#*[E.[D\"K<GB9K;6(;28VI@\M&D=7.Y@8V<R(.Z#;C/O[<
M@'6T5BZ9J4>H0G$D/VJ/F:".0,T).<*WH>Q]P:UW8(A8YP/09H ?5;>TQQ$=
MJ=W]?I_C1L:;F4;8^T?K]?\ "K/04 01HD8VJ,=SZGW-3T5%),L>%Y9ST4=3
M0 ]W5%+.0JCN:JD23_>!CB_N]&;Z^@IRQ,Q$DQ#..BCHOT]_>K5 #5 4!5
M'0#M2T5GWU_9Z78RWU_=16MK"I>265@JJ/4DT)7=D)NQ>Z"O%OB9\;=/\*M)
MI'AUHM2UD95WSNBMC_M8^\WL.G?TKSWXE_'*\UHRZ/X/EDLM-.5DO>5EF'^S
MW1?U/MTKPTGN:^@P.5.5JE7[O\SR<3CK>[3^\[1_BI\0GD9V\6Z@"QR=LF!^
M0X%-_P"%I?$/_H;M2_[_ !KC:*]_ZE1_D7W'E^VJ?S,['_A:/Q!_Z&W4O^_Q
MI/\ A:/Q"_Z&[4O^_P :X^BJ^I4?Y%]P>VJ?S,[+_A:7Q#_Z&[4O^_QI/^%H
M?$/_ *&[4O\ O\:XZF22K&,MU["D\'07V%]P>UJ/[3.T/Q3^(*@EO%VH@?\
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M_P \X_\ OX?\*!$5A_QZ_P#;23_T,U;-9]@US]D'[F/[\G_+0_WS[5:S<_\
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M8.0#N**YG0=5:[_T*43--%'YGGR$$3C>REA@_*-RG /;'X=&Y8*2BAF[ G%
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MX+[B>XN+BZF>:XF>::0Y=W/)J//O3,T9KGDW)W>YU1BHI1CHD4==/_$@O/\
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M(_L[P_S_ ,MIOY)7NHM8?XT$C=V<9)KP?]H^**/3/#Y2-5/G3<@8[)7=E_\
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MFI:*@DD6-=S''8#N3Z"@"8D 9)P*K;GG^6(E(^\G<_3_ !I-CS'=-\J=H_\
M'U^E6Z (TC2,;44 5X#^TO@:;X=X_P"6TW\DKZ [U\_?M+?\@OP__P!=IO\
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M=7XX?K-R3-&:CW4;JD+DF:,U'NHW4!<2X/[D?[Z?^A"NA+\US5PW[G_@:?\
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MN:7=0!/OHWU!NHW4 <[XK;]_:?[C?SKF2U='XECEN+VRA@C>65U*JB#)8D\
M 5ZU\./@@\TD>J>*H0YX9+(\JOO)Z_[OY^E '#?#WX7ZSXLO(;Z=9+'3%8,)
M2OSR_P"X#_,\?6OL33[6>WB!N+AY7]"<XI]CI]O80+'!&JX&.!BKE !1110
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvm_10qimg3.jpg
<TEXT>
begin 644 cvm_10qimg3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %S B(# 2(  A$! Q$!_\0
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MQF1<;@&Z$ G&1QD&@#H**86 7<2-N,Y[5PNC_%#PAKGBZZ\+Z?=7":C;P&Y
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M64ZKJR22VL20LRLD8R[%\;0!]>X]:VI[JWMH)9Y[B***)2TCNX4(!U))Z 4
M7:*XNW\?:9?WGAL:19WVKV'B!YU@U&SAWV\(B!RTC9^56((4XYKL0Z,Q56!*
M]0#TH ?14896QM8'(SP>U*SH@!=@H/J<4 /HKGYO$.BVWB6R\-2ZA"=4O4>:
M&U5LR&-1EG('1>0,GJ363XP^(>B>";W2;35[;4)9=6G%K9_9+5IA+,>D?'1C
M0!VU%>>77Q.L[73=3N4\+^)9[C36MA+9C3F65Q/)L5DR<,!R3@\ 5WP=3CD
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MGOIUG,H3[00'FB!PJF*/8"!AN#P37T;10!\DQ^%O%]]\-O#?@^ST%;2_O_$
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M@^*RT539R)'/.X#2W"@C9Y@55!4?,S8R"<U1O/#WB73O#GBKQ'X<TG6'M_\
MA&8=!MY!%,EYK&H2R RWC+@2?NV=OG8#[IQ\M?6]% 'SU\*O"=YX;^,.JVEQ
M;:CY6D:#8Z1#=212""Z8#S)75C\@4,0@5?3ZFN;^-D?BC7/&/BO3Y_#6L:G:
MV]A9V&AQVUI+)%FXD4W5R"HQO508^N0#V!-?5-% 'A?@;0()?VA?&&M7OAB:
MT_L^TLM.TJ6>RP!&D/SR"4C!8D[,J2<+CH*J>,H'\;?M$^%]&>'7+/2-!M+F
M<:A:VLT2?;FPJHLQ3;D("<].V:]_HH \)\9>'Y[?Q+\*_"26^K:AING7C7=Y
M?!)9?,\I/D64K\I9Y""2_H2#6'IW@KQ+HTOC:ZMO#U_*NAZ[=Z]X>:6=F-W,
MUL46-026==S$DMUV@#/-?25% 'AWP7\+^7+#XVU:?4KOQ#<:7':W<]U9O:!7
M9A)*KK(=\DN_&7/R@ *@ R*K?&PS:OXR\ :-IEOJL5U9ZTMY=:G9V,SK8P>6
M5/[Q4*@MN&.N"O.*]ZHH ^=_B!HFJZW\18_ 5Q:7]CX+AT54LX[33VN$NIW?
M:X$G^KCE51A6ER%RSXS@UQWB?1M8U+QM<Z/>^%=;OH;;7M-TC3E6VE>.STJ!
M5D=UD(VGS6&UFS_#R>!7US10!\[:3X*&L^*O''Q$\1:9KJB'6732;*T,J3LL
M<?D>>$8C=]]V3L 6(ZUT7P-T*\T;PWJ45]88:VNOL5KJ?V=[9M3MH^4F>)@"
M'R[JS$9;8#S@&O9Z* "BBB@!**** %HHHH **** "BBB@ HHHH *\LUB^U"T
M^*@NC''<^4MO!8VDD+L720_O9(V'RJP[D]E]Z]3I,#(..10!XQ9:;8WUU9Z?
M<Q2P7=HE\^MSK&0V"^Y"S$8?+!6 YX%;7A&Y?3O$G]E2:9<>9<1EDFE/S0Q8
M+@;0, $DY(_B.,<5Z;@<\#GK1@9SCGUH 6BBB@ HHHH **** "BBB@ HHHH
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M&,\@>XH4D]A-6U9N?A1^%<K_ ,)]X4\E9?[4X+;<>4^?RQTIW_"=>%?->/\
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M **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH **** "BBB@ HHHH ****
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MC&AV ]+>/_T$5<267:***H04444 %%%% !1110 4444 %%%% !1110 4444
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M$EWM:S>0,H"G!W.3P1L.[Y>^!U- 'H-% Z44 %%%% "&N5U;_D<++_KSD_\
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MP],OK+"/_(JUZ?5(3"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M  @#Y<$^Y-=%\1M0(TFU\/Q/MEU63;(0>5@3#2'\>%_X%5;P<,ZXX50!Y+
M=NE)O4H99:1X+U%;@V>N7DPMQF3%[*-HSC/)Y&01D5IS>#= MY8(YM0U!'G;
M9&#?2_.V"<#YO0&L"P\*>(-)TYFMUFGN;RQ,!WRC=:.LF\*I_N,">.Q'O5FZ
MT7Q?/<SBS:1'COFG@N;J0,5!C<$  X Y !'KR.*9)O?\(#H__/UJ7_@;+_\
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MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%% !1110
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M0C7N% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%%
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MHM>WT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E%%% "T444
M%%%% !1110 4444 %%%% !1110 4444 %8^NZC_9NEO*A F?Y(_KZ_A6Q7G?
MB;4?MFJ&!&S%;_*,=SW- $'_  DNL?\ /TWZ4?\ "2ZQ_P _3?I6/10!L?\
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M-1_PA/C/_H4M8_\  1J/KM#^=?>'U#$?R/[F8/-)\U;_ /PA/C/_ *%+6/\
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M 4444 %%%% !1110 4444 %&*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** $HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@!**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvm_10qimg4.jpg
<TEXT>
begin 644 cvm_10qimg4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %F FX# 2(  A$! Q$!_\0
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M=K';%&Q&"."/EKV3 HHY^R#D[L\C.GWW_"4ZIX%TV&ZM=*NFANY;E2VV*WV
M/&C'^)F4#V!)J*]DOK30M2\51PWDBVNN1RQ6T08L;>+$6U5[Y&?YU[#Q11S^
M0O9^9XQKRWUIID":VIBN?$<QN+J>59I8[54 ,5N%B.2<'&,@$YZTSPC9W\^G
M^&--N//>";5+C40)(W01PQ9$8VMDJ"V#M)KVKBBCVFEK![/6]S@OB'ID.O\
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MBN_Q2TG-M6*C32=SA=/E2;Q[XGU&[4E],@AMX01DK&4,C$#_ &C_ "KDM/\
M#[G_ (1/6%COAK6J:FUY/,TTG[J'YG9-I. I7:,8KU---LXM8EU98=MW-&L,
MC@GYE!R,CIQD\UI4<UMBN2^YYEKECXJDUR[>SMO$3V[/\AMM5MXHR,?PJRY
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M '__ ($M0!J45E_V)%_S_P!__P"!+4?V)%_S_P!__P"!+4 :E%9?]B1?\_\
M?_\ @2U']B1?\_\ ?_\ @2U &I167_8D7_/_ '__ ($M1_8D7_/_ '__ ($M
M0!J45E_V)%_S_P!__P"!+4?V)%_S_P!__P"!+4 :E%9?]B1?\_\ ?_\ @2U'
M]B1?\_\ ?_\ @2U &I167_8D7_/_ '__ ($M1_8D7_/_ '__ ($M0!J45E_V
M)%_S_P!__P"!+4?V)%_S_P!__P"!+4 :E%9?]B1?\_\ ?_\ @2U']B1?\_\
M?_\ @2U &I167_8D7_/_ '__ ($M1_8D7_/_ '__ ($M0!J45E_V)%_S_P!_
M_P"!+4?V)%_S_P!__P"!+4 :E%9?]B1?\_\ ?_\ @2U']B1?\_\ ?_\ @2U
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M=1U33]'LS>ZG>Q6EL&5#)*V!DG 'U)K+N/&7A>TENH[C6(4>T<1RKAB0Q[#
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M>>*8YH_->!8$<*(U"L<B,*3E?N_,<$UZC6-_PCNCY!-GNP0<,[$9'3@FMF@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %8US87_ /:IOK.ZAC+0B)DEC+=#G(P16S10!E>3X@_Y_+'_ +\-_P#%
M4>3X@_Y_+'_OPW_Q5:M% &5Y/B#_ )_+'_OPW_Q5'D^(/^?RQ_[\-_\ %5JT
M4 85WI^IW]J]I?-IMU;N,/%+;%E;Z@M51/#LD4MM-'::,DEJNV!Q98,0]%.>
M*ZBB@#EX] FMS)]GMM'A\UQ))Y=GC>X.0QYY.:+G0);R1I+RUT:X=F#EI;+<
M2PZ')/45U%% ',3:!+< ">UT:4 A@'L\\@Y!Z^I)_&M+R=? P+RQ_P"_#?\
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MJL+NU8A5N(B3T <<U9HLUN 4444P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH HZM_R!;[_ *X/_P"@FG:;_P @BS_ZX)_Z"*;JW_(%OO\
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M:HYDAC@2= JD2N"NXY(SR:Z^@ HHHH **** "JTEG:2N9)+:)W/\3(":LT4
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MB#3X8-JC:]H2<Y^;^+O6FEY=VM^L.H7=NT)A:0R;?+VD$#N>G-+_ ,(OH?\
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M_D$6?_7!/_013=6_Y M]_P!<'_\ 033M-_Y!%G_UP3_T$4 7**** "@T4&@
MHHHH **** "O-?B?,8M.MUEL0NGR31F[O6GBCVH"<*OF'&[/L>,UZ57F'Q6F
ML;C3+'2KB"8R/<++]H\F5X[9<$%VV#GTQGOF@#I? ;RR>!-+>;R,E&V_9V#+
MMW';R."<8SCC.:ZJN0^'Z-'X"TM?LLL!V,=LI)9OG/SG(!&[[V,=ZZ^@ KD]
M1\%:3J<MW<2R745U<SK.;B.3#IA-FU21PNTD8]S7644 <SKFFV-OX>$<5K$!
M;B*.(E02BJP  /6M:_U"PTK3;C4=2O(;&SMT,DMQ.X2.-1U9F/ 'N:K>)/\
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M+^"158J2L@(!'45H!@0"#D'N*RQHVF16\L5O86T(DW$[8E')ZFFVT6JV]I%
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M?_0EK?'0U"ZESVCZ#J***L@**** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_D%:+^07?8T**S_LFI?]!3_R"M'V34O^@I_Y!6B_D%WV-"BL_P"R:E_T%/\
MR"M'V34O^@I_Y!6B_D%WV-'\*/PK.^R:E_T%#_WX6H+.SU2'4YY[O5?M-LZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYI?[?L>O_"4Z9GIG[-_]>N@TJ*R32X%LYH[FW .R5"&##)Z$<5H^5'_<7\J
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MN PW#!_*IZIVUO%:6L5M"I$42A$!)) ' Y-7* "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<X'4 #DYKT6DP,@X&10!QWP]UC6=<\(I>^(;:2WU'[1-')')#Y6-KD !?0#
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M110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110
M9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9I,T
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cvm_10qimg5.jpg
<TEXT>
begin 644 cvm_10qimg5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &! 98# 2(  A$! Q$!_\0
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M#C<?2N;7Q#XK)Y\!7(_[B%O_ /%5U?44T(H.0.: .8_M[Q5_T(ES_P"!]O\
M_%4?V]XJ_P"A$N?_  /M_P#XJNIHH Y;^WO%7_0B7/\ X'V__P 51_;WBK_H
M1+G_ ,#[?_XJNIHH Y;^WO%7_0B7/_@?;_\ Q5']O>*O^A$N?_ ^W_\ BJZF
MB@#EO[>\5?\ 0B7/_@?;_P#Q5']O>*O^A$N?_ ^W_P#BJZFB@#EO[>\5?]")
M<_\ @?;_ /Q5']O>*O\ H1+G_P #[?\ ^*KJ:* .6_M[Q5_T(ES_ .!]O_\
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M31 O=:>2;>8YP6CSS@XKHZ .6_M[Q5_T(=S_ .!]O_\ %4?V]XJ_Z$.Y_P#
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M_P" RUTU% ',_P#"!>"O^A5TS_P&7_"C_A O!7_0JZ9_X#+_ (5TU% ',_\
M"!>"O^A5TS_P&7_"C_A O!7_ $*NF?\ @,O^%=-10!S/_"!>"O\ H5=,_P#
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MU% ',_\ "!>"O^A5TS_P&7_"C_A O!7_ $*NF?\ @,O^%=-10!S/_"!>"O\
MH5=,_P# 9?\ "C_A O!7_0JZ9_X#+_A7344 <S_P@7@K_H5=,_\  9?\*#X"
M\&'@^%],P/\ IV6NFHH YG_A O!7_0JZ9_X#+_A0? /@PX_XI?3./^G9:Z:B
M@#FO^$"\&=_"^FG_ +=UI/\ A O!7_0JZ9_X#+_A7344 <S_ ,(%X*_Z%73/
M_ 9?\*/^$"\%?]"KIG_@,O\ A7344 <S_P (%X*_Z%73/_ 9?\*#X"\&D_\
M(L:7CT^S+7344 <U_P ('X+_ .A5TS_P&7_"@^ _!?\ T*VF?^ R_P"%=+10
M!S/_  @7@S !\+Z:0.G^CKQ1_P (%X*_Z%73/_ 9?\*Z:B@#F8O!'@^WG2>#
MPUIL<L;!T9;=05(.01QZUTU%% !1110 &B@T4 %%5Y [1,(V"N00K$9 /KBN
M1U+_ (271=,N-4U7QMI=G96Z[Y9Y-*(5!G&2?.]Z .VHKDOLOBW"'_A,],'F
M?<SI>-WT_?<U(+'QB5##Q=IQ!Z$:43G_ ,C4 =317,_V9XU[>+-/_P#!2?\
MX]1_9GC7_H;-/_\ !2?_ (]0!TU%<S_9GC7_ *&S3_\ P4G_ ./4?V9XU_Z&
MS3__  4G_P"/4 =-17,_V9XU_P"ALT__ ,%)_P#CU']F>-?^ALT__P %)_\
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M]F>-?^ALT_\ \%)_^/4?V9XU_P"ALT__ ,%)_P#CU '345S/]F>-?^ALT_\
M\%)_^/4?V9XU_P"ALT__ ,%)_P#CU '345S/]F>-?^ALT_\ \%)_^/4?V9XU
M_P"ALT__ ,%)_P#CU '345S/]F>-?^ALT_\ \%)_^/4?V9XU_P"ALT__ ,%)
M_P#CU '"_&#Q/XPT35_#.E>#YKI+S4UO"(;6SCN7FDCB#1J0Y 5-Q^9L\ UD
MGXS:W8S:Y;WGA9'.B6L@NI$G*J+J*%)'4Y'W"7V@C)XR>M>AR^'O%%Q>V]Y-
MXATN2YMMWDS-H^7BW##;3YO&1P:SKCP'?W=]<ZA<7N@SWMS&8)YY-"5GE0@
MJQ,O(P!0!@O\6-4M;W5EOM%L8H-%LQ+>HM[_ *0\K6_G@0(5_>)C"D]<Y.,"
MLAOC9KPT.WNSX2MQ=217=R0]X4C:&"W6<LIV[LE6VX('(]*[E_!NI-JR:M]O
MT*348XOLZW+:&#((R,;-WFY QQ].*@M_ 5S:VWV:TG\.P0KYB^6F@ */,&V0
M8\W^)< ^HH XJ3XP>)[&'Q!J-UHVGSZ;9:I';I(L[!K.W:V2;?,H!9OO ;E'
M&3G@9KW"UF2YM8;B)E9)4#JP.001D8/<5P<WP^N;QV^U3^'9]Q0L7T!224&U
M,_O>PX'M6\FE>,T0*OBK3U4#  TG&/\ R-0!U5%<S_9GC7_H;-/_ /!2?_CU
M']F>-?\ H;-/_P#!2?\ X]0!SGQ<\1ZQX:\*:=<:)>3VUQ=ZM:V3/;6ZW$VR
M1B&$:-PS\< UR>C_ !4\7V6J:3X8\2>&&EU8012ZA*"(F1)I)%B?8,J&"H"Z
MYZD@9Q7?W?A_Q1?+$MYX@TJY$,BS1B71MVR13E6&9N".QJ"Z\'ZS?ZG;ZI?:
MIHES?6HQ#<2Z&'DC'^R3+D4 <GHGQ<UC6;O18CH>FVB7UDFIS--J&T^0\S1(
ML65P\F5)*^X'4U0T[XV:UJ>E0WMGX40&_OK>TL#-<E$996D7YS@D,OEY.!CY
MO:NW;P1J#R6#O>>'S)IW_'F3H*DVO?Y/WOR\^E);>!KRV>62VO/#T,DLPN96
MCT!06E&<2'][]X9//N?6@#@+3XR>*[V"^U2V\.V-Q9+I%C?062SGSU>662.1
ML_\ +15,9.%&[IC)->Q^&M:B\1^%],UR!XGCOH%F!A8LG([$@$C/J!7,3?#^
MXNX%@FG\.RPI%]G5&T!<+'NW;!^]X&[G'KS6I:Z)XKL[2*UM/$6F6T$2A(XH
M]'VJBCH !-@"@#L:*Y=-.\8+/&TOB6QEB# N@TPJ6&>0#YO'UKJ* "BBB@ -
M%!HH 0\*3UXKC_&V@ZCXFT^QTBUN8[2S:Y66]D=!(3&H)"!#PV6VYSV!KL>H
MIC1AAU- 'SX-!\4'Q ='O4E>^CM5L[6_BS\K?9W19R2,"/&-P!R'->H^!=#N
M]!T6>UO(WA>6?S/*,RRJGR*#MV@!<D$X]\]S78&%3_$WYTX1JJ@#/% #QTHH
MHH **** "BBB@ HHHH **** "BBB@#S/QA:^)[CX@:+-X:NI()[>RN25F+"V
MEW/&I$F.-P!++[K]:Y3PWJGC/0Y-&T8S74MM '.Z[A:26_\ ](F\S)VD[@JI
MMY &1U!KT[Q+XIT[PS!))=PS32):S7A2(#.R,#)YZ<L /K5&R\>:1+:W4VJB
M32'M+G[+,EPP8*^P/D,F05VL"3GCO0!Q5EXG\<:O$\%I=7=O$\I=+E[%6D5?
MLK2["-H4$2 #H?3->J:!<W-YX<TZ\O4V74]M'),NTKM<H"PP>G/:LW_A,O#'
MVR[LO[:MO/L]QF0L?DVD CI@D%EX'J*=:>,_#=Y/;0VVJ1F2[8K"KJR%R&*]
MQQD@@9QG!Q0!U%%-4DJ"W!IU !1110 4444 %%%% !1110 4444 %<7\0E+^
M$9$^WRV"&YA\R:.*23:F\9W",AMIZ$@UV+N$4L2  ,DGM7%MX\TW&F3-I^H?
M9=2*A+H1C8N]BJ#KEB<9PH) P30!YK::EXCD\1Z1=7EI<)$HM8].M(OM*F>/
MS'6613T&0 Y$N3MP/>MG5[O5+CXC6%]H]Y<7+7-Q:O I6>+R+;D3#85\LJP!
M)9B"#@>E=]H?BN'6]2OK!=.O;.YM$64QW* %HV+!6X)VD[3\K8.,'O61-\1K
M*SENK/4M$U*TNHO*"PR^7^]:0L$4,&V@X1F.2, 9H [Z/.#SQGBGUSND^(+7
M4[H6D=O/;SM:QW:QS@ F-B5[$]"N#^'K70J<KF@!:*** "N;\7B4^#]8$$\T
M$C6KA9849WCXZA5Y..N!S71,Q!&,5Q>H>-M/TZWFO&L;^YMH+B6"6:)!L3RR
M%=B21GYC@*.20<"@#RC4[[6)=+LH+%KF&TM6N?LEW$ETJ7[YCV&,$EA+DN!O
M.S@UTGCR_O+W68'L7U.)TMC%IZVZR(/[06= RMM&#A.[?+C=BO0-&\4V>NZW
MJ.G6,$V;%VBDF9TVLP.#A0VX?4@5DS_$C0[+4]2LKF*[!L%D#2*@82.A4,B@
M'(.74 D ,3Q0!W41?D-C( X':I:Y#2/&%CJ]U!9+:7%G=RF:-X;A0&BDB(WQ
MM@D9PP88R"*ZY3D9H 6BBB@ HHHH #10:* ()9!%"\C$A44L<#)P/:N=7QYX
M=S_KK\C_ +!ES_\ &ZZGH*Y#QE?ZY8:1:?V!AIY;E4F"(LDPBVL6,4;$!V!
M^7TSZ4 6/^$[\-_\]K__ ,%ES_\ &Z/^$[\-_P#/:_\ _!9<_P#QNN3TKXE/
M>/#9VEFVL.L"&>\@#01^:T;./E8?(OR8.3P3WYKK_"?B6+Q7X:MM?M;>2WM;
MK+0K(<L4!QEA_">#Q0 S_A._#?\ SVO_ /P67/\ \;H_X3OPW_SVO_\ P67/
M_P ;KI^U% ',?\)WX;_Y[7__ (++G_XW1_PG?AO_ )[7_P#X++G_ .-UT]%
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M/,5QE 4E0D@-GCK@U[=7.>+=5GT7PIJFK6[1B>TMVDB$Q(1GQ\H..N3QCWH
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MBW4/$5S=17ALYE2VAN@]H& @:0MFW?)/SKM&>G7I7;""$# B4=.P[=*9%!!
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M>#C .>^: .CB.[<?IVQ4U11D,"P.<XJ6@ Q1110 4444 !HH-% #"P52S$
M9)/:JAUC2!_S%+3_ +_K_C5IT62-HW4,K#!!&017F_C:S\.^&=*L+FS\):')
M+>7L=IF73@X0,&.[:B[B?EZ#UH [TZQI ZZI:?\ ?]?\:/[8TC_H*VG_ '_7
M_&O#F\7>'UMG=_ASH\C3:5'<V:PVZ-YMXP<_9F^7Y>$)R<8 8'D5VO@^U\->
M)([TW/@W1(&M1;_ZNSC(8R0)(>J]BQ ^E '>_P!KZ3_T%+3_ +_K_C1_:^D_
M]!2T_P"_Z_XU0'@[PEC_ )%;2/\ P"B_^)H_X1#PG_T*ND?^ 4?_ ,30!?\
M[7TG_H*6G_?]?\:/[7TG_H*6G_?]?\:H?\(AX3_Z%72/_ */_P")H_X1#PG_
M -"KI'_@%'_\30!?_M?2?^@I:?\ ?]?\:/[7TG_H*6G_ '_7_&J'_"(>$_\
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M:AACD<92-GVX#,!D#Z>M '91ZKI:@AM4M.O_ #W7_&G_ -KZ3_T%+3_O^O\
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M/ MYJOB:QUC4[C3U6.:"YN6MHI4>62+)4 ;]I'3E@6 R :S_  ?\0KK6]?\
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M,(,* ,\ #/'O7=H" <G)IU '*?V%XQ_Z'H_^"R+_ !I#H/C$CGQT3_W#(O\
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M'R>7Q@YQSQS7MD9Z\5RW_"N_"'_0,D_\#)__ (NE_P"%=^$/^@7)_P"!<_\
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MDA=-L,#8/F?+P,< $9SS5?3? 7B!;G3[S4=#$D%CK5O>V]I)<(&BC^SF.5E
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MV"\C,D)E*>3*78XRH##@DKGC-;R_#W4;O5K>\U*%[AVU??<2&^;,EG]F"%2
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M%%IX;TZP@T@PV=GI]E;W&FQWP47)BG9IE4@X =<$$XST.*]N\M,8Q1Y:CUH
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EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310791470432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,211,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310792140224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,614,115<span></span>
</td>
<td class="nump">$ 4,738,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">373,069<span></span>
</td>
<td class="nump">294,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingCurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">863,104<span></span>
</td>
<td class="nump">1,019,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,857,788<span></span>
</td>
<td class="nump">6,055,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">6,899,819<span></span>
</td>
<td class="nump">7,350,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,442,619<span></span>
</td>
<td class="nump">1,495,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,592,663<span></span>
</td>
<td class="nump">8,129,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">148,394<span></span>
</td>
<td class="nump">165,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">2,319,101<span></span>
</td>
<td class="nump">2,319,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">1,438,403<span></span>
</td>
<td class="nump">1,475,441<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,698,787<span></span>
</td>
<td class="nump">26,991,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,999,214<span></span>
</td>
<td class="nump">1,448,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">621,601<span></span>
</td>
<td class="nump">566,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DueToEmployeeCurrent', window );">Due to employees</a></td>
<td class="nump">558,103<span></span>
</td>
<td class="nump">363,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation, current portion</a></td>
<td class="nump">2,074,490<span></span>
</td>
<td class="nump">2,010,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation, current portion</a></td>
<td class="nump">226,155<span></span>
</td>
<td class="nump">226,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,479,563<span></span>
</td>
<td class="nump">4,615,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">7,412,252<span></span>
</td>
<td class="nump">7,957,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, net of current portion</a></td>
<td class="nump">1,373,340<span></span>
</td>
<td class="nump">1,425,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,390,155<span></span>
</td>
<td class="nump">14,124,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 600,000,000 shares authorized; 74,084,041 and 63,787,104 shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively</a></td>
<td class="nump">730,839<span></span>
</td>
<td class="nump">637,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">531,662,716<span></span>
</td>
<td class="nump">526,241,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(521,084,923)<span></span>
</td>
<td class="num">(514,011,861)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">11,308,632<span></span>
</td>
<td class="nump">12,867,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 25,698,787<span></span>
</td>
<td class="nump">$ 26,991,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DueToEmployeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DueToEmployeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310947574448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">74,084,041<span></span>
</td>
<td class="nump">63,787,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">74,084,041<span></span>
</td>
<td class="nump">63,787,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310794874848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,430,063<span></span>
</td>
<td class="nump">$ 4,352,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,463,355<span></span>
</td>
<td class="nump">2,133,378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,893,418<span></span>
</td>
<td class="nump">6,485,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,893,418)<span></span>
</td>
<td class="num">(6,485,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(170,103)<span></span>
</td>
<td class="num">(197,696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(9,541)<span></span>
</td>
<td class="num">(25,941)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,073,062)<span></span>
</td>
<td class="num">(6,709,524)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (7,073,062)<span></span>
</td>
<td class="num">$ (6,709,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">65,325,855<span></span>
</td>
<td class="nump">48,470,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310791487408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">$ 13,214,890<span></span>
</td>
<td class="nump">$ 474,223<span></span>
</td>
<td class="nump">$ 499,832,063<span></span>
</td>
<td class="num">$ (487,091,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">48,907<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">48,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">202,307<span></span>
</td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">201,421<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">4,980,000<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="nump">4,955,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees, amount</a></td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(6,709,524)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,709,524)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,018,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">12,650,260<span></span>
</td>
<td class="nump">$ 500,186<span></span>
</td>
<td class="nump">505,950,994<span></span>
</td>
<td class="num">(493,800,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,787,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2024</a></td>
<td class="nump">12,867,083<span></span>
</td>
<td class="nump">$ 637,870<span></span>
</td>
<td class="nump">526,241,074<span></span>
</td>
<td class="num">(514,011,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">57,134<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">55,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">$ 396,087<span></span>
</td>
<td class="nump">$ 1,546<span></span>
</td>
<td class="nump">394,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="nump">7,552,500<span></span>
</td>
<td class="nump">7,552,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">$ 5,000,300<span></span>
</td>
<td class="nump">$ 75,525<span></span>
</td>
<td class="nump">4,924,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees, amount</a></td>
<td class="nump">711,381<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">711,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="num">(650,291)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(650,291)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(7,073,062)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,073,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Pre-funded warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Pre-funded warrant exercises, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="num">(14,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity based compensation - employees, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,084,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2024</a></td>
<td class="nump">$ 11,308,632<span></span>
</td>
<td class="nump">$ 730,839<span></span>
</td>
<td class="nump">$ 531,662,716<span></span>
</td>
<td class="num">$ (521,084,923)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CostIncurredInIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CostIncurredInIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310795391904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (7,073,062)<span></span>
</td>
<td class="num">$ (6,709,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">995,192<span></span>
</td>
<td class="nump">1,004,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">396,839<span></span>
</td>
<td class="nump">218,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">711,381<span></span>
</td>
<td class="nump">1,383,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">57,133<span></span>
</td>
<td class="nump">48,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_GainLossOnPatentImpairment', window );">Loss on patent impairment</a></td>
<td class="nump">9,541<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">79,724<span></span>
</td>
<td class="nump">100,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">193,842<span></span>
</td>
<td class="num">(98,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncreaseDecreaseInDeposit', window );">Deposits</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(11,884)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">473,514<span></span>
</td>
<td class="num">(765,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(15,291)<span></span>
</td>
<td class="num">(8,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Due to employees</a></td>
<td class="nump">194,797<span></span>
</td>
<td class="nump">148,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,139,973)<span></span>
</td>
<td class="num">(4,887,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(32,954)<span></span>
</td>
<td class="num">(51,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,211)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(32,954)<span></span>
</td>
<td class="num">(64,861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and pre-funded warrants</a></td>
<td class="nump">5,000,300<span></span>
</td>
<td class="nump">4,980,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(469,020)<span></span>
</td>
<td class="num">(504,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under finance leases</a></td>
<td class="num">(482,411)<span></span>
</td>
<td class="num">(426,593)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,048,869<span></span>
</td>
<td class="nump">4,048,494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(124,058)<span></span>
</td>
<td class="num">(904,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">4,738,173<span></span>
</td>
<td class="nump">4,145,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">4,614,115<span></span>
</td>
<td class="nump">3,241,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock', window );">Consulting services paid with issuance of common stock</a></td>
<td class="nump">396,087<span></span>
</td>
<td class="nump">202,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NonCashFinancingCostsIncludedInCurrentLiabilities', window );">Financing costs included in current liabilities</a></td>
<td class="nump">220,220<span></span>
</td>
<td class="nump">43,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 207,735<span></span>
</td>
<td class="nump">$ 244,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossOnPatentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossOnPatentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncreaseDecreaseInDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncreaseDecreaseInDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NonCashFinancingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NonCashFinancingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310889722464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of December 31, 2024 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2024 is derived from the September 30, 2024 audited financial statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at&#160;the lower of cost or&#160;net realizable value&#160;and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities, and are expensed as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $250,000 at December 31, 2024 and September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2024 and September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Fair Value Measurements -</em> In accordance with the provisions of ASC 820, <em>Fair Value Measurements</em>, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#8217;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#8217;s money market funds approximated their fair value at&#160;$1,000 and $3,480,000 as of December 31, 2024 and September 30, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, <em>Segment Reporting</em> (Topic 280): <em>Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;),</em> which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790379440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LIQUIDITYAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LiquidityDisclosureTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LIQUIDITYAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LIQUIDITYAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310889709120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">C.&#160;<span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2024, the Company sold 7,552,500 shares of common stock at a public offering price of $0.31 per share and pre-funded warrants to purchase up to 8,577,500 shares of common stock, at an offering price of $0.3099 per pre-funded warrant, for proceeds of approximately $4.4 million, net of issuance costs of approximately $0.6 million. As of December 31, 2024, none of the pre-funded warrants in connection with the December 2024 offering have been exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company determined that the pre-funded warrants sold in the December 2024 offering are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#8217;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the transaction in December 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Other Equity Transactions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In October 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited (&#8220;Ergomed&#8221;) pursuant to which the Company issued 1,000,000 shares of common stock in exchange for services. The shares are legally issued and outstanding.&#160;&#160;The Company determined the issuance of shares to a non-employee for services rendered or to be rendered is within the scope of ASC 718. In accordance with ASC 718, the shares are not issued and outstanding for accounting purposes as they are unvested and forfeitable. The shares will be recognized on the&#160;settlement date and measured at fair value when the shares are settled for services rendered by Ergomed. The Company incurred share issuance costs of approximately $61,000 to issue the shares from this agreement which were immediately expensed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Underlying share information for equity compensation plans as of December 31, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:80%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Option Activity</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">502,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,833</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Share-Based Compensation Expense:</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">711,381</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,383,909</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">396,839</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218,386</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at December 31, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">85,339</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026&#160; </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-Funded</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/31/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,577,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0001</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/2017 &#8211; 11/19/2024 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">610,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.70 - $2.18</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 -&#160;11/1/2034</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024, 8,577,500 pre-funded warrants at an offering price of $0.3099 were issued.&#160; No pre-funded warrants or warrants recorded as equity were issued during the three months ended December 31, 2023.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024, 1,450,000 pre-funded warrants were exercised.&#160; No pre-funded warrants or warrants recorded as equity were exercised during the three months ended December 31, 2023.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired or were extended during the three months ended December 31, 2024 and 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024 and 2023, the Company issued 154,615 and 88,573 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $0.85 and $1.56 during the three months ended December 31, 2024 and 2023, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024, 500,000 options with an exercise price of $0.70 were issued to a consultant.&#160; The options vest immediately and will expire on November 1, 2034.&#160; No options were issued to a consultant during the three months ended December 31, 2023.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024 and 2023, the Company recorded total expense of approximately $397,000 and $218,000, respectively, relating to the share-based compensation under various consulting agreements. On December 31, 2024 and September 30, 2024, consulting fees of approximately $51,000 and $52,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790327616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There were no related party transactions during the three months ended December 31, 2024 and 2023. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310889685392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"><em>Clinical Research Agreements</em>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#8217;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $0.7 million as of December 31, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of December 31, 2024 and September 30, 2024, respectively, the net book value of the finance lease right-of-use asset is approximately $6.9 million and $7.4 million and the balance of the finance lease liability is approximately $9.5 million and $10.0 million, of which approximately $2.1 million and $2.0 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the three months ended December 31, 2024 and 2023, the finance right-of-use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $0.5 million in both periods, which is included in research and development expense on the accompanying condensed statements of operations. Total cash paid related to finance leases during the three months ended December 31, 2024 and 2023, was approximately $0.7 million for both periods, of which approximately $0.2 million was for interest. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying condensed statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying condensed statements of cash flows. As of December 31, 2024, the weighted average discount rate of the Company&#8217;s finance leases is 8.46% and the weighted average remaining lease term is 3.83 years. During the three months ended December 31, 2024 and 2023, total finance lease costs were approximately $0.7 million, consisting of approximately $0.5 million of lease asset amortization and approximately $0.2 million of interest on the finance lease liabilities for both periods. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right-of-use assets or lease liabilities but rather are expensed as incurred. During the three months ended December 31, 2024, there were approximately $0.3 million of variable finance lease costs, which are included in research and development expense on the accompanying condensed statements of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of December 31, 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,065,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,108,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,622,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,486,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,074,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,412,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of December 31, 2024 and September 30, 2024, respectively, the net book value of the operating lease right-of-use asset is approximately $1.4 million and $1.5 million and the balance of the operating lease liability is approximately $1.6 million and $1.7 million, of which approximately $0.2 million is current in both periods. During the three months ended December 31, 2024 and 2023, the Company incurred lease expense under operating leases of approximately $0.1 million in both periods, which is included in general and administrative expense on the accompanying condensed statements of operations. Total cash paid related to operating leases during the three months ended December 31, 2024 and 2023 was approximately $0.1 million for both periods. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying condensed statements of cash flows. The weighted average discount rate of the Company&#8217;s operating leases is 8.98% and the weighted average the remaining lease term is 6.81 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of December 31, 2024, approximate future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">303,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">443,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,165,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(566,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,599,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(226,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,373,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790061280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">PATENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2024, the Company abandoned three patents which resulted in an impairment of $9,541 on patent costs. During the three months ended December 31, 2023, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;7&#160;years. For the three months ended December 31, 2024 and 2023, amortization of patent costs totaled approximately $8,000 and $9,000, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">148,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310889732608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants, unvested common stock&#160;and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The calculation of basic and diluted net loss per share includes 8,577,500 of the pre-funded warrants that remain outstanding as of December 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,073,062</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,709,524</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">65,325,855</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">48,470,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.11</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,837,177</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,839,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Common Stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;1,000,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">18,981,427</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,986,278</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310889709120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">J. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310794558992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at&#160;the lower of cost or&#160;net realizable value&#160;and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities, and are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $250,000 at December 31, 2024 and September 30, 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2024 and September 30, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Fair Value Measurements -</em> In accordance with the provisions of ASC 820, <em>Fair Value Measurements</em>, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#8217;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#8217;s money market funds approximated their fair value at&#160;$1,000 and $3,480,000 as of December 31, 2024 and September 30, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, <em>Segment Reporting</em> (Topic 280): <em>Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;),</em> which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ImpairmentOfLongLivedAssetsPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790535216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of equity compensation plans</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:80%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfStockOptionActivityTableTextBlock', window );">Schedule of Stock option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">502,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,833</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">711,381</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,383,909</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">396,839</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218,386</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock', window );">Schedule of warrants and non-employee options outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">85,339</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026&#160; </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-Funded</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/31/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,577,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0001</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/2017 &#8211; 11/19/2024 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">610,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.70 - $2.18</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 -&#160;11/1/2034</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfCompensatingBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfStockOptionActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfStockOptionActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790083472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,065,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,108,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,622,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,486,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,074,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,412,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">303,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">443,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,165,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(566,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,599,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(226,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,373,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790375840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">148,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310897000752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock', window );">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,073,062</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,709,524</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">65,325,855</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">48,470,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.11</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,837,177</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,839,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Common Stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;1,000,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">18,981,427</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,986,278</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310794552528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedOtherAtFairValue', window );">Fair Value of Financial Instruments</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets', window );">Concentration Risk, Credit Risk, Financial Instruments</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivative asset subject to concentration of credit or market risk or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 83<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480647/815-10-15-83<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedOtherAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of firm holdings in securities classified as other. Includes pledged and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479035/940-320-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedOtherAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790116768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">17,787,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">1,283,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">634,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">138,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790070224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">502,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="nump">15,833<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310895619008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 711,381<span></span>
</td>
<td class="nump">$ 1,383,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 396,839<span></span>
</td>
<td class="nump">$ 218,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310794768656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 3)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember', window );">Pre-Funded [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">12/31/2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">8,577,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/18/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/11/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/30/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/13/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/15/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">333,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/22/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">200,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/24/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">234,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">10/30/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember', window );">Consultants Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">610,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_BottomMember', window );">Bottom [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/28/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/27/2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_TopMember', window );">Top [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">11/19/2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">11/1/2034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssueDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssueDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfWarrantOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfWarrantOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_BottomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_BottomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_TopMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_TopMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310794680096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 18, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,552,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">74,084,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,084,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,787,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 5,000,300<span></span>
</td>
<td class="nump">$ 4,980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetofissuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">88,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Cost of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember', window );">Consulting Agreements Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ConsultingFeesIncluedPrepaidExpenses', window );">Consulting fees inclued prepaid expenses</a></td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,000<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember', window );">Restricted Stock [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,615<span></span>
</td>
<td class="nump">88,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember', window );">Pre-Funded [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">8,577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">8,577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 0.3099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsMember', window );">Changes in Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">8,577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,577,500<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 0.3099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ConsultingFeesIncluedPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ConsultingFeesIncluedPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetofissuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetofissuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310795391472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Nine months ending September 30, 2025</a></td>
<td class="nump">$ 2,065,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">2,838,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2,929,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">3,021,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease obligation</a></td>
<td class="nump">11,108,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on finance lease obligations</a></td>
<td class="num">(1,622,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Net present value of financing lease obligations</a></td>
<td class="nump">9,486,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityCurrentPortion', window );">Less net present value of financing lease obligations - current portion</a></td>
<td class="num">(2,074,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityNoncurrentPortion', window );">Net present value of financing lease obligations - non-current portion</a></td>
<td class="nump">$ 7,412,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310794582560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Nine months ending September 30, 2025</a></td>
<td class="nump">$ 276,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">303,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">443,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Obligation</a></td>
<td class="nump">2,165,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Imputed Interest On Operating Lease Obligation</a></td>
<td class="num">(566,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net Present Value Of Operating Lease Obligation</a></td>
<td class="nump">1,599,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityCurrentPortion', window );">Net present value of lease finance lease obligations - current portion</a></td>
<td class="num">(226,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityNoncurrentPortion', window );">Net present value of lease finance lease obligations - non-current portion</a></td>
<td class="nump">$ 1,373,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310795425264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,899,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,350,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,599,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AnnualIncreaseToInterestPayments', window );">Annual increase to interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.46%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AnnualIncreaseToInterestPaymentsOperating', window );">Annual increase to interest payments operating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 2,300,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExpenseOnReclassifiedAssets', window );">Total depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance Lease Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">700,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of Finance Lease Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest Expense on Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeaseExpenseUnderOperatingLeases', window );">incurred lease expense under operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable finance lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Total cash payment for oprating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm', window );">Weighted average time of maturity of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne', window );">Weighted average time of maturity of finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvm_LandlordMember', window );">Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingArrangementDepositBaseRentAmount', window );">Financing arrangement deposit base rent amount</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AnnualIncreaseToInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AnnualIncreaseToInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AnnualIncreaseToInterestPaymentsOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AnnualIncreaseToInterestPaymentsOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingArrangementDepositBaseRentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingArrangementDepositBaseRentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeaseExpenseUnderOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeaseExpenseUnderOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExpenseOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-44<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExpenseOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvm_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvm_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310794620784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Nine months ending September 30, 2025</a></td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total</a></td>
<td class="nump">$ 148,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310788409040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment patent costs</a></td>
<td class="nump">$ 9,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod', window );">Weighted average amortization period for patents</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310900235616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Net loss available to common shareholders - basic and diluted</a></td>
<td class="num">$ (7,073,062)<span></span>
</td>
<td class="num">$ (6,709,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Loss per share- basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - basic and diluted</a></td>
<td class="nump">65,325,855<span></span>
</td>
<td class="nump">48,470,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310790309952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">18,981,427<span></span>
</td>
<td class="nump">15,986,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedCommonStockMember', window );">Unvested Common Stock[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">17,837,177<span></span>
</td>
<td class="nump">15,839,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">144,250<span></span>
</td>
<td class="nump">147,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46310890861712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">74,084,041<span></span>
</td>
<td class="nump">63,787,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember', window );">Pre-Funded [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">8,577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #Y@4Y:$(#N6LH%  !^'P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+696W.C-AS%OXK&G>E3'9#P+=O$,S:;M)[N)MXX36?;Z8,,LLTL(%<(._GV
ME0"#=RO^ILR2A]A<SK%^Z':0;HY<?$EVC$GT&H5Q<MO;2;E_9UF)MV,13:[X
MGL7JRH:+B$IU*+96LA>,^IDH"BUBVR,KHD'<F]YDYY9B>L-3&08Q6PJ4I%%$
MQ=N<A?QXV\.]TXFG8+N3^H0UO=G3+5LQ^?M^*=215;KX0<3B). Q$FQSVYOA
M=Z[C:$%VQTO CLG9=Z11UIQ_T0<+_[9GZQ*QD'E26U#U<6 N"T/MI,KQ3V':
M*W]3"\^_G]SO,W@%LZ8)<WGX1^#+W6UOTD,^V] TE$_\^"LK@(;:S^-ADOU'
MQ_S>@=U#7II('A5B58(HB/-/^EH\B#,!(34"4@C(-P(\J!$XA2![<E9>L@SK
M/95T>B/X$0E]MW+37[)GDZD531#K:EQ)H:X&2B>G+C\P@?HHV5'!DAM+*D]]
MQ?(*_3S7DQJ]@S[R6.X2=!?[S/]:;ZFRE 4BIP+-"6CXGGE7R,$_(6*3@:$\
M+BR_9^LKA.U,/@2*XY3/Q\G\'/#Y_#5;)U*H)O>WZ0GE#@.S@^Z'[Y(]]=AM
M3W6TA(D#ZTU__ &/[)]->-_)["O800D[@-RG=[$,Y!MZ8MM X\82/="(F9!A
M'_?N0W_E+I#[^+1\?)H]+QX?3*B@24O488DZ;(+JLEB!AFBA6N\K^HV]F6!A
M)UO]C<G0&3DF1E#;DG%4,H[ DKWG7JI&7(F>W_;&6H3EV.Y_,B&!JI9(XQ)I
M#)9IIGC\C.D^I%L3$ZS?T# Q/0H7E+6$FI10$[B[I$)D2$'BJ;;XF5&AAU.D
M!G1CM<%N_;Y]W7=L$R0H; EY74)>-^EPJXB&(9JGB;J<&.<;V$:*U%A_H*HE
M&K:K2=1N!+=3<02Y/-K3V#B27+"I;9VPKBW>64; 3?#N(B:V0;Q%OR@'N0-!
M8<-Z4%#7%I14H*31K%!TR">VYT)JXI6D,C7'(]CQLS%4N;"J+6<5:C 8(ZJ9
M8<E$P'UPM+ED=<IKM8$--FC+6F4:W"C4W >A"G*N@MQR86ZSL,\#C_O4\]0+
MB% F?FYHY.TBU^ JV& XCY1U6TPG117?J]/F!@S;?<)&QBYR#:Z"#6Z8;,ZG
MS'I"V.R_;PH%8Q=!!U=)!\-1Y306\2A2K[LKR;TO:H+1;VGH,96)I+&O1B8C
M[W<*,\5CR-V&F9M>%3A,QV."\7"@6L;!A%CE'@Q'E;.NB1[2:&WL3_,+)KB/
M\61R;2QZ%X$'5XD'-XH\B]CC0DTD-%NWT#,)4[6:JA</7;N^>="%G=U'(VX7
M(8A4(8@T"D'/]!4M?-4Y@TW@Y<SU=7O!<C)081:/G(%Y):"+5$2J5$0:I:*9
M[ROWI/S\H&Y#ID%S?L%O0L@UFG.NY'.>ANQ A6_$[B(CD2HCD489R8A-C-BP
MWRH-5(>8V":M"VO;LE8YB<#AYAM65Q\\"O3,C[&1%'9["5@<4R-F%Q&)5!&)
M-(I()\Q\B%*<2\$/0>P91Z@+EB\S(V<7T8A4T8@T6O0Y<2ZYFD5#]&>PKQV'
M+Q@2@B?F=MM%/B)5/B)PI,D:ZDPP6@\&&XQMXVH6K&J+544B D>B#SP+M#L]
M1 )S"FPRM$?]Z\'(N$ "2]OR57F(P%%FQ;Q4Z*K#9(V> QF:J^[":M)98#0R
M=A&*2!6*"!Q=G@7ULS?JMVC-0R/?A>SS\M&(U47X<:KPX\!)I:RZNU=O1^,M
MJUTZOV#T\'EU9]P7Z"+L.%78<>!P4KYQ?4JID$R$;\7JB!$1]JI;PX-E;1&K
M8./ 0:1:+A<T3H(LN0*,L%GM"A>L:PMYMIW5*-$L8E6'^1:J7OBAIR4O(RGL
M6+/"!:O^+Z=UML.I5R&SC=\$>?HU*M_L+,^6F\NS;$O5JF[/=Z8_4KV(F:"0
M;934OAJKJ5KDF[WY@>3[;+]TS:7D4?9UQZC/A+Y!7=]P+D\'^@?*+??IOU!+
M P04    " #Y@4Y:Z6PJB'X&   ]&@  &    'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;*U9;6_;-A#^*X17M!O@Q'P3)>7%0&*[:+ LR>)TPSXR,AT+E415
MI))FOWZ4[%BV1#$)U@]M)/FYTW/TW3U'^N1)%M_42@@-?J1)IDX'*ZWSH]%(
M12N1<G4H<Y&93Y:R2+DVM\7#2.6%X(O:*$U&&$(V2GF<#<8G];.;8GPB2YW$
MF;@I@"K3E!?/YR*13Z<#-'AY<!L_K'3U8#0^R?F#F O]-;\IS-UHZV41IR)3
ML<Q (9:G@S-T-"&X,J@1?\7B2>U<@RJ4>RF_53<7B],!K!B)1$2Z<L'-GT<Q
M$4E2>3(\OF^<#K;OK QWKU^\?ZZ#-\'<<R4F,OD[7NC5Z2 8@(58\C+1M_+I
MB]@$Y%7^(IFH^G_PM,'" 8A*I66Z,38,TCA;_^4_-@NQ8X!HCP'>&."W&I"-
M :D#73.KPYIRS<<GA7P"184VWJJ+>FUJ:Q--G%5?XUP7YM/8V.GQY/IJ.KN:
MSZ;@_.SR[&HR _,OL]G='!R K_,I^/7#;R<C;=Y3H4?1QN?YVB?N\3D5T2$@
M: @PQ-1B/G&;ST5NS*'-?&2BVX:(MR'BVA_I"[$L"I%IP)426AW9XED[H'8'
M524=J9Q'XG1@2D6)XE$,QA]_00P>VZ+[2<[V8B7;6(G+^WC"U0KP; &BZD)\
M+^-'GIC@E2WJM2M6NZK*_7%,&:((>2>CQ]V +#B?!,@G6]P>5[KE2IU<;PJ1
M\W@!Q _3DY2P4EQ[\'9>37P"6=ABV(7AD,+0MQ/TM@0])\%YF>=)+!0HE5@
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MY>;>-$62T9*(.[:A%;Q9,5X2";=\;8H-IR2MD\K"="S+-TN25T8\J)\]\WC
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M&\21?1)_1H7[1C:LD">7H3Y7!UX8A4C3X4[C)J[0^L1WLS^R#__/:'$S\?J
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MI<(9"SX@BO]$1".Z!,_T_<.I @X]K"0M]=&3K*1L_2K]NER_B.>+;.L'[&H
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M8"Q.I--.F(6X(,U47G)07ZT4 CLS92VKM:Z6(C/PJ,JI7"QT):M,RT(X+%8
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M!!;2 CRG=_OI@ABT7TT=_QM02P,$%     @ ^8%.6@G9$5G?!0  )PT  !@
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M<[$Z6UV<\+>><ELG?^O_DULVO7C:E*7PQH^RIJL9N.[);6AV_?S9^<NSMR>
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M3]M:KT7W&0_]W%B^3-3*O:'K:X,[ EFKM& 'L%' *MY_Z>OA/YP [OT+@.
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M6)I+#:4M,/-[(?0QL0L,UV3R&U!+ P04    " #Y@4Y:];-I&ZH)  #6'@
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MK%#9*&M6":G=E.E&-)1HDGQ";Y^<&(CNO/# Y&"!?&'F*MD[J6SU Q[K?..
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M! UZ%P,/5-V5ZX&1I>N$:VFHK[HPHXL,E4V@]QLIS6%@%VBOQME?4$L#!!0
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M?+U1905P?R6Q_343:Z![#T[_ U!+ P04    " #Y@4Y:LX_Y"4L"   _!0
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M58 C)*'UJNJL5RF(6((TXOJZ6L8 #F/%MM% TC2%^8DN(I9T%(HA^I9QO4?
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MI,')R"U7.(H*90$H7TAIMA_60#O<#O\!4$L#!!0    ( /F!3EH]S0\$5@,
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MK$=.WX$,<]Z4YK/<_(S;?JS 5);:_L*FRXT'#J2--K+:@DE!58CNR;]NU^$
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M!JLE50Q]^TUB> O,]7NQZ_L^_(%<G4SM46(_[-M$"A,*!VRP"_L0NCX+=N$
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ME0/8_4I*LY^X X8FFO\%4$L#!!0    ( /F!3EJ.?-CY/P,  )0'   9
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MN!-(YFE*Q.]K2/AN8#G6\X-[NMXH\\".^AE9PPS40W8G=,^N5)8T!28I9TC
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MQPE1'3BJAN)YN<FON=)'AO)VKP]I($P'_3[A7#TUS+FA/O;%OP%02P,$%
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M)PR\RL [UH-?&?C'&@250='U8=GW@K@9E71R)O@]$KJU0M,'!?N%M>(KSO1
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M1F(UU)6&VDJME?.MJ;H0V9'];FV_>ZE4=5]FP/,<_[32FL*"P[!*IWEP >;
M5KHOX"BFZT)4UTN]6K<> WWCGJP/94M2=1#_:*I^9HS9BLBZRV I*:VK0(IB
M58]0300M]36[H$)>VGJ8RK8*F J0[Y>4BOU$;5 W:M%?4$L#!!0    ( /F!
M3EK?LFUC1 (  - %   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;*U4
M;6_:,!#^*U8F39NTDA?"BU@2J:6M6FD4!-KV8=H'DQS$PHXSVR'=OY_MA(BN
M@#:I7V*??<]S]YQS%]5<[&0.H- SHX6,G5RI<N*Z,LV!8=GC)13Z9L,%PTJ;
M8NO*4@#.+(A1-_"\H<LP*9PDLF<+D42\4I04L!!(5HQA\?L&**]CQW<.!TNR
MS94Y<).HQ%M8@?I:+H2VW(XE(PP*27B!!&QBY]J?3$/C;QV^$:CET1X9)6O.
M=\9XS&+',PD!A509!JR7/4R!4D.DT_C5<CI=2 ,\WA_8[ZUVK66-)4PY_4XR
ME<?.V$$9;'!%U9+7#]#J&1B^E%-IOZAN? <Z8EI)Q5D+UC8C1;/BY[8.1P _
M/ ,(6D#PKX!^"^A;H4UF5M8M5CB)!*^1,-Z:S6QL;2Q:JR&%><65$OJ6:)Q*
MOLQ7*[2X6Z+I?#:;/Z'5P_7R#GVX!84)E>@)"X%-H3^B*R1S+$!&KM)Q#=I-
MVQ@W38S@3(Q;2'NH[W]"@1>$)^#3R_ 5E!KNG8*[6FTG.>@D!Y8O/,,WY8SI
M'TB7-MVUFA"1LH+LE+2&:V"Y3$OLDU'HC4,O]"-W?RSBM>.P/QJ/?"_L'%^D
MV^_2[5],=R'@ZKXJ,LC0CQFP-8B?I_*\2&)FP426.(78T<TN0>S!2=Z_\X?>
MYU,/\D9D+_2&G=[P#9\G?%7U\6 T&GC>7Z]S,>;_*G*/^LW,NAD66U)(1&&C
MZ;W>2.<CFOG1&(J7M@777.F&MMM<CUP0QD'?;SA7!\-T=3?$DS]02P,$%
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ML%W :@?R^_- 3?DY402[BGG#GF <21(,@5KTUV@<(ZL3P\>_/]A3$D5)XD<
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M0"%KBD+6%(6L*0I9T_\DZX?6R[_^]=:N22U5<_!GW?_-V1=02P$"% ,4
M" #Y@4Y:!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( /F!3EJ:Y*<+[P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /F!3EJ97)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ ^8%.6A" [EK*!0  ?A\  !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /F!3EKI;"J(
M?@8  #T:   8              " @0X.  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " #Y@4Y:!(4%=\H"  #$"0  &
M@('"%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ^8%.
M6MU?,VR] P  WPL  !@              ("!PA<  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( /F!3EI=@OX\Y@8  &4H   8
M      " @;4;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" #Y@4Y:7GHX^L('  !M(   &               @('1(@  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ^8%.6@R(DT;9#0  024  !@
M             ("!R2H  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( /F!3EH)V1%9WP4  "<-   8              " @=@X  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #Y@4Y:4Q5[0AH*  "K
M'   &               @('M/@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ ^8%.6A+@"!HU @  ,@4  !D              ("!/4D
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #Y@4Y:];-I
M&ZH)  #6'@  &0              @(&I2P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( /F!3EIO<LYU_@(  "8'   9
M  " @8I5  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M^8%.6A#O>Z-'!   &PH  !D              ("!OU@  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " #Y@4Y:LX_Y"4L"   _!0  &0
M            @($]70  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( /F!3EHX_&"1=@P  +LE   9              " @;]?  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ^8%.6HU1]$!/!
MZ H  !D              ("!;&P  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " #Y@4Y:/<T/!%8#  !W"0  &0              @('R
M<   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( /F!3EJ.
M#6^R6@(  % %   9              " @7]T  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ ^8%.6HY\V/D_ P  E <  !D
M     ("!$'<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /F!3EH%9Q#0/ 4  +4?   9              "
M@8R%  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ^8%.
M6G^XWBWC!@  ]#P  !D              ("!_XH  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " #Y@4Y:343+NPH#  "("0  &0
M        @($9D@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( /F!3EH5S\A)*0,   (*   9              " @5J5  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ^8%.6DS!@<O?!@  1#
M !D              ("!NI@  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " #Y@4Y:Y)"#060"   "!P  &0              @('0GP
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /F!3EH%LNXL
MC@(  $ '   9              " @6NB  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ ^8%.6CNE??K9 @  /@@  !D
M ("!,*4  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #Y
M@4Y:D7XI(> "  "T"0  &0              @(% J   >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /F!3EK?LFUC1 (  - %   9
M          " @5>K  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#
M%     @ ^8%.6@*$-CDD P  3!(   T              ( !TJT  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #Y@4Y:EXJ[',     3 @  "P
M    @ $AL0  7W)E;',O+G)E;'-02P$"% ,4    " #Y@4Y:+:',F$X#  !K
M%@  #P              @ $*L@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ ^8%.6N ]"5=H 0  2A0  !H              ( !A;4  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ^8%.6AR:"5V, 0  YQ0
M !,              ( !);<  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ "D *0 6"P  XK@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>215</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementOfStockholdersEquityUnaudited</Role>
      <ShortName>STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShare</Role>
      <ShortName>LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareTables</Role>
      <ShortName>LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails</Role>
      <ShortName>LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails1</Role>
      <ShortName>LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetailsNarrative</Role>
      <ShortName>LOSS PER COMMON SHARE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20241231.xsd</File>
    <File>cvm-20241231_cal.xml</File>
    <File>cvm-20241231_def.xml</File>
    <File>cvm-20241231_lab.xml</File>
    <File>cvm-20241231_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cvm_10q.htm">cvm_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvm_10qimg1.jpg</File>
    <File>cvm_10qimg2.jpg</File>
    <File>cvm_10qimg3.jpg</File>
    <File>cvm_10qimg4.jpg</File>
    <File>cvm_10qimg5.jpg</File>
    <File>cvm_10qimg6.jpg</File>
    <File>cvm_10qimg7.jpg</File>
    <File>cvm_10qimg8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="332">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvm_10q.htm": {
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "cvm-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvm-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10q.htm"
     ]
    }
   },
   "keyStandard": 177,
   "keyCustom": 38,
   "axisStandard": 10,
   "axisCustom": 0,
   "memberStandard": 6,
   "memberCustom": 26,
   "hidden": {
    "total": 28,
    "http://fasb.org/us-gaap/2024": 22,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://cvm.com/20241231": 1
   },
   "contextCount": 83,
   "entityCount": 1,
   "segmentCount": 32,
   "elementCount": 296,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 332,
    "http://xbrl.sec.gov/dei/2024": 30
   },
   "report": {
    "R1": {
     "role": "http://cvm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cvm.com/role/CondensedBalanceSheets",
     "longName": "000002 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
     "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
     "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cvm.com/role/StatementOfStockholdersEquityUnaudited",
     "longName": "000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "shortName": "STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cvm.com/role/LIQUIDITY",
     "longName": "000008 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cvm.com/role/StockholdersEquity",
     "longName": "000009 - Disclosure - STOCKHOLDERS EQUITY",
     "shortName": "STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "longName": "000010 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "longName": "000011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cvm.com/role/PATENTS",
     "longName": "000012 - Disclosure - PATENTS",
     "shortName": "PATENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cvm.com/role/LossPerCommonShare",
     "longName": "000013 - Disclosure - LOSS PER COMMON SHARE",
     "shortName": "LOSS PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cvm.com/role/SubsequentEvents",
     "longName": "000014 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cvm.com/role/StockholdersEquityTables",
     "longName": "000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "longName": "000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cvm.com/role/PatentsTables",
     "longName": "000018 - Disclosure - PATENTS (Tables)",
     "shortName": "PATENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cvm.com/role/LossPerCommonShareTables",
     "longName": "000019 - Disclosure - LOSS PER COMMON SHARE (Tables)",
     "shortName": "LOSS PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "000020 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinancialInstrumentsOwnedOtherAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinancialInstrumentsOwnedOtherAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cvm.com/role/StockholdersEquityDetails",
     "longName": "000021 - Disclosure - STOCKHOLDERS EQUITY (Details)",
     "shortName": "STOCKHOLDERS EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_cvm_IncentiveStockBonusPlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_cvm_IncentiveStockBonusPlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cvm.com/role/StockholdersEquityDetails1",
     "longName": "000022 - Disclosure - STOCKHOLDERS EQUITY (Details 1)",
     "shortName": "STOCKHOLDERS EQUITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfStockOptionActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfStockOptionActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cvm.com/role/StockholdersEquityDetails2",
     "longName": "000023 - Disclosure - STOCKHOLDERS EQUITY (Details 2)",
     "shortName": "STOCKHOLDERS EQUITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31_us-gaap_EmployeeStockMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfCompensatingBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31_us-gaap_EmployeeStockMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfCompensatingBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cvm.com/role/StockholdersEquityDetails3",
     "longName": "000024 - Disclosure - STOCKHOLDERS EQUITY (Details 3)",
     "shortName": "STOCKHOLDERS EQUITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31_cvm_PreFundedMember",
      "name": "cvm:IssueDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31_cvm_PreFundedMember",
      "name": "cvm:IssueDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "longName": "000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-11-30",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "longName": "000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_LeaseAgreementsMember",
      "name": "cvm:AnnualIncreaseToInterestPayments",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://cvm.com/role/PatentsDetails",
     "longName": "000029 - Disclosure - PATENTS (Details)",
     "shortName": "PATENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "longName": "000030 - Disclosure - PATENTS (Details Narrative)",
     "shortName": "PATENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails",
     "longName": "000031 - Disclosure - LOSS PER COMMON SHARE (Details)",
     "shortName": "LOSS PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails1",
     "longName": "000032 - Disclosure - LOSS PER COMMON SHARE (Details 1)",
     "shortName": "LOSS PER COMMON SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cvm.com/role/LossPerCommonShareDetailsNarrative",
     "longName": "000033 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)",
     "shortName": "LOSS PER COMMON SHARE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r389"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r389",
      "r478"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r413",
      "r414",
      "r415",
      "r416",
      "r468",
      "r479"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r141",
      "r147",
      "r385"
     ]
    },
    "cvm_AnnualIncreaseToInterestPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "AnnualIncreaseToInterestPayments",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual increase to interest payments"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_AnnualIncreaseToInterestPaymentsOperating": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "AnnualIncreaseToInterestPaymentsOperating",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual increase to interest payments operating"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment patent costs",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r18"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r60",
      "r74",
      "r93",
      "r125",
      "r127",
      "r128",
      "r129",
      "r131",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r234",
      "r238",
      "r250",
      "r289",
      "r336",
      "r383",
      "r384",
      "r389",
      "r400",
      "r438",
      "r439",
      "r473"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77",
      "r93",
      "r131",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r234",
      "r238",
      "r250",
      "r389",
      "r438",
      "r439",
      "r473"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "cvm_BottomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "BottomMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r45",
      "r91"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r45"
     ]
    },
    "cvm_ChangesInEquityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ChangesInEquityWarrantsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in Equity Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CommitmentsAndContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "CommitmentsAndContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r154",
      "r155",
      "r374",
      "r436",
      "r437"
     ]
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r413",
      "r414",
      "r416",
      "r468",
      "r477",
      "r479"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r324"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
      "http://cvm.com/role/LossPerCommonShareDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "terseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r324",
      "r342",
      "r479",
      "r480"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.01 par value; 600,000,000 shares authorized; 74,084,041 and 63,787,104 shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r292",
      "r389"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r64"
     ]
    },
    "cvm_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ConsultantsOptionMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ConsultingAgreementsOtherMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingFeesIncluedPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ConsultingFeesIncluedPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fees inclued prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CostIncurredInIssuanceOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "CostIncurredInIssuanceOfStock",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "[Deposits Assets, Noncurrent]",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r20"
     ]
    },
    "us-gaap_DepreciationExpenseOnReclassifiedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationExpenseOnReclassifiedAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total depreciation expense",
        "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DueToEmployeeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "DueToEmployeeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER COMMON SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - basic and diluted",
        "verboseLabel": "Basic and diluted loss per common share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r112",
      "r116",
      "r118",
      "r119",
      "r124",
      "r229",
      "r232",
      "r248",
      "r249",
      "r286",
      "r301",
      "r380"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share- basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r121"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LOSS PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r120",
      "r122",
      "r123"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation Expense",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r69",
      "r81",
      "r82",
      "r83",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r107",
      "r126",
      "r132",
      "r133",
      "r153",
      "r179",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r269",
      "r300",
      "r302",
      "r303",
      "r304",
      "r315",
      "r364"
     ]
    },
    "cvm_ErgomedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ErgomedMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares issued",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ExpirationDate",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Financial Instruments",
        "documentation": "Fair value of derivative asset subject to concentration of credit or market risk or both."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense on Lease Liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r264",
      "r388"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations",
        "verboseLabel": "Finance lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r267"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation, current portion",
        "verboseLabel": "Finance lease liability current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "cvm_FinanceLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "FinanceLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less net present value of financing lease obligations - current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under finance leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "cvm_FinanceLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "FinanceLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total future minimum lease obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nine months ending September 30, 2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest on finance lease obligations",
        "label": "[Finance Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Costs",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r266"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease right-of-use assets",
        "verboseLabel": "Finance lease right-of-use asset",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Finance Lease Assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r264",
      "r388"
     ]
    },
    "cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTermOne",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsOwnedOtherAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsOwnedOtherAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Fair value of firm holdings in securities classified as other. Includes pledged and unpledged holdings."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "cvm_FinancingArrangementDepositBaseRentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "FinancingArrangementDepositBaseRentAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing arrangement deposit base rent amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year One]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r376",
      "r385"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nine months ending September 30, 2025",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2030",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Five]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r376",
      "r385"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Four]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r376",
      "r385"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Three]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r376",
      "r385"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Two]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r376",
      "r385"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r283",
      "r284",
      "r376"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r376"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r431"
     ]
    },
    "cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average amortization period for patents"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_GainLossOnPatentImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "GainLossOnPatentImpairment",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on patent impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r346"
     ]
    },
    "cvm_ImpairmentOfLongLivedAssetsPolicyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ImpairmentOfLongLivedAssetsPolicyTextblock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "IncentiveStockBonusPlanMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Incentive Stock Bonus Plan [Member]",
        "label": "[Incentive Stock Bonus Plan [Member]]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "IncentiveStockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r308"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_IncreaseDecreaseInDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "IncreaseDecreaseInDeposit",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposits",
        "label": "[Deposits]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to employees",
        "label": "[Increase (Decrease) in Employee Related Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase)/decrease in assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "IncreaseDecreaseInSuppliesUsedForRDAndManufacturing",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Supplies used for R&amp;D and manufacturing 1]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PATENTS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r151",
      "r152",
      "r375",
      "r376"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r283",
      "r378",
      "r425"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense, net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r419"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest amount",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r90"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r73",
      "r75",
      "r134",
      "r135",
      "r136",
      "r278",
      "r379"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_IssueDate1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "IssueDate1",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LIQUIDITYAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "LIQUIDITYAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LandlordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "LandlordMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Landlord [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreements [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435"
     ]
    },
    "cvm_LeaseExpenseUnderOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "LeaseExpenseUnderOperatingLeases",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "incurred lease expense under operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "LeasesPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Future Minimum Lease Obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2030",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nine months ending September 30, 2025",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Imputed Interest On Operating Lease Obligation",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r93",
      "r131",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r235",
      "r238",
      "r239",
      "r250",
      "r323",
      "r381",
      "r400",
      "r438",
      "r473",
      "r474"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r57",
      "r294",
      "r389",
      "r412",
      "r424",
      "r469"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r72",
      "r93",
      "r131",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r235",
      "r238",
      "r239",
      "r250",
      "r389",
      "r438",
      "r473",
      "r474"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "LiquidityDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIQUIDITY",
        "label": "[LIQUIDITY]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r47",
      "r58",
      "r70",
      "r78",
      "r79",
      "r83",
      "r93",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r113",
      "r131",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r229",
      "r232",
      "r249",
      "r250",
      "r299",
      "r344",
      "r362",
      "r363",
      "r398",
      "r438"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common shareholders",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r99",
      "r100",
      "r101",
      "r102",
      "r109",
      "r110",
      "r115",
      "r119",
      "r232"
     ]
    },
    "cvm_NetofissuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "NetofissuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonCashConsultingServicesPaidWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "NonCashConsultingServicesPaidWithIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting services paid with issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "NonCashFinanceLeaseObligationIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonCashFinancingCostsIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "NonCashFinancingCostsIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "NonEmployeesMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "NonQualifiedStockOptionsPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Option Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OPeratingLeaseWeightedAverageRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "OPeratingLeaseWeightedAverageRemainingLeaseTerm",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r382",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Present Value Of Operating Lease Obligation",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation, current portion",
        "verboseLabel": "Operating lease liability current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "cvm_OperatingLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "OperatingLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "cvm_OperatingLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "OperatingLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash payment for oprating lease",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r266"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "cvm_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "OptionsMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Other Indefinite-Lived Intangible Assets]",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r433"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense",
        "label": "[Other Nonoperating Expense]",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of stock issuance costs",
        "label": "[Payments of Stock Issuance Costs]",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expenditures for patent costs",
        "label": "[Payments to Acquire Intangible Assets]",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "cvm_PreFundedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "PreFundedMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r166"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r324"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r166"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r324",
      "r342",
      "r479",
      "r480"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r291",
      "r389"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r137",
      "r138",
      "r377"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and pre-funded warrants",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r78",
      "r79",
      "r87",
      "r93",
      "r97",
      "r103",
      "r106",
      "r107",
      "r131",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r229",
      "r232",
      "r233",
      "r236",
      "r237",
      "r249",
      "r250",
      "r287",
      "r298",
      "r314",
      "r344",
      "r362",
      "r363",
      "r386",
      "r387",
      "r399",
      "r410",
      "r438"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r268",
      "r288",
      "r297",
      "r389"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r65",
      "r68",
      "r296"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r180",
      "r273",
      "r274",
      "r290",
      "r295",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r341",
      "r343",
      "r371"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party Axis",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r180",
      "r273",
      "r274",
      "r290",
      "r295",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r341",
      "r343",
      "r371",
      "r472"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r311",
      "r312",
      "r313",
      "r347",
      "r348",
      "r349",
      "r368",
      "r370"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on obligations under finance leases",
        "label": "[Repayments of Debt and Lease Obligation]",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r376",
      "r383",
      "r475"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "cvm_RestrictedStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "RestrictedStocksMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r52",
      "r293",
      "r305",
      "r306",
      "r310",
      "r325",
      "r389"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r107",
      "r132",
      "r133",
      "r153",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r240",
      "r242",
      "r243",
      "r245",
      "r247",
      "r257",
      "r258",
      "r302",
      "r304",
      "r315",
      "r479"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfCompensatingBalancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ScheduleOfCompensatingBalancesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity compensation plans",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r53"
     ]
    },
    "cvm_ScheduleOfStockOptionActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ScheduleOfStockOptionActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock option activity"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and non-employee options outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total estimated future amortization",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r432"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "cvm_SeriesMMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SeriesMMMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SeriesNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SeriesNNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesRRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SeriesRRMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesUUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SeriesUUMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SeriesXMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SeriesYMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Options/shares Under Plans",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Exercised",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215"
     ]
    },
    "cvm_SharesIssuableUponExerciseOfWarrantOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SharesIssuableUponExerciseOfWarrantOptions",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable Upon Exercise Of Warrant/options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r38",
      "r39",
      "r69",
      "r81",
      "r82",
      "r83",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r107",
      "r126",
      "r132",
      "r133",
      "r153",
      "r179",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r269",
      "r300",
      "r302",
      "r303",
      "r304",
      "r315",
      "r364"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/LossPerCommonShareDetailsNarrative",
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails2",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r126",
      "r258",
      "r282",
      "r307",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r345",
      "r346",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r393"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/LossPerCommonShareDetailsNarrative",
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails2",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r126",
      "r130",
      "r258",
      "r282",
      "r307",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r345",
      "r346",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r393"
     ]
    },
    "cvm_StockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "StockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation Plan [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, shares",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, shares",
        "verboseLabel": "Common stock issued for service, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, shares",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r52",
      "r309",
      "r364",
      "r372"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r52"
     ]
    },
    "cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrant exercises, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, amount",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, amount",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, amount",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r52",
      "r315",
      "r364",
      "r372",
      "r399"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of shares issued",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees, amount",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r34",
      "r35",
      "r52"
     ]
    },
    "cvm_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrant exercises, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/StatementOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "[Equity, Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r49",
      "r326",
      "r342",
      "r365",
      "r366",
      "r389",
      "r400",
      "r412",
      "r424",
      "r469",
      "r479"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r92",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r246",
      "r367",
      "r369",
      "r373"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SuppliesUsedForRDAndManufacturingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SuppliesUsedForRDAndManufacturingCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;D and manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SuppliesUsedForRDAndManufacturingNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "SuppliesUsedForRDAndManufacturingNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Supplies used for R&amp;D and manufacturing]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r423",
      "r471"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "cvm_TopMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "TopMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingActivityByTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity [Axis]",
        "documentation": "Information by type of trading activity."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingActivityByTypeDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsLossAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common shareholders - basic and diluted",
        "documentation": "Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r117"
     ]
    },
    "cvm_UnvestedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "UnvestedCommonStockMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Common Stock[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20241231",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r62",
      "r63",
      "r66",
      "r67"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable finance lease costs",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r388"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic and diluted",
        "verboseLabel": "Weighted average shares outstanding - basic and diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r119"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "44",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-44"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-7"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479035/940-320-45-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001654954-25-001578-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-25-001578-xbrl.zip
M4$L#!!0    ( /F!3EIU 7YXL T  )V    0    8W9M+3(P,C0Q,C,Q+GAS
M9.U=W7/;-A)_OYG['WAZ:3ISLBPKR34>NQU:DA--94G51Y,\=2@2DC"E0 4
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M9V/W\;H5DC8D%L8M0 +HVM#Q7'3=VB+2^OVW?_[C\[_:[;]N9B,P]*QPA=P
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MXKI%?T][[;WK]G9]_ONH3;!=4\\D>+5VJ&J=ZM_GVLBE3G@#'69W<XE00+@
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M'9$<?_!#(X2B'H0^*USN^W;@ W*B;_P1MTLUZRA RHIH['^6EC?086/.#)'
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M6Y:-R.KW8)[EIM'$;L9?V7T@F%B.1T(?T1]N--.(]B].9[JIC^?1T32@C8?
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M)*O2 4 J_ORK6!-8,RDI'@^DHN+>RIH F,E/N<.#5+A2KEY]4;&726_GF-R
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M)*5RPJ\%6)SN"R(&,(*/BC/54]'#>:(.%KPBW[\*MSL8\-=]12&E'*B!5Z)
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MJ/<GA4JLWJ#G$U1/8>XR+G60_PACSV[LG>8BV!)D:$W&JJZ&VHWGMC7@C7@
MLX)(']OI%26YFTS+,LDDR/?\:4VGS:RHH_90U:,K:=O4!KB,^<KS.KUZSY=X
M 6B9NO>AV;O>S+_NVO/W"==GB"NMCJ\-@/.\Y(BR4R4X6$Y,V(-*@>1:3[Q4
M+1A-< DL0BMV=\6*TLRP7Q%)YHR<U1M>5K^@VST)=''GIO64=2QJ78HZ1G:L
M8)ZI+8M@ALB939 )H5=. E]F=E887A?0T@KL+K@K&4CU@^_,G=LADIF4KLIG
M[RTJ4WP)+Z&8QBZQAU,33I0[0*Y&/4O=GXCW4]VC:X/\H [5?2(+E*8V284T
M,*\ KY9B5((]1YY8T(A<72)L%=)DLN!W*JU[-7C <^,%:(/_R3L%J1/40) *
MS%J2'*38\0-:3&P3YLTF? *R$ U 58QA#+.5>*.S"P/\G_'JJ]=(GGH=#3P2
M@:^E5)T"<Y1%"PN:\**T!=0RT9@&.*J WXF2;JKE=N6?:;0\3LUKY+0\/"B"
MY+PV8$(LL,MH;D\= ZC3 (_SKH#*FQFI4$B7!AWM40OY-!(JL(7'<&E-3(A
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M?J86<F=G7W,VKUM:(*VY^R!"Y_#,;FQD&?3ZAGXG1@QU!J>3A%<9K!D'=+M
M"'9.-QZT/%_&N:%M(49LA@75D]P1UY3 ]I<3!PY-2#1R"O9J"DQ6QH?OG?RR
MUS^68\H&>67;Q.,TOH?OO&#RC4HL\#]T%V.#GJNU1%T3"Y,*DXLG(FV<Y>%T
M7-M6T&M?>F/?T(0,Z2V@RFZ4#S1,2] 3&;*V8M$>K_6.!DVZ[TIZK$W@V)VJ
MF@2Z&@\A\!K[0>3-/6/C]V"'MM!N17HEHPE>/NW0MC GE)6Y0DRQ*-FUZ@.B
M :A;=R9?GS83@K/YPC79PLA6H+)!WE.O\</#.>,L37//GM V>BW/F4EKZ+Y(
M!K6L1<K* FEA^DW3+4HD'<KK^EA>F^T_[)D]4K5VE<E@W E\W4NG1O=X_8F+
M6W9SY\92G*Y8'7N')K@S=,%<^U"+E *R8H#U#KY_9O3] 1P* \?2=!]&<NJ]
M"=Y0W.JU59>"M!-:HIH2Q!:4PFXE1E,T,L&K^E3\%9_$X]O?3P]WG\'F]I?U
MX]/F]F>PNGK:_+)YVJP?]1Q1WJ>.WD_ARO['WHL0KC,>?<D[<;1,5H%#G'AW
M9:? ]MKL%9@]&9\_AHR\7T]7^!4/'XSM%2^Q8A(8<I>606\V45: [E?(K;NY
M<U,I?<6LDKU&6*8NF"O3;U8(V<BFQ8"LG M 2[J@]#T4IF=O4*GL)DAP13S+
M1\QU4JI7RTHL/(N]' [/_K#B!%,D1EUY:D'./1TOV4=IP._4G;DA!*,>V\/K
MQ;9-HM72]$=%(S+CM( J94Z.ZH#I&W6Z4+.0.VT9RYZDN-/E6-5CK:ZG"XW@
M&T\7O*P$XT\7!-W<N;',W(SUP-Z1"5%>NF!N>[IP*,S\TX5/7@ #NX?3!6%!
MV@DM44T)8@M*85<Z4^1JC:[=%_ZFTX5/F]O5[97TZ8*J,%@TD<(GS(?CF_7<
MHT_>NJ193VG0++E*E&)IB958Y]I#RPARMH0K3IAQ" 5?2IA!-Y>[2O!=/<$P
ML^5K&D(AJS2)@R]<U=?)LTBLP\5B=O8@ANWWELV *[V9K>QQ_\6''%,RP?V5
M[BQ%/=>B+73L)WLCG;)K39E=I!@E?P.):<92F66:@*KJV3L^H-VA.M?((H=K
M5W#GD6T7N4^_LWSOA8:SJ.TP>6V64\,:.8.S^Q_(VXRN\/D6) #A40D0NQ\!
MERYY$ N5I-N:M._OSFVFTM(HI?'(!&>^+I@K-NE8"+%*I!BZ:*$E@&,11AUK
MU>P@3ML_L3AY[F Y4]6O78^U&L%SC[5VN4,"-RO%^*,M05=W;C S3P)Z8/#(
M!,>^+IC;'FT="I,[VCIC_Q*0Y/_(#>(;](D=?4!Q$GDV7GB0'[!1+OXA)\DR
M7I0](==?TU#.^!^ON%70 U[$K%T7U9\2J47 //3FTXEMC'NAS@:H6-OU$[A>
M7SVL5X]KL+EEP?!7M]?L'^N_/&]^6=V02/F:K:T>VFKM.)56__])JS RP6U3
M5[TK,Q@I^H+-8;DO7(#CQP$3(:OMTA^+&@P5J/%TOP ';" #!P@ZP.!]@U-B
M[UQFV_:)#1>JW)I8*I_'!$;)V::M8JUJ+TKJ9IT+\'']\^;VEMR9W'T"]^N'
MS=WU_R<):TY["B?*5M!2^9YZK%,+BJSQ7R7(H697R *2'^_% ^>P]M\D:-MX
M32ROKW!/V+92A2VAK#)SY9T.EDM5">2$N\)NL"N!P)[O[V]HKJG5#7B\^O/Z
M^OEF3=AZ>W=[2:F<<SG'/#[#%7%MS!]</9H^BYWSEH[?6&X>L@D61U<XI2 U
MT8).JV862JA;*>R8RT%3J/.4HR_\96)_RM\0Y&X0@)>61X.@]AH]1$3DJS"(
M]SX9J%EL_7OH.;]ZR:N,4\,I!2DE<L=JEHC<LA3FA@B']DQW+NP^\%?#DF>%
M'?(I !J4\PLNC^LH<6Z3C.'0&];CZ+S:1Q%>)O&?C7<L0X,A;E.Y6ALL4T#Z
MS&(Q=G5'0#\1>KWE)7REKAX%@VNSLO(1MG0G!R$!)FG"3NC35O##+YO #:,M
MR__4D$]55EMA^I!V%2KD$Y%392>V:#:=F. ZT@FT<!E\O7F\NKE[?'Y8%].O
MZG:%S#),DLGD%O'C%I:D5 ;>J 58C*U1$$E?O[JCN0EGG4)PE7F9W@&3B9@\
MF_)25=U9WJ(7&*0)Y\C"(?0])\MC=X_QD5%"_O/.3:TT] \)BYNV_CV5K3"3
M7)^-4<@]UT?!+#(E'%LC$Q)XGJ%*E>3IJ\<-36A]_[!^));V:7-W2P\5'I\_
M?UX]_$9^>]S\?+OYM+E:W3Z!U=75W?,M/7JXO[O97&W6@EN^,_+H(XR]^,[-
M-P-NE4?O)?!<SR:O9]DV$B]Y[G&[V7A1\X2^)A]]CF/W*>4QMUNX<.:J6",1
M)*N_"JGEC!*3W =[>FQOE0;8N(%CPDNU7BI1&2>D4'(&D"^6WH3F"@;'DD%6
M-/B=% YHZ2>^9:L]-+C9_.5Y<[UY^HVSN.#(J-GT<\%EF_J* .T .!S;P[,_
MTVC8M#= JV0KR\25ITBX\?ZQ]QPO>;_V8ML/XWV$:@=YDRRKWWB$;%6A\1N2
MLLB#[= 9W0><1'-+5D+9,.R3(;K3GT@!K#BW'!BA^STQ2[W:L!,L"ZE;4=3#
MRZ\1BA+LS>%D,H<FQ. 18:N<2#W=7?W7G^]NKM</C]2=0+'I/AROD=N$U]!W
M4!0S_+=A@AI&:FOE]*AE8B%5_22QK>F(7M23?VCL2C6'WFT[M6O+*#WX5L=4
M$_81[1%STFSWMP/HX24=#2Y\#Z/D_2F"04Q>TX1!T\EDLYK*5W-R52B^E1/K
MI+G\AI.Y">]1VJ$MD^YA?;-Z6E^#^]7#TV_@Z6%U^T@\B>YN]9SM\2HC:39:
MJ#,/T\'(A0;L7T[&WT>W:C4I\I-=JQ+T&YHS,=>$*:\+Y@I1T_CUM!"0+P4<
MBSGWJ1AQ_O$2=G<2.%<A/9-#@<T/TR2MI6;+WJ("V<Y=0H7=T0^'RZ5NEYC6
M8"NWPW>?/V^>B$/!(_,*OZ.7$NM;;;=8@BI)FHQV);#MK3NUD"K3(3'?G5*%
MGKI8S7/$3IU]4F,I?0ZH@\LFS( =85=]2@_%T$NB0D'GF0?[\'XJQ)6]1<GA
ML=[/8>A\\7R_,:5KFR*4^DVUKEK)J4I:GYU5+0=PJ'../1UY)5X0WGX(GX$K
M[#])&R2AQCQJ+'<*5?G'2>5$:XF[=5]I,2CR$Z.4IC[ST3/]3)CWVF"M)GDN
M110W=();PRC 9H\\FG]\A1%JNH3CBBN\CFN 7+B8X\BR9[5H.$2JTCX*K^BD
M4%8N].\>'\G[7D#V!'>WX/'/JX>UEJFHC%]H ;C"S'R[R[&RV-X2TXXDVA/[
M1LM0;YIP!/+Z!OL)U#)A2FE&6+DO2S5( !% =4R:/A[W5HS^L<=[NO6;A#<_
M7USE4R4QY.+;I'I9YC\\&4\G)MR-R:&LOC[Z^+C^RS->$X/U+]IV,67LXOMR
MGG#J^>9,YZH\)&4\.>30GM O6H9XHYL&7U[?(#^!5B9,&\T(*RPZ: "F8M*L
M474V;Y@W1 KJ2-4,.\\JOC2+(3&>C,<FS!ZR.*MV2O8M#/@^*_D'W3<4+-I2
M.6 <0??>>#$AIZLV/*%T9<I!MAH5V=YS.!@O3 @\U %R[=-9>N]0BLVG.RT$
M+R6F'"WEU95FGFE5I5("&BG=U#@-IS-5GDTB?G9#79..YIB,]U"$IML%LFH(
MHW>)+N/)LG4N7#BVJA Y4O<(,F"KRZG=SB?7E#2M('E[__!O<+O[XS7MJBT,
M]BZ>,/<1GD6U7S"(.TZR.=1>)?3$-579+,67!@T JS<%J<(%>Q_Y#GY/_]><
M!7OY)N23%W@)NO'>D,.P2MZ@U.CIN['B5D)T7U512I^2SZ9+,]C7"FXU_TUR
M^HJH_H4@S9DCMDD".45O D4@#X\!ZX38O#X?SQ;:G^@VPZM<5IB0SX@>;7_$
M0)RK<+M#0<PB?^S2I^H;W'%XD_J&R HK%AJ=3B4I/)KJ7M'"H57[8A@+IH.)
M$4OFDRM06:.1MTF7M$20+U+[6X 8X08FV]=K](;\D"[JUU\)/B0DLI2F2M]_
MZ8H4??X;U6B_#M'$&9APV-H:<-7;GQ5 ]P:Y(EAZ0,-N@>6V"8U:^FZ$)38-
M#2K,K$#+F9F0TK85V+H\83=AS&Z+6;17=FFL^^ UI.8\H@;YP8O_?A4AQTO(
MOW@G?B(-E4[?C<"+'MY<<;8!G W<@0FAUZ2!UD0&/BJ2X#],$1!-[;M4.]RB
M)_A5]NB#)ZYR3RJ&7-R*ULNF7F*6M30CG*4,RNHA"-$"6.W4C4CM[G.SW4$O
M(G/PG7L3!B]T0\QVR$>8%F=+VD99S3ZU?76RS:N\)GMY.W2'KLYSC5,P5SAV
M*(>8+1^7=.F3H@"D96DV7I\PME^@OT>?\6Y\'Z'CY8&<-6NAK\Z\M:Y4WMY)
M*]-N'XQ'<VC"$5Q'V)6 YK@80,L!N8)TL_0Y1G?N.DZ\+4RX.5S+0NKX5@\O
M3ZJB!%M,6Y/!S 1/#!&V,CV>8YI]X2"M.\,3^I+S(XG" /_39HQM8\3:%Z,R
M!W"W*A8S ;<K@Z51F@]' Q-VIJ>AKVY5OQ1B@Q;*TWT8;;\B9^_CX5A_2IGF
M*WY_(OE[&ATB.Q:F\$CZI.H63J4[E<1RT8RL.33A-4X?=:B<3:=E$IN-6 0L
M.U<DV)%#[C-L?')U(:?CZ>FZ#'M;:ZO9^G2H4+;W::'*CD 6<#B>:=[\= 8M
M8B M"H0[%J\Y+>RL[#N.G^#E(_1)\JBX!?UDU%7S3[Y*50(VZZ9YYBQ'>Z*F
M[J@;*5AS60?2>Y:SLO%7&$601;.X#8/U=N>'[PBQL17?[9,X@0$)!M""H5V+
M5,W:TZI>97*W\M+$QV/+@<:PNX^:B!C_)2V?W@H&87")TD^DAC@&X?$CN@^C
M<DDQLQ1L[Y\A<7"47/2V*D'A@53[BA6.I.35V<N<R6(\TND1=#)P$:/=?4*B
M&6R]P-ONMR2=*0ONLP\<% $WGPM5]X;N!L4Q&<PHHK/7"<3N5)(Z@I]0T3S1
M.Q3#/ L7[GQA@G?1R17H3OPP^Z@9U,^ AV[.&;3B)TIKM-J&49+FXTK78:U.
M./KYA/ISCSZ;INXTI(_RT\=-D\' A/=8YZN9:-PE80)]@-(S;R<;AS#WA;/N
M&QX0(14V(6E6NJ=7=+O?DM$>1C%U%PM";!3H?])?288DF_S@^7L20S9UZ2$;
MGCU+E]1F%ZSB\ZKW(^J:M+IW.?^WV9',9#@<ZSR_UUMKT8"."ECH$']%(#C
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M3YY@WL,H>7_"&Z"8A!'">Y6/[_E?!%QI4X#*' =MJU5,=2"KS9YES.;SQ<
M%G;%7;UXI-* BH-\2>#C.RC^2DK3'93>AW%\"/QR%SUX+Z^)@+(">84!Z9M
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MJS(WO7,^G(WC/;J&"1K65"#_HZ('L14XA\>OAU_8>=_"G6A]FR#"5'G42N0
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M3I1^5Y64M ;4,?-H[D=VQ .M@3*3S^MO :QJF%Z6%I38@U]I\/*S)"O*J/2
MR'J8W&W+#7^.O%H3( 1=-@.UPFPFG8P<1S<U6L#DFH.C+C,)IN3<6P6)1^<T
M[PVE21\\%*^_VO[>0<XGW*_8D.WV27IF5IX]:S,T]%RVPM///ANC<$C:1\$L
MEIME.UKCZ9RQ2M5L7<=/@.,WM*R&<\L MN;?Q/&^?C7,$64KS,7(6JIR0TU0
M)%X+2R$M]TJZL(FI%4OW+Q[5JW1,_@\W^%_XC]F?\/\C*3[^X_\"4$L#!!0
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M1%;6SB'$RD0\0HL!@.EH"A+$3<W$M8[X>MTI-;#I("WATQ<8D%P523L^-8\
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M&@K3N5&&PCWM^2Q,?9=LP]CDW64=\5&RM9R1>X-AXXWM=9/N_!NGXOCEO7H
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MQJ'-'V^%<J52O+A1X)]JL:Q5M*]7B0$7C]\ PAA(G'M+?UU_7*8D<&S_NN\
M>^KV4+=0@,9FI%W<T _7GLPM52#^O>D-=.LWHKM-V[@#Q&RU'Z6+FT)!J1<T
M9>WQ Z"R"3S!MXYQ#Y]Y6TV@?''S=W7+L7'QVX]<N;B!;\H+QKYW]0'J=SXX
MER/73R"^">R_T?6=P1]/NMMQNSZRZS]T:TI@,[HCW9TC1</K#.D<Z#Y?2%/;
M9%^\=.^>Z/.P (,,S#'@X.>+5OL^,<\J0/92"?<HF-A&$V6C-*;^R''-_Q)C
MP03Y)H43?#\Y)3&U&FXA_I/!Y%J>-\UL8G78LPSFU)GZ:,*@G9K-Q*K*OB8V
MC[55$U,WG]BM,QX[]MX8H5K<BA%BL]P-%U1!@E<4_L]')Y<]XD#"5TM*K:24
M/KQSV:,.I']%J]:JJE+:<'+TS=_ &S%@FA-B>]0;:[C@G+T25!'?9M$C3_H,
M/VI\UUVC,\$'O5_@0=]KV4Q__>(Z7KH6T6):1-MX\RN;<]76"V-S>9JZ@Q%^
M=>^X]./U=>/:JZH*NJJ/T:JVQU5Q$#9_3$R7_B9$X@X6MH4RI$S/-/+=U 5^
M9Y.+:VJ@1)>X;^: K,TXOZ/K TZ+-[5\>&?CU25TE[Q',NX3=_TEU4"-UFKE
MJK;ILL@ 5N//[LC$\4P_58AIZ'ZJZN_\-[\_$"#>DJF"[EH\3]"J18TJALM-
M2="9$(2&_4HG\&#J?=-")XA9_\OD;S93+P:VW<8SOS=M#/O0T9\ / -S GX"
M0__Z6,ED$:":JQ]?Q+/Y.O([PQ>8A^<1OS%V7-_\+^7;_2X'='EYN^4 XEUX
M*9TS2!T05:1C/Y.!I7N>.32)05>V9^J4MUY.G#HMF# ("Y\O:[]+J&S,)2 #
MK^F0?+XOMD'<)+/OF0R@SM4L9%3 XB_[)D)M^P7X(^(^$X_H8%\T;...O!'+
MF> <#@*G^C)Y=96,E%&WD  7>#=?,31_[=$# !A$HE']:PRH_GSAF>.)A3%X
M^MF(!J<!@X4@.GGYPS-HH'#NE?2OG@.&%_Z-QOJO^5;0&2^Q)(/'"0W;!7\S
M#?P[R!I7HC,EJ0<MMZW_38;HYG]\$WR4?/N$&BC!W\!-<7T,BMU$4PQ^%WT7
M3M.(/8HKB(9@WP1_#P:Y2FS'DMU99 2]V&\@L8@!T/-=<^!SYYZ#9<?[Q[>!
MO") V5\-&.S'Q#('IL_F(!DF?$O/ZT)F:< ;#-.:^N8;X9:42<"&'5A3 ^Q!
M6#%:P5.?*IG.L*F[-H@&+X@%?)NEOZ#QP_0N,"I^O717OEZE3C0D1KB>3>&A
MK0\/+6-XI#!/#@_!X'% Z;$*'K$ 30Z-]!TY15@L4BH\J'#F4$CLPCDIC9S\
M^R._@$JAZ;XZ8V*(3?XG2[?;X(%%]$I,^Z3H%<83U_$/!:77O0EN*WD 7C-:
MMJ_;KV;?8D$P[]OL4?^/X]YB!(F1,_A1Z@JS)"U++/-3A&OP3::Z-:?<6>C0
MG,RG(WM#;E;4B)O9N0[JR@?=-BS'%519>JY_W<.\P,ZP91OFFVE,=2O2F,G)
M[Y [Z=ZMQYUT:S-4F>L<P0E&-;$Y,J$R$]3:7F5N=.J84VL[:I6"[,S,J)5K
MNUU2*UMSE+Y/^-.5XN$"83'U#G_6%-%VAT]Q31M7C7%Z%HZG(#N2]-?4+,59
M(K-HA&E77LMN_CF%N?Q3=VF.G]@BK>?JF$_9&/A@Z/FS;S.\S!$9>TO7)+I/
M/:=R<AH)J&@B&BEY)'&=;5<RUN_Q.(124&LY"=:P.#8(*.">[OSH;4E2Z]$0
M;_$:3C$"N DE:9;8*9 SMI!3I.FBH[&<IGN5N)D>G^5T%-AF9(&_G#3B1/E6
M2,*YU#FNW^,4%-\;VWD*2?HF+:3\VA-_)A9>D'T"X3GK81$9EMCM?9O%OWD'
MQ=WXD@>7[UOH;+%Q*81%+6!:8BYS<IDCB)^08E/VG,DQ O*]L D7<F*@V6W0
M,\3!-\?WG?%I0"&^EAP-'_ T<0TLH5AL"'R 1/'E'2&ANO!CXCT_BTT?FI70
M&?*3H8Y++Y1'Y$@NXFBIT&Z? !6"11PM%1X?3X *P2*.E@J_G0 1?CMR&OSK
M!&CPKR.GP<O+"1 A6,314N$D%//1TN#))?=3VQ ]G6,%%>96(3H=5H27\["/
MX(Z^*%'M10#*XT4YC#* 41Z_. 'RY8&/HR9?'C$Y:O+EH98C)EX>HSEBXN7!
MG:,FWTE8+>='O#R<="0$7)00UW;LYGAB.3-"! \5=*=]SS1,W9UU=2Q'0G/3
M(AJ^7\C.R"C@K9*<C$?/C4$1C&#Y1U!*=0DM@T=25G,N?)D3]!@Y-.7,K&4/
M<,IO;,W?''OJ8=Q:<$%+>_LDBP,L7XCHIV@+B@;1M<1;'N&2CHHTB49'Z2LY
M,MI0O^[(F>44>(2;AG^?ZA9MK$/7Q*L2'R=5UEC-$=)H@6 ^.NHL7<>1T270
M+\_$UTV;&,$]*K&)0ON>XF]8_1_4)HX-?YVK0Y>^J".E4,,P3!0"V-C--%KV
MK3XQ?=TZ"4(M7=N1TNMH6H6L2:.=-OK8<SY:+O6.VWU=@[2YN#P30N=R]I@(
MNJ""=2Z(/ZXVLZY:G:10+D^/BUZY6!2#+D'S^!WO_F:+S+K>\/SI7B[./PK#
M75,H%^?'1:]<G(O?K2R7>D>=W;",M+FX/!-"YW+VF @:=2^K"]AW)6M'(@^9
M9&T;[)9"N=(X+GKELO_ =%FLGP40[:(HNY*(RFY'/1-%6V2V/GZYH!0!1V(M
MDD]JNT5.;9.M\*5[%RYK3'1OZI(;TW-*1;5Z#=\%/P^^"OZ.OW_W+EK/V7OW
M.LYY],N-W@?C/\V]D[;\)?$GV],Q<77?<;=<Q;O?XX=WQ';&IIWVVG57DWC%
M57+VRQ;]!"]:L(43^./R#;PR?US#O)RI.R >^^N(Z 8%%PQ^\]77^Q:1/']F
M 4J'@(F"9_Z77*N3'U^^FX8_NE85Y2\PO-]W#("@#S_TC>#Y;YWGN^9SX5NG
MU^L\7DOER0_)<RS3^')Q!>^GSRY[OOC^^2L^SA6=U\W72<K4E(G_A?YUJ(]-
M:W;M@YKU))M\ET )Z?:7L>Z^FO:U,OEQ<?/7G]2*\N7KU23VJOM.NU?HMO[=
MO);HNR3ZP7WCL?7PV[4T_S;IL?'\2ZM]+<'[ODC(,@7=,E_M:\PD).X7V!O/
M=QW[]>:EW>HU[Z1NK]%K=K]>\4_W,W:W>?ORW.JUFEVIT;Z3FO^Z_;71_J4I
MW78>'UO=;JO3WO.$_JE[(W #?,>6I;O+VTNIJ)1+]3U-8I]4_^I-=#L%I;6)
M?W%SWWE^E+X"T]F.3>6*.9"XX'TFPV5)$A>2K:/B,(AY?><,IFC=82[K!94)
MYH^W0D53BQ<W\,._4[:.1H#-Q3G=+-CL+3GITZ/N_B%U;/)YQ_N:U6[]?0J6
M'7&MV3.9.*Y_(0T==ZS[N'FP?C*X[CN.U=<MRP&9\R.QKQI"J%XM5;[,;RU#
MUD?^*_W]I?'<:SX__"8]-Y\ZSSWIZ>6Y^])H]Z1>1P(^[@&S2JHF=9XEM2Q]
M,CY+G?O=;GGOUZ84$R"A\&C<]F!L2:UKI9U,X#]3#RR=V9X8]MYQ)7]$I#\#
M7$C,(I((WJR60G[."G]/].U-YC0DT'=MH!,(+QX9^FQ&P'"P$_ K7=S<D0'S
M(355EG"<%![?AR3M/!\)M]/B:32NL3F[ESF[ES)B=ZGWW&AW6Y21<QX/>#S@
M/S^D5," 0WB']'OPC^0[T5]^O\Q$>>U0OD0+Q*"-Z6&\1QJ:8%3;4\K!F0F6
M)G4#[^'5;?KF!(8K8 H45+56J^]74J3*\(13T7=<\#<*8)(,P""\5K[,T3#E
M98QT!8L,_6M]ZCO!!RZ6Q6"?,.>D5/[+A30@EC71#>PZ_?.%$O=5@BF,"/VA
M6D8L+/9'?E+H/Y(:^B5LE%KM+U_>B.N; ]WB,_6="4JOPUJ7&2'JF;R:'G*E
MCY4N$ZBJ JJ;#X7N;0L\B6>09(T>=276L#>O?&/W/MW>@%;;"]  SOM!53;
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MO"G(7V_DX#%T< ;FCW1_?N[?]>0LZ:D2_3%?PV=)MPWI4Q&7"','6,#7_?_
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M7O-?O4*K?==L]]C.IVU\>:TA8_L]T5])H>\2_8^"/H1W7$NZ]5V?@6.U3MB
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M_F \FC_0L(TN3, <@CZV?9Y#  +I"<3!P"1>#T;Y9M&S*^(-] F\S7>GA,W
MM*?$:(#JQ+_\KFEJR:ADH-(:EQ*#'7\-W2=0Q8Y+IWQ-J_E3S-U\:W1;-*OW
MZ;G9Q=@ L@BE7_?E$3;[-_RNV_JEW;IOW3;:/:EQ>]MY:=,\S:?.0^NVU0R
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M+E>KFU!:EEB3F\V(O.ANP-HKWR7AE7H]G?3O"2Y3$SH,2>"5INCR!YBQ"_=
MJRXL0EE<P>V!M,5?M'C;BLZ025JZ(6ON0:$\=T="PL-+&*AR<5.Z++W? E"=
M%DW&Q<K9Z"?SP7F<9I/%+ZS^MFCQ&"-M$]\9!H/2#@P9K%2YK"Q<Z:742+\:
M(F.UX:@C>8H<8 GD-F$+#],X$MHAXIFH05?0B>?4>];$G>OX\7;@[:7M*=6?
MW-%=L)&TB+M+2%AD/OT&6^!=^]BKB>;(.T @>EYMT?GH(,%IRUF,S;+K HAH
M3AUVF3RP=1)Z+S['8%841N@()LT!?OQ&C(4+3F1)?Q\1?M>=S**N48EE\8NU
M[/0UNML^UUL']!.R4'C5,CK4M&EYKE)-2;K[\<1J?O5N*9W"F_ZQ.<1N8GH#
M<.2"6F P6.S"H$E+Y"$;PL8!5 ;>I70/[O5H?B;K0H;[8V&;(=K=-@S,ZZSR
M (M]LYY'M$J36KZD9_4N0F@^?,CR(Y=0C87MW\BB_<63?ABB@.5T;\/&VO!E
M,YG;V?D.'U&G2'Z?+Q\/189!G<OY-/AUJ47A;\+G/UC8FX8ROH>V7-"H":\!
ML]2>6*1X&,70DD!;LH<8!HM=:EXX-9:WIMN$]46FA1K"ZH3LAV/FIH=->2E=
MH\@2YO,5Z'T&%B2DX6[*M;P;71 <B]5Y,^>L^!,7Q>FYW@FGI2B7ZO3R9,;F
MOE:NIQJ"6D%54RZ)[LSH*UZF&;Q):S^L*+B5M:>D&CQTG=S@6;#F_5A[Y9U:
M>^DGXDL6OT-K;_%*3YS-,5!#+U-SI2+U(I'GG4=LIC/PG?30#$V4H6EFM#!F
M-SPHEIX";[X1])=GUGS3?76P5=HOM&KR S91@;\%B7+\V[ O6]SFBDKA1EE9
M-#UPB;^<+B9I:(C[RWS$=&\Y)BXRBA/0F@#IU^D7J C,'?[!4\IH-2K>=B[6
M\9H9(X$9SG>%GJE&;:-X=);]=Z$702)QA;F [.64M-@F)FS(&Y\'IA$;097[
MH(P[_X1GXJ<9L%6U=IE6^C9LDNXG5T>/!U)7QD[CHA31H#0,+W/+')6P/18]
M 6'=:%E1[-@N1ID,83E]9O6P76,E_,,:M<MJ8@0=;>,KX!T %FQ>?Q:PQESF
M89A*P[JI;:M-U)*V5OL.I:#65C/&@L@IK31!A>6VY28J"XIFH'&-P\4WE7N2
M>#08R1@J).B%67,,TS<#!Y1UD-S9D5">2+D\D;*8)U(N+S+!S^%23NA($0V]
M_5:#X*;.;:R6P!F8.O1FBT5K1 2]*Z/<^[B_'N]2S!)L%M7",;UX'>3]E4%>
M> 5[ZU+[W<&(&%/J2.+>?,-B$W%\-#"I'W:'<MCB'-RLZC,S_BK@4]?ZU'>"
M#VC!!?8)+[[\L0K.<^(O$GQS%0+[CN\[XRSJ/'_U?->Q7V_:.DMKP'[A7Z_X
MAZGEGT=@0]--)-=@)WUW]4D6\T@IYQ@H$P/W\V+E%C$"U-_5I>9[E:(H )L6
M'O[_?%'<0;G%4!T%6]RC3<>9;4Z[1;L8J$AN=E;D9-?F://WI=1\:MS=M=J_
MQ+?SRYXHO%B??NF#UL<>([91 !(Y[O5/@P$APV&"5U84S=QREBW:#A(#P]3J
ME#HL:9SOY*)JZ.I?]K5K!QV9<^1PF.#(]1F/BLLO86VK=VY#<?[(,>7(.200
MI<\WQYYZE#@+7(=T[8&A:U;*Y]LL>N1)G^%'#>P$UZ;]E[GZ\1I!(N.]X_Z"
M8>^/..5:32ZE>!V'IN]&_#BD_^R!']N.7?@[-M:E9Q Y3QZ )\LK>1*(%-*(
MDHA1Z-@8LRI7:U6Y>.R\N3==R;B1BN"<&??$C*NST8Y6+\K%FB97*T?.?7O3
MC(S[XN3+F7!/3%A=RH2<QQ@CQNF#Y#D:=JQHI=3@^*$)+*8JG'<;(Z4H"%.<
M,CNNSE->X#0>#S.6TH]Q#TW>U .,@QQX[>NX8MW[1G%'-0A6\ZM&(@3F-[[%
M@LD^L:!\Y.2)&HFO;Q>)WZGP%2MT_I-"_\DHA%[92PB=M@1]A(T9>5*3YJ$N
MB)_O:@;Q0S<1SDG6/^,^=3@?T4D06R(*65$/9W(J9TAE350JB^E+\>"Q](I&
M,S$$<6-.V(&JE;9.T]C65>(TIGZ1U[)90M\OKN-]Y )T64F__BP #<]QY*QP
M6SCT6L2,_P9B,KR,*@C9<\ =]R[F]#MQNXI?2,@%QAXLJ_*A+*M[1F0L]QR8
M5Q\YFRW+-4W+#2LQ1MX];--;9VDQV&I' =OT^SV')J'H]N0$RQP*@O53YK+*
MH91#$TG,BC1FP&4E\3CL3$<^+0,Z/U=..5>FO7<I7R=3OW@7F.O4<I:9W"1,
M/TC>.'28/$B.UF"_?M,MO&SLY2?)QW8HDY\DYR?))P3G(SICS,^03YZ^^>GQ
M1K-L\K(QHN;!IR,M?3[_LS=G5)LO<[S8D OSVX.=ILF "TH?!X^P"C0+_%;>
MJ=JQ.\/GL!@.<TMI2;%;5A80/VW0/@_;UGNIJJJLU=Z7C!80)CE YP&:'DI/
MB4D>,4 1GII<5]Z7MCXT4,2,6;9C=<)R@;\9/RVL[OU.X/,KOJ%F/0I6TNH5
MN::)QTA"C2PJ-NMKR_JCQ&91K8&@?U_2_M (V2SL^O%!]Q1<#:B?+*7%J_0%
M;:!H^<;PPU@O>V<2=;-R";ABY@"_8?4R6:<Y+RSY)SEOO%T];009=8@.FE+%
M-=964^!U.EEQ2M8("WM4T5+<[V?!1I_O^<X+0K)6D5C8_/!M#;<"4V*P"UI+
M[I]A67+8*]SLD/C\[.L,*LO1QF>T"!SMB@;"SH]Z$3"0?8]O4Z+::H"U>,U3
MP/B[8G,BW&+;.+LF>?@08*5A&S$5PG'2B=9_(@<2*Z-AJXO,91WFXA2XVFW$
M/>3\(XI,KAV0W.&^T9*[TAVHC-/<NCW%<GG%/]H7 "4%[6[1Y%G;F2G>]+%!
M\0=2[DI:P@?Y,<$Q(2H$#VVPD=/S^.D9Y&,ME+;Y.<]\^2,P!N'+]D&!ESTF
MYF(C\T9OL9X>&ED4MF.[U$Y&1= *IKH=P:9>W-2NU-I545%J[WS]@S+UH:3(
M7%SKX^$L9755TX5TBCJ!H.WP J9#(/Q#_X6K]8_T$RW+VCJATM,E_5):;Q</
M_3ANU#6*_2W"38 2:B%\N/66EM9ZZ^#4VJ-DV*49L$+D:\6UPQRK(!%8&2CW
M0[%?K,R+?1ZJ%#(7[: 5%YG)\?)R7C:'IJ3WQ5L.P)>7Y49'Y4I5 7UJ;G3L
MR.A8V(UL#4+MQ>JH:W)%6>-2X>G27DRK8WEUT^7 R=;L*%[6<K/C8&;'^AF!
MJS"1M#LJ5YJ2:G<<B\&Q[QC'O\[-WDB_?KP<>?]:;FZH5ZJ&YH9(H#LE<T-5
MUM0:*73:B[6A%M<LH7NZM!?3W%@W.)8"G&RMC?IE\7W?Z8-3ZURLC;7ZQ:X#
MB:2Q465R_WB-C7U'-WX[-V-C[1Z5,>#]MMS8*%ZIY=S8V*'.4-?4&2ETVHNQ
M4:SDMH:(ML:Z,;$4W&1K:ZC%_$3E@,;&9G=?EF#BW8E*^:B-C7U'-AX?S\W:
M6+OQ1@QYCX^KCE**130WJ@+![J3,C>*::B.-4'NQ-S1-DTM:\9P5BI &1W'=
MJ%@:<C*V."[7N7!VNO@XK,&Q3=9>.B;FSU*HZ#]>BV/?X8WVF26,:NM7:(MG
M#ZW(&*U>%4NYQ;%#BT-;-_/O4"FC1461E5KUG#6*F!;'NJ&Q-.1DG;U1/FN+
M]* 6A[9-SEXZ)N8/5*CH/UZ+8]\QCN?G<[,XMLE7?GY>D;^AL*RAW.38E<FQ
MNHOR8DKMQ^2@'<GS:RK"F1SKAL?2D)-UD*.2IW <S.38)FTO'1-)DR.0_<=K
M<Z1$.1:5R\K(^'AR2>$>"\<+V<@#EKU_@*K%#<-PL(=L"U>8)L4K#:^R8"7F
M->!Y^*IOAS96LJL4!R1=G3ZXA(S[N5TKEZO5O#'I<=8B!(2MO@^S!&'9VC?*
MI:(H>?UB04;."GOMJ\:A5R-F!.4VK&VXK';1*8=2-KN#]8U"C DA^D&T@=[*
M YU::G1%^NM/M:*J?I$63G&SQ.V>,]EF?JIZI=93;:Q#7E,_J?A/>:6:BU&+
ML>.!#*J*>NY7>2(#Z/]O[TN8T\BR=/]*1G57CQ0!6&Q:[)F:H"2YS)0MJ87<
M]29>O.A(R(O(=I))Y2*9_O7O+/?>O+F 0 *$,!,Q,RX$F7<Y^_*=M<NDDGC/
MT\G)Y031JFVDDR)I6%7KK[--O'RRI&1'2\BM56?14H@$@])_+)GWJF&MY1I$
MEB7]0G;M!-5<40]7Y;G,6N5RA:5+D7,N&@>J&);87"S:L47 Y?C?>$2NG]C,
M11M!+YX/#XP[+H<#EB[ T3/!?A4DXJ0_"M/US+?U,R9]#CVQ[X$?8& H6G>7
M_^>NVKVZN+RZXY,H0S:L-Q=ZIW$5$_M>5/NAL+]5[2$\Y+UE>X_V%"3A(MZ*
M?!I"?-O6*$1.^,O=]?E/OQ"&,^*@GR.3 *'_YSO[%XD%/I."5DBF.=HCQL4/
M_BD:.,U@#7(M)<9ZS5ITONCEGXD;3S5F;.DTT5T8MPKW?C[":<F1Y?I68=<[
M#Q%_D80([(Y0\#%-PAP'- E3T"3, MA[Q9II/!5:&LH<!S[JKL\'K<YYQJR.
M[P,1132S*?4FQ$L&5,\.P%J34%2'%+HS(/%C"W@E& X%G=$$S3B4'#,-R./6
M K[3,D?0LQ&>GHZ C,@;$=)>5F ;-X_.BAETZU&$0LZ42 =5E!Y.$*;_#E&$
MX%]M(!QF(>-!EK,4C375B_>,MRCCE5=L-+>'\>J55KO<52^E+2(>(;VG51"B
M?M:>%LO>""<[[P@%&OXX3"94IQGS<2UWF"V:,4*G^H;/<\9+&HN;5M?&$!]C
M) !/\3$\L-5-<,^-Q]EZ8:<)I4(_P=E<MC]5ZF26(&PM"8E]JV<XD:B+%O&#
MM6+&7_"M\=YX.I@I+C\&H9PR]B*THG:K<EPOUC+1$<T.9.4-D2<&I[V)HSA%
M\ZT($VE%]/<*SN2:"/CL07C3"MIIQI"N03 &DK/DK*[LL"Q8D!J$%=4LG)GT
M2'XDRL '$8(;:MVC;+0<.Q;6T'9#Z\'V$J&&:?'[9TSB>@0Q.M->;"\)</:B
M:RH?=8=2_UZ,P1'^=9I^Y<:>XD<=T J.%%>_D7KH^GR[?\@3ZO !T1\Q*O01
M3N<?>#@KL%!/9U#]G/AMJ[R??RUD_\;.LUYK%]L^GZW!L]Q6>[OJ?+.F>J.]
M7 Q94B&\O7,/+T8:>FTIW#Z:8<BK>7&/;CQ"OUG9W OXS<"XR^6WESP79KE,
M.J;K#T(!K+FF+)/I_H)&L V=H%P*5#3JS'!&I.6.Q\)Q@>F]*?'9H^MYTO:V
MX+"N@@>F,R*S9LMPB_31SW[K,QT?\_^^8:-]<S:J=I_B(+8]/<,3J-^>3,+@
M.] 37? \7EC.C"WCA6M84OC*@J)Y=E(N*)[0X>URFVB6#M_6[>-HW[+MY^U4
M&L5*A!>DUF2UCU9#=DPM>9!@><)RDTAQ-@WEU/NN6=?^#$KMB4DL/SY2:LIX
MQE  [RQ#I.V%JT2>NAE,+:9?_2@P2C4 B\>Y"<7$=IU+9J'GW 7-6&[7GT>&
MLZH]C\ZJS:.MVF!C(4*S0SU?V,%<QR )0UBQ94>1P&!WA-$U7(\26E&JA?K"
MLL=!&./$ZW2F<"C&MNLC^:@YPFK&L:S%6D>>=4GE,:,#H'ZZ,!I"7H+<\NSD
M&SN,IW=@IT=\WM&%&PV\($K".1-BUQ=_NE@\_G1[^;ES=WEAW71N[_[7NKOM
M7/4ZYW?=ZZO>BK-\VZGGP>X*!9M*?J G84_P.JW8N,^71C=GCDM_?=I?>ERR
MHGVP<L9N3(*NXSOGQ-OWPA^X8@'RMZ0L "\WECGOXWJCT3I9*V-<+LX8Y]=?
MOG3OOEQ>W?6LSM6%=0ZO[E[]=GEUWKW<%MY81?R7DMZP9:P3M6Y%).QP,+)2
M'49I[TTQIJJZVKP@Z/I6)[F'_V3V-:UXJEHA-8ENE)^:6!5KDH11@@X5_.5Q
MY,+!97]X;]_##R_#^P"\.:MPS!4+E'\-?PR&UH/K"&N@ON((4-3!!%^CXY%:
M/DGK4+Z':K%//D16,@$;D8:[!_[01>LA"-$)N7>C6 X2C>+$F:+"%]\'E 6D
M@"<:?#6K!P:!F+WS>.1&Z=XM-[9&-M9)D.G@H'W!I(.2SUR]-B 6MRB/CY>#
MXI0'7&[DDQ&F3AP$U46Z-FEL+6AK5=LY8\L"@8:4>4R.?]&H!$;T<%LV[;V@
M(]YRXFO1<IK/&%;)2Y/=WO:=P4 >;A^XQH(')4.@"[8BX%^NA\E4'XC2^M4&
M7P ,:E&QOMCAU$,&.D V[(&PN8,U1/R<0\Y']!/7PY(_RB: U1TXPF,CWAY@
MN,%&+J:X6YF,0"? '8*(8;,F0KZVB9L'\#8P[1/T-?O3C!P [D\W(*POZ+Q\
M RU)PJ/L+3<CO/9NMYL*M#ATX?_BWB)@FDCE2YPPN;=<*1D>TE=_O.A@BAF$
M5^*A'*.*K'/;MQV;8RQ??\>_7R9A,!%\,'1(ELLY'!LN)QS36QZ!\*;6%(Z:
MG9@0,]DA>33@BX _@S\C[P?VB48*"EE+V"#+\$=8^3,SRWA</HQ3Q22D#/HG
ML<&LZ"2ZA!U:BHI#W@5=DKQ1+',%T>SPXTV"%4!2$E4;/_U23(K]S.>39D[5
M$9 FF=A3RP:W#M[LP?9CW#P>$[AO4>##9Q,\8C*([>^86G/!>PV)RL!''+O)
M&#Y#WR\6/GVJ!#[ZG!-,D V"*.:C3V*D>U>EUOC&X.7!8V324<4BD@3KVA.T
MA0I=#54:T/?XAT1]CT#!PJ_234F/$PD#-Y: P,?OQ2;7P)/QO_%)D@0;1_QK
M>FA%ZG$.M1+570_B .4VW.LIKQN(13S"R:A0JTWN0YSQJ/')<"D#)%\D&?DR
MLG"JP;":X,[1VZ:#X0UYKMUGP= 7 QN_H>/F]/,@2J/$<(OX2J07N*4^J-,!
M7!)<0ZT8IEV#][&O<)Y?X=S:5SC/KW"6WEZ)'SALVL<#>S5^X"(*NU-NGLV,
ME&8C:<C4/G!Q/PB^94L!AB[+0^;M$L9'>WK1$.OQ_"$%"RD:91%_Y(71=V]Q
M6=?#K_ K7-,*3.'C6DDIJ3:%Y\=93V;A%'*<=8MV>5)KS=\E*1TP)?S!#()(
MA?TR=' R'U;IV2?T6:UF!6=S5BLIUEB4 F;5C;^0 E:YO_I1K22%(#=(Q49L
M0RQ^J?-1UEZ^Z7,.[Z]@[XU:$6ABX;N=E29:U=VN<INS;QCY5>9+R!R,*!^2
M8(&7- "M$N\-HP"/8,[@_X\$5O: _8BA"2N"Y7CP_S/B@;V88#C$3 I:ZQ2P
MJ%DO2TRK5Q25$1NQ?8$/=P08]@.70DU)1$:SA1$D^A%&1ZVQ &/42/YPW'2*
M7^7-HO,5R5"0?!B>G,J 4SX<2^H6YI#%2T*6(J,+8W4R&G3MWPHR(L%-!JN$
M#F<E$:(Y0A'\A3X0@W)@E!/B1AF7XJD0&Q:&X&U@'(#\*!D+=/"/:-_",=-9
MH(A"GXZ# $#$5)XPL"-8 >;\C#ACCBB?7R*&T8K%K9W%XW]+7??KQP*1J[-7
MO:RZ:+47+PE9ZG#2F(.[:'O'_&,HXCSK8T!JP*-PY3O9KXX7I$.L(O,'[@2#
M$S) DN<5>LB0 @M#.!_Y>Y)E:+I3$&(I?DD?N.1:U18UESZQ4LF8JUGI#-^&
MM4&ALMEQHP$J,BO$()"T6O.QO9Q$@-W,YN/3^1 *KQ$>.ZVUBJ6O/VN3O7 F
M:5U#JMF,3><3JJWCQ9%O%MZ^:>SDBH-OU?+HCW>PN&L_*\2JD1B\![F-,:Z?
M?FG63IL%% &*C;[(MB!FR-(]1_THM;ZPW#]=O 3^V=;BC9(=*?&L5>1S:94;
M$4LO4U5UNCAXPZH<XP[7]9!=L&Z;!XY"&<84!35>392U^#DMCBS^['-2 F>5
M5L(<]0AGH]6&%/WEP0-7.@JF25&S_F&'+L7]^,MI0#Y*T,Z(,N%ZXM-*&IJO
MR"1)(?)?&N8N\R2"L&25_834"CH\=JC71)V%*H>\M 0B-:;J=Q8UGX[7Q%;J
MT.G+YW"H*R&2DA8G@T@>U$67B%[E1.1+_=;F1>QV6O?:M_['!BLDG%IU61:?
M+?;F=&R:5P/'-XC<>&$Y5IA?K&N=C^IIK3/\N\Y%#Y_A_KP@+$$7_:AL7:,!
MZ8)7@PU(M]A\1 &+E01*YE HG )F\3RYT@H%,A[@IYQK#7Q!IH<V+4,JJJ&*
M%!N> '37!^I\Y%+HV)TD;&*3@8OR(1H%WLS,=R[^PE8[!VIT':OF"W1.?:F)
M)/VKX&TT$O A_,KU,O<]%BCK\),Q&&#C9,SK4C_3I* L2T4/E'Z-D] '@;?;
M+--)*=\:)E0ZH(Y*NG'*>>-R]IQG,:-LA@0:N8^4-WZ_.1B:60#BBX-=+A3%
M_&)CF4@\I=3=[/+A^?E58R^>&,9S\JV<N*OBM][;21RH#TBS\R<2O';IC.QK
MHL1>49Q2FP\H3 K)O/:60 :_#=#K5A[S+NO-+T3;RN=BMQ5(]GKXT45M\K_H
MG3ZSYZ%1.3IN+X;]N<T RAL;>HEG7<H36\H.KPVC6SJ=XLUO=SO!O7F>R^N?
MSC:3X0HD^5QTMJ4D^44BKN Q=X_">Q!?2-\^7XZ?-LO[)%_[3K93CC,B[%90
M["[SRMSBC&5Y!77OW6/P?!8Y:YR]?1;9I#HYW1)"W646F=O__2P6P>CO<YFD
M63EJE/=YO_9E;*T>.=L24MUE)BEO%7D!DWP,DN?[S.T=\)@WJ$::1UM"I^5=
M"FE_PM:PSA,K7 U/S9W"]BR><A]R>N??(@P<.QK-9:?JDXQTT[FXZ%[]9I['
MQN]J.]4/5Q^6)@B"/KR(2P*VB_VVALM6R4QS6TR69:;G*J9ZO5(_VH$HP,9T
MTV<1198[GB0Q=^KKJI%L34#*2N7C\O::;!.:[& F][7FEDHNQ'U??57 *1R&
M;5\JS5]DQ<IQHQQ.:BGEMDPVZW";%=65B+'E.<+R!=WIEQ86;SF?;0T[K5!E
MM6;U"R[.-,]ECK-*Z_1XKZ:64U/^DARDYXPJ?+H)%HD&_I;0]UZ#99AQH?*
M?#U[OGGOAF_XF6QI1;#6__JI2D4!)ZV]\GJV\K*JL#&_^L89;Y65-)L(:+06
M2LS.Y*&KP!^L@HU^.:FTZBLP_;9IT.,N3:HKP9A"(!R)*X7E]EQ1F?:2\;=,
MV)U9V$VRYW@D;.?/Q [!GXQFHH^K.CH3QCQ]NDL3A&94FWMV'U$7$:$N]_2/
MHA]2G77CC,#-&S4)CY[=BVZVEI!-^!>D?*,IL 3W:!#<^^Z_59.!:MH+<_7O
M^7[GOAW!KW6[,W<WR_XX=;([7LN[)I"4W*V^%";E; 4-A[I96"UM31 B]:<@
M1.;M<X5 *>O?YQ-P("50*7FR>!Y8RMD*P5*RI[12.)%:R2R61>E@A7 IZ]SA
MO/;(Y?%2SE:(ES)CUZN#$IG;Z)="B>0Q(%X*]:&UG@)HS?0"SK /ENI//5LQ
M)@=:M?0%V63YE>K#,]>SFE[=.0@VBP%QW N?\%NH3=7!E!4#[#Z(=4)Q%"[K
MN6 <RV!QM([7U%V;O5B5./JZHM[:.5=<;)=] LZA:'AN$,"A= +=0C@-9<N>
M,S9V0T@-^MJ7@FPX.UT&LB$[CF(AV :09BM&5<'#N+XQ:?Q)Y(8YL W'M=/Z
M#-B&]4W7V&-\SL?X;.\Q/N=C?&X)DF?%5'9/=*)B7WU><.8:3E?FZ;^@XW1A
M?*R\VL4TC! SC-Y]Y^F^\W0K.T];2_5@S*7Q]72@GNQ *GC??_KJ;][WG[ZV
M\-[WGVY$GB_5,+20/%]E'^II^;#2U[Z9[93F^R[4C7#,4MU#BW+,2[M13W:
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MU5PX+$8LHR[ :%K:4O;!7N 9_<!OCUQV@ 2KZ]W/=EJQ6E[=IIV=!9GU^K;
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M<ML>P#^9IKQ@8,MA3$AWF&RBH5("E ^]&>=J>.0\]T7\2#(MDSC"7V&A2!B
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MSVHWSDIBK/DFB0(=*>?P/K2G3[V)^B?@5<VSEKX<767UAAN;4Z07=WQO1>&
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M0F3-7?$US%'%JCK6++,W8/726 WC9DG/&5N]RUP.%"$GJ3N2+I[_FBD*1'D
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MMMI'[]I'A;I;"J>7M+\9/1QD!AM#R.TX-UP/+&,:?(X#&V8JPXRB3=4@IC3
MH<;Y4:JU^P#+:QS.5U!"PQPVE28!9(OW(6GFPA&I9"&77> _LI.'E,*K6/TD
MYOE5ZA6N/+@TJHS/0!NB2NG$]*>H+&W9L):V E*I$2K%I\O$8.<IM/^#[7K$
M=OF1V/@*[G?/0#9BHQU#E:H/Y!@GO7"J5*.H"#:JF8B%1H4S/SF'&4GSPV>,
M?N+I!S6KHQ=</CU!@Z72K?/(!'J6 ;6:@K"6D9[$R*)^T>PC4C#7] F9WL9B
MF4AIR3UU4+$=5TE-(XFR*61C9^9+P/^*\?0-O>&*DVRD;:94PS,':A];CX+(
M$6^&*O%P:C?F8"J(-.?!M[(#O,$Z_<*#]X35P=HFQ*O[TDG1ZM1?N1.8GZ&$
M& *N1-9MNAKUA"^?;CMZ:-A7WZ5,/BS'@04>?/W]D"0T8?V4)CZ!LD>H(RV0
MD7 &DL$C-Y:XJI*KRN782#9/DP^ T;NI*A>$IT<8#P1^\J8ID!J7VQ'>!.5O
M9<X619A.FNHYWD:+* MYY C5'6+'Z=4HTHWY/39Q"&&<8HU?E'*O#&/@DNE$
MXH!RNJS?''TXM#0I!/J"\GY4^^J8W1KYB>,V41B6 U8L@7MWJ4[39>>#R@3U
M%#ZN5V"&0GSAFG4I>RODL>,>#;!>1$L5$T$X01+7!U\P= >DH7>#Y[I7UOGU
MU?GGK[WN]=6VV-C[G,L/'F%1;G&/I98VJ5!&O"^9M3H3AJ9,>JKYS+(]63_\
M 6UO[-'-_Z&T9W=^]WMY02Y9Y$KD58QA.N4XYS-R0"R6,_.?72[LES4&?J9Z
MFP<HI&5A75D6=JAJQ/>AX'TH>!\*?IF@ZC@.^0 (R^&7I%O*A!;'/X6V+N2T
M02W"4+(\8LN?C/+*R<&834:H&GJ72C'QI#;R$C-.)D/B5<I&290-2(:G38*(
M(LJ.Q&-6 R?+LE>$H8#O^YL]GGS(OI$M6)SK@$88=GX41LCM!<]>\.P%S\L$
M3Y&'>8*G=6/.K5.RIU#+4E* F$W-P*)HA(E][Y-@F#D+M4SNY"(X_JPYR=:!
M@VU!8VKH4Y.2(WC&H8R(9.(MQ>$YN5_+@;][\;(7+WOQ\C+Q@K7-,ECUOHC_
M;[OCB ,J]]+A,:N^GQ(TF8*T"G-YOAA-SVU-J])D35T&GT"5[7//C ZS222\
M[#-W RA[452NS^Z?B>M@!S2A'=L3%\%5;D44).% 1";)O?%(5L_EIB<<>JS[
MW\^QU=OG*HRAZ[/*PDZ-8")"&6N-1Z&>.H53;55Z"KN.T3<78+F20UY!DB9.
M[-.HY)B;KFP>E6>!PHMM&LH> 1T.1M@3I:.H:B&D766FQ@SRWPN?.F5@S[%:
M' TTCFA<!DV;5M_GEFX'QST'$]5^DKH5N)9^"+^.Y%ANLL!!FSJ([T%=73AU
M.3_[["OUU]",9L*SD9WC:N%]09UOZ"(,76(53%=0"BC3(<2GC&M_$"-WX F*
M:M!"]%RN!-Y$];((V DZ7(YVEZ]*!WI):I7]W^.W#O]K5!"IG=ENE'IV)K%2
MQ!JEG^]H(PL'?\GX/ 6HL?5&MT=KJN.XM::-BAXMAB1%"8D(,X<RH@4?)^ET
ML&0"-.OHXIW\A<#N$@Q])R$[NF .VGT4.BCAX0\([.3*1$J!ODPN< +!_BTP
MB#MP<4.89P"BH+RJ 7:$O5-$\MS^164*/*099UVX ^&STQT24B61"&>L"2]G
M,/+3>47?_."QBA"!B#9+3W-UZ"[3'J;U!ZD5S^/F-I4-.E"P'IC4B.UOB#U.
MW9^<P*:91DE4%#]THYQ0P-M+)JKP*0P&0CA16JP5V5SY@*]-I0]-A! @'5)V
M*UR0EY'V9?Q#?TA/74].AX<[L-L@.XA])U(<[/1$&L?B2;LDLG!P^=B6(SNP
M_I8J&/[:/+) _7LJTYL5ZGV1 E50S8!+8_UT?DO=!E9VN'@)Z9\0B;:*+HPA
M/5%$*_U %@]2@V9R,1PB,@$O0R&JZ;>J5TEQFR,ZD"3?1)PF)F5B#U.>L$NL
M,LF$N[.DEGUC]F^\9BXTE(V=6*.&WF%.&O!4R3ZI2S0Q-<>I4F;% IKK^!ZD
M7.,R#NRE&X]%B#D_+.Y@O#ALSB,]#!K-BV7#7Y8;QPE"GY@+S>E2D]\K:IWX
M/5HG"&.65P6!D=E7E" J!/<_*B&6:Y@EJF0)C,PF+<=/P2,*%%6:(\>A^:0J
MDS"+,Y.G0"Z/4'1@+$&11&X%J1E4LR[8$@E1XH2&\<'H?ZF]A'MD\6#(&PQR
M1D8U493T,6]!UKD3)/U8\E"9U#+H5Y,\5<UR>RY\!E>Z[WG<5 7@\;X"<,VD
M=L$&%$7S8<=" O%9;.Q=@-0<]\%N;]8KLONXW#J.1B"X% )%?YKK<?[K4:VN
MU15OJV>.3$JGY9(4Q]H'^3")SB,<<D:*]HE>("[.4%GPG+^V:FWU4JS?B. !
M_2FO-8E8,PX367F3WQ%+U-"4-<$POZM6NBNV9?*;3M^/\$?VE,T>-K8(L9Z\
M0().!^KJP]5( ;@9QWT+":SY; ([RQ$8&0=1&97-(;*5$H=>4:6<.EISJ*/P
MSIFT4C%HNYQ'KG"B@N219I9'"FMNYT[QAR5$D'3U2JLML1E"445JP/X.<N_4
M! SQ'6T^H!=%=%?!K&]8SG*,L$LR8-$(X:T$)@;*O,X:>1^9:L&".U>^P@[%
M"TT'#F01XU[:)?&W$IX]3N5,VGVY 'U+]/Z2=U!]?\378 I0/_"K)" I%A1E
M</ERBZH;FA']CQ%X=%4N>D<Q#+_6Z+X"?)]@*F2H!M^A/RF5FPBM:3P:',H0
M2RUUW,@>8SWIO_D#N=)=XJ4EQ9@> ZY'+U+)KC&F,J;"VO*(77K5'/;54*<4
MKB,$\+BH1%K9T 3746>-O*=?*'4RUK 8+T"]V3#N7RIPZKA(>_R GMV $C7:
MV<=X"D:N*.3(+ATC)+)KC]!F&HV]V'F(C)6F;2KR*9I5&<V2X(>8C'&I'%T@
M8T*V%_B&_9+91QZO/;,+CI(ML%>.L#]]LF@;&P:Y:4#8J4W$WS(M:,VJ<"@!
M)M9-3I9/G[N5G0CA+6U&<#J%!PODXM\FL<\Q;9O&5856O?USI7#,"UD4+/$U
M(;F1$<QW..)BSV P("]3-)=1 .YOYH\E+AJQ32@\%<^<)&#(#OB3O#&;I<79
M#N6"E/DC$I\A_%'/$PHC]@\I9EU$G!LW:O1)%0B',I;J^1/;=68Y,NS >"Y'
MVG:E7V@)"S>5SA>&=+Z4HF WK5IS/M8,[<19!%6*E<LA?[[LW/34E%@,Q3%8
M-[;11 L;,%& =J+JT2? (:#T?XE!O#7QW,6[33A06,5OO;>3.% ?A!3,I$\X
M!'S:?E8$>*W=)R,W%K1K\1[4RF-H9TN(5O="%<9V\ !^PEF_R%W_]=/Q3]E.
MF+-")TP_B.-@7!J57B,6@:QJNB/9_H5E^R7*]BRNPNN<Y^)1^-VAF/)L1IK'
M6)Y\3"+< "F9-L&>B':/B!J;("*T)><2STWGXJ)[]9NYMP^;.^[]_;[\?IO;
M>K^S!<:'OCWXAAV0OE.%\PK"]W\9# 08DC^]9KGREZ^?[[J_=Z\N9_?=UG]^
M!>90;RZGP?+U_#5/\<-AAN(7)VPR2^&)K4KKZ*S2.FYOX<G\N'?2;)Q5&NW&
M:Y_,4JP^I/]Y558GKW2[2.H)';31)973YPJTI"+<QE&E?7:ZD*YZ?1[?D\):
M2:$) NQD&TGAK=DO=]=WG<];3<E-H!.LX_3$A[5HT*=>MZ2]TSRJ'!TWGR+-
MYEY*O;V[;;8;E?;1V3;>[?R*U'W%\KHJED_V%<OK;EA3)1W4X!"KN;,N/4<U
M>2 *9U^V0!:;J3"?K-':=,HI6RP:R08EV4B3[:PRVTLX+04KU:6E)?6K)3TG
M.F4%B[H/[3%#6Z:)52Z7TKU9]A@G2#'P$O=/I!B9,O^J2L@4G*!<$X+<4=XV
MWP8F&\Z<\OX1&K%:UCGG^O-Z;GQL52EL.$@+4PB/A9M!5<T!L9JQLRSLHEI2
MA5M+)B&/JS;?3+6N:A:;3) KHLB<M=D6-8= " \0GJM[?HH'2/7#E&>$%]:L
M/^2(N-)UE[7')+ZZ.NKKH_[5;+M/S>(^XCE-=C)_R:1#:>9LOZ7YX@'."\/Z
M8,0"DJCEB%Z>:]?1W;_X&]DM5.P'+%ON*^2LGPUUOEBV_AS;'9&*.SR_#4GK
M4O;C159IJGZK)2=C)?Q'E!%U=KHWH?>&]#1&^$L&]71$- C=/H,?W-AA;'6[
M%:L;BS$O_&06@79\/Z$F?VKS E'V,0C'L)WJ[[I8E0#NN("E)R:QS%8=J2I5
MW8*F>MIGKG=BH^&&E?D(NVD.=V>$AC .[2E+__Q QJ$N+^9!J[*<*4SKD7--
M9THKR$X\U?R<+YG]5^+<<UE_?XHMRS;W!=>L3EJ R%R:K@#'O*L&60(A[B.+
MDZ#$FJH10X(ZXAYSQ/ ^W6482U _6,Z4A2#.*-1G5#$68!'8%W*O6B%UW2KL
MFD*#(;;[C2>R0Y-A@*-TV(/ZG3X"=57ZW:0XS,70UC0*=DJ8(S<"V4D\AY4;
MH8LX@7!"\'RZ!O$=OB [\> Z95,DHI(IJ(0X))A4N307U%$4AZP371]H;BRK
MU;3RY)Y"V6TJL2AHJ*QQ #M1H_0EO?[BN) 42GR@A%XIHYF$/Z:>T5)RQ^-.
M?Z1 LR>2D+DP-)T&/Y<C4W[8B5M 6_TSU<"E2D6]&/Y$!U#G[J4Q?"WA9GDE
M7U4;$-F^:=D^/8_\TFHPK"81<:Q@X.!"P9VZPZB<>6W?Z#GG'U,_N%F'C$O"
M3N<@#)EHT&)@Z[#P/&;#63]B.Q-/D.JF P=H2;]7,SDC_\VC3#26BH2(O],F
M7T8$L[PC4PE6-TD4'($AZ%0?6%8LSMX*[22W\)TAV9[1PG%NE->6D*[Y9^XK
M'TID%K,/Q,9)M'2QDLP=+#X=VFYHT1!QE,"2>@B\!@%WJ908+S]TB M2^"4<
M\A"I3KQ.[]PZJ9]6Y-I@:9DEJ77VJ%;8_)/<!O[J0,[%D,^20S$.F<:-5:+"
MI^<$DFH07M+VT Q!_N&IP;C$7]')J?8&HX!P:.C;Z.U1*Q[0O9"#+++?HS^D
M#$O#*8A<X?6@F4!_1>^EMQ.ZW\A]'$@#7;Y#PJOH\1BX5OH6_X'P=; -Y_O$
M5</=J:#2C;Y5AVAB2&> 74KPE.V8G#]>[<S.'KIWXKY! 'SY[\Q98 $\"2LT
ML^'^P5*AT72J+EFW.-#&P2 3!#Q*6X.#%VP"R*:"C;# 1@=9HV_>]3&FA-?-
M9'K-!'/CV5@E?Q7XU;^#8<W"LNP;1>+._N77P$\B_DA)]OPKTZ\H\TU^'9$@
M<+*H0O</Q5"$H<)0HHN3W$,_D+P#1B^( 'X$@>\3"HV&C07IG+<!B%B!#Q#:
M?R<$:>D&M>10PU. .?P(3E0!6S'G(=81(H,KJ<-\9/Z>H5/\M!D",5<8R@B>
MXY+3+F,H#,.B2O3%=YK^)A\J,5FD))$6/LH ,K^YFS7E4/T)?;^&_ITA"J-$
ME5LK_C6@7G"N3#ITDG")2(ZXU*"E]# W5Z5BRQ!!:G4D"J7Y[]@8.QMX 0D;
M^D549E_2$^54"2WJ= -#F'5Z4)!E1O;0H(^[D!375'X[SIP4ZRRMH,B" F'&
ML"=\<!).$)A87RB?')WB4+B(:\)D(0T>V6K& ^=& @Y@ (+=;'C73Z47DM_*
MAQUBGV1$MCDI3.X:(Y)17Z$EHQH.S>>0MX?N$4*_*ZPM T1*PYWJ \*./=_V
MIHB" RO(N'226/H"L9X"G&RO8TE$Y'GS2[IQ94I1=C :_@>2TTR%I'2+-C?9
M_D >X4$;NFF/IAT9R%,J^D431]#V2->EU.H.];?="C0EZ.Z9ZQ19<'@1=SU;
M44B_)$M/Z0^?4EOY@(<4&A4\7W+=E>M3Q(VB3Q&2C*X%<T%$%,H)D0"*?.E*
MG4D2H#[]&4:HY/?4 HVD&6-3>;ZPSNW0@X6Z8SWG$A'?)'2C.3S'CC$DHGPY
M<T/HUB#AY2"CJ-DEB&G@6MZP4D%;2=2.(8^UZU:TG5Z/2E\XDI+CM3+#9\?V
MO<[G.FXT\>SI>V!("ME:K@/?./GI%XQ-6LV:]?>OG:N[[EWGKON/2ZMS=8$?
M?%;_?='MG7^^[GV]O>Q9G5^OO][A]GZ_O+-NN[W?>SJ^6SK2\FURMXDTH)$/
M932(19PKI[OZTTQH!R@M0 8AZ#_F/M2;6],YM>MYY=-]7OE51<JI%"DM96V=
M V7?7G_ND5"YN;T^O[Q .;(%0F/-2;%+U(Q:L5ZX$1K;*!G.&:61=?$-PA Y
M:,#N4$?K5VW).&XH4JS:- Y%*2B$,S6"GR70M3((63$05,J^>3YRQ="Z_"X&
M"9E;UXBA*$+&SZ:_I;@X/$U%)ZGD5_,IX#!$RXMFH())G+E)LA[ $":OWC<<
M0AX,:(:<^0?HISGI]0_,ZY_HZY=QO%+\&0,'$_-7\+\+/5%CA.J1A1C \ED]
M\?2_--%C9OP1MI,?SR8\I:_)*"(0@@EU(.O+[*5XM[B R^_2XX UCUT>]R #
M7.@25'B%483_!"\&JS@PZL790GRT=(75.# ,O/'+(S7-+W4L>I?G:<]TXNDR
MAOM$(R7H68>$DVUN&8/EX!B.90R2\'<#'*,J)[AFRT6>H$M.\<-_ U63!R=I
M,3!H,?U[FK8)% %F,VD5"A)AKHE.@'++ QFZA>V!04[A='5I*35DZ$6O>1'Z
MRQ&*' A,^5<<)TD*S<-4 ,5--; IH=38@Y$Z!'Q&=DDI+BUY+(C=O!N8X&4G
M_7)91'8E(J@RUEX>.':9.WT4,E:F!=8L,6/B4R@''WYN?T,))Z)L98.QFO]8
M0>W"#J%.+5PQ0R*2TN\TW,]GQ#;F$O114R+A<P7NVB$#X8XAMN2XL4%Z&&5T
M[JH#&I@'E$K04!V0#-,-)-K4<D""+?XU1=R-")=-C(.Z"G-SH4B%X=28WEWX
M03D\Y\([V:1X_+']Q;.]O[@64BOT3B_K2)[]],M-Y_;.ZG;?LJOXO+W7CZ07
MW5"Z\:O/4P]HN';/]CA9<\G1VIP!_I61P&XDP&UM"\[OM0&^LNZ=S+?5VZW*
M<;V-!5<ZDH]9$3I:= 1HO 3&WKE@&XL0;3VLQ,?T.A5@2T]#A8]WS[;%/;IF
MC3UX-V-5F$%. J6E>]+3;QW8AP>-0^46&]39&5!0OW[6;);6NIFCG&)*/?"%
MJ'IZQX67)5@GCZ.<[8'R6(VOLE$1!1-,ITD_3MT5LP=]0:^;)HUE_6#E7)5I
M\#YF-=#GSWCYO, 4-%1!&:(F&KBQ]#8Q)^'[\I"T]QQ03@USM[)D7.Y&G]HR
MFS<_'2OKVX7'/^IZ8/D\3)]PYD<824^Y[?2!?33<;9-%/'&/*7$N])?'&'&6
M55;.]_'\/8?2Y6 W3)(0;U55YJ:>2&Z.BZQ>)#O+-TB,LHKF=VN('CU(@PMJ
M5A7N=\SN*/CP*@"#5W*/D1I^_Q1C"='LZYA)@KO T\_61W6IC]I*'UW3@7=3
MOME%)7,5^$0'01+*0";*$"0W=M2!WYQ@@DR!C":K.0F1^C8!7JX?]=O5.I:I
M.+EY5T3C!!3ZU!</;'2]AU0X@+XBA=:/3@\&)%YO=9S+ZE5_/S0]GC\3.X0E
M>5-5PB"X*J$87]R%FUJ:H!LI,]"9'M?249GJ#Y??1V[?14M<T_2&'?"G73/#
M*,UC(K[0/ROWLOYR1/]3P" X_7D5S;E7"9+F4^W7C96\:^%6Z^*6RSN?5[ F
M27&OB@+W-I[Y7+2(%?ATRF\?/(S_*;XWZ[51//[IEV:='?9M/\@9RV<]U+2K
M=;3>K7-M':)UF]W9<]&'MO,\?BQB;4AB;;Q-8I7+5XYFO=D^>II4UQ@T^Z%#
MI\VC?>AT.T.G]2;P2/>WJ\[=EE3:O.0E&5ILM6>^]\8(,^B6&#5!MQB*TE4*
M:4Q*1@EO9:C!YP(_)\$Z>9N;W$94R$!Y3BZ3D.GR@&LDL%S;&ZK9T)3N4_ET
M# \E. "9GF<G\2B@NH>M*@PT^.!E(FH]X&@IUJMZ^-HL<=5M<7Y]>W-]V[GK
M7E^]EHV0D=Q\+>VC-;M _)KF9M[2WLAKZNMQ&Q>\MR?0Z9ZYF L[%N]E1.ZC
MZ(<)0OK46Q38:9<=Q7J6\>OTO3D%<14^]8I6]BYZ)X_G-P$OL'X'@0PFPJNR
M\G::VK.O;FTR-G,EK^N'[<+%K(AE;G2-8J&&;7]'._;,'3GLK5$R-S9F25W;
M B8:C,1D?WO;H&?RM[+GK*U3-6FUZZ95S1[Z=>-QP_IFPG+OY)-'\=C[Y?\#
M4$L#!!0    ( /F!3EH2@-SX=4D  -12   /    8W9M7S$P<6EM9S$N:G!G
MU+L%5%5=US^Z*4&ZNZ1;Z>8@2(E(2*>4Q*&[CZ" M*" @'2#E'1+@W0C2'=W
M'\ZYQZ?>YXU[O_>[8]PQ_G<[%F/57GO.-=?\S=_<9PN?@2\!^$_EE>0!)"0D
MX"7B'P"? V0!-%3$A?+K[STTM'L8.!@8Z.@8^%C8]W&(\(F)"/$)"8G):"B(
M2:E)"0DI&2FI:>D>/'A 3,'$RD3/0D/_@/[7(DAH]^YAH&/@86#@T9,0DM#_
MKR_X-X   \D#*04%B0% )D!"(4""=P)T ("$AO3;!?QQ(2&CH*+=0\>XCXF%
MF%"-#R CH: @(^1'*( 8]4>, Z@$:(0/>!_?(U(W16=P)N8+C,W$8)2I:"/1
M&#UBXC=S";J/24I&3D')S,+*QLXA("@D+"(J)OM$3EY!4>GI"TTM;1U=/7US
M"\M75M8VMJYN[AZ>7MX^;]X&AX2^"PN/^_ Q/B'Q4U)R5G9.;EY^06'1U\JJ
MZIK:NOJ&]H[.KNZ>WK[O8^,3DU/3,S]FEU=6U]8W-K>V=XY/3L_.+RZOKF]^
MZ84$H"#]>?U'O0@0>B$CS(**_DLO)&3/7Q,(4-$>\-XC?*R.;NI,Q, 7B$$L
M$YM9T7:?D5_CB,3,9123E$E@F?GXEVJ_:?;?*1;T_TJSOQ3[AUZS #8*$L)X
M* 0 "+CE"6?+0/ZK<&XTQE#X*:J NV^8HZ#3LMH3#G8"RJV<G-E-@,#<#&[:
M"\=GT7J/5 60SG))5FDQKJ(*6T.;2,R+.1:,=HP)_5U\MW-GA[D"U#BDR:^;
MQESG:#@Q#U?0WYU'S-'AV_#7I#(O=O0/VG,EFXW(B<0AE\H_&LC\A*QSAEB/
MF63UQC%<,,P1B@(N^U969'O#O+]<7]4:;X;$^'H]"TG]1]/ 6LP'=,<7AH<=
MH# RV(.K5U.G7)?V.5ZF#Q^6ECFPU#8VI*ZZ8$/8S.EZ%UO1#_U_KM*C;'%P
M=CR48O=*5!ZWSQCQ8[0JR$U\:]^DX'HQ:*:V55)'_J;JF:6=O-/ 8]8/T3=B
M^5VW6^[J^=921$V3FS'/JB<MHQCC?TPY=9F_H+8KFI&_SN&H_S:L 4B&AY^D
M1\Q&%X./-N;T1P7!=[1KB[K=E#_B#2PN">1WO@7=G]VD#2GPZE\!A?G1%.PV
M.,0N]QLY+'8T4(MUS0\>Y(P\/?[ 40X\F4O'_S"!"WF$9YG5M "B!5,.1Y2>
M/<2QOG#IR=/7-UKLA_B]M#-$_E[!D>W0SDDXH&D%>#)B0B(HNQ)#_917? \Q
M#5+I%"8VQ^BM'R8=\#B0[MMG#P1H$]PWTPTQXWU=(DW;+^?-X?=\\H7\1.FY
M_3U)2C"XV-=7N,7@4_:$Q (0+?3VF04VA0RJ>!W]:9=U"P_XQ173KM.5T')I
MQN3ZV,%JE%6\??P]OU/*KLU]4?7:_N\)FX')P(489_=#&)^AN$U""\6HZ3'.
M_D;";-XMD;-D8\RC[H(H:JX?7#FDEDB^4W2=CF$+C"U'.N$E3>)Y0C$\B<LS
M@LK]$2DU(3MC2AW$T8)R]%_W[#O+*;Y19.!E;)5Q7S67[OC@=7#ZJSZ;>,BU
M";[%8$H>%!Y<[Q-C"B3#U@NO (#G/JZ&&ZFK=%1>X&<3/&L5K5-5^[*=VLD!
M0<G'MS1](99:+G"@$9O$8K[6Y^#;9C7@6T*R*M;3%8._[7.^$(CW9GWB7(5E
M:M9?GHI.RO(A&Y<&J^X[)"TE')YO/=&B/3:EX)NFAH *RXQMUUE;)2M&/9,=
MWJ(?%#6P0U>'(6&"N8H,W._AU[<JQ]VUR[XJMJI$LBOO_!1RKCPVM>R%=9*G
M#%04^K!:=-<#G[=3H="Q=::[K4:GF%Q52T5+2(_8J!GQ1"V_\Y/!J*-_.B;P
MYOL2-< X=.!SEH%GD-54>KN"'L'M'@7J@ -'D=O@+X8VE_I-13<1UP3ZG=^+
M4-Y]'>-U[YU%CCSQ&I)K[5)\0FK\:$(@XFUP$_$"0S+;P[67V3YTS*8B42GI
MY_G8O-%O1]"K1XTM75=5"6VDR"EKW^T)J$@9M%9&D&=.L-2=IFFXDDZ^\14!
M[&?RG5GS^+R#KX*+O=+HT!;\D_T)S5?)QAZ6K,9^2V6LK1-Y$&]@\X *S$8?
M8PM</N7LAK%YA;X8@S%<R:J&W!J%/JO[.E'J:%\EH%.7_ETW'!^#*?AG#U8?
M$ZZ/MD/,,;_^F!3=%>?^7)/2EZM(PT%[5\*JF5H9(^R@!2%N-ODH7895CX/V
MUY*SX<?-RBO=]7E7OG*3CDU40G&)SL^F3TWNS])(KOHW6IQD6<F]Q JCT42C
M$\(CWH>L3)7EJ*R([]JC/V\9A8)(@KLZ^_U6]%;KU'J^JU-@RP>H*<[O2]-V
MR7G33'>!MZJ+\R-D:B%X,[M'7C[>LT<EB^D\;1M<XKSE @6/='FIWE%C3U9>
ME:S<]U.PQ%D,MLL>*9-0<5_.:8I0?Y4^^.X[R8 \/7(ZT^;FX?5K7T&259OC
M( /Q5GPXT"Z;";&(8A@[.>?*Y8LH+K!O$U_A)@]1^XXDSB3NR0-V_-8B,>7W
MHJ@Y+W=9[VQ.YZMRO^\PCV54GXAUJR^E SW)@T2.QY*\O>@YHR8"4(7CF#"!
M12JOD['A3K&#-+NLL96QO"H"__#O*ZLN!_4\.1C]:'WT2PX](J6;W8LD#DUT
M3D?,46DU-_[-5;.1VL/"*?BQ-0G,9M8KJ!9EGW8;49VG7DMZA!^;7.FF,8SX
M*1V_>#&MTGP8ZL<STH=6A4[4C?/%!=7D(S)Y!5,E-:'SM^(CZ/-C\2N(80L$
MR43%V9287S]'795R/M2^E,0BS,*<;D&<I!99:.U8FK96SKD%ZUC?JU4NX7*H
MBJ_#:>I4P<'R'BG2\SY"386HHPZ._I\^TY;2:,3J_[F8ZUGK"Z62YI)$IZ U
MV+HV#RY%.5^$&0('"SFOD:0F*^4 YX:8#@C2SDU 4OY.&M&8H[W IP$AM9_Z
M7R(<WB)5/Z;&1:=MK^)N8EXN%JH&&Q&.,=J;N?5Z=(,\;159"&!MLR(7)*/J
MTM3-,6^:V'/] ]WN<*>F;\5$S:IF/MV**0*Q+T;PBV/' Y_'M!D3AXA;KXS8
MC7+;I:N\Y?+Z80L'?!!+?+OV<382)$8:>!@$Y7BOY)",]CY<1=#-0Y7+],L$
M?CG!75O=\8&M^"*REZP&:;K#T7ID]]!/?>EGNNQ S\%74?9OUZK4;J6EX<":
MW^/,*^%.PA]7X$X/??^#<YL2@=L@*?<8ZU>:PP\\6456&6?3<4.7[O1IY+CW
M[!RSXQ9O*<_8"1W")6(JZX?E%A;98<?G10NLH^<TRGJ5B4^M]QWW[?+CADZL
M(V-EI:YJ0H @69QOKQ\S"LI\']KLN'SZH*:9TD^_@R*2ES])O00XI="T;/MX
M(BWQ^8()L+&5HC@RFJJPX<G-L1DLT#<H"%'"1U?4>JVFZHY3"ZR]*A&*718'
M4^UC;T\QC&O6N7I:']]3#GO5+W4N07C%M%GB?!.24KC3(%'B;5K0JS_K01^J
MY/10MNA(UNIEKYHWH)T*%?LY)!],/%3H;'O!JDY$/G[IXO!J_O1(<<A[B%^:
M$G3TQHMU[]2ZIV-*7G3 M8DK)8RWMO>'1%3.\9MNKT*J;U+XRDB69"%[66\-
MFY<4QQU8G$/?$_2^HB9:;+90O:L62BZT;9A@^D'R\>G@QA<X8"V]R1BY&H )
M;0PX[%>=V*_NEV^N+H^[_D(*8WW?>ZJXH/3Z ./[L[?>C4J8+GR^SM*4EU+W
MCJ+6:]+!PB%GQ[@I!"&#YF]9?V2+?']@2/(B\+V("$E\P15H.:2"0W]'BGJ,
MYQD6[?N*ZKKVHA@^$1'R]IA/#X]N=6278[T$,!(NO%G]3^QLS.*$[C?M:3!=
M#Y&A</=UJ^IO8(-90]PR3)O,';_T3N>-&GZ/I#7:\_";X?*)[E1#URG2M=8O
MJ!EU][(_"&38H;*1]P[^&(IRE\#F'\UAI*PX=AX+IBTTQUG1-U3P!.)=&)-P
MU7MNI4]PG GGP%'V3!?O;;FT>]1)N7D.)=7ZD,*4A1]$3\V2'WRCV!0$:S1,
MG=]WIXKBD'S,E?2EC;!#X$E/XJD'#\KELWVDBL\>&3CVONTPK*EJ$3KC43N'
M0X=5L(7-RG6>-!9Y&(RY>[5\S7VUQ-%D>XHR(5$J$6*%,Q_5^8K"/D_ZN/?M
MR\(7;>3[AK9R8E=F73RL"08ADQFW=$G4!3M96LP**:?E&$SKK:&2Q9Z=X[:D
M^ 9@?3<RG2ASEFV[DGKPIQD2#K)ZU&*\2]42@%_U2.%MU:=#QO*C_4A.;[P?
MI2 W\D$R4*.9RU.7 .//:9P,H% X@.,GFF/R)8!LM*I9Z@+OJU%PL)G2"O?[
MF+N]#XM3F0VU4V>W=TPJS+!"IXHGS+6R$LY)^C(6L9:J'Z(679X+905&)L\>
M4VLH%&[Y9,_V>]M8.AWR/0F1CZRR*V9[W&_/2HTL;>:K=H\UO(DNQT^ZLBJY
M1ZU"JR8<;-%@(%*:@T"D=B''NF](;;T2EL\YP0I')B%NXCA""]/*P8O/QZ;E
M0[P_2H1,F%\^4U5[&J3@PA%2XGXQ-Z<<$JH?H< [0+7G-(A=!NI;CRM _337
M2D'E(KJOMS'7&;==Z^D99PLNG+.Y4*64Y405!G@_8.:#XYS(7X8#/VJ/\ *U
MV_W%YCI\''\\BST,8R27?W<0B7=@Q_4T,*I^E:)8: 'SJ"12^^+"!^TSP9P)
MS5-FQ2/&>OHWC^" 79"\_Z K'/C!/_<3[/P##MC.+1CNXC\;IOY@;TVI6\M'
M^!0I:FGU/=(6A]%SG*?CVFD+X[>Z0U$. MG4<4WB+A*+@F$<WO.- Z)S44TC
MZ&HU8K0517I>@?8E!X=NJY+-U0M\(VM[\9H7?<_H+L&T=!A7M'#@>7([S;UV
ML*+C6AU;A5^%$748#=Y1BUX@9[02;77N<B]K[1BKDIF7X:*Q6'$I+N6*3'Y:
M)[Y"1:G'0*.73L=]6.I=&A9+%E?M=8N3-JIPXNGJX'RCHWA%&@(M/&F!([N+
MHQ_#RRGWN<T4HLQY_7*-(L3*8?0#2O2;3'&VZ5!.$YS^57O5SH;4'+'(1'O;
MH\?.F!^KK,ELB<\WT=/>8FM*T84<:OHS*$>DJNQI+^Q';Z\9[?'H])^24\<1
M4R/[6(D6);L9TT^<ZZWH">)P/_SBX#=AZB27V^MV @>\&4G,^!9WOFD@[?!*
M4UVVD!T9I=63A955&:!-#!SO-<4]:!QB[)=GS8/29,9(K$I,3A[%A&A*DSVI
MHI7/F/T"8?W9:#^71[>?.OCA )Q4T]HTU4*WVW!0C5V3=;*@:%K%74<?2=[!
M,O;X(<N&ABC'Z"7)UJ/[:%4RYDG(.'# T%6:^CSF#90[SU@JTWSY5L0AE9:?
MH?,^QAJ9UO"\-CWA/:1O@R#Y(TB(A*AHW<B9N)&4ZL.^>ZAS%7RX730D+N@H
M*(%&W,1(PS^]##H\7]B>&F[5?% J:7]OR[R*<U$W^;2HQ><U>>#YESDX$"J%
M/LEX<DZ':7-I<^&U_W20=&E4WI52*.#HQ;AHC^U>00:NK2JFEXO]JUV]#W)5
MOKO]D*\_!T:#K"+(,>X^O8P=\IDD;Z'SXL&BJ+IJXC>KJ?0V73FYZK1O> 1J
M(*E7XWW3V^7AIG9/ZD.VC0]-S$Q5"KE=27]59"R/L.A:A:0R[=H)V"R<#<CZ
M;\JGH7=\!\7G(GG71Y!A:SAPF"E-.*KN_6=#(1T=>A$#NR%&XB8A^[/N_3]-
M5:^M#J+83&:+8^>AELC509L!^/R? Q1GR%^N_\N%\26KFQ)Y#94P!48V^ST,
M/PZCH]?8KLMMML$!R6PXT!),ZT=W.@NZW5)#K=(T_J.N_H]A0%GN?S-93YB2
MYX,[]ON?-C4G/4PMOL7RC\;,J5KJ#O6E_L-T.6P"@_;RQX1RQ+8D!("6FAB
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M5W#AY%G9S_V>_SV],(=_]Q#]:D[E.(?,D]*^Z9BYN$CX,SI3D%>;5/S4='C
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M;WP_=3[^VAPA*Z+.E&.48W&A<?W=D7\<G[>,N!./-M&CU.5SB359"&)9:%.
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M6.7.:#X2%2UERJJHUGB]'5^&RGP."P'43*C:QOK=-D0W$429FSQQ!VVL.7G
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M:/#+JR2BT\K=<Q,J]#$^Z1"Q>1?V\"N3Q+'3*86CB30Q';C5.'EFGW<_QIX
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MDQIS)5_28PDMLGZ[A/6([5-*9JCX>=)9%R3&9=URL S.B @L%:[7&[H;N%;
MBT4&@W>LG\'!G JC(\,..J+<>C5QRA+L19-SZG1<QG8]QT4WSZW;S/5W],E'
M"ZP6R\VLL!S?T9 (JI"S)0.KB"=?R ZZ\I4)OT>@9V<>TP9T;SY)$V4]NM;L
M5Y@[S@P?.B*S2SB?W>/VI+24J/BEXZ:UV]?PXR/]B5H070GG%X4/F C<9VGR
MXR)<AO$]FE7A76ZLJL:?BY4>]ZY]@92@#-O>BCX6+/,0_*A#*>VAS:I6H^.H
M7B7U7,SFG7#)RS-!P&UD_]1#J-W2KZZV*F@84[K6'-J?3_DL]]97-\]C]ZRS
M2$THX9BSI7BI4G+\/*HA[=<(Z75_-%4<P@#1C[&V\K)D:4S2WGH(2"8EG,%-
M99_#G9D]H]?5.) A)6-ZCY[U4>?3723WGC"PR+C'6;XZG'^::BD[)_+$/I*,
MF0_A2O<9O%%3>S&XIHIX6L14R!\7_SVYJ**C\AFGLE(.>O> WLV7\H4K0!]2
M?2?E,F\Y6#[R ^'D;F";M;^KC13\Z?H'Z4*H*\9KUBV;J=U7[@]R25>EJ&U$
MB 9N2Q5<KQ($BS(;3&VN"!P4;M"H[XAC3J^4[XY/Q53X_P!BNKHP8 #NW0^F
MX"R.;_8?#XE!-_3+O3MCU<=+=Z>0G6BH5I)!@7;;P.U9./0NZ2C[X&]/TO]3
M)ZD$=T'FXAZIF=YLS!>\W8"Z=L  SX'+4?5_'G#Q.#RDG8%C,U$C.#8SO37[
MQ[V%*PL"=B7X9!Q\<PYI#_WK+BO5B^9_,$0MZ0/[8Z)]!/P[>*\_@%ARE,!:
M:%H,T9 ?F:8Q_OYCU[P/QVTV#!&2II&J,2%/]#9&F#^)4[PZW':\WK5F?ZXD
M:T>,9C@RY*469S['A#.;U8].7[6GG<AF'CNB$)H5ABEK/<;Q+D%,.[/],362
M>T8S8B>J@,C##BU.<H/C=Y7'O"XVQ&HF8XHU+54$]8K6JDS2@X([$_&GQ* O
M>8#$HL^\E\BJ[N1L0<#X\##V8P%.^F 3Y;E564*VP,3/F<MU2<M-HA;.NP[&
MY4-G@:O2]5&8'ZEL;03DUF(>A27(6NU!MQ:/PBY3B3"47E""*!]=HE)\W!*G
M2/)SD*Z*]>#L"7^7:RS4J=5T0ODBCMZ?T0G2&)ZIH'IS3OD992_Q"[(:@R^0
M^%IX9!.!95GS>(IM;RQ<17E(J2[PX;[]IY'90:0?R.KS([;X,]0NHG 4)UN<
MM?ZF0FSH^@[27*"(2, ;ZIC<"/UX_;@N*J 3(+X_KH8!X\GH\LX*>P]@ ,T<
M)K2F[S;V5YT,-U99&VXJZ--5T.' -"T9SQS2MV\PP(T?"5?JE&@A%@;4M5QO
M_D%B9X?BK<WZ/)/L5_U-0D;LI<VJ</K(X(YPR#:LSQ7G"V19P1P&Z/K>^Y^/
M:7#_XZ9PO<IZG,@['G1VASM<)7-9-'+&N3&?FD@K@HTO\J1-F,>D 55;.*E$
M5.W; QGG4BV]9Q^EQKZ8$Q+$Z*8F-X<8(8%VU,=O].5\J_2,L.B>6!T;3>)%
MM"+-E!E[*5#F4@S%;X=QE#E&"V9XI[ OUB^[!0<'YR1:!B::IPLZV7=EGQR\
MZB,K=.%G=JH>(\W.(-V,E-$#']'4P0#[ZZ"3FE/*#S"@U?NWJ0ZPCC=QVEXG
MBHG>[ PJ6VX-3"U GWNH_$F9/L=?FYX[R4"0+-)?;<& !XB-';<G"DH&:K^C
M.6,"!'2=-LN2[?X-O+&NT 5I#F=2N+J*/C8X+"H4$PCZ.[IK741TE5"??@-/
M,+\[NU8K^E>WY.?JX*-U\ Y\T>Z_Y@[\]%,HP3W])G;[(^YF8[K 11DRT)L4
M!><PE-*!F__A9Y+1L_\WU*HS8T<+_SRE@?C*__DM1MTSB^?\6FJM+=]$[NN2
M4R#098+Q@O1@P )8&^YGK;W:FU I"9NT8'*ACWIZGD+726YF-=E$8[@B_()H
M4D&$>(C,FCF,M -YU3#9DZDJE$G'8?P;YWO.HKHA\@X7^S32.1,&/^38)\!-
M%G.F@M@/U("ETJJ15))*9>UT^_3@Q](,&"V1$1*DUT% G8,H[QLY_X9*3=V(
M*#)55OP)5)'1'7OKX8Z'L\_UI>:#*-[%C>*LS%<%)O4/[W*>/9INWT:T8P^:
M)-&*=B0*>?=ZN#O7T1N]JTTK26Z4,4YA7,NHHJ%*D]N:=G90?JTD@EJ$SO^M
MM.!,R(DX95")0#=>"X,Q!=PQK=3QN[B>#&265X5-CSWY&AC1VC3E^)1Y@X'E
M??B!:55A]2=CFJ?*;F&C(*RH/:N VE5PR]:^QR.C<.SU%S.K9[NBOD("X[S-
M8751KM$'*HH@J7\A&EZ#B]*S[O_NK%Z@ZZ^S>@ QF7 ;L'$]A$QS0B5J2.X<
M$J[8W3I<#PVF^:$2\:B_GYW6D@Z>0&LHG <6.Z^6@^Z--,%^M4-)OH\L=5'H
M_ID$-+:P90IE@".$3HW$]5^(<N CYC(X/Y!L>+PB;_8'/("$W(&5S\WZN.%V
MB5E\P]BQ'C+"+6WV4]?S=UTP<K<V// $8F^ F^"1[HAWP1(^(_]O*.P1?_Z$
M==8S*SC<\_J4\-Y<'.!@&*P, W[Z0#;+BKX),@#HS%ZHKN=@OWJAFD.POS7/
M^=#P5B$'=OOZUQ3=W,*G\+=Q.BO*Z5YBUOC&CAO99THD%_-+ZTR-: D&'/[:
M!V_JA,, ! 6X^<G<<KJ%7Q.OP(#&WP>_X]1T;NS3W&P2A-]??E[YB5(P 6>O
MS1=5,"#%&GR+#KZ5I_[W"<2I>LR**.LGE+/<OE,[,JC5',* 2_T+ZE-V>$S\
MQ'R?B0$E^=5QAVD+ Q9E[\^E$6=9BAXHA+TND>80$0N@]/:J9"B^QB[?\XG\
MQZ?+?Q35*I?AN?EY6IXF6<T>*RP/;I^@2BG +JW5*3BGXXV#599.;W]VIP,/
M%P=D<AI=S.>7@UJ3@M4;JBJBHK $^KFUZ?U)W+(DX5X)BNJ9[VLR*CXA"*P%
M]0WE(U9M;:N9 CU(I,JMQ9L $&6&*!G4DF P0E,>M&S9@B%7:W+Y0]/WIL.<
M#'!B,%0MR-O:4 QKU&V?(,@V5K2OPGNQD45#@.("#*+\(M+&#+!.UBJ8E24W
MM<3Q1R4R\<((DE5_@H+Y=#,M)SM>W>1I,^A-D]$0Y!HZQF;+YO(^UAZNEN)X
MZ:_Z&;YZM\1(W&< C=6P;+( N0>/L-=::Q=&2N[,^<MFGSMVS"L89%V.=CV4
MKE4TA @!A33,*++&)OO/B*@CBC#N4M-4AT\1,)/F^\8"=^O+#\X6(67^M]ZW
M8+BGS/CCE*$77.A/Q7])(.8 #S)#!AFZ5TI3:3S3CV91X<''+'51F'?!W!3*
M2'ROT4D3;IG4EU^T(1-/#6)MP\HTBC8]PYO!;9Y).6X\)M^27+D/#/PG[X)6
M3J3-OUVDB9WFDU#'<[\:^$5VD=ID%UL!699R@6Z<$35+(%5R!23+]UWC%CA=
M'!;T!<^4$FF]3*'/1O8JR(-@F9U'NBAVL"#F<'9=\)YI<6#.M%6+/A"3$^FX
MTW_Y5"-:ANA-II0)8@5#0BW5PLL&/=-SXH3[A(H:\,^RA?M\"H^)>96LA[9K
MWB5@T1QUAW=]_(YV'S5T[GPR88"CP<U^^"XE_^_,#H>4;UU*>C;G./\:__&/
M\8.H3+F:2]*RV84<RV7=A0Q)\!6W@"NLD?RC1;_.DL OI=P4D3YAK#')F(HO
M3K:?U!5J!8=\OYF8]9X635N/SKH]M3DJ\F.# 2O7N!<=)T6U,G/4+X'@W2$8
MX*IP<[FP(C.5!CU-NCAJ:/^=*L0#F8^&0ODOA\[-8, OYKM;FZ/?>45]U!?I
M<(P7"N7QB <?P&T$0GYK8<&"@/P)$06YBZI0X2QG\T]*6L#_;0T<4]G;--.0
MZ68ZG3\D3B%BBWZKP8J[NQ.8ED3+R123&2JQ\_#)M&A0B-OX?B46/Q]:Z=2<
M;FYG(7+:;B3:ZA/:3RN3%_G$<9*C#L/Q?;=Q)(X3Z3K:K]#"F-6OR"2SNS;M
M9)NN->S%*=AK=M0'3+/GIN;T&R(=K.EF0Q^SOBS \Q1G?NO52H7#G2@OQHDU
M8&.4T5[2R['BA\:$+W \%,7EIR]M1_B35(#96H9H!OY^#?XKXX:UU=['@D:E
MH0C244AH^91>^'L;)GT_((F6&0[S&;+THDU-64/BV' GG?W[@VI0 <.,CK&1
MN_^EA^A !O#BF,VRNE\8-#NJ\]"HQB!&^(]T LVE%AO[>@7]EDE7M7B )367
M)V17&8OB@^ZIP1$/Z&T=[GD$_8UPRRT,Z#%OB-*H"=:$A"*%SGTWCH=' #&6
MM!$1,65>E0WY3M+=F+DX^):(K[3!IY7IA]L&')_=,6WT_ G*/E#&<_\. ,*\
M\^;^OPVE5P,Q?O\4CD8($N#4D/5X_PD4 P[-AIR?O1P^O9.#3]$;SV5Y1$[]
M<_;>Y3.%Q+/]MI.N-*9@Y-8OM\%PZX2C1TFBR<3,JBZ%[J2S(? IK5ZD2/S-
MK,\EUQE8=)ES66;DC*&RHJ:^WKNY_0'O6(M5*.JV0C)BE&7R$7%2LKD^:OGX
MZ4YFK6,5WX$ 9*ZSIXIO:*O:F;??W)-F5$0XVV!6*EUG6TE/8A6?]0M+W3X0
MK@\#7LXT'/'[G]GX')I_,.?CBT.>TVYFGRQ=^[D3.9$"=]D:8TDT[P?2G"U?
M'E&%+\F_%NYRH%0G6#[FQWP(%E 4/@5G%1@5A/W(E%D.[M-^5/3V\*:#)!KQ
MRD1YSZOUY%/(PU]+#80M63KFPQ9)>'1C['MOR-G>EF#;Z5CS\?B+BCKW"_+V
MS&Y?]U4&G''BFSL=&#'>D,33I(SYOZ/]A(K@)10<BOC:ITU9LOW=4,%NG.*/
MK[='>8@5(C# ^>?R3XY=&RO)/MNL6>UGCYC O&@K/[MVVF3!@;'M/<_BEZ_.
M!*UM4D=YOS5V&::_]T]>$N]')2.JS+:,]VB/+&RC#GB@926G2,(7F7ER_N)R
M<9_ZT0HI]8HXE<R*S>4UW%$46MWN1!<6M;=ZY/9 JRM/"E_$ \4FD)%%>%/P
M[<[^HO30@,4EUZB/!T!/T_G+L_S"K+QB&CRTLG4W=)^;<Q<_ _58^9V];%(!
M Y*<[U-*Q1\H_2\WF 3Y&GYZ8>Q+&/:9)2?[SX^- Z,%JW5#A7LTT=VQ9OH\
MD/VH=,0VP'ZBRW6Z^\[W;(![[X4FB53%)(7-3O]<]=; RRT.ZS=E%5'++DBV
MR3U/88!(DL5JW/-1&XX$]>H1HXJZ,#G-]Q/]...#:8CT*!384Q_$;QHY/%"E
M<K8*LN^^Q9Y;FE1&]ZD\3$.8I#%^0K,B2/4949Q(I36BSS1S=GI2?Y92FIY-
MZ?'CFFS@1]-7P]N6D-$.W0J]U\+H-%5A,M-DW:&1PH\,0R1V?$6YA.P[\P5.
M,3?K6+.VXOCX7.L.GW<;5T?(K#W=5,W]>$$J@E/NJH#E5_)3BU17OX-"45>W
M]B?7XQRL&7OO5F)%!1K!=2_^_$+E\V[6JA:T-?+H#TVLDU#ZI/9"#>Z4K?C8
MI.QY>0>Z*R[L9+9>J)'-6VK4SU<O"U&SDHF&N?)RU,E0LY,Q;N:5U1]\/F"^
M=+VS>+&B.8%YQG#&/#J:##Q!068'_DC\0 A+'V&(,6IL,KD_VL>RY7X2]183
M1S(L&,H\[_4 %ZS;09(E;7-(9*ZF)ID-X'BI9">C7!0AWF6 5TF6#J[W^*'>
MY?M[(BPS^JHJF]IP_Q,5RSQ\*T(@9;0AWRBX6SX3![EG@'9&8#@#%!F*-X&#
MRS#W[-O?=T_NO4,?63+J>FT!#QR*94Y JX,62_7ZXR'+*I8#MZ5$5_XD$&17
MJ/_F=^I;<U?/C-T_9F#SK /# W,\MS+B?4A.XP%>>JK"5380CMDP=N6.+8.^
M_NUMQN-63PR<6A::XG(.*9[=:EZ3O%^,4QRU*MOY\- M[GA(MG&@H8++8M45
MKRHR>9B#G9=!$:M$?(: 2\<,J4I?=FM'$T5GQD-R1+$XH;NZ/$*6W$@ _/(7
M#$!'*8SCDD7VBT'B1CZQ6BF?(2^I/[,#]2_."7:\UQBCIM.GHFJHK'!+>UM,
MYV<RNYV?8F!$4-V/^.&U0)ZKOS\O.6MP-GEGE8XY,;/SFB[)FQA%]/Z5K9!Q
MBNF-  ZZ2--$,GT=E[T?O1!NMF&7,->SN9%!E:+R.;LK)D=+,^;X=?+**-+N
M4CG2Y@:&\"+292]>&+!$7J?D0+DJ:_U31^Z#($[1VD_U5SF-AB\Z15DI$:2?
M!!&ZJ7V]E2WH',YO'A;(##)V7O*WB&9%B;R^6U9UPVG./KA(QM%H+X!&OX,S
M\9FK";H^/7#(S!W3P&_?\*H<T"H%'SVI_,,Y'-A>R S7(Y89<NYU"5"]A0%"
M-U/65N?A"QTC-\U>S*DI-U(-MQ?A]RG%J0M0MX[[1&$@/LA_CQ@&G,R#[[.*
M@R%7!]1WIRP(%H^IRW1@P,"]-TB1F6:' 1MUD(O!W[S26<\[/;OU'%OEGPGF
M26YN1+[%B7I]G6I29.:DAT0R=O* F9)NNAA]36W%B''IL,^\O@[OS,RO1B4"
MCD'I11P=-F %-5&*#TPTT^=B64*A-4!A1Y8HGU^[8@Z:"E-]_/W[H=L',\2"
MU%*>G?)?95KG ;,A93J?S$XZL3=MPX35@[ER8]\"E++)J&JRC']DMQ/#&9="
M.5F4Y[<PSON$WL?=N:F^:B 9<1909&OQZFII8KYK?&R0MRPQ[VP'I=>^0G(R
M>B!@_!VCH'KCZBTC_0&S_2D,>"@?_G2.O_L'G+Y3&V3H)*,-\X1820$:7M#A
MRX<V_O EB1V!,!0E"T\,+)15_HERX8!O4+G6[N#B*T0/YY7IH;'[W.]X7314
MZ%ZU^_NDA03T1U#G0"S5:X=;E)HE?%/;/E07KLB#CQ[??]UYV\"UO/#[<!?3
M!P:$<BJ,UOXVR**V?,]JVRMX/!_Z,X3#@4"3+9/-7-'-UKV);6/:649_AVY"
MZI.N\0J_-##5[\ YDR^GRJ* S^70Z9WLA5)-\H+T]77T:@]Y]IPBZG+H*4AL
MFU^5?'-!G*(C1.>.[@^54BS_6/_$YC08?+V^T%^M/ HRZ6M8-K*!"TAR-;&P
MB)WV:;@!S!9^^\JJ82<7KF%W2-0?/5A MM)P9(BE%,22C$CX%AXJVOY)GDP6
MS&/CPZ.LW1<'BYVGR1*9E"508VA.F<JRDW'X)IHO7*U^A&A;YY2LC\_+J3 V
M\S0-=0HVO??&\!;L4 H:A@&?'?O>E^WPJ,V8138;&Z/(!,K,SDT2H'A(R[AN
MLB3C6$H/OH[^?THW\ZBFKCR./PP21 =<0$$&$(B'M:06%*B0@!U,@6)$$:2B
M3-D#51:5/3P6E2)%$4@54 *$'<%3E@*.$"$*@NRHD24&660GD25D?9D7J=9S
MAIDY/?WC_?.[]W=^=_F<^W[?>^ZO9(11VV'[KO+IEMTMN#NLV^:'LXV.AHL"
M"O;MB)=27ZF1('HRJB.4UA*6+K2,J0%F]@\-[PAKGWD=1;;33@P(#&7J//AA
MWE(?/I=;MWLV6+:OE?H!^5F=)85WKSJ^R"I/)%=Z)@]03+ER0$2.1>K60_+R
M+W5X+G$Q_544 D9MZ[\PEQA.-]KGW*WURV)AF1^+].>) 4ZF6?\CR__ PQW&
M@[Z.1V_/G?7$+A>Y?@FG/$\/+-XA(JW#,5A)/X9];[ .A\D8]2T:A@-Q!92P
MT9AE[+A(N1QC%E,=\EU?ULW+JF5')C(I!]5G38_OV3D*3:S3<(5ZL,O-=!$<
M)4A(>8/N(E(5X!3S7'%S,/(]91K?E++J3E2=F\5G&"92B"X*]DVQ.C J"435
M:436^RBPX'NP'F8A)"#_?8#/V("H%;K<:7Q\<[8IPO$W3!HZ,%*$.'.'<P,%
M@V@Q+#18'GM*'?,^#\_9A4>?]A#UK>3*0GT:!>3UI\>X&1W)T^$/HN-/6'=?
M0DE1=5[*0B3+S^I:7(?2&3BOI>_QBH9D8XM;)O6.=+F"G>#>OOMSSPD7*$[7
M^%$XYQ%4(@%[1'D[#I,AU7VH\;Y]P4Q=7T&PC>E=W_H;_?:Q>6=D0PUD'&BH
MA+1&!:V"["?&S67#\6Q[+P_;;4F[?+P.5*LXQNW3U9<Q%S B5!X]W$0KWD_*
M*27ZQS[K?_3CU2*"<G7U[I/QMCK:RCU*003GY!]\BUM3U&KS?BZP"]?$3&-R
MMRN,ZFY2TW9.=DS*-]TAJM+,'/L.FD\[:CX7+S<13,+:#?DXG9@/5THJFF83
MZD)&VDSZ;ZON\-KW4WKP^?)8L^?J#99(?T:NW/"Y"UZJGO/W>NA"_<?*R@A
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M'A=:[H:SU(^!^N#_@DLSD]$ 3[NH<8_$Y<-0\34*O$EXM_SX-S1X>T8TW)_
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M[A .'=(E(-W=?0YYJ'/^Q_M^^KV?>K__=WWC+,[,VGMF]MJK?FO/7"*F$<O
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MX(:FD3/*<EM;._I)^56;;A-=.Y2&NW>ZY:@P T1Q'@8&Z'5&U UY:^)FWZA
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M2?HJM?@<OCN]) 0T?>A>B@!I/>6C 0^ROE IDN+=H9/U).N"1:V2?UJ)(K.
M4X[;NE(T3U+F1LT<4#_?-+SXS+-,1AOMK8)E+^/L11'*X;HU;@2N;JE5DMPH
M-8D]G&^/%4UAX$BC-:];;2"/H:!)U93@\_J)MIUWJ'LPS[^3;-4@Z<970T!
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MK2%B:68]!C=OW8:'<IC1.Y0T;EI)1\/.#_G\?@30[KNB_, 4/KY<,^^IG#Y
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M_*IFX3_1&PO=7XEDNP)J4!);2%[%8@)_^DW0A+\LY4^!E1U;!OA[=M;." 1
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M@??@'+?UEH!:V3!;TY6FB'/<KJ3_P8+L+M+A"U#UQNT*:E4; AXL*#9D(IE
M.K++W?'&O[;P-RDL09];ZY^K$]XX3#W)"[?4,!XE1<Z=C+,^JSTL^RSJZC3:
M?RVOP9LH#-=PAQ@!W-,DXIM .OKS?V;>O^@S4AF<2-O!<&B]>YR&DV;ALB<V
MLU972T33*[Y],/ R;(N4-CII*4#6[4K353<_ZF5-"]8X87#+Q/E^3WIE@)UX
M.:_/$AN]^#"WWY*/"E;JC=A4DSP"P*4^ZJ#. ^<OR:/J/5@H38OE9*ZQR'T=
M*O?V.?M]H0TX^.!L%0'@@?7<528Y;8V"._UG$E07>UP=RW3ZB*)I FRE^(!A
M1J49">"Q^%3UGZ:6+*)T3R.9_,O%E&W:4[F[3"YE?KO<]1GXR>Q#%#W478<Q
MYNYY.^=!IF,OBSUI8VD?83(-/ 6%K-2+.QZI:\-ZWC2.*WVSM"36.[ 6CN8+
MR,=RCFNC(3A*;,%2EZ+_((.6^_N,!-7KZ<#E<+FO3N(0@+3";H13 S(/D1N<
M;?W*0Z7<(>VU[6]A>\1=^7UTH?I]AB[?JBEXQ"MZJ2B=2&ECIL\%*U>TX",9
M'*TS-5?N1[2>0I O<7O5 4Y^G].8I[A.3<9B?VHS+<Y[TOONYSTVNI2GZF%.
M>4NHW9PSOZ!O:60]$$:U,?_$F\(LBCY)?&NRO' 8%-#\&]P91L*=B9)2"KB4
MAO_9#XW2MW 65S48TW9@5NA#ZL!?.OPC<M(>Z8DX];^"-B!M);.LIA[?.XK&
M @E,-ER1?B8MOR^@NW D>^05)F!6Q9;HWBSFWOPDF5^*Y/ B&WG4N(AD 4J-
MBQ&+9^06R'#VEZ/?>006"U)4BVPV'B#-+;C>%TU#*UYK[%,9^.M.6&[K:M0$
M$F4EH/ME-7ZI>\^[G7V)C&3R,J2OL?^C@K]I8#4JT%Y0B6!/9^2HZ6ERSAWB
M$FJ-;&;F;F;,IS&8.,<VW %>T1A>MIZ)$3Z&JZUWK+;VT_":IEP:H[XQD[QA
M<Y.GMHWC"*A@6F=31Z,:>IZ!IXS:PW3S1/Z4:4W>Q75L7J_V$_6&<:310-4
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MK#QI"MV1!__0@H'OLR6'>[OW!0LNHWTF>IQJ<5CQSK_9VP9I85/%K^_Q(.-
MR'^$U.J7B*T;W(-<J,X&M?ELWGI,FGWOM!HJ;O[F0.9NDO:=>KLX'/;!_4'B
M.WO3H/:AL\7G;XF6Y#:ETDP*TDQ"18OLYN6R?F(.I9; [%7JCJLC-)4:T^T.
M:JJZ#VJG<)Q#9\M18.:^X@PD^3_+2IN8:Z-[//$[M86B.;ELP]6*BI\[.=*&
MMB5.+39?_6[LV06W(3N)H%E97C.53R^"<6M;E'/U"Y@C18PM-F1<#(,TJ-"]
M0P'HP6,MH21[X\)J7IC/WEC.*I4\>&Z#A+C8_-"NV]NNP#C(VI9=:0I4S=5T
MQ"7U3I-/SH(J6W->&2CF0MF=EBB>;JW:]^LZ!U4^.;<Q[CON'K[>RA6?TXF6
MEJ;"2]/"D&._7<H' V8>=N?]UQWG56^>_M3)X.6P[]/+MZ0ZZMU;K'W4Q"N#
MSD[*5MF=C1/"@W1ZH]^&?S]FE&U6GO816Y^1 U"FL'L\>M(U:6_M2M9>FKW>
MN5)Y4I[K6E)\G]05+^?M>S[LLD=''?:9>I+9*]>O+'22;":D0*] U]P;VFJ6
M$B_86=8R1T<CP5_SK"8;/J.L^']QZ/=XY(N];\E5OC1\31?N;]' %).>P+O;
M W9YLYH2J[';=TISS5H)KE:LTW:DQWLJI1/9Y%IZM>4213B]XP1>BJ?1[Y7T
M?(\29;@-2G71*T[0V'03*RAD>\#9A4SF2J%5P_C-U;7\SXDIHQOKMXLPY6^*
M^V] 5CZOBW2MJ,&#N[[5S9V.N0,9H>+OJ %LM(TVR?4I&2B-"I,\&'*C7*.G
MH?3MKN<;$OQ[-QX&,#(-B,-0W<HKE/4*P&U'OEF!RC3'@UM5YX-YF?X+SFZ3
MKOULBR'^OG43HAAM9P]AJ=H$[,UQ073/.9.W2XHG-7>^7S:CE. 2XGA\D!]+
M*IVT/+3G>('ED^V:7?*UO1"^ANJQ+]>LU3#B8R#Q8W4P1R[R,O_]YJY4UY.(
M-@ M0 0@VNM=36*YN&$4!=W<6AG :+@1 -EKG79).D78/HW*N-_$?2IR4,U
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M.IZ_:,Q*C#,[Q$+Q6EYM_M9DWH&U)B!<*BJ-,1S<O?1HJM,=6_!^_=96K5K
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M=-#2LOB^(G[HZW)KH/;"ZO,$<I+6V0?8RHF)O:S'>;EJ?!?7?MF.N8^]4Q&
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M!O<"4P,;[\*ZUL21@N(4\F0[ ZP?'X@^B.TIT2LA?Y5^BII"](J3/>+G\)/
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M3R";C0FC^ O>R7I8/3[M_Z- ,+?Y('$TEE2Y:.4A^M&^Q/!%%2.^[SZZN,/
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MY]A4K8X6?/=+/I*'A!7\^OE=&GOB?DJ!J.N.(Z4WPRT;>U?O^:)?ZY.#Q8"
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M1MM/)>+%8'.V1EUM\EIP/MI,%9E)IE:FX];SROL?V&+1O'JL>:G=_WX9YJ^
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MD[__E5OLC^=P[Z_T L?&-4+?@'W:M*&"8_X*J F/30Z<12??=\37_"ZL\\M
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MJ;SCFG'[MM'QU#-%HZYVEJY.<*A4GRECOPD_NYF"T:QXQ%CU/TV[_QF@\OG
M (:Q%!A@- WBKTBLJG"X?%!HXWYH*WJP-F0Q4Z<NFA6,S=EES2OO_2^E@K_"
M_T(C-0@>C_7EL908K>O/>VW[#F/8Q+=#F$GXVE]"<4QLWM@(Y/-#N4U9O7G&
MH>Y2")?-UAJY^: ^*K"(;@PCB>58) <GTBA=Y$[X5':/T9GTF^ZK9X]ZD+3.
MG=/GPHL7KVP8%84H^$-(LU(WGU0'&!H""C\5:D866J1:8MC<F646>5MQ1-]L
MYZ#=U5Y_D+OV=IK>44AN$6\K:[AM7"_(\R>K0EF-\VT3WE'];^CFW\.6(VC3
M9PJNB$7'K:0I=X'1%7B(.(4'F/G:U5'V@GT;AIG%HLDS*CE"S=3@_\Z7^?\K
MUG3_#JWC^L?]=46V>D6I]5IJ=:V3G*W3+_HP^.TVVWD"W?%02W-PQGNS3X#L
M^[]\P3A/5V:SY[%FZZ62-$S1^",C[*2TL;1+<K;H,KVVN7 6\E$0;-CXLO9K
M9Y4)N-M?B+7<[_<&$UC/\?X"!JS)'Q* QCF%'FY!1SG8$>PT'N%2OY(S8(!?
MQY5Z2V_VZ0B<[?;5.U9$TXA?%8=N&10BCH[Z+QKJ@Y6'.!*$-=1G$F,^Z1GM
M"5V\7]$53')RY V-T=ETKBC.1:6, +:M_G$R76(C^L89!_!4C_HDEZ6\N=5&
MU@B*<2M/3'XC5)K*CRCV3S,^B4XN^VPC:.]EXE1@L)3/RU\U_/,96P_61A62
M&JJ*G+.>8YB#0!0,,%_=;BAXM!#B[L 7Z.TZ3J,W"^^"KG_"8\NJXP,A0I6<
MBY-->L%-5G\:ULWSE/KA2GY,]I1H?3$ET@UA 9<_B:N&TO</#+#^NW',#HY9
M[DZF08<-, !#R#/QP<NZXQ+>; 4#=NHZ+BKKK&\3WN!DRK+9.7YX+YE4:"G2
M5!VX63'-8?/3)=/\G3_G?[;0-+8"^#H6@==_6V:[Z!SVK[N8&X][[U$8D,OD
MB%.'65JH\G]L">=O2SD9+H76#9&LK5\:&@F2>-$9L%LKE\>\-^JL7Q,06H0A
MKOCSW,D#1V>=[Q%_;UPJTUSCVJSJ=)R1Q_[)6IT?^&;.HQE4YKCY'^7=&2S2
MH\1ZOE7\SG/ RXHX855).O7 ;ES?5"H K;B7A*[9LY%AV>&'O2Z.30O_OBJC
MJ;^N&K$Q[?B\?H>I%[,=)9#>/,Y!Y/M'L\RW;\]S<)WR6C]OK$O<>;#.I0LW
M1W</T5J_"(MC-L!-24&-HE[/5PU//\CWJERP6L%+MRU#V[1U2U K''[ZII$Z
M;4R:2@[P:&=J:&P^*H)86SHX<+'4);"N(V%_'98F$\>IZU<N]JRZ$UL;95Y2
M25]9>A4B?+BNG!1]P$,\@1^P71GH15:RVJNWM/=*@--(XM$N(A"I9/4<!MBL
M()@U8C4P!C0<;*1#"CSS]68%EB7%#+WT=C'?)9^^=(OA>0\#A%(("(10:!^I
M2@/G.5@=@,%5M+A-,RC,S?;VMDR=@Z#1KB ZN/]\GP0)96 TO:[XZDV?EA%#
M\[R^DA!/4;Z?0&&& >,[XB1II1Z<)J#TS>"8''EEE+@A=4:!H<T3,%5K,ALS
M>-9=/"')EVMY XMG%@%[4$!O;T"2)7#@]O6\EC+$2#DTT!C7+Q%EBE;Q%/?X
MIS:.DK!('_!:DO"JD"NC6JD26J#=G$ZZ,8N IL=_HI%Y&H[H=E[1L+82O]Z&
M79DSOR_;Q:?LA!3_LDEV3#?^$R6!TG=2/VS#J3L9)]L\F\LJV[+UPNIH%JZX
ML(A WKTF^;G.(<22;1L:K#OIYOD[+?Y2URH+>R>$IMKX D[&*C=M"T3T.)FN
MKARL<61/3+WI.V[DF>DLEEXM&& 5LERHT1BSPL;"2_DDCN+]P)L^%=!:!_DW
M; <Q)?-92&$2EUUGFQ4C+BTF[_D:"7*22XR33@,U_S$A>7U.>'E^_TFK>6'U
M$-5'4^DB+0-4V9P3&KKFV;!6_3+!.J=\J:C\6+D \86Z4YO0\10RP>O^;H65
M03*&F%J$:)J@#TQ+JTLV*.COVLA]W5->0V[R#? 269E:H-QDOZ9:N %KL'#-
M3/8#P;'D%62.6]BH_,MX9S\#(ET*$K$$B/S_J^:K@^)JNC<O3G (!)? $ CN
M3H DR$#0X(,[#)+!-3A!!P*!!"?!92"XNP:"#^Z#0]!@ 4)^O-_[[GY?;>UN
M;>T_6_O'K;K2IZO[Z:?/.7VZSU5_>-5O.EES1$Q/,^^DL/62<F9K_GOF]![V
M43+\->S9AD6U^U'TQQ7;^)&O\"/)6;(M\4*M$<W<>!?VS[*66>P8LW85#,U7
MM<6S_85Y=Q2>C6FZ!CVN253 XRY^#*X7<.+/I6E',2U*,5QZ?(R$!K]+!XW5
ME+SBT@T^1E#]BL2_&L,I&3=117@/F49(XRF5:PVB5$"-4%,V6&L#5\["S\';
M,@A&]F!))ZJ=?.@+=.916IG@XL)"_K<5Z'M+MD\Z!\?\237H@L. []3EK;?1
MO<U\<J?PY=Z8;N!;_P&,7O_"6SVXE2\&K_]^K=R,Q)RN@GRMKPTB/@NH++;Y
MX+0H .X<X6SYS^) Z__.6Q+VN/>66N/_T8#N@;U&FRNW\ N9\WW1N[#D\3\
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M1\U]<#*MA2CY0_3\7Y4+2,3"SUE[4E)2CF#NQ]T$EKR@,(ZB<]!9#L$XZ@]
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M9*)O38(;E9P_WFC]/CM3B,6.0B9\OSUN(0KH=:J(:>$Y[I6X>J?./_0TG/$
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M+I3VMB)_[XM;P4JG-_<&O[+YFP4J#QR*D:OVKAF&)WYH+M*MU0O5@7D"[9F
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M4((T>!AP-C:>GYW_YN$#HV\AC6U)_*JC>:BJ73]]EMZJZ\2SH%F?=DU.#'K
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M$>4W+CAXC]\3\!"1GO @X\NHHY@X$=#Q!J(2/HO/J>Y&H^?3."5ZYSR%3LS
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M^K&W'_5@ .3MW"_"R0ALZ>T D=BC$R+_R7 7&!!X"0/NWM(LK;#"@!S\'1B
M< 0#H*7[5MG8>K<^_487=/HP8,VO$P80R5]>173NOFB& 5VW_@^L+6DL",D/
M*Q"M>]04*2B- PSH5[]O!U?>X''ZGTJNPH"(BL((8*NSL>TM#'C&./& LO3(
MQ!M_!\^RAP]*67<XC3  7%:2&R#B\'^X^>_GIO.1&]QC_U.3WUTM-4^BC0XQ
MR$ET'4TXL^SI2E1+?_S4JR-TYA.Z)B\RNJ38NS.D]PXR8X"'T;\P@/UO#$C]
M&<3;C4QR:#WXR+*?FGR2BZDNT$U)B2VU\@."L0M%6UR1U $#*SS")/(^R/D
M//A1@(VY=N9"+ OKIS*8Y8*_<_:H.X;07NGH9S SZ:(*;V^B-'7L'X+[S>H?
M@LN[]>_7@0'QOQE )OXM$J^8/ B"T313HO)LFV6^(E%AJI^+9+FY30T.+]J4
MFI?9QK=>.Q9L(;R(Z:D'6L]>N=I3^W1P._*!UIQ;-T.*EB#Q?O42)A^KL2!&
M,8*_R3!9-O;Y'_)\LOQG>3[_BSS;3"39/%<&1C5JY^JI) 12M^N53"[?@D">
MA2UG[V<(A[8L/F(Z?C=>IF8]I!:'U*]&RO?^@B!G./A@%[C8/CP!R3[EE;5/
M1,2S7V3X]MG>^VD_X+WP9XW]O7\JKRL_.WASVI%1;+BJ;;2LC,OE5I1@MRW2
M;74^CLV6]Q<+^*<<-\& 2&I6B%1(P8SEY(G=$?]<#"CZF0FZ_@0^T[)4@HY.
M+IG8#][>B)U5L'_XJGZB;N,LN]G4.@23'-WJP.'V(#\>]SY'/Z,KXS;)*3HO
M2Q>X@ &/RB>" 9-ACTP&8SRND?)W+.AK]4X0>\;VN>QY#Y2 ):B5E&TH4O.F
M3,/,QRI3F";Q AF[*"77N!7Z7<C]^V,)%[L+/+,T6JMG^7^:"P@]# 8]H6SQ
MK-<RO]]6M+WVT7-<JWH4T\[_6DQ>GSK)Q*47DUJ*PG)#CC3W3MB)G=A42D!4
M/5[.QL9'+O$Q>41[DE@0,T.^*?/YP_)OFE@N#)HUQ%B7'R<WOE$'?'EX ^RZ
M3> /.Y$KK;5^-+6 RQ>:I H6_X(\W._F&ASWU K(?0S._&I6V?#5O\;\'QTE
MZSZGTB;YQB['B31M_?*IZ:3E0K >%9)747\E-HCZZ>E\(G(@7E-SS9Q)FVO$
MD5T^3VF370+W$[UM*IEL[)N1LP6UFHC+$;!8NO6L^.L7ZPFR$JCTQ66IU'/G
MA:FGJV")3P\8]0ELI$>N;QKE,\=/!PZ(]WR_?[X2TT'>HN$9E@A13UPWZK,X
M;6](JQ@%V?GS!_UP(R+A+>LA8O1ZOV[F&R>-&)S )TT- XA;\Y9M:(S#WH0J
M54H<?7MY+?D.&/_\"PB2SREON3Y_#779&.84L/KZZHEEEGJF6+PW40'?CWY"
M\RHX3"ILU0Y9M=D.(BB$DSY,M37)]7,EHZ>=R6Q#&^-&F&WWJO#B'A=E5GI,
M'=PQ^6"DKT"VOJX>R/M7<JK DET@)Q.JF<@@V5$FWW1C4J#ZD,1Y9OWF>X[3
MRHC.=:&V!5<_%$4(OVA%3-JK>!N7#WJ:.A@DQC*K%,C#;[M'(K;M'\B@9QM]
M:3]GM13M#QOY>OVHL[L,A8X7IW&XI%JU4U$G<DX2I6F>X<,->!VR)JSJ^5M'
M"R]7+K952@TS;Y^=1Z^^@A@2N*WAA',QA_R4'+<O?VEHN,((P4X<%E-THF'^
MM#A2%CA$"4Z@">T0F>''H/!AX:@P$Z74])B<>#^V/6[_(:&*X6P)!3&C>:,
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M11ZQ6L9^<TN6E4"6QG[1+.8H<6"IU3K'*4FO;61UE4+"X>)D<_I4!WS&T4R
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MG[VCWP I*>L.J@2>&)[M'2=J*":@Z:K6Y@[H$"5I@>";NW>QL5VDJ>8S3F%
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MN-R+?5W"*516S\6R;NH5-7$K(B/Z7OOF9,WST. T&'0EJ$2C9Z!S0J'MR$9
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MIH^'7,DOU2<T_B##);I!^OH[3S:#<)PF8=3ZTI?>E_Z]?1?.#_6MN/:?#R,
M)]<'5<AB]Y3A6,%B;^'BP%- AF4@!XXRQUZKD\Q(>CJ6=]E8=^KP74Q1F8[^
MQ\"*99J>-83[1AH=_"^"T3WJ_9T!!+Q#MFZ8H@-:G*@C37%$4>]NG;6XCVF@
M"@GG"O:0EK0Q9H%!5G"F/T 9D(GYKX='A-7YFO<KR$+NFF>1;4U5_RNN@4X<
M:06.#L1&!K#0;D<&VPS/?:B!R^9?R/F$(VC-6N75^_C$-YTQ3F)$)LVT(MUZ
M79X^QR_:=:#L*F_ZLIE 3SWQ:!"'#W$G[E6K1%#QU8C-XEX 4?WOD?JIR[F\
MUF0'23I;C$GVX3)AV5$78;GBCP;6NA;0:WTM3<UJP12"+BEI2]<$CROZ[XPK
M8#[K7$T,SG\SA,J.L!LHY+1&# L]U:?$M9R"ZBND?YB=+V.G]3471W --\,2
M&,/H%P9?E;1CP2\/GP'X[#6R[*# :M/JN$['FN\+VMNHY[P^[T<!E\2G!E%U
M"YB]Z<-CY+_F5^*F!A8573/P'(1),\E]3?,:4N2KIVD:FA(F20>3NM\-_$V0
MY4J( #*F.8N1XJEI!%N1%TT#_O/;NE?OOJ9RND:IJ_:330BI8N04:5)D0M.\
M$L7.M$*Y[^U^NBE$%C0W*FCG*.R_8^N(AW@#$-]X,X"%>2/.B]%%0S^%Y/_B
MUZH#26#72.'=J/4M.@%%11"ZZ@.<G-70*4-"5] KA0RE>D*9TE:6,(<Y?F_L
M#^P6T("%12+.0^KA=E5R;*P4HTSS$QD;UQ:W$#4" );<$):P[4A=\MGHQLG?
MV17M;<@M$F3-"'C?X1KC"4LC0QSLS,3^DMUBJ1- L6A@)VHSSH-:PFU&8V 8
M^5-'98HT*3/1:S1 59JT%H3)N/XS.=LFF9R*D*7<VRE76DQ@^Y'8ZX"3"7&*
MJ9RMN@JNY\_:HGG^WO<G"5.PP1+[C[^+7SA75Y PKJ@VFHS@6@%OGP&9YK_A
MQ*+/ $(Q<@O\P6= 5_-9V",BW3.@XZ4!;Q)=-X!+/GU-"%PS?P8\&/Q3C<CX
M#'ASVD5YB9'X#$!\:6R\B-L0SW7L.V2Y9\#7EP]A;O\4)/Y^8&Y'#1SG!#Y@
M_'X&1.8\X:]^$]TC9GQ"!CX#>L>1':,?F'W+; FTFO3/);TI3Q36/;+7TN>%
M@@?)W <N2P3320V;S@A^(1?EK(ZYF_BWK1XE2-035/Y)ED%=;4XDIK4YR*7(
M+CFXD^D^?J=65]D^>4)XC&K.&5D4\5F@TVS'D^IK1+#F5 MZWIZ/0]%CF*L3
MSWM-=*^0RW"%"CIDCQ1;)VPU:$P-0CQEZ(/]H:.CNPEK2Y5>W^\]U_!2JN A
M9Q8&'GL42ZHSU,$U\(>=R+5H&?D)/P43K!1N%R-XP,KL*RCI)F<N1C0%VMH)
M;9H9^<&2TP.7]TGI2<G)49G]>JAO.)M%HU:XW U"=UH].;*MC;T(0;<S$K8S
ML6_XP\RBK]-0M>5C;_"Z]#A0N!"14.T,^+TF$*-$]]/2ZD$*K%A_!)&U?3XO
MYFWEZ\\?<JT$S#*"J6 *A7M/GV+X:J<N%T-^K,IYU#LMA0Q5AF^!.\RL_2 H
M:5&NJ?._Y>$>34IM12 K^NV2&^?YT- 3USH9XQRJACXTXNL"N*O<&>'WJ*!N
MF68C-B(K1]X#D_._1.4/-8?G:>,H(D_O8!K)CZUUJ4W1>0E&!H--:-WQM$LH
M.FU6E(PI?5C.8V30.FD?F'[]?PUNWK\AX/4+9KZZ_@L!,Q/_*P2@Z$BY!)Z5
M/5 _ \0&1<\X Y_88O^O8E)+=*.8J9;RC:V'ZWYL46X%9Z14GP6=DP"5>[^:
M^C/@OX[*_L_-8P56T__[MP(V2VO2Y2S@(+<GG&;".W6:E1-5LY$_J(H6KLU(
M!)VWKAVEAZ4D1F_AQ=+3[)=,QZSVG:T_MU$G6[L2*J5E=]]P/OWV7&E<_ ;W
M!!790IX!<S>34OETH1L[@C_ED:6&J!YW?#?IS(0LZVLHW\#Y#"=II[,GV*AC
M))RJC 9V+W10'ZT1V\7$!$YLKO[/K8BF_Z7*2/Z2#$^U?@^LPEJK))C2S>U0
M^W^*2M$*G+#KVB-A23++P*#%KD$2<VMQ=<Y2C$N,PI<]^,$F\&Q(;L*^AM1.
MEGN?_!E0=<IP/C? AMBSEK_-5 A$B@D(JFWQSO2*[-$=R>MM^^[T686GZAL'
MY\"&F]^ ]C8-M0NQTZ-X5C[<%90-_&,$#U2K.G?L2[_V9OR9FZ!?*"@Q(*[2
MG)B&02D_.\M-B;27FI%<L+P'+6<H<F+-\K)L,->D+:Y[8#H^L$:<-%T29P$X
MP(OL$H!A&3@"HO,N@6OZ_R.<_X'%3*SJ5.;$L Y#@OH,@:RI+1U:XX, *$<G
M"FW0U>R_JMP!UID38J]=VCC.IKQR%*MK8S9(O5G9<8_][IV=29,Q>*MP.;$.
M#@HSL5EKX*;74!)3OG 'AKH*IGVDN* _?\M0Q=/_A W?-_!W$/=*M[^1'M)*
MU)2C"\DUHC_^7B]K9&DF>^/7DBDLNP6+N+)E0AQ=ASOC^=1X%F@FYX3N.]"$
M=[4@.%DM  /DB"][M2K@CHX%AW6I<6TZDPQR]'*92SKQZ7$%_/J. OS"_+T^
M%G@(NR0IW?.UI2[G3S>Z- +9&?Q1'H75A?$>1]XH=P/0/T44:3"=IF= =[KM
MHV,M_NS(U;W8/H824=1[IXA%.3HF4C25F()$PVHI@+=(R-D&S+&4!_1%FSI5
M0&LX9/-"5SU&.H&/T8- U2"2\H=;'_/L_V1L(."(ZV6D!&/6*SW/_"C H 0>
MT*)TXS-)H^RJ-#U36F[_UA=B4R*A=\PJ%+HQ2!]D08O,&WZ]YT6UFW'%&-6B
M5.SEJE'3$-0]-B6_8XE#P+(51^AT_V/M LHX6;SJ]5NG[2PYY!D0-L57ZD+=
MJ@'FG@"'I/6^^X@5L-_G6I,(C0"$8H?>\-:I+&A[9;A)1:P((/;^YN[1 \1U
M'%'#:BAX8^S213%X'(\9)RDT4J02EED5CSI XEC='PH%WEDA9I'ZSJ[\@N'>
M'I_2IZYT7:\PL2K5#KO44-JF*B^F#!GK.-<\M&1@\NYN3*/A>6K>"=;^T2U=
M'MT/]"8AB@I^@Z*X[HF+#)0'S->?<3O#?<C9[+9TU)1C51*LJ>;HW(R=@^1V
MK9%VRN *7<YPC>WS*\+F"]#Q\>@E^M>W)AG"G@')T<X;C[J;7>-&\W.!E@9#
M1=T%28VJ>X@-!@=.:$:_IBI+%K'#=9-@PM-UUU$0S7AQ=P178KMK#TPBH?A:
M,T9KI'-A)L39*FQ)!>U4Y%*"UO5C4=U0AB#!.0*+Z+'A1G(L86:'_V<[BB['
MT FY#=(1Z45U;=J&5-\\J5KI>,MDWKH;T0"1>]1#N);".CLF7QCKJ:I>36-#
M6P.?Z@^3MSTEZFPX"(+2>)Y;6U"^<GA*SP+P.\7*TMS2HGZO$RN.*;^."F?X
M)*0S*<XE#3.GU$T$:[:LUI]MFX?0M4CG"^@DQ]<9[?MU*"+"#PHBLB"?<12]
M?S]9HGXR*4<%X6?X^/>OA%S4D;V3\TJ9YI<R:%'^<ETZ?9-!^.#WD^\XM&;%
M.*,HNH!-=_:0)L.\K'F;'*WIHYT:<!<;ZS9@L$F<+N:O-#H7.^-*+4\YUN&G
MJOW"-NH(^HKIUWOLUF1-Y4N2%UC@M'J?K5]]AFQAP&#5GY^;U''UY41R'"W1
M( O"S98XU4%_7!ZBMIBH-&-CA#1*X 'K;&YS.)=[H->;'/4V;9,KQLBL0T_%
MVP)+/HE7F=B*4<%I9+&E<AK'<Y\<5&K>8@ES?NC]'[X6R!&8> CR1TMY27VC
M=!"G;WT)O#.61VB='0_,Z83/@+>C7.O'A*+7.(%/? :!*K)X6$D(@X_-&X2/
MZ'=\3QB4SX#HB>O3<*-+]KU5^,=_.H'P$ ;]___0H7LIEG2%V_*P^Q/9BIIC
MK/_#-V;CJ&= \27C18F-'U^I4G9_CMQ:-&!.ACTM'E-"6>49T$+$(+Y;YN-L
MF//RK#+/P)O)UXY_P%Q?DB21HEB\U3+-HG?^=B2W6\XX6XWRU7U[]AE0\ZZ[
M24*R5GF!]0*)J?(()W'[@@++@^(!6JTB1N&,G+AAYXM:L]="F_D(>0]9I_67
MT.H!;XG(OXL3V\E,Z4[=FM#O>D(Y>QHJKO;G7=S'&Q0@XL1])UC9%]!6NS^M
MC()M*@3*U^XV,UD'O5E90,+IQ_,\P<=S WB[.QZOOFW?,YIH/S-^24$.30M,
MB GWGCWL=X27C@]$HO^<MO__;H^AG;/1<MXL]T*%-2.LUI$%3L53?VHL(I/O
M%(:<,DA7-Z68%$.]J:]3YMQBT:P]ZK8CDPTD)'1B5>6B$OQ'?%[_7X#/#.:7
MU3[=T5^N^;89^.,G)65Q_=SLA7)U4L+B/>XK+['\Q^3-(QM4>CSVU4]D0J_1
M:Z;V?<RD&))+6OE?$;5^\@]ZL5B'6IX<!OIP6G&(=IY-4ET.^RH+40*O<138
MR0M)JTA%C,QGQ4],3 +N*T7\#"@,_L< (7"QC3IPO#TG<*WSA6LMN]<HH]"_
MOHD9&;9SSMQ'0W,B3W@<1,^0I3!B>%FW_U1MPK3''%T/CUWS;<>CQ%CT2AV\
M"N3((EB\Y617Q[Q1P#X)3@4<%>9[1PC>]++_R"GJ!7R*& K3G2R LM7(.IKY
M2TQRI_HZ!5A/7-3&5G:6LG,XIXTC%I9$@C2[SD^N1U?6A&;9*I<8)H7JF!NP
MI+&1W$J!/,X9U@B7&NB/$E"E2LC3M1E^"WKC'+4]=B;2[Z[*&D<2+ZL>&L2<
M@XEE_\R*\! +7!"@;KG#"G"5B94=89*, $A[MU!,/].2*/3^$W<EV #QU5]L
MQ9CY3/0D-:'IY7H!D: _<IZ.Z'WT#=$8I74?AQ%<]X2!*!& 5BFND5A*/^R^
MQ-'8W[\*C&P!"1$%K-NU#6K.GSZ7K"-X  B$"0^/U81[.+*\Z3149GZL*2--
MOXR)F+B*YQTIAIV=;;,);)E[2CKEX$B#1>W6,2%<:OJ7Y9CY[OY22/JA-SI[
M?OR$1OCGMW.\EE_O(#G'82] ),+&G?SN\J8P:H+Y#R'"KY.H\X @,&/V#W/Q
MU0+;/-_"^?WQW)N4]T@N\G'O'4[ZW[2KRN(A9$FIV@VYMREP,9YN2=*487]
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MII7MS4J-G>WB4S2O8_K<B-60B(:6N9TR>&\%==:^CJ==>OL^CH!46IQVR+[
M?@M:&1:5/%1$M^8B()*<8K6!27)]95_J&+]CP_!=^14G["V=2L:![,,>XE@
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MO?0MEKGUY4A1(=^+;\PY\U"^:8)GSNZ.E;*5</0["L:[!.C!J N\QQ3)O&.
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M$:%D_3)B%Z#S6.L);7)I[M0665WC8+E93HOQ<:'YU\_=J7PDIHP_WO:Z231
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M'K^6ROIZ;UGM*T.XUFXM(Y%QV&V'CI5<YE,10$,/3.9LX6EC54'-N)A?3(0
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MQ44UT2J],:@U'[8,O"[K+JZ"'_F47#$E'^(\R2\--<)=E4WM:;G.IZMTGK_
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MW,19]S2"QVH'#(EP.?2'S";A8F[D3R96QT)FMW@(";D2.3JI:_"U+ Z6RA'
M8D8#DB))WAC"K[L0P'=(3T):4_A#+H'*VI6&MLR3TM/L:X$/[YHW:/,1P/QG
MI*6J RUF>!$BJ^S^6<5)(V5JW M^Z.U3''6:<BT0[P?>H/]3_LF5O!NES(N4
M_'?;*[_)OWQ6&AHS9*26$9OQ)J;+2.^X-Z>K>4[-OE+[DNO;MM <P\'I^VK3
M:);&'0XQ:P84OY+N;LJU*NM@F"$"8,YO!YW=\D>^GW1:LV^0G=^*;D5_*>%%
MWXWS^HTKZ!)WHC?;#%YW#*]/N<%XO2HWC,0+_+\'W@[IH1SPIV$\\.8N>(C'
M183@R?HN.0*X*Q2/9(N_;;:V)UXU_+92RPF7>7^D"\R,))XKB;A8#@@+F/L^
MO+&&/T;[B?J"ZE\GF%[N=:&HF<;HNGIXSV46<E5^T9U^Q:F$FYXLOZN?'+*X
M+4Z+_D7)17: EU;\DPOI,<6.'MO J7>$R:W'ZG?KZ5H/8KJ@FOX2U%,;.M]C
M-QO"Y4V-B-,!RB"T.)H%"!@!X%6WS1\OYB('L^;G8%ZL2YQ8S#7).#C&Q&QY
M1D6PR],_00!M>P?5U[#7AN=[(#AW!$Q_C@QI"VXIP&]^C?<0Y7FZQ"G&OPE&
M-0G#5##7R\9]-^%%R'R38_*:""9A_\TG#9-GQ\\+UL4.1'&!JV2H<VW%^U44
M/'8.7P]?F=<#+T?!*QA&",  Z?EMW"WZMW]@PB)?,C*[J7YE&GZF3;3(7X!!
MQD^?W&3X6?<+SH.W#5]H#G63Z8_ 94K19J#-.Q?O]6R/Q=;GQT)M!WFG2?NW
M(627!;T0'8R3@\)VJ(Z>MC[%:ISZFUA&.6A2NEAIR_UH+,PZ?:I):RZJ.;P0
MM]0HE'YE?KY[\B(S,Z7K<>(OE"A3;R7^R_9RWJAB28"RP9,1V6,)/]][[L3,
M/$P8*C,3;VWO7?B[<TR1]M$79[(_E2?N?]+]"&7$)V59(P=MW1"*8W9E_H%D
MS+WTPJ&J+15_U;WXUA$CTO^[_S.&=0Z&TL-!)_27ZSS'.H=7M(0ZXT[;A3)]
MBHG6U$\M$M<IPAZ?KIPR#9M"ILWN9.,2.2)-R0<)59I,]B.%R^'NOQH2^PA>
M#P;/WZWCHF^C8X'L^,QF6"DZVFI'&0X\G6O/4>['(]I5'&M@7;+1H>XI$+ .
MBNN!WK^\KZD2)XF#\1FEFU)P7\R 5O\AE]A(Z\Z6>,Q#I"K37RREG'>G=W^
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M>C1!?0XZP_*M0<,]YDU0O1T^P:-3UFR/Q4>R.FY0$1Z!4K! V)HT<[PKKR[
M^"6K^S$KI18D2[14(/$LTSKO==0,M+Z?#'LYVC6BC[^&P@KW;$##CO"U@:GE
M9*FMF\\P/Y]7J8GH=$JL]X"$/M7:F%)M79TJ>A5$_O4PW_'QO8,6_U"3XP'
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M/J=F#?VPR6WJHUT&^?4-2_CPHH7Y1\N:I@Q(<['+BO^TH'UV;>[,3+,NL82
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MWA^Q?=;3GDMT14>\F).00=>:4EZG^!8D-#"!<:<%X(2KWWC,^DN #U!&D/"
M:=\W4&W8C5+/WO&#37V.2&],VW' M\I]K_!E=?434^X(*[A0;8'N+VNE,KNT
M?$'T?'JT/";M[B5N$/)DC$)U4+G^2:VMKP[OJC!UZ_.QP$LL7PRY397?,6.9
M8X*Q5U3WFOEYLIT$C7*[8):);7>O9XMSJ0SG_L#8W:E#H E"6:!-L#&QX!5M
MWA^I)=;>Y#-'2M(%8N?EHD@=]MHS6<[W6D\';=CL/#&,]ZAI/ITZ='K-.I*V
M^YH7-TI9Y+24[C1X--$F'7_O^2T6"8?;40;Y;D3K&%!M[>.S\6K!'QVX-3&
M$;H0L/PO*@C^/QOMX?"_ %!+ P04    " #Y@4Y:MTYTJGIM  !R>@  #P
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MDGF%I"E.2ZL]\<QE<F(18]Z7%\N$X6Z);"5/=FMOSMT/8R1T93]IDHSE+_L
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MN? "H0*!1!7B;D!7\[4$).@ &Q!!_>\)(4L:_..S/AO03".  ;J@=X&9?'D
M4*C' 9UH.+I(]*JEEK&TP2F[_?!41>:S_,A3#<)"&?$=B8FTFMTS3:I; );O
M2!#L#O3ZB_N!O:=7Z.A79Q^1H, B)"A?%:%V2@'33(5O[@K<8PD#[$C];GV!
MBW>YS_CKS @>*G3 !CH?"#Z+$R[4.M>;H?[_FABJ6@@OWL$K&$08G2:&$G?^
M'50Z@L3_'6R=%[S;E@R7X?@)$'TL%_KX\EM'T!)LP=2%'.'C@X!+_CZ/\?S+
M_!$%]>FB'((A_+\E'O!B/ />&?QF/3:?[T9\OQC%6]-SG1C4MOYEHC60&W^5
M3 XDP;7C$7\%R,P2^AL@#A*TC F^/C7V4Q/T_,9?S,B!\E]^ZPY:@O[MYN^(
MSB-$?J+=&(5%734?YU%_:SHL2ZN9__OM3$!/\K6>/QPYF@]EN?395 8G>JX9
MB-G.[U4( C:(-B-!7G2_SV;\U?'2?Q4_Q.US67N&N _/(^__M=GAM0AS[*T%
M&-=5#A[3U<;1E FZ:Y!RO%QXV]7'7KJ8B"<U2E\QPO&>\/:3,?%E@N:;N!:A
M2LF5MN4UI:1!"AG9#^GJ9T;3:OO/9!NN$U\9"6JB_OD$;Q-8/L1REPM PM<U
MAEHO0VU7H:;R")>K]?7U(GL$8?'U,E0![_K_?*C%#RPB-"7$&70O?4(%\!SV
MY7,\) A,>YJ>_C\(#W^E=4X]P[%]&WS8N0N!2! _)\%"$9*@M$C\34?RF^[O
M0DZ(KYURE>K_GUBDBH"<HI^$D9\O ?9D8 2'YJ53/N)7$T"",,=]H>O,R:>M
M/Q=_XG4%RD6"/,!G"EO,2!#+I?]5JN]_ID'ME/ J_3^VAOA_08MW^1P;OG\Y
M.#BHO09GU+VNBV70^>I_H1T#:+$O(=C_&[^#MRDXX/#PN;"PH+6_2?N[44*^
M0 +80$T7H&O+7D<.N=?%OYKOI!BL1^DB__AC/@/*3<0V(+0^WCVG:'O(PI5$
M8O8YR\,NFJ,'-?M$:^3V#.$0U,!TS8V$X2.C#::T6CGY/Q[P+#0Q0KLRP)NK
MX$U='MV>Z],W]_\\?7-:MKL [Z<EAHNDY[83J>79)32&57JZFN1MWI%#RTK.
MFNV__<&5?IF@1?;$((GTK03(@'0SKI Q?,M !S9YSZ>O1'J%,5HN6O^PU;"$
M(D70L:O=@2WM!QN4_GQXX5*YYI .E<KXEO"KP3#>K[=2Y7!<O+A?R#R88+::
M>G+4_0;LUQ]#E:!*4<G/I=6:]VAIO]OUE+XB.)?F4E-SFEO 63+>EL\8S4]8
M$2I[!%D2&ZEDHYJ7]9,@V7&Y)\J/NJK51U1,_A!]A2_\@RMQ([6_ U,1;4VX
M5+6D@9&C34,^\Y;2,?;!%6^&?^L%3GF;_C!;FFG&G0YE_?2WSR)^O)5 3?G:
MJ:E=R5]6C!O0U[3/5[;?$9]&%#(Y:SPG*>M,W\J^'B/T2(1VHT<E>_^X@"34
M88HJX]6MM=N"L%@16Q:\Y)3FB[%O^18IFF;V,^9C>YF1O1ST9JCX]!2!O&LV
MG0H_-#KP;O8)WC/0TN22"MMOZYZV9;:VD1/1$7V-^1441\WO_JE6<V)TL#+6
M,98](VC.PKFRQL+,()X,-X6JS1M#WVT,' (;U8 V ,55=36*)+IJ2/N'/)W-
M#"SN6X[R2YM;"+=EE'X/5>H0).@WF9H5"7QC[7,(@J+ 3EE!S!W]&QHPC_^Z
ME#_@LZ?2$W3&UFK@$M=2$$ZX#;G1O!#Q&1@:MW#&_>A.//G!U3DL5MK]\Q*U
M8>^/:#4%/YV,[P0?B$YX" 8%A6[VK$D9BC]9;[;&?\/&DN'?9$.L->TLJ,;<
M!LDS>>ZS_DV EK=?4W-+?YC[K$*ZAZZNRJG^DH&=KE;4[S @PNE S73#DV_Y
M7N"1-9YX+UV-H9J%:6MPU -4FE>T^(_5'Z*&3:XFCQE,"'VJ3X@6[:+,H</-
MJDL4GVJ>?E:2I%ZPJ,3ZE/TC:];]M02N1TB0H;=0>.;]ZN&""J%GZB+2)]5B
MIHB!@E<&G$H52!"^(>@#/^JNW'0^V].[Y<YN">W$C1:9ZCUFAI>12H)LK)$\
MW5F=.I/^UMH?[J*'K!6:2J>Y.+(CNJM-[FC/0"A65["V7N"0TEZ52>UT42BY
M!&1;W,AD*++CO@/Z6IA3X/#5^AA-CHMD/_VY)6M>*(N5 LT,)L6--OL$/ ,M
M["P7KRG$; %[2#@YQ);B0)MA_,;F*\6:I5,7*UCFG6+2(XQ!Z]R.X[3JRGP=
M3K:IB]EJ:<&#-GD)##4-TG(0^&WN2_>//]1Y,ABRBD*R[]XU)E(0,Y7XXX\7
M,U,M-/U\BJ8VIM[$LUO&\X*=Q!!TUJ]9UD-?3\N<17R/MW07-[JTRV7*".UN
MW6V97QLXXCED<SO] MU.762#;*TAZ+S!1RGGG?%P<NA4A_WVF9K_9T4%J0;*
M3.K.KJ.2JJ),\;0&HS/7A&&6]#+^*$>ZQQ'>&!LX(..ZW0#&ET!Q&UHV,[AC
M26TV??HR:>ZLP_/J4#O<_/C1L6<E4U^^-OR4DMI TV&DN'O;%J@[FX*Z3H#]
M*-^NGR=Y'%S/E6L?%,1-^U"VZ:X_[Z<!)D=<5S0BXY !JB%1,2)YBJ%KHM4/
M %CLS[YNX:U@$L\XQ[V==(Z=&20HK9ZZSKT301V3Z0K5?=A-3T@3[/RYYLWD
M:;5)B/MJ0XC3/>*' LE*GPSR!MO$AL^+UB\F\%L=P7.U2-!M),@T]$;71KO,
M[J<FJ[G/2!"UGMLZ5Y\':PR+Z576I_/OV1;:CD0*BF\ PT V\X2P907JXT/J
MX^)[Q:F.L[CC;?>@$]9T40_FJ#GQ<2$C]U:A"VJFT,-S3R3(L_CZ2&0T(3$6
MYTI$L^[[;);T+J9B?6"WTTI!@OIG3Z].8-='4_,KJ,\OFX!]8OQ73[J-I6L"
M'C6G @/+%,Z\C8[PVH7M5O[N3O[&.D74T+I1B4==!&FG(HAIXP^H#W,WU6 3
M#)AZ\?HK8T(D^DVW-[3CJSQ'SG#F670$E..7'#/ QG7PX>D?-DJI;SQ6=7[X
M*D]LEIJ_[_L9;>48;J)P3Z/LG);=\(,W<EQ\X =^O/WVRB9[0GW?(UE"I>C\
MU >J/_G;=5<56D;U[RWXV'\3%]K\ 3U3J;L+OYJ'SEO\Z@&QZD61H.3\W<MM
MZ%G<U\7UIA5F'CRTO;E@=O]L:0NV+S&],;W*XDX2?NTZ^34?O96K!$AX"W;)
MH'EE2) K$O2A. VVH/I74S7JLIN3<3;R\>,N%40)Z-Y$\/7#;]69&G.;?;4V
M^$CHDZN*PS9Y,$I\5 UGPL.X'E94@-8?:"O:% !K4%O 1X2CT-T-Z#[Q_%7Y
M\_X=0>B6!\3H-)E[4$\*"6H%GTDCO#6+KZ[D$ _"STR '@4Z(/VGA)\<>%LA
MUPP\"O^G&;B_&Y"2IIL>76/A I88;)T^#PF:'P$""+03?M"]F*N;E7J7%\EP
M,8[M$'#RC-J)+&W997^<RQ&1[3H+$ QY86 T2\G*1X*@2DA00#J""/T]]!]2
MF,&5)0BH#1)4MD\9,^<Q^)8?ZY$ BIXTT$N\VPN_NNGX2SCU7HH'+=#)4*HA
M$-E($ 'DI(FZ?X?Z1/>G,MY?RB2%4<[$@+Z!D%(M^<(<X(( [B9OT3LB -R]
M"-WG2>O;VX7-&!_T/AN6:SB'H9)^2:?>&A^BWDMM^$/XKTF'R?HZ;)!KEP0"
M+AF%6KR"(Q:A9?M4>JZ'&1_['K>5-:T$/J'Y@@)9@&_P7X 11$\!W]!>HVK[
MO4AP%J@O,#9@I_O7HT7EWB9LAGI2/9RCX;PEZ!<]$O3/#. _&8I_.A-@".OZ
M@Q[H4^__"[GY+W*]:2)!Q +4:'PK/(&I.$/M.^/[V&W$T.\L8X0S4?^)YSK$
MR@VKWKNG1&5Q_6F7_8D5A>R76F-L#J%/:-EFAP.6=.>6+T"/)8&8^Z5>Q>_U
M+QPWA6;AGY;=R%NV9\WP.*@>AJ-9N( 7DOT][N;TY?S8MK6U9_52CUP9#;$8
MV?Y"VD]VH5P'9-DLN(T_%]8$:\2I>/" WU=$ *5Z/.Z D\Q74,PT5R_"BW4+
MT5\(P0,;QPA6'$'>U@O42]+>=:+_'+L<Z4HW9'52; F@A*1"^U> 2I-\_=<D
MS$+8/^L'L(TN6HR&6?@'E<%F/'QE*=ME9C-/DQC/%,[4@-K2DC8 6SNY1%S^
M'-64->_"$4 U, . C\&FN0412^%7JNU.>JZ+R;[4ONYZ<&8V0*SU+['7GA4#
M=&[_T@G>SJ,"^MZ\B:*>74&EO?2]XC<_C0+J']#N_B2AWLLY I]?P8#:.7P]
M[5U50OIW.*[4VDX #=#?&G0($=#B?VB03H/V'_^A(8X*:DN]T<0(9#(1G G.
M,H4$+2BN)Q]>7=>;[)_Y^#=^Q&3JVBGZ17'@5M-A.Q@+C'4"^PD2:)I_H;RN
M><'/@)JW"=2\Z^RKRG&]:D>"\LZ2_D !E$;?YZE_&L$!9Z;\AP_,H&\&#B^!
MQ%>QU8F9<TE>@"SH ML"5LQS0.8T$O1+*& C]/ 2^MM&N4MS?R!A_PH#]A/%
MGQ2_40##^5]@$"#R%^LY&O;U6L);&HL1Q"2^P/ R/G\Z]?,YR74<+W['\3H0
MMGH;52S7\M.N:7'_0@O;RW'@.+]J^EL0J"_R@ZY]Q)\L=13NYW7WZ47 /AI<
M;WV/0HL%E_*R>L#I]$)-0AA_G>$E^>:O[>$(FYS<DK^;A46B3?[GX3N6WD[C
MTGRYR>'-VB,R,.YHJHYJH07$J"GK+0A+DZDX'BSVK_\70H(Y<70[\]-KZ9[8
MPB5&4S-M)L;AN)NSP14J3+L%*WYDZ76^2_$!L]KX2-#SN?S^O DM]*=/]T0(
MX%7S--I/4 V2SFB6!H;+[S[F 6-IIE2?R"U;-KQKV(\MI1'6/];3:TFRLD0,
MT7!U,!K-T,X\)=@,JTGKY8NPBT\R#S8GD2;O'B]A-9TF"WF+9OW,?GRJAN..
MAOFI+DL4:U'G5*:ZS/O%+9JRYE[?U!G!WK=RSR.:OY!ED]H+/'W-J!2EPY(4
M!>G3'C_1"P&OFP-+J1G(UJ5/\UO%9-"!<2!IO)N1H,Z'=L6K>@&U\P?E.3^/
MC-1"MV"D0'V9_(. "=&S'WZ%$PT[8Z6&VX6IP'OVJ040JHYDUV=CQCFN8I:H
M+\C9H'OJX+,5ZDDOH&2GE@$)AN:#!(4I=,,^>]W_A@1%)8K+%9()5_8@049G
MG0B_'CTX"1Z"#P+8!EU_<VV;_K5M/VVQAZV8*/P\&V.'!/VSP+^IH\@_CUFD
MV#W7&#&\&%+C_#]CBB0OPV.(E7FA 25+!SK".!\@#T?PR0O'+*Y89K>KPLY8
M +=4!FGI>(&7C?B$SC4&%+1/3TR"H;]\_E,8U-BE&N&7_TN3BM'\(6WR9?'%
M>2(.<?_?;D'^B4_#&=[ZGU,F(D$LB":3YV*V]RJ2Z(9HO*7#"9OI8KC8*AYU
M9K'_,+0*XF) !T5*?@&-*5\ VW=AZ)&2^4%P#ZA0J.#_JNVKHN)JFK4G@002
M- DR.,&#NVL('B"X0W 9W#6X#3 X!)LD.(3!W=W=8="!P9U@07)XW_,=7?]W
MSKGY+^JBUJ[57=*K]M.U=U?KRLLB>%4[Q3_4,X7:NTR;$OUX?RLV'*Y#;Q&K
M%N"L=U+DOZ:QY0TI*[7VIJVM7*$!16%$A#RX$O,;DWY :>G[RL[>M0H'Z_ L
MVX@HZ>&=RH]P$JGXPFC84V1G=#:,5C;+,077W+:#=6YY+]JV;'\R[,QM>AOJ
MW2:U@/J.>+#4M 5=5@U&BKMHIN"\J<"'T31Z)0R.U[@=LM3'ILSH ^VE71\G
M[[33-4JT#*D""V23S5A S=NDR#JL57W,BQ]3E4TF&O O!WJWD"[D10[RH@3G
MX/@1J8SW/2:H@$<T$)5S*_3XJOW%\9CPUA[?GH@] ?_FMM<WJV=B77<C?P"I
ML[&IL^5B57>/F$Z2E.+ZJ=AUHUA5L_(C1];V (A]8(48';-U"_RK_ ,#HMR_
MJODO6:S'IW\ EZ[^EIXY#V%,_G=/_@ .=L_8_EH[0S<4ZP\62/S0^RQ$[&\@
M[ _@!-7_]%'T^E&47^QOYN]59F@T^ > <\Y7GX,LH3@XQO,?[_E/>O=0_.+0
M^X?:.\B'LSO)QST%]9W8\#("PH3V#[LZ_B&?]S!VRG>/Z?X'\+<-+/?(ZW"^
M*Z,U!]]J)VV*A=9'1/0#@G/WA.+.X)%[1'T_P*M_ (!';$4HP_A@?AV5]=?8
MV.%4T>!M_W]U!_Z_.B#VX _@OV@6[\]Y)[GXMY&6DCVDFFB7_F"Q'=/@?QON
MO[%4CZ/'0HWZ_[;T.@?<_C!Z*O8?FOY7WPL0GC]Z&WD7>_('P.6#S$,\QJ;Y
M/RF3>"OVM]G_X1>CX3;<[=2_PC,:#.9_C/]_U3;O<3:9>TS>Q]E0'I/*1/]?
MR>"0]A\34'KD$AU/UK/HR9SB5=$OLI*HQPX9$\/;%GS3/!>WL<YQD#LN!GY)
M'AS:$F33V7(S>+)KIBZFB3<3# RY4PW<^_(N3DXVO<F/FSJW?R^"X ]Y%G27
M>VHI1JE"!T'UFPUA<%M:R>?)G6]O(H!+7:)I(P+",@529K2S1[!J'9U,]-(C
MA.K[VLGVL ZB/P 4Y>1%1&,+! KNSC"86&OPL:[QX2^(5&AV< Q,%A^@>1/'
M,>K')+C?2^"XM\B2#,:2XW$1E!1I[E<Q9!A*IA>YC#_P'L^>;XB?<2O%Z<%B
M347 F+JK>FA'TT .(LV1KU,]:9QS90L%A-^I0<1%TWXVLD%<L;2Z?FN6N?@Y
MY&7)/X,R@88B)L6!:TY0KPW(10G/,N;NM@IQ2V05IBG?TW5,GW"-Y4PSTSS^
M%3;U#Y.9=BZCS-Q>V[53%R1,/,T09=S6[.REG/N$I6TD#2E* K!PC-F/\2[2
M;7T,=^&Z0+LF04$A2B=!(^9C+(@[(7QT8OZ[.HWK/%>/AQC<F].(-9-'[ZWG
M88W=W:]SHHHF$I?,C6\%/%F6B!8VU9.\[0C7!>++Q;G1P7S\R(ARX^"IHTS+
MPHYCK>%525HYVM:"5_F[F)>+%F,X X4==-^O]EU,3MKFI\8X95Y6.$6_28'#
M*2V%78F7H^<,>2L3<+"7MC#[>?A#M,]U>:4P%=#F?T12HB1"^ 42._\ <+G+
M7D<.+NI;GW:!GNVF.$.UDMF9T]Q,\$\$U((X14"Y?O[O)3!C2W2HE+C>\'0^
MH1SE+! ^[\%6W6H)XMX8 D'MH133/\;I(?Z8(Y[G"XLZW$],3!)RG9FK H;Q
MZS\_&:-?K&-QU=MQ.Z0Z5JZHKX:@;X#-6L,(NYE>H+S&;/N*_1S%]-A[JV[M
M5"D1:2#G[V%7(/-L.F7PBM#)Q"#@=7L8_]HV&JK'T[)26%[U[$F?O]V6?J$G
MGGSN8*X9/M$F+HZR/&GN;VQV\)ZMBA1^_.1?-8?_%U$6YD7+MF[\*"H<>6J#
M?/HR\U6PG!8YCU/PW&R1OJ20GGSM$8%J"'7R$GY%!W4KCLV$_!8K"X:4UU5X
MC=B;I>N^;F^_ASJ\2UV\DUZ9A==<@BWU\942-[*F?;;8UEV(L)39<WV97)LW
M"MAYY$EVZV=9Z3IXW.;:HK.J0&<<HJW288B9QR\M F&_1]#Q@F%\-,.;3@>3
MLZW_ W9YR5BS?;]XM*@C.DO[&'X&7_?U,3='D:>/;&/3\Z-.&L[O&,Q:G,\P
MPQU) L8&E228H%@$QL.0@NYT[O26FMR44NK6\GJ])FF'IBV -,E] C 8XH4H
M7S\9B^ 1.V1JV@[_.'TL7&CI&(1 "T3YL@OX/$\;25NNY!2MMG5:K2O5%W'D
MD-W2'*LT#2M)0%^+T>7B[*M&:=M^EHM&CVH)W.#6]U6=/*RNKWGAVO0KOJ"I
MUL<2'48"MS^7L(/+W2B-OUA>3.5.J'Q_^<DA7;H7]GWO=UAJP4+7ST7Q\<]C
MC7V^'I@ ^)D#B?JKK 81M#S+LJ"CMS/TTRP7YF '3I\,=W;[L_PT?(.(Y7.&
M15E2OR.Y'G+^4]Z<_#N6QE.E:/+10^HPJXV&$"[ 40Z(SGN]T1(F*D;X!V#&
MDEQ:G!YZV'.^_-4 IDJ@$8A167E$]CZKH%7:236/R4HOA&2ZP&WMA1N6X"+\
MT[3==@+Z$>5*K8_T@'O*9PQ2>2(/M#%59Z9Q:F566G$YP),$9T4OO[$8-U 3
MO.$7/-C.7"QDM 9$6E[DF4=SR++?RRFHY;4^-!0CV=DH=0]'JV^H"K,&8CX=
M#DB$+*6K)J5/%TJ_^K);)X6G3O(?5>)_0OA1)?L$W@0IOT/WV:,YLXM9M^/G
M0S54EA+$\5%UR^_W]]R=K2/ N7(N-#[8<L E8/1I_V^W@L%#9_T$=T$<&*U%
MEIXB=CR9]+P<W3+80K_VN"D0Z@*?+;*!TI9/T=<&4R&L2[-K/!%N+"_BUG5Z
MG9^1PG9"MO'*7/RY+:I,9[BWB11NW9\H;,H7(-%0+W9PB K?Z%<E7,H&]]I-
M+NF3_. $GM9'NXT!1YUBO06T75BWYO#J2\)FJY,_)-<(:4#$Y3FRQ#]COT![
M3 ,V04 STF#Y$;QT'^S_U";NR: GO(O+LZRK**_+#;^*9;EE=M>4D\E+M21#
MMG_ML&]#_Q)VLK6ARXO8VU"L Y.PO!\Q#AL^4*X.O4DB>'B=>WLDPC3%,**:
MJ(>+@&XGZONR)1QAZ5A,VS7?#AF( O,)%JQ6IH,XY0:TJ./[R$;TRZ_]?*Q+
M%T%&BYI;ZVY"+:J(MV]LV82?DD6XQ $ "5[T(ER&&5*D9]@?/)O_ -#M+4_N
M2Y/IJJQZ5S\(\B?#7M!?#;"EQ2SY#9LN9<Z&'G?>1FZE^_CLZXL6.7VQHXV<
M?4$-?18FFV&*,F[&?D$)4?3NP7/A<*8>^K8>8&=WP># \EECVI;-6*I6(,;.
M].RNI:?J_,E<78NME>&K;_(GHCGKWVHZJ/1YYA(YQ=5LAD>[/,>&I>_,3"FQ
MDY? #"X.3H4TGIM&+XZ,Q\TJP@T@&#_,C4$O:NLX.L= E/'FR9+F6?V . F,
MJ3PST K.C"V/F0']^^KZ5SJ=9SI>A#@.A4JL4,<?5V1-^D="_42VF=&!Q^I)
M,W*O=[O/95M)1^Z+\)=[EI,J6.N<2KA9;/5$;>G8V!(A?);N NV('^.MQ,L[
M=8:D4!&=3SN7XXM#-&^G#B.!CH6G*0S21F\K&KQ0RLAS%B'3+H.S%#0>!&"&
M0N[_K=>@ /*D-*QRG_,^W 5D:O=P8Q"R83&,JX0V='8*81*<:Q?%KPED^3%E
M0*T08=]^^R'W$69HK])6)6NH7+\\:"-6[LU:=?;2,AUV:&:H%>7T\U$YQ6I-
MK]/:=S2_->VV?ZO=>9^6;8HLWTC9C)\G!UGT=8J^2>V*RM/^,$?,U>S20>I1
M*>R$YS> Q%VEQ.1\&L=?+/;ZU^WMUDEN"D$J%X:(C5!:;FW QW%IJB3"18DQ
M9C3)V08[Q^O]8?>3\_TX2;M<&6:&E$CB,?<Z?KN!NJ!3)/BTX^+GK)R-9:[>
M^"_K.Y+U_;&ZFE'HI+^5?H^'R^T-6AJSGF_M>CV\PA&-@J%4K?N!<$(4[O"L
M!AE3"1>9K7"Q%KFK/6Q5(M[VKD5^ZJGDUZ]3 ><X"CN[*=KL"<68'F# )%ZW
M4Z$0>ZES"E.R(CJNL%^\=0G,)!XRX.NI,[+.T)IRPVA*$^8IUI'ADDSUNR*J
MBSGM^VJB,=9F:"4'LZ>;FNS+@5_;]ZF?T,:&7_QL$):PFCU]P6J6'-C4"Q0P
M%Z",PS%2JG'0/EF)*:--WYN-<;;]6LVVU<B9HAIS_@XU*#<(!ZW%RRFVCW?$
M&.O;)1)64U,:0]R!R80L&U8]P55/K!4IF/\UHA>D'#'"FER@[%&L"V=:EKG<
ML-Z6VZ)=/?I87+\4\_SY1NAF8C^>L\B1J'E-[/O8#E'BR*<R!96%4VV5 >>;
MB+D'+[\CZ+W?OFKOY)SBE%U)B99Y2S,(3Z&^]I4T8&" 'Q_IV+.Q< &/V*J?
MI:EL;)JQPU3MS>8)'AJI"JY^=>Y(LOJ\R3^\=H[7"*M9R-H+:YB07;L'K\*@
ME"9F1MR<>AS7Z1"<QL0R&#5G6I8-9E3\Y^V0NZ9Y@@N6X7H9[_)N/P0Q++\,
M9=7(((U?P-EZMP^S;C=!')$XZR0Q3WZG"0Y>G0Y4&H::^Y!0A%*$FF:9=%/U
MTT=T#HYMOR#\_%)<0.""__(8'+>W:!RB</_#GLJ"D6)$_S4V^JB?9_:P0*J+
M6 \QQ1V-H$"E7HZ=$][$$GR4T".5V99(CJQ7AGI\!N,0QV"&XF-34WJ/?37\
MFPB5^-:[*A)J^S'J\/[](*$Y"=J+:BWI11GT]R\PN J!]"C1VV6U[QK#BJSS
M=YWWN#Z& 3<X8S.QUC!/Y#H010),-)8,'<M5@<IA:EU6+!LM=7%]=M:8SG(O
MEF!8'5^AS2CUA2C?46!&L1WI"<PJ)$V\LCP27Q*K/]+%"\_&]6XW#'VF$.<O
M;7!3>/5T@&7XTY88=PGDB4:[@.A75+54C:G<Z/[4RT.@26A(L;@Q7&"__Z=+
MQM* 6GXM/_\7<L.<(=(Z I?%B-+O$/;8-WCIZY9$;@*HN.)]2C@U(@\4>\XY
M-XO5+@J;4L $[2$N;@\Z-VS/I>9#^J+].? 1]?2O&W-/1&N=>_3KO<IW#$\Z
MZ*'LGH6V-;<8'>Z[@M(I5U@.#9OZ0H "RNV"X6>L7C@+:OQ-W\+Y""W<T_?@
M?.\*"9]3=9!O,I"X++@'[\F),+5-P7*K)^U8:!W/)%]*#[>\ &!&WS/6]#;D
MZL*7EAZA,Q+^SLN]WB2 ]+7X=AE^?@)S!!F0L[S_LS/Z16%2'FU1'G\ORUGB
MA!0^7<?_\;3MOY/^T0^$'YIBDX^(I!IXU@KQIK%57':@]\PIH&&#'KSCHX7F
MM;Y;XT^VK.@#8K+F(Q:O3)X5SU;;2K'J1W-_F4DQQ#W3F #?\9!(3N+,#.ZG
M;A%M+GMX]0> +T-WD:BFH'-49IK.W81]TJU_G[RANL:@01_@_(((C=1F3U Y
M6G3"9*"83+S36;UK4WK#V=*')C X !@&*&/F/7MW5HK8\H/<BLZ@5M'@-D^6
MRVZH#O=]!YBEGS7%L/4E[(9-\M<P;($[%4S96S^991PR#.YY_ &,L:]R=&P_
M3W.^VBW57^SQ^*E@[>!J:T<'WDR8$JGOYJ3@XM<2JL/UZE42*!C:8O6GGEE/
M9_I*#27$P0.3 5T_2TL4!ZM4V!E7QSNVV<E*=4D&QQ/12GJ;4H+7C:M/]355
M20YY?Q\]< ""I%I>0N4@/,G %X2L0%FOVSZ@,93%TTAN[I!GLWZ&,C/7G1..
M$9FGY7#]VSW&TT3Y:/#\,'JK('78=ZQBQU4K6?+'=0,J$\]H*76C0E(F;#Y%
MS\MWJ8/JR!'P:M,I/M->;;8XP^'U_%XZ+;1D,733PT,I1-+9&+KFE_Z^4YQV
MX:Q<K>'E=J$*!!3O0<AUX'V/CY24/!WVMIUU,5P>*Y2B8;'V3#5BBP.<4SG%
M-UP;UT,4F,Q,PT5#-_ @P,.MMGMD3-4@?</YQ%$RC0[^'X!GR?<MK@9LSB<=
M6Q"-)8%OIM/U.>!U7Y:":RA);?TIS1P5DL LWM3-QRM8KI&SP/V@^"X'J38P
MZLD3U$@?O7YR4=/LM*=<6)_@Q4HS[5'M7-(UI$^XB-?W364^.L':^>>14&M?
M?A^-:I"IV^?<(D:7('[J/<89+Y&R<%\MNT)]W=[&F/P,YBM.:O@H9)?+@#N*
M 7/CY40Y:7 0"=.H4@_TVX:0/^:^HQ3=[944Z%V^7T+__$UR[[:4/7P.D)B5
M@\=?NI9[2QZLTE3\UGT4SVS-HGGO:*A;V=^$&\:E6ET-1F"$G3MX"*B]?=/;
M/BA.PBY^4Y48Q*'F*29_2I?A9K+XT[!1(2][^3[_>+1GL8T^A9]666-MS3)=
MP'5)H!DRI]Q:-<-]S8-!$@J=74>-EVWH*MKQ^KD:ZO4\:WV5<'>1+H59\W(>
M+H5)')J4RD2_*!Y'P(%UJX4!#?5 @<SLI&/!>E)BGK4L]XQT%S6QN<1R/8L$
MK,6W4V++M1/13-"D##O9'<4,,F3G_K,6I"C4JE.*][W?V* FMV3M]>WZQT(Z
M3H==Q-T-)T'++(.UW\4S]8ON)[.R+:1%;FV!OV=;*WCN>!EF<5,=!#GH)E*T
MA["0,L[/02\L3VV6"-R_YAKJ,3*_B$Q:XLSJ(\)"VID\9_=GK#><^SBH7U<E
ME='V(J]K:4.%(RI6^!7R75]&>:W8\>J>35C>^HBXS:2!#K-J),9'U(HP:>=^
M=_XE]N^]0'(O^G&+D6'!MCL:K2J%-XH@.A,,Y+89N9)SS+=FLWZFU5B)3_UL
MU3C/]J9TG]6= 0=L]FTK&O39F+_VNM2[H@8(32G^M%&(=AN?F6X6;$R>TA]P
M"_BL+8_7O]YUU$\9'#\?K>9PQW?9Y&.E]0G*&S:KP!O?'C=$4HBIY!_%B/VE
MM2;+1RPRN\J_*F^FJWF$MCD,;QD9$&X6!>'\&."ZAGD^B]5*7=?0F(!.UY"I
MO\+]%,'#\+WO:_GR^\3 N>E/B4<*3@>ZK2<-4<HS9G5BH/J&6O,8LN?K[T(^
MR"<X/GG)__L<PJA\_>%[/91I8?N<5?^5(_E;Y'!)1)X\2F GF\LJ3+TIM7L*
MWCU[MO3.JI0&Y:"82)OJZT0=]F&]4S1$9 ]9DK[$ZWV'$$ V6I[;O?T*"&?/
MQ_>K>\JN; 03:K*GR5[IVCS)Y>JB\5_$+-'=/)*=QN?LK_P2G5.FTE$8&_)I
MY;X8<76(>29[EAL7 ZE$[V(=]S-5%2/=*I1>O.,C5-61],#3FI,:Z;Y<Z_]6
M+QZ2'=O4S"YL&0AM*"JE/R6;Z6[O\GG6[-+>90NJM\L,AT.*U4"F4"&H%/$5
MCMM]PAT4+PPQJQUS(VJC_\,MQA]9'?3Q 5.,>'=#M8*Q8DF\@[_7_^4:]^8I
M799)2NW$$*D]9#!!LEOQ,O@,*4'M3)[+RR\ZLSC?,ISNU[0L/:%DJD;%@?K3
M-$YV[7Q7A>G"(NEP0GO\+ZP3]'^\-0*EQ@0DV$VL415&6TK\C@9,$Y-KN<BI
M-+,9&/^M\ +6.C.ZEXY*#$/F;2POZ^KKY<:CU3HV;<1A[2R@!=<H>0<]Q^(!
M[=%_"6.[8R:CF^O4_-VR'^P^"Q*"=[YX;HJ6M1F\4+L9X*.Q(.RTOH,[XO+%
MY(,FV]=O2#- XZOHHT_.TEPWQ$6@DS\ V>J*IG((8O]@+@7Q0J6YLN\5>ET8
MO$'/I-3147940"#U 5>16W?/O0W4=%9#9TW/'^7Q=7YE#\Z)84J#S:D$*+Z2
MO8I,[#.D\#@3'NI@R]BT!1$E-R]G='LR78'/T)P4C8AV\EU3#TT4%"(.1QH@
M[W26\RW1T>&]\KA"0>C\B'R'ESJMQ8N)!LLW^9="ER1)[^+?GHG?MGDXJ.R/
MVN2U!7(/6;/X-MT>UL)0I//&MP<3Y' I4D7,;7]'>_]UB$G;@=333(^V.SVA
MBUQ=2#X:*F%A]O1C;%R*IJ$/.$/N%&,/2C53/1,"J\GD/>L^?M-[O.65=KLL
MT\\N4_2KY.+:YT=4EL35DJ"-_*X'R8$Q@X7[GA:CS-=V?,H-\H!92-KZ]!2K
M?:E2CI\7S_ KN.S5ZW="ILO5,<7L7]P'CN=@.*G??9;E^5;8 GE(2$ $. ^9
MM7/Q(V]*XG,D:<"#_*.^;9*K]=D4!-=*""3;6UJZC $GQTM5^B%V.%XH^ 1V
M)4G.R:$"]Q6=8K&GC.?!.*=A>?/<(CKE;".!9VQ@;(C)[((>=?KG6A;;@<7(
M41DY1>6BSJ&E48,]<N.!/#?QVR>?OWR@)\HU_B&^ (Z>X*95)TF"XE@BJQE+
MO8U&UM(BK8,#AAV;S.6!7WPFEN3D&GL3ZONATOZVH7TYZ+DRF0 ^VAUENM@\
M[)#&VOYM;1V!8UYG;G&<&04;9NZKSC.O&T)H0X7Y.A.+D/QT-1ST,P=42"DC
M$\<1>Z7PBE%V5+YP3YG;)^<J3&K#[E6T8_74@&/?(!6)7):N$8,"L@@^P.#Q
M9!H,]B?T5 )EO$.:.M&]35@QMJ8..>]XA0O_HGK-*+0-=@L/X;X5^.QC)WTD
M$W1@&# :SDI)<,UOF(&V/<*[VI[NEU>B>6JX<A!^D,'9+TLP:BBVOITX5E9#
MOM."Z#CM"R>8.E2U><K0BYG_P8S]RTG?;;NTVO9C](/5]7I-;[\HT*CKB:38
MX4U),CIP#4^<.#JCHUBOF:W%*_\!A.!\N/5#CNZ'\0U1&4C?DEG(Q&\R.C<
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M47V:L,M0*%UOM8:G>HJGF:M3GQ&8'"\^-@R#D^>WL(+UA\IOC%S")N\DBE=
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MB6-;^V>U]^]^-65)^Y:_]@W#_>Z_.OJE88QT2?GIKF.3,"&?[#",B D9_1,
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MF@"7@/I_>CQW G"081!@.>%@: &P.#!P.##/O0 J   & >;/ ?C;@(&%@T=
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M5#=&R=DKTP$G1QT/,NY22+K.:E%N5J)5^)M'B\=->7P; :<=]F*\:_?WG,\
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MS[@ZK<NEXWQ(;>?BY+Z_"]K'HSEK.>= U]1<7Q]C$6'J3?.FT+X4GV<[3@^
MR256)AXIA.N)5O,MNY]TI2]JSF48)1+,6QVP<E$'N@TZ.D+1=%B/5XG%-4Q'
ML;.LKVT,5M"VYQ\F$8'7:VV Q[F(AHY+925]EN&THNP:&56H\+@[-C %M59
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M%]]-5[U5;_=3U5W5GQ:CQA%&?[GU7#=,G=*KQ;$L[13%RTDPSU9'5Q&9^79
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M4H6]N@!:#XD8%K#VL=+L!##X?\9YUT0;[&8D8EI7&*?W>K9D+@X\O[^Z<+:
M;FF#1>]^XQE7(LC>EKU%L$08/31]&2"QVXUM0=2[R[4?291/V8T:Q2PQTN&W
M&SV>6^@IJ_P*_V %=X;OEP=4104X?+=G@>L<9:_]8L\S.V<X%X72,CXEFF_Y
M]>*X,]]='M-2;:;Z*UB/=G!GO!!M+>5M]-'NG+OH71X! CX_XH5(_QH*W,J6
M8P$,-[85D.*W.@_0U\A&Q__HO9I4+QE[A]1 '+X#92[3VTYN\,6CRK^(NHF,
M^WK*+)8+_70 >N^2X)::]WH68KHBFD-W1M(\#J[!1&%ZJHA"F>T6WU0),\6?
M.^%_4BMB-0H] ;)O ?G82E[+,:Q99"?!#^2!Y=!3CI1BH//2XLK\#>^[7W7;
ML(BMH59-M7KAE$B]X;5PM':A/I<+*O-.OA@**N5?!6F!!?4J=-!028D%?/TU
M FEGM]C<RS<>[ 4X^C^$*\4E'@!O6^\8XS[]T$-AZ"4@-HLOVOQ,W6B^*C-[
M7+T%A4V<6#=%C:@32/4FG>84683%]T%L\Q:X5<IZ_<3K$GOK9U52/BT*KP@Z
M:=_$:Q-\CK4I@XP3>,>HMTTQP:8XTS,<V1A<R,7L5]3*XQ)&E-9/8\&^Y(S"
MIH,$!1!/U^1]WYS&3X)P<M"TP)1PO+!E5(K)Q^^A"J:XU#.,8U$0 ^-NH%>1
MJ;38@:'05GA*]J/DD'B7U<E6TK9WI0H;HT&ZS4V9!ZP00\PF"4V#)&KU;)0.
M*SW-1_VJVB(<=27>3D>U"7A4\M)^['O-$<( ^.\ /)4KT)EBQ-.#&07E_:!X
M&C3/[*R_>6@X'^B\:C2O5F3:[^7>^CGD\_NS>!^-V-R/^V$Z)VR<%_NO]:ZT
M$(INX9D\'S;#8B^K:Z2GU[*Z-?;&W9S3V)V"*-,P*(9 NK(H:*#/X%@+#W,>
M*=? 1C$M//@W?W;@55\KM\&(["?+1VK=2 0%=D,U!HIX!,N,DAM#9Z_AWG99
M0?0^[_^H5<4EE^%T+&/]BVZ_(DA2:Z919;ZH*7I8M9%WZ(5,_I:CE,Z3:5=7
MI0[4;V@V<N;Z0&+#B"RKLG(P@J)'+XYCDTMI8&_@VLK)G-< D1"-//H)++G6
MI.*YO;\_(_1@-4(]0])B$8Y\:L#!I 2TIJ^=!MNB5!64#0?88>D10$^3'(J+
M'X6\!(Q+I.2M_W)3/27Y>(%T4VHZ=[BD<&\)<T;TDC[&,"T,%4)*44QKV^[3
M'<>ES)5H;VF9OH[#BN_4D%?A[D"9#6;]:]*44Q3J/FW^+(IL"Q!+R9M*D_^\
M4'8)%_S7NRG@?/M?OX^^!W5\S%_3NZ<7$6U' W*_,S(TD+[:9ZJ/OHC,P4VM
M)A&M[0>0H#!3?V&5O$/1OQ\%*1RQ7UG)IWE>+EF@/97*6'J+%_B>^\2(Q'#E
MTZU5?Q)_/\+Q0I]OX0474G]%($92X"1#7[[_<__CJL&-+)+ZT"M.IE7-,'6C
M%Z13%EYL=3=&'[:^AXO$6EJ&',JDO.E!,,FUA_-G.$*O=V%XLGXNS]NS=NA]
MY&7/3A[5?XA-I"#K%?*6?)=Y>X 8ZEEF(V$'[E35?;![RO7YN-,<O2M4:4PD
MS*C].]C;=0BS:&J3CLRQZI@6%MWY@HN!%\UV1?4XJ2XO?8N M\][K'76/7T%
M@<D:$Y/^8NZ=-L?W&Q]Y_%.XRTW$+,U]"]&!8*TAD_8*^=QG(UF.%"%!\ W>
MYV[A9, 1"XY.K70WP&54]!X_SG]%P8XZ\WR4S8D%G8I13WM]P(J!JIF,;.#$
M*%,OQL']EX)&2RJ&XY.=BA^6/$^9F*.]Y\^<C3%".M?68J?4H]C8V:KY[HS"
MP1@.Q\D"+:X&I5DL+)P <*!&!,-FR:-#O7'-JUH(H00GVL&*;HEC$OM*WRBG
MCNI$2@:YG)0._'V\4:(Z:WQ)_<4R_=N9Y3GU$*M7<;W;BAW,X62N3]7-IF>1
M)8U%$N'4R3[LO4WW0WX"*2\(GB0C WU/FZR48VWJ^&7E6B?9+PZ+VA:P#Y43
M*$\LX>_['BV3Z@KI,I0O(^-%BU\M++%3L0F,=^72MYO,MJB.B,V%[;)DI C9
M]FWP;-X5)L_KY.%>*VC/<1R1+BH]#Y\N%ONNYSG1S9,OFOYJ+9%+] *BIM?K
M"SJ)XAN5>>3*#O$H;V36E4)7 #.1 C8]\3]NOZD_1?N893K!?W@8L\<\^1$,
M,@L62D%I5M!;$OC^ .!)&D2C\@X729WWKVL>V&\!W4-8Y<R<=NJ9,UYPE"75
MH+CQXE7P2&U=\@?2/+N.]JN,T;]H1IT]KE.LW@OSPZIX98["31E<!!8F6J8^
M45=CU9SP>%4,"[T;]&B)YN0=]DY/)./!?(7E2QE*=![]U=&?UZ-$MG"TS%[@
M"B:H+B9(8ZT'#'>76BLSJPM)V!:F1T,KUBYFN&!DT*C_#H_T('T]ZZM=+S]V
M6FY>WCQU0HLES2'9(GQ57O2]I&PV4VQ6@V*!7\6F6=',RN9MU5K<Y]WC$E>I
M P4-P[1 #NC7N0MQ37WK*(=+NTN, AJ!&9]"%_@,K)0Y-C.>RD\I?G+,A7_(
MI+/4=!])T-U_HMI+*7&<]P40ZQ*FDEEJ#B&DD\0\/)?EF["KVL<4H:I_P:%U
M<D0VDN5W-,;RM;2T^(,OD '"N>A0V"I,XUYG!O5-2+N$+/,:3)@[X=H+-IAT
M>WU^J=T8@3?L!I-/XKJA-E4QJ\=%H1?NU6J=01:U?E\IM#M?T9<C<C-2HA[H
M[G_E$C'.LOCE*;?,IY,R" 7>^+HD/N*SST4YD4]2S[R[.5CX6>0:92&!PM \
M7]2Z.MZ7+5C>0FRR#-Y _4!2Y \;^SIK '=G5W(KHI7>R69]KS''U*7B-9P\
MY].]R3;\TRK[>.9>J<MY.E;.\-DFFB2_:]<#0''Z8O$7IW9K<WV\B=(E:35]
MV/AJVW,KCR6<H_=AN<4AAYDNY8)E2^:Q47Q?Y E"@:_,[3C()W3ZIG:JEP?#
M!NA=+R\KOWNK]W@IFF*S*%!;)E:;$+5%*KI+O3$)0=LVSEQN.64*JUR"C-Z9
M(C#5U)&)O93F>DTQPU$"#99/@I9"E5#]^Z>R2'Z8TC3#OC4"#P\/;>?>?FV+
M,@L658PX]-8XQV6_=765Y%#0]+6EK#MVQ2BP!]LI:!L9&SZQ69JD:V#)YD5E
M=@%\5R0="V 5:3F,\U.>=A^>FUY$$BHS^_G)-U! &,'RSA9-6+BIF 3:8;GR
MPJ.N_&T4?DD,J9UR1#K@/ZK #1K:VZ>V[-SO#F,$71HS,0QYNK\ERMLW,Z8W
M<%LS,R2#U<N+"F+8._Y19L:B=,S<TN275;Z5ZX-CJF3<P'W)<&8O\A\70^AS
M<+ [$FS,^K#OR*: F5\.7] GR?6.CFYW+RTOJ;B(_MIG=#U:U?0I*RM8EOJ?
M]NJ;JIRRJL);YJ"C2E!<XIA#H _!HO'WGIB=16*S=%/Q51%P1:"EU6:V'D1#
MBD;8OD4P3DSN\[Z A-AW!Y'J?(YP%L:%R?RVG.J,17S%!?Q%O!A"8M(G@]W8
MP522N-><FE]/Y6,VV+6DP8L]^-<<Z/*E?GAV[)?XGX2#3H+?J#L''*Z4?<;-
M;D-9$^TCUZDN7[^+$5TT8?)3LWJ30,EUP'$*LJUFML-%_%#LDSHH35R,/J:=
M@AN-/_*G_*X0=>3/[%5\:$J,6;QB-^Z8*'YN7-!UY]/MV,REU/ZU^W!\BC^\
MTCOH]>]MD(/?1$!T@6^A=[3L$[ANB$L6.8:!^A@##=7230K/FU<JIBL7>U),
MF#)"ULPA28DU8+^HSS+Q-M5U1+V<7_PX\7R9 MKJ0U$&RX%+*3X ;.I^[%)'
MP&WS11_)CZV9(/IY0K,^LOB6HZ$&HN+K5?RUED4MY$P=B?$ 8*0,FJMZ=\?O
MC?1C[M\DO<[!R# H(/Z>IB/$Z+H N!*J89[>FBJ>/MZ:!)7":FU&\)8D;O!=
M)B(/W#+O*"E^]9 D_1$0T*?V75%$LN] 4X6K\1G"R=!Y6']U?<UO)8]67"'+
M)7M;E%2G($_*TK$6=L&_'^@N,OME?15W92AIV<C(KL$NC8 2X-^T@)Q_ 'C<
ML/A)-F0J7IP+U-C"?+%AQ68!9<O8NCNV7NDNSNN?!A\ ;(_E&CM1+<&N+M'%
M1BW,"U=B&Y@JE>G'## XV!*6,)9>L"6? 6CPQ4KD/7FMFZ9EN&0BZ\20:/2$
M5[E"N;=IW8MZ0>S9@3]]61SQ.\)WAH\\4 6,/)4F-PC=".KA#2_H3R&M*G'/
MYF1G^,3IMDSV]AESEF=Z*N%C[%ZDZ!U7\9R?KI8LQ?>5*]_,_MY%W,8@D-VV
MUHC)6:9,GVP%2N#,?#: 1;&*T]J6F-6  OEH1(&4P&'[N[KQ^YTON K??R+>
M13(U?YD<S4CH@24N\D5!(T? N]9!P3^SXW$IIW4]]?3(%<*//*@8U8I;#US&
M=PR#+1)9ZPMA/+BRH3X=XN4MB#U^]>:.QO"-53GSV6,XKT^@L4WH8L>KFPA-
MB4:3F22$(*D5H^(%/<37 1&8YE%N!T%U.2"I1B@?O!(+.CUQG) I'$8[L6KR
M1#9+K27K:(H+>V SRZD1=_0&E9J(]T#0>1HBFN=U$E[J#:N"^ES&;'6J8;C6
M/LO/]])N/1.>QKR,GE2ZZ"Q1X-/CMJN0])TH)P@H^ZITCJ&9OI^RV >D44B0
M@8,,CR?>U%V9<.]J3[.CVH*CS)]Y?@1U8_DF[0\P076T]!33,$4I<Z7(F$J:
M&YOJFX# )D.R3Z]>+DM984ER2?\$MHL$)O*Q&F G+^U/[4?L[.CS-9HSL?3.
M&SM1&RAT8 1S 1!>;N:[:BT)AJTSEE.](YHQI$F2#4\V11KKJ=:X'YF+*J=1
M@KG0.\NNAC:O;++X"-G;O+ )JWAX6105AGI=FE"68F-_R2F8UD@DVUU!1&5R
M)YZ&V6U@7E.KOZ3*.QAY>>8L9:[C8]9DD?N(J&"JJB03Q:.0S",XC=T*]=9P
MOM]]GUJ7*5)X1:>9$GL>H>)>5%GI(*AZ#H<UQ4]2P*-2,8;9-*GC]2B";RT#
MW1.-C$WX8IP(E<VC2IS;NZ)Y1@*"JTM[@8%B+]8'.2^@4\<&)YCRB3ZBS0E8
M%FLOZ&%/?3<S]["SK_H-0KME@FWM/@_-MD1+GZNT %1NVOM&O$*S-TD[%G4/
M]EU<@18C,;Q/L(XZGQ(1YA1^\]5:"_4KGUU!,&?:C$U+IPJ1"=%( 2<;U4B4
M>$SL9F&?]6GHQ"60T.UH1AM+_($YHW.66F;GS@-G$B>2B^$73A7[)(<EZ)SF
M,]:U[WB55=3V9B?Q4'U$([:[ZBB:Z9E*%RM-7MR)JS.#5[PAD&/+J%2*Q%',
M7/ 34%%"/JKVN^\L%R#NLZ]8$_QJQ-\:STUD/>'$'4JD=DL@C?Y/TL(44L+]
M9M$CS;4\U_C6']6,GC="(Y3B9H)I;,W7?.J,X_5AZW<-WU#B4Y2K8;;&'\GD
MB'1WS/XW#[C\I^.O3P?.9<T5^>,_ ,"5=@\ TZF@/?YX^FO-"Y;_:_=-_]P]
MU7C4#D4%"?8,Y,OD%\'#'UD$8[ ]_?-!6SLXN42Q1\GR(%;RHF0J$BM4<; O
M4)?*=VY^#7&%9ZH08A)X)L>C=* D:?CV^/FT8J?EW1IW=T  L&W:G]FB#)O8
MA#8@FJ$!?C_GJD1\]YF0(L_*<H7[UU;_Z;.QT]RDDD434_L6,4F+J;8[;S.H
M0\-+/YTT%XO5ZH!18_L^-7K!IXW"8DG9A./O?-\XR[_!U3@T_6BV'L>T:#!Y
M$:>*&4X^NEPTQ1#$-Y0H/\3=]-XR>>Z+YL1/(03\X]#^++#,>-E@R*$.9Q".
M.9#LEM-C Q2L#_41M_\%E5UHB+%)BN2DKP.\'"8,%L']7,PSY)9A?"P:KW\6
MH/[%(S67!/X%[F?;Z*<3P5KY 7P*F7=[#L^\%AY4#07T*>U^?57K+<P)ID#R
MW.Z<J/KI-7NIT#D257W5B'U-NI5*&]9*RI!MGM<8[*JXU<TE&H;G:\/GZ!#6
MM.6^TT+Q $ [U/VAG"H2@#Q2?[P4=J6K1"]CX$+G!@V-%4ET272V'VT/2]TQ
M>DD[G0N,JB+1RGW);BB+^D0:\/[GL7XPD<L 0_P,\@5PR;A>&'2RC0Z'IU(X
MJ^9\OMTL"=CG\>GL\YTS<UM/F;R@,CRSM78'CPF#U):;0VWUC?OBGQ$X.R]+
MTT;<SGSA[?0LU)HXYJ2^4L'@I_!3*3MVB'WR<R3E5=J@%C0LIXH'1[C\ZIOR
MYI8?Y4LO_/2PVKCXC>"<HMND*;X"@^".3*EG1QUN/X):+ZZJ2]6_!UV%%WE-
MC 9=J;1^#)U9GT(X/*$E20/ZQS1MHKBL9;N,+I-TI1('OIIP?P#@O6-9-5%O
MFK]YJAAKM@#P>;36+-_WB+1/<1RE$O VJ3O5O!B36_>@>>V7'.L@0SRU$M4\
M (670(I*N/*6*;,%LBG]HA61E($.A9UO"=&Z+WW&\06C[1K>)GQ8FT@]O<PQ
M0;Y72L6TCI]N'1DE&&Y.K)VOB,]J9F8&4.HZNKP946:OS!YN'>C=\O2T .N#
ME2Z%"_V.\&\2ZI1>>%$^]DUD;9AK>PF^KE#DRWBAR#C] &@8HDM,?0"T*N >
M%WO!G9IFGM>$5#NQ@PPQG*B-KC/]Y(V8N$C/5MYE< 3*K+O%XC63B9T65&(R
M]0^RSF^IM+ZNXZV+4V+Y "X4=Q9YIINJ%W#"VH#E/]*3*^*&-%$UQ8>EO0WM
MY+?)W:_2O5=D1WHI/B]4T/]&3+%U<XL3HC0HIHFX%EJ29MS-*J>0=9VMA8I8
M#-):/3,I5EMM?::/90EV"^F5M -L)0V1N"[&U#GL,F1_LTSLH>,1CGLC0RPJ
M?8E2[*1_K7N_VR.2FB1P"6*W!!8ZX>?45I&@%SZ)LGXKXC'8AZU6?BV_T:V>
M><F8$]I-U>-YOIAN;3L2P;ST(?MY0%AL*"6>W9VB:=>V#:^<I\J:G?;(U-+R
M,(%Q%M>5 +M+E(;VD!&J&7Z6D^L\ \Y+=91^JIG4G+)#%5#YZK!X&_%IAZ4&
M@R:/_TE2(VE9)R#7UT5E4;;IAL$%JF?N+UQBSVNK>^O_ U_-I3!F\0/>4Q]C
MWBWYUGLOH3ZA=3>D#A\51Y]ZI$"+ZG8QE)VN?9&6*Z5'-=!]*[3T<"I:O,IA
MOIEL9,)$/F]=Z#(2:3W!+\S)'B/FQ<E8;D#[BBRQ-I:8@TQZ,0PLCTX%-%+[
MWIN:YL9465Z\:  )G_[>[U<:[I%)6[@;E8<%2-+W[Z'^2,J78YM?QAM2T.(C
M)HP:.[N*,/,H!ZG=+K##YD,_\43^.%X?">*B\(PG$:Y$Z;2=.S?L+%?S=D!:
MM+82PT#T\@S:W 58/X]5SB>TL78;)8'XKKR)!7 /&APULVJ[6_?D=//IUTY$
M<R[I6/9C;S.(?DT649[)/Y7NK"1/B" 8O212B>GQPW2"BGFEFLI*GFARPW?>
M:Y\,T%[UZD$C71LR"UH4V_@=^)KY19'&AHL*%D\.0<$#_:-)W^0_XR=_.E"D
MO'-CR"6&1JX8*%5MZM75^RT@OX[YU\&X=AB3O3@>D0V@5&/TLR)ZA,F&)TQR
MQH.=0!^^B2Y#EJN[G2WK+>&=5KKX0^IC>LX'  =*PGBW2QJL?D>G@LE+3J1*
M#&9/?0X!(>G2T4#5!["!5_72FFMW7;Y.V$+8AZ0Q#2/<0H5?I57SBZML)R7]
M#)%#Z21T/&(=;:?A*]W3[$#U-;_T2][23O_DH8E%/H5A%@:_M!Z,N5"+F_'/
MJ&[15(J0^9<P5SX]AUQ IE^9>>CQ :E:_T)Q[FTO<IH@?IC.,F? $W\A0KJ?
MW["[<[#,4#; R2N /V=K%+OJNUT-K:@SN1+ :;ED,UC8_)$0\D^"N6KK7L9G
M;/5NQ!@M6OJU8FI62%P-RHTH*N?U1@1@&Z5U*<Z1^)KF500T&-:R<(#\<Y+
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MS4"UKUDJ,^P>F,XU[*T?,6F7JD6>FRWA*4KTS$)V8SRR9AK86>38<Z9,Y?B
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M6*;=,G6(')%>L._Z_\F%R?^#@?:P\+\ 4$L#!!0    ( /F!3EJ%,'O'  @
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M7VFZ+F]=?)'SLQ4Y[R9'Z2/BSH[YQ;]V\07+=2Y8]GSB^<07'[_@XF-/ )X
M?"&Q+R3VA<2^D-@7$M<5M#YQY<N%:U,N["6CEXP_5@[*E_[^^*6_GWAF0-:<
M?<(_$Y&^N.K?!P]@9P7 ETMH?DT!\*/UH-4.+['8=W%F?W(L%1S0?YG<^P-0
M2P,$%     @ ^8%.6O1+,UC4 P  P X   P   !C=FU?97@S,BYH=&W=5VUO
MXD80_BM33G=*) RV"=6=S2$17E+4)-P!E:[]4BWV&F]OO>ONKA/HK^^L>0FA
MD-RE22J5#Y;M>9]]YAG32DW&VZV4DKC=,LQPVHYNLM_IHN'74-2JK]ZU?G"<
MGHR*C H#D:+$T!@*S<0<^KV+SOB*:$.5X[1;]96KF8R7H,V2TX^5:?_+U.E<
M#B^N _BCT(8ERQ &H^MI )Z;&S LHQH$O04E,R(J[5:^,;5:SF3X6W^ENC)S
M!IVKX>6OP;YA"%>=\<40H[CY(@1#%\8AG,U%H-@\-2$Z+MHM;904\W;_RT_#
M\^$4&GZKOG[5JJ.XGK?AV>-OJJZTWXF9SL/7B?(25Q@*B*00-#),"KAE)@63
M4OA<$(4(X$L8TUPJ S*!;O_2F72'T)4*7Y'2X,0JOWOSWO?=L"NSG(AE^>2%
MIX#B@509]L#Y#(E4I>.<*B9CH"*V8.O1B&8SJJ#A5<%W_3,@&A+&$8W;5"8T
M*A0S#)M&1 S]1902,:>81I8QK?>S6.6[2:(*%Y1B^C]3A8@6U=+C)\5$Q'+"
MT1DZ-^R&PBA)6(2)8)U695U+&?$3,8I%C%B[**5Y=<?!@ F"MWAWV$$5\!V>
M(F9?A;Q0NB X<4:"]QY^J4UJW9JMKVREUVBZ55L_B65NYW%7?:/TP?UQ$V%"
MU(P(JIW1@M,E=*+RD'S7]6V5I#2S>C.J2TG*-'P5\A:;.Z?!:PZ&(3-.-Y%F
M4L5(+3HG$2(@<,,=<TX3$R92F. 0D82W+#8IBMRW%6PKYSF)+8H^5MR*C:(V
M(5)J^2'PFOFB%,0;P<K!V=NPLEM[1M2<B<"UVG=I(U7&AXUO[(E&A*^3-C*_
M[^_QYIQXIP=#_'O/4SSP]<0F!<?QC1"'W,[.=IX4_;-@BEKJUQ87=_@[(3BT
M"KSF27RZ1=G=]&TG;PTU[T/C++03LJT%+^KAD_B^:@Z<QE$'Y58:7O?Z=@\U
MGL?GMSAXA9J?#QXG_DL"CPED^6RU&'"I&,($TA@3)9 VJ"3,;I5<46T!6+5B
MPCF@&6X&Y%$4Y(A(O:+J9,NOZ#!FI6O+R:A5\!5^=]BV=O]4\&*99]W2QWCH
MQ7FGZ5KB&="9PN6Z!.^L7'G-(T33L,KGRP#^(3\?C7O]L7,^FDY'5P',.(F^
M@I<O0$O.XG6VC::UK^OZ_05X))CG6^TGX/D1[OP>U<-Y;E6_+;4=[8//#ZS^
MEPKYP/.K]'J%H0-#OX>C-V[YVT'2T2UI8;7_5?24<__/L'9$]7]9T_%OU2>7
MMR'6'1/+GHYF?]&20DLR=1*2,;X,]NGTB'?[%[/]-U!+ 0(4 Q0    ( /F!
M3EIU 7YXL T  )V    0              "  0    !C=FTM,C R-#$R,S$N
M>'-D4$L! A0#%     @ ^8%.6K%K9/K3#   (8X  !0              ( !
MW@T  &-V;2TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @ ^8%.6JFQETD0
M%   524! !0              ( !XQH  &-V;2TR,#(T,3(S,5]D968N>&UL
M4$L! A0#%     @ ^8%.6J3@%)W)0   _DX# !0              ( !)2\
M &-V;2TR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @ ^8%.6GSX @@),0
M*)L" !0              ( !('   &-V;2TR,#(T,3(S,5]P<F4N>&UL4$L!
M A0#%     @ ^8%.6G%HR0$$MP  5U0(  L              ( !6Z$  &-V
M;5\Q,'$N:'1M4$L! A0#%     @ ^8%.6A* W/AU20  U%(   \
M     ( !B%@! &-V;5\Q,'%I;6<Q+FIP9U!+ 0(4 Q0    ( /F!3EIM$%!6
M/DH  .E1   /              "  2JB 0!C=FU?,3!Q:6UG,BYJ<&=02P$"
M% ,4    " #Y@4Y:D<Z5UUM"  #L3   #P              @ &5[ $ 8W9M
M7S$P<6EM9S,N:G!G4$L! A0#%     @ ^8%.6B<@:UH):   RW4   \
M         ( !'2\" &-V;5\Q,'%I;6<T+FIP9U!+ 0(4 Q0    ( /F!3EH@
M/<.!GF\  -&    /              "  5.7 @!C=FU?,3!Q:6UG-2YJ<&=0
M2P$"% ,4    " #Y@4Y: IP ?793  "J80  #P              @ $>!P,
M8W9M7S$P<6EM9S8N:G!G4$L! A0#%     @ ^8%.6K=.=*IZ;0  <GH   \
M             ( !P5H# &-V;5\Q,'%I;6<W+FIP9U!+ 0(4 Q0    ( /F!
M3EHKAO="K7(  +:!   /              "  6C( P!C=FU?,3!Q:6UG."YJ
M<&=02P$"% ,4    " #Y@4Y:A3![QP (  "060  #               @ %"
M.P0 8W9M7V5X,S$N:'1M4$L! A0#%     @ ^8%.6O1+,UC4 P  P X   P
M             ( !;$,$ &-V;5]E>#,R+FAT;5!+!08     $  0 -L#  !J
%1P0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>cvm_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20241231"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-10-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_UnvestedCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-11_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-11_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-12-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_ChangesInEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_ChangesInEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-10-01to2024-10-18_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-18</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_ConsultingAgreementsOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_ConsultingAgreementsOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_TopMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_BottomMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_ConsultantsOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_PreFundedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:PreFundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_TopMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_BottomMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_PreFundedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:PreFundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_IncentiveStockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2024-10-01to2024-12-31" id="ixv-5662">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2024-10-01to2024-12-31" id="ixv-5663">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-10-01to2024-12-31" id="ixv-5664">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-10-01to2024-12-31" id="ixv-5665">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2024-10-01to2024-12-31" id="ixv-5666">2025</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="ixv-5667"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-5668"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-5669"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-5670"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-5671"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="ixv-5672"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-5673"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-5674"
      unitRef="Shares">74084041</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-5675"
      unitRef="Shares">63787104</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="ixv-5676"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="ixv-5677"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="ixv-5678"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="ixv-5679"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="ixv-5680"
      unitRef="Shares">88573</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-01-11_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5681"
      unitRef="USD">2300000.0</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5682"
      unitRef="USD">200000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5683"
      unitRef="USD">700000.0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5684"
      unitRef="USD">500000.0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets
      contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5685"
      unitRef="USD">500000.0</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5686"
      unitRef="USD">200000.0</us-gaap:FinanceLeaseInterestExpense>
    <cvm:LeaseExpenseUnderOperatingLeases
      contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5687"
      unitRef="USD">100000.0</cvm:LeaseExpenseUnderOperatingLeases>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5688"
      unitRef="USD">100000.0</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2023-12-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-5689"
      unitRef="USD">700000.0</us-gaap:OtherResearchAndDevelopmentExpense>
    <dei:DocumentType contextRef="From2024-10-01to2024-12-31" id="ixv-6312">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-10-01to2024-12-31" id="ixv-6313">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-10-01to2024-12-31" id="ixv-6314">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-10-01to2024-12-31" id="ixv-6315">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-10-01to2024-12-31" id="ixv-6316">1-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-10-01to2024-12-31" id="ixv-6317">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-10-01to2024-12-31" id="ixv-6318">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-10-01to2024-12-31" id="ixv-6319">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-10-01to2024-12-31" id="ixv-6320">8229 Boone Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-10-01to2024-12-31" id="ixv-6321">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-10-01to2024-12-31" id="ixv-6322">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-10-01to2024-12-31" id="ixv-6323">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-10-01to2024-12-31" id="ixv-6324">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-10-01to2024-12-31" id="ixv-6325">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-10-01to2024-12-31" id="ixv-6326">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-10-01to2024-12-31" id="ixv-6327">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-10-01to2024-12-31" id="ixv-6328">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-10-01to2024-12-31" id="ixv-6329">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-10-01to2024-12-31" id="ixv-6330">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-10-01to2024-12-31" id="ixv-6331">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-10-01to2024-12-31" id="ixv-6332">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-10-01to2024-12-31" id="ixv-6333">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-10-01to2024-12-31" id="ixv-6334">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-10-01to2024-12-31" id="ixv-6335">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-02-10"
      decimals="INF"
      id="ixv-6336"
      unitRef="Shares">77211541</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_682"
      unitRef="USD">4614115</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_683"
      unitRef="USD">4738173</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_684"
      unitRef="USD">373069</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_685"
      unitRef="USD">294097</us-gaap:PrepaidExpenseCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_686"
      unitRef="USD">863104</cvm:SuppliesUsedForRDAndManufacturingCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_687"
      unitRef="USD">1019908</cvm:SuppliesUsedForRDAndManufacturingCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_688"
      unitRef="USD">7500</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_689"
      unitRef="USD">3500</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_690"
      unitRef="USD">5857788</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_691"
      unitRef="USD">6055678</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_692"
      unitRef="USD">6899819</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_693"
      unitRef="USD">7350364</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_694"
      unitRef="USD">1442619</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_695"
      unitRef="USD">1495937</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_696"
      unitRef="USD">7592663</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_697"
      unitRef="USD">8129753</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_698"
      unitRef="USD">148394</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_699"
      unitRef="USD">165492</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_700"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_701"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_702"
      unitRef="USD">1438403</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_703"
      unitRef="USD">1475441</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_704"
      unitRef="USD">25698787</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_705"
      unitRef="USD">26991766</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_708"
      unitRef="USD">1999214</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_709"
      unitRef="USD">1448467</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_710"
      unitRef="USD">621601</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_711"
      unitRef="USD">566042</us-gaap:AccruedLiabilitiesCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_712"
      unitRef="USD">558103</cvm:DueToEmployeeCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_713"
      unitRef="USD">363306</cvm:DueToEmployeeCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_714"
      unitRef="USD">2074490</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_715"
      unitRef="USD">2010995</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_716"
      unitRef="USD">226155</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_717"
      unitRef="USD">226969</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_718"
      unitRef="USD">5479563</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_719"
      unitRef="USD">4615779</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_720"
      unitRef="USD">7412252</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_721"
      unitRef="USD">7957925</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_722"
      unitRef="USD">1373340</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_723"
      unitRef="USD">1425979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_724"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_725"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_726"
      unitRef="USD">14390155</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_727"
      unitRef="USD">14124683</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="fid_743"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_746"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_747"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_731"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_732"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="fid_751"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_753"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_755"
      unitRef="Shares">74084041</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_756"
      unitRef="Shares">63787104</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_733"
      unitRef="USD">730839</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_734"
      unitRef="USD">637870</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_735"
      unitRef="USD">531662716</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_736"
      unitRef="USD">526241074</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_737"
      unitRef="USD">-521084923</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_738"
      unitRef="USD">-514011861</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_739"
      unitRef="USD">11308632</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_740"
      unitRef="USD">12867083</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_741"
      unitRef="USD">25698787</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_742"
      unitRef="USD">26991766</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_784"
      unitRef="USD">4430063</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_785"
      unitRef="USD">4352509</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_786"
      unitRef="USD">2463355</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_787"
      unitRef="USD">2133378</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_788"
      unitRef="USD">6893418</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_789"
      unitRef="USD">6485887</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_790"
      unitRef="USD">-6893418</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_791"
      unitRef="USD">-6485887</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_792"
      unitRef="USD">-170103</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_793"
      unitRef="USD">-197696</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_794"
      unitRef="USD">9541</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_795"
      unitRef="USD">25941</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_796"
      unitRef="USD">-7073062</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_797"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_800"
      unitRef="USD">-7073062</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_801"
      unitRef="USD">-6709524</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-10-01to2024-12-31"
      decimals="INF"
      id="fid_802"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-01to2023-12-31"
      decimals="INF"
      id="fid_803"
      unitRef="USDPShares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_804"
      unitRef="Shares">65325855</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_805"
      unitRef="Shares">48470600</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1312"
      unitRef="Shares">63787104</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1313"
      unitRef="USD">637870</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1318"
      unitRef="USD">526241074</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1323"
      unitRef="USD">-514011861</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1328"
      unitRef="USD">12867083</us-gaap:StockholdersEquity>
    <cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1354"
      unitRef="Shares">1450000</cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1357"
      unitRef="USD">14500</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1409"
      unitRef="USD">-14500</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1314"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1319"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1360"
      unitRef="Shares">142822</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1363"
      unitRef="USD">1428</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1410"
      unitRef="USD">55706</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1334"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1426"
      unitRef="USD">57134</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1366"
      unitRef="Shares">154615</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1369"
      unitRef="USD">1546</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1411"
      unitRef="USD">394541</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1339"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1427"
      unitRef="USD">396087</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1372"
      unitRef="Shares">7552500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1375"
      unitRef="USD">75525</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1412"
      unitRef="USD">4924775</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1388"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1428"
      unitRef="USD">5000300</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1436"
      unitRef="Shares">-3000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1390"
      unitRef="USD">-30</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1415"
      unitRef="USD">711411</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1399"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1431"
      unitRef="USD">711381</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1400"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1416"
      unitRef="USD">-650291</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1401"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1432"
      unitRef="USD">-650291</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1402"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1403"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1324"
      unitRef="USD">-7073062</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1329"
      unitRef="USD">-7073062</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1315"
      unitRef="Shares">73084041</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1316"
      unitRef="USD">730839</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1321"
      unitRef="USD">531662716</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1326"
      unitRef="USD">-521084923</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_1331"
      unitRef="USD">11308632</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1332"
      unitRef="Shares">47422304</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1333"
      unitRef="USD">474223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1338"
      unitRef="USD">499832063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1343"
      unitRef="USD">-487091396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1348"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1358"
      unitRef="Shares">17724</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1361"
      unitRef="USD">177</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1394"
      unitRef="USD">48730</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1314-da2283"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1404"
      unitRef="USD">48907</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1364"
      unitRef="Shares">88573</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1367"
      unitRef="USD">886</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1395"
      unitRef="USD">201421</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1319-98f6cc"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1405"
      unitRef="USD">202307</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1370"
      unitRef="Shares">2490000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1373"
      unitRef="USD">24900</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1396"
      unitRef="USD">4955100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1334-99eb0b"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1406"
      unitRef="USD">4980000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1339-0cb39c"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1397"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1388-024463"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1407"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1424"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1398"
      unitRef="USD">-470229</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1391"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1408"
      unitRef="USD">-470229</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1393"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1399-7dcbb8"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1344"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1349"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1335"
      unitRef="Shares">50018601</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1336"
      unitRef="USD">500186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1341"
      unitRef="USD">505950994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1346"
      unitRef="USD">-493800920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1351"
      unitRef="USD">12650260</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1112"
      unitRef="USD">-7073062</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1113"
      unitRef="USD">-6709524</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1115"
      unitRef="USD">995192</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1116"
      unitRef="USD">1004633</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1117"
      unitRef="USD">135</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1118"
      unitRef="USD">2504</us-gaap:OtherNoncashExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1119"
      unitRef="USD">396839</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1120"
      unitRef="USD">218386</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1121"
      unitRef="USD">711381</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1122"
      unitRef="USD">1383909</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1123"
      unitRef="USD">57133</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1124"
      unitRef="USD">48907</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:GainLossOnPatentImpairment
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1307"
      unitRef="USD">9541</cvm:GainLossOnPatentImpairment>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1309"
      unitRef="USD">-79724</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1126"
      unitRef="USD">-100546</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1127"
      unitRef="USD">193842</cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing>
    <cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1128"
      unitRef="USD">-98765</cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing>
    <cvm:IncreaseDecreaseInDeposit
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1129"
      unitRef="USD">4000</cvm:IncreaseDecreaseInDeposit>
    <cvm:IncreaseDecreaseInDeposit
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1130"
      unitRef="USD">11884</cvm:IncreaseDecreaseInDeposit>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1132"
      unitRef="USD">473514</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1133"
      unitRef="USD">-765078</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1134"
      unitRef="USD">-15291</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1135"
      unitRef="USD">-8924</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1136"
      unitRef="USD">194797</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1137"
      unitRef="USD">148454</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1138"
      unitRef="USD">-4139973</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1139"
      unitRef="USD">-4887928</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1141"
      unitRef="USD">32954</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1142"
      unitRef="USD">51650</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cvm:GainLossOnPatentImpairment
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1308"
      unitRef="USD">0</cvm:GainLossOnPatentImpairment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1144"
      unitRef="USD">13211</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1145"
      unitRef="USD">-32954</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1146"
      unitRef="USD">-64861</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1148"
      unitRef="USD">5000300</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1149"
      unitRef="USD">4980000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1150"
      unitRef="USD">469020</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1151"
      unitRef="USD">504913</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1156"
      unitRef="USD">482411</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1157"
      unitRef="USD">426593</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1158"
      unitRef="USD">4048869</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1159"
      unitRef="USD">4048494</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1160"
      unitRef="USD">-124058</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1161"
      unitRef="USD">-904295</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1162"
      unitRef="USD">4738173</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1163"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_1164"
      unitRef="USD">4614115</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1165"
      unitRef="USD">3241440</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1169"
      unitRef="USD">1087</cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1170"
      unitRef="USD">714</cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:NonCashConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1173"
      unitRef="USD">396087</cvm:NonCashConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:NonCashConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1174"
      unitRef="USD">202307</cvm:NonCashConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:NonCashFinancingCostsIncludedInCurrentLiabilities
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1177"
      unitRef="USD">220220</cvm:NonCashFinancingCostsIncludedInCurrentLiabilities>
    <cvm:NonCashFinancingCostsIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1178"
      unitRef="USD">43019</cvm:NonCashFinancingCostsIncludedInCurrentLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1179"
      unitRef="USD">207735</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1180"
      unitRef="USD">244659</us-gaap:InterestPaidNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1181">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;A. &lt;span style="text-decoration:underline"&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The accompanying condensed financial statements of CEL-SCI Corporation (the &#x201c;Company&#x201d;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#x2019;s financial position as of December 31, 2024 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2024 is derived from the September 30, 2024 audited financial statements. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Summary of Significant Accounting Policies:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at&#160;the lower of cost or&#160;net realizable value&#160;and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities, and are expensed as incurred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#x201c;Plans&#x201d;. All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $250,000 at December 31, 2024 and September 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2024 and September 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Fair Value Measurements -&lt;/em&gt; In accordance with the provisions of ASC 820, &lt;em&gt;Fair Value Measurements&lt;/em&gt;, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:8%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 3 &#x2013; Unobservable inputs that reflect management&#x2019;s assumptions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#x2019;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#x2019;s money market funds approximated their fair value at&#160;$1,000 and $3,480,000 as of December 31, 2024 and September 30, 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update No. 2023-07, &lt;em&gt;Segment Reporting&lt;/em&gt; (Topic 280): &lt;em&gt;Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;),&lt;/em&gt; which expands disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#x2013; Reporting Comprehensive income &#x2013; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#x201c;Cost of sales&#x201d; and &#x201c;Selling, general and administrative expenses&#x201d;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1189">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1190">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1191">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at&#160;the lower of cost or&#160;net realizable value&#160;and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-10-01to2024-12-31" id="fid_1192">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cvm:LeasesPolicyTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1193">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities, and are expensed as incurred.&lt;/p&gt;</cvm:LeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-10-01to2024-12-31" id="fid_1194">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#x201c;Plans&#x201d;. All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-10-01to2024-12-31" id="fid_1195">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1196">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-10-01to2024-12-31" id="fid_1301">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $250,000 at December 31, 2024 and September 30, 2024.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_1221"
      unitRef="USD">250000</us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1197">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2024 and September 30, 2024.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cvm:ImpairmentOfLongLivedAssetsPolicyTextblock contextRef="From2024-10-01to2024-12-31" id="fid_1198">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;</cvm:ImpairmentOfLongLivedAssetsPolicyTextblock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1302">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Fair Value Measurements -&lt;/em&gt; In accordance with the provisions of ASC 820, &lt;em&gt;Fair Value Measurements&lt;/em&gt;, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:8%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 3 &#x2013; Unobservable inputs that reflect management&#x2019;s assumptions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#x2019;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#x2019;s money market funds approximated their fair value at&#160;$1,000 and $3,480,000 as of December 31, 2024 and September 30, 2024, respectively.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsOwnedOtherAtFairValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_1222"
      unitRef="USD">1000</us-gaap:FinancialInstrumentsOwnedOtherAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedOtherAtFairValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1224"
      unitRef="USD">3480000</us-gaap:FinancialInstrumentsOwnedOtherAtFairValue>
    <us-gaap:UseOfEstimates contextRef="From2024-10-01to2024-12-31" id="fid_1199">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1201">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update No. 2023-07, &lt;em&gt;Segment Reporting&lt;/em&gt; (Topic 280): &lt;em&gt;Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;),&lt;/em&gt; which expands disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#x2013; Reporting Comprehensive income &#x2013; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#x201c;Cost of sales&#x201d; and &#x201c;Selling, general and administrative expenses&#x201d;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cvm:LiquidityDisclosureTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1182">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;B. &lt;span style="text-decoration:underline"&gt;LIQUIDITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#x2019;s lead investigational therapy, to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to the Company&#x2019;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</cvm:LiquidityDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1183">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;C.&#160;&lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Proceeds from the Sale of Common Stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2024, the Company sold 7,552,500 shares of common stock at a public offering price of $0.31 per share and pre-funded warrants to purchase up to 8,577,500 shares of common stock, at an offering price of $0.3099 per pre-funded warrant, for proceeds of approximately $4.4 million, net of issuance costs of approximately $0.6 million. As of December 31, 2024, none of the pre-funded warrants in connection with the December 2024 offering have been exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company determined that the pre-funded warrants sold in the December 2024 offering are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#x2019;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the transaction in December 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Other Equity Transactions&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In October 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited (&#x201c;Ergomed&#x201d;) pursuant to which the Company issued 1,000,000 shares of common stock in exchange for services. The shares are legally issued and outstanding.&#160;&#160;The Company determined the issuance of shares to a non-employee for services rendered or to be rendered is within the scope of ASC 718. In accordance with ASC 718, the shares are not issued and outstanding for accounting purposes as they are unvested and forfeitable. The shares will be recognized on the&#160;settlement date and measured at fair value when the shares are settled for services rendered by Ergomed. The Company incurred share issuance costs of approximately $61,000 to issue the shares from this agreement which were immediately expensed.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Equity Compensation&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Underlying share information for equity compensation plans as of December 31, 2024 is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:80%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,283,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock Option Activity&lt;/span&gt;:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;502,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,833&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;40&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Share-Based Compensation Expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;711,381&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,383,909&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;396,839&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;218,386&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;&lt;em&gt;Warrants and Non-Employee Options&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following chart represents the warrants and non-employee options outstanding at December 31, 2024:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2026&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="width:9%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Pre-Funded&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/31/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,577,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.0001&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/2017 &#x2013; 11/19/2024 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;610,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0.70 - $2.18&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 -&#160;11/1/2034&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;1. &lt;span style="text-decoration:underline"&gt;Equity Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2024, 8,577,500 pre-funded warrants at an offering price of $0.3099 were issued.&#160; No pre-funded warrants or warrants recorded as equity were issued during the three months ended December 31, 2023.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2024, 1,450,000 pre-funded warrants were exercised.&#160; No pre-funded warrants or warrants recorded as equity were exercised during the three months ended December 31, 2023.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as equity expired or were extended during the three months ended December 31, 2024 and 2023. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2. &lt;span style="text-decoration:underline"&gt;Options and Shares Issued to Consultants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2024 and 2023, the Company issued 154,615 and 88,573 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $0.85 and $1.56 during the three months ended December 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2024, 500,000 options with an exercise price of $0.70 were issued to a consultant.&#160; The options vest immediately and will expire on November 1, 2034.&#160; No options were issued to a consultant during the three months ended December 31, 2023.&#160;&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2024 and 2023, the Company recorded total expense of approximately $397,000 and $218,000, respectively, relating to the share-based compensation under various consulting agreements. On December 31, 2024 and September 30, 2024, consulting fees of approximately $51,000 and $52,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1433"
      unitRef="Shares">7552500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="fid_1232"
      unitRef="USDPShares">0.31</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2024-12-31_cvm_PreFundedMember"
      decimals="0"
      id="fid_1236"
      unitRef="Shares">8577500</us-gaap:ExcessStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-12-31_cvm_PreFundedMember"
      decimals="INF"
      id="fid_1234"
      unitRef="USDPShares">0.3099</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-12-01to2024-12-31"
      decimals="-5"
      id="fid_377"
      unitRef="USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetofissuanceCosts
      contextRef="From2024-12-01to2024-12-31"
      decimals="-5"
      id="fid_378"
      unitRef="USD">600000</cvm:NetofissuanceCosts>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="fid_359"
      unitRef="USDPShares">2.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_370"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetofissuanceCosts
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_372"
      unitRef="USD">500000</cvm:NetofissuanceCosts>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-10-31_cvm_ErgomedMember"
      decimals="0"
      id="fid_1239"
      unitRef="Shares">1000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-10-01to2024-10-18_cvm_ErgomedMember"
      decimals="0"
      id="fid_1437"
      unitRef="USD">61000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1202">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:80%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,283,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_278"
      unitRef="Shares">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_275"
      unitRef="Shares">17787200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_276"
      unitRef="Shares">1283760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_277"
      unitRef="Shares">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_274"
      unitRef="Shares">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cvm:ScheduleOfStockOptionActivityTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1203">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;502,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,833&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;40&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfStockOptionActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_284"
      unitRef="Shares">502500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_285"
      unitRef="Shares">15833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_281"
      unitRef="Shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_286"
      unitRef="Shares">40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <cvm:ScheduleOfCompensatingBalancesTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1204">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;711,381&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,383,909&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;396,839&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;218,386&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfCompensatingBalancesTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-10-01to2024-12-31_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_336"
      unitRef="USD">711381</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2023-12-31_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_335"
      unitRef="USD">1383909</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-10-01to2024-12-31_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_338"
      unitRef="USD">396839</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2023-12-31_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_339"
      unitRef="USD">218386</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1205">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2026&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="width:9%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Pre-Funded&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/31/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,577,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.0001&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/2017 &#x2013; 11/19/2024 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;610,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0.70 - $2.18&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 -&#160;11/1/2034&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesNMember"
      id="fid_299">8/18/2008</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_SeriesNMember"
      decimals="0"
      id="fid_308"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_SeriesNMember"
      decimals="INF"
      id="fid_316"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesNMember"
      id="fid_325">8/18/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesUUMember"
      id="fid_300">6/11/2018</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_SeriesUUMember"
      decimals="0"
      id="fid_309"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_317"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesUUMember"
      id="fid_326">6/30/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesXMember"
      id="fid_301">1/13/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_SeriesXMember"
      decimals="0"
      id="fid_310"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_SeriesXMember"
      decimals="INF"
      id="fid_318"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesXMember"
      id="fid_327">7/13/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesYMember"
      id="fid_302">2/15/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_SeriesYMember"
      decimals="0"
      id="fid_311"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_SeriesYMember"
      decimals="INF"
      id="fid_319"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesYMember"
      id="fid_328">8/15/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesMMMember"
      id="fid_303">6/22/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_SeriesMMMember"
      decimals="0"
      id="fid_312"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_320"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesMMMember"
      id="fid_329">6/22/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesNNMember"
      id="fid_304">7/24/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_SeriesNNMember"
      decimals="0"
      id="fid_313"
      unitRef="Shares">200087</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_321"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesNNMember"
      id="fid_330">7/24/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesRRMember"
      id="fid_305">10/30/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_SeriesRRMember"
      decimals="0"
      id="fid_314"
      unitRef="Shares">234009</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_322"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_SeriesRRMember"
      id="fid_331">10/30/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_PreFundedMember"
      id="fid_1229">12/31/2024</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_PreFundedMember"
      decimals="0"
      id="fid_1228"
      unitRef="Shares">8577500</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_PreFundedMember"
      decimals="INF"
      id="fid_1227"
      unitRef="USDPShares">0.0001</cvm:ExercisePrice>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_BottomMember_cvm_ConsultantsMember"
      id="fid_306">7/28/2017</cvm:IssueDate1>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2024-12-31_cvm_TopMember_cvm_ConsultantsMember"
      id="fid_307">11/19/2024</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-12-31_cvm_ConsultantsOptionMember"
      decimals="0"
      id="fid_315"
      unitRef="Shares">610000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_BottomMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_323"
      unitRef="USDPShares">0.70</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2024-12-31_cvm_TopMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1230"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_BottomMember_cvm_ConsultantsMember"
      id="fid_332">7/27/2027</cvm:ExpirationDate>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2024-12-31_cvm_TopMember_cvm_ConsultantsMember"
      id="fid_333">11/1/2034</cvm:ExpirationDate>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2024-12-31_cvm_ChangesInEquityWarrantsMember"
      decimals="0"
      id="fid_1303"
      unitRef="Shares">8577500</us-gaap:ExcessStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-12-31_cvm_ChangesInEquityWarrantsMember"
      decimals="INF"
      id="fid_645"
      unitRef="USDPShares">0.3099</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2023-12-31_cvm_ChangesInEquityWarrantsMember"
      decimals="0"
      id="fid_1304"
      unitRef="Shares">1450000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-01to2024-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_499"
      unitRef="Shares">154615</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_1245"
      unitRef="Shares">88573</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-10-01to2024-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_501"
      unitRef="USDPShares">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1248"
      unitRef="USDPShares">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1252"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_1246"
      unitRef="USDPShares">0.70</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-01to2024-12-31_cvm_ConsultingAgreementsOtherMember"
      decimals="0"
      id="fid_1249"
      unitRef="Shares">397000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsOtherMember"
      decimals="0"
      id="fid_1251"
      unitRef="Shares">218000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <cvm:ConsultingFeesIncluedPrepaidExpenses
      contextRef="AsOf2024-12-31_cvm_ConsultingAgreementsOtherMember"
      decimals="0"
      id="fid_1255"
      unitRef="USD">51000</cvm:ConsultingFeesIncluedPrepaidExpenses>
    <cvm:ConsultingFeesIncluedPrepaidExpenses
      contextRef="AsOf2024-09-30_cvm_ConsultingAgreementsOtherMember"
      decimals="0"
      id="fid_1257"
      unitRef="USD">52000</cvm:ConsultingFeesIncluedPrepaidExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1184">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;D. &lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;There were no related party transactions during the three months ended December 31, 2024 and 2023. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1185">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;E. &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;&lt;em&gt;Clinical Research Agreements&lt;/em&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#x2019;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $0.7 million as of December 31, 2024. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of December 31, 2024 and September 30, 2024, respectively, the net book value of the finance lease right-of-use asset is approximately $6.9 million and $7.4 million and the balance of the finance lease liability is approximately $9.5 million and $10.0 million, of which approximately $2.1 million and $2.0 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the three months ended December 31, 2024 and 2023, the finance right-of-use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $0.5 million in both periods, which is included in research and development expense on the accompanying condensed statements of operations. Total cash paid related to finance leases during the three months ended December 31, 2024 and 2023, was approximately $0.7 million for both periods, of which approximately $0.2 million was for interest. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying condensed statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying condensed statements of cash flows. As of December 31, 2024, the weighted average discount rate of the Company&#x2019;s finance leases is 8.46% and the weighted average remaining lease term is 3.83 years. During the three months ended December 31, 2024 and 2023, total finance lease costs were approximately $0.7 million, consisting of approximately $0.5 million of lease asset amortization and approximately $0.2 million of interest on the finance lease liabilities for both periods. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right-of-use assets or lease liabilities but rather are expensed as incurred. During the three months ended December 31, 2024, there were approximately $0.3 million of variable finance lease costs, which are included in research and development expense on the accompanying condensed statements of operations. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#x2019;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Approximate future minimum lease payments under finance leases as of December 31, 2024 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,065,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,108,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,622,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,486,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,074,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;7,412,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases two facilities under operating leases. The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of December 31, 2024 and September 30, 2024, respectively, the net book value of the operating lease right-of-use asset is approximately $1.4 million and $1.5 million and the balance of the operating lease liability is approximately $1.6 million and $1.7 million, of which approximately $0.2 million is current in both periods. During the three months ended December 31, 2024 and 2023, the Company incurred lease expense under operating leases of approximately $0.1 million in both periods, which is included in general and administrative expense on the accompanying condensed statements of operations. Total cash paid related to operating leases during the three months ended December 31, 2024 and 2023 was approximately $0.1 million for both periods. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying condensed statements of cash flows. The weighted average discount rate of the Company&#x2019;s operating leases is 8.98% and the weighted average the remaining lease term is 6.81 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of December 31, 2024, approximate future minimum lease payments on operating leases are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;276,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;303,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;443,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,165,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(566,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,599,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(226,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,373,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-10-01to2024-12-31_cvm_ErgomedMember"
      decimals="-5"
      id="fid_668"
      unitRef="USD">700000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:AnnualIncreaseToInterestPayments
      contextRef="AsOf2023-12-31_us-gaap_LeaseAgreementsMember"
      decimals="INF"
      id="fid_466"
      unitRef="Pure">0.03</cvm:AnnualIncreaseToInterestPayments>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1269"
      unitRef="USD">6900000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1271"
      unitRef="USD">7400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1272"
      unitRef="USD">9500000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1273"
      unitRef="USD">10000000.0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1274"
      unitRef="USD">2100000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1275"
      unitRef="USD">2000000.0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1276"
      unitRef="USD">500000</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1268"
      unitRef="USD">700000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:InterestPaid
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_459"
      unitRef="USD">200000</us-gaap:InterestPaid>
    <cvm:AnnualIncreaseToInterestPayments
      contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="INF"
      id="fid_1280"
      unitRef="Pure">0.0846</cvm:AnnualIncreaseToInterestPayments>
    <cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      id="fid_467">P3Y9M29D</cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1281"
      unitRef="USD">700000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1283"
      unitRef="USD">500000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1285"
      unitRef="USD">200000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_463"
      unitRef="USD">300000</us-gaap:VariableLeaseCost>
    <cvm:FinancingArrangementDepositBaseRentAmount
      contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember"
      decimals="-5"
      id="fid_1311"
      unitRef="USD">2300000</cvm:FinancingArrangementDepositBaseRentAmount>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1207">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,065,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,108,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,622,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,486,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,074,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;7,412,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_432"
      unitRef="USD">2065000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_433"
      unitRef="USD">2838000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_434"
      unitRef="USD">2929000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_435"
      unitRef="USD">3021000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_436"
      unitRef="USD">255000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_437"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_439"
      unitRef="USD">11108000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_440"
      unitRef="USD">1622000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_441"
      unitRef="USD">9486000</us-gaap:FinanceLeaseLiability>
    <cvm:FinanceLeaseLiabilityCurrentPortion
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_442"
      unitRef="USD">-2074000</cvm:FinanceLeaseLiabilityCurrentPortion>
    <cvm:FinanceLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_443"
      unitRef="USD">7412000</cvm:FinanceLeaseLiabilityNoncurrentPortion>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1290"
      unitRef="USD">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1291"
      unitRef="USD">1500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1292"
      unitRef="USD">1600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1293"
      unitRef="USD">1700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1294"
      unitRef="USD">200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <cvm:LeaseExpenseUnderOperatingLeases
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1296"
      unitRef="USD">100000</cvm:LeaseExpenseUnderOperatingLeases>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_465"
      unitRef="USD">100000</us-gaap:OperatingLeasePaymentsUse>
    <cvm:AnnualIncreaseToInterestPaymentsOperating
      contextRef="AsOf2024-12-31_us-gaap_LeaseAgreementsMember"
      decimals="INF"
      id="fid_1300"
      unitRef="Pure">0.0898</cvm:AnnualIncreaseToInterestPaymentsOperating>
    <cvm:OPeratingLeaseWeightedAverageRemainingLeaseTerm
      contextRef="From2024-10-01to2024-12-31_us-gaap_LeaseAgreementsMember"
      id="fid_1299">P6Y9M21D</cvm:OPeratingLeaseWeightedAverageRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1208">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;276,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;303,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;443,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,165,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(566,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,599,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(226,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,373,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_444"
      unitRef="USD">276000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_445"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_446"
      unitRef="USD">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_447"
      unitRef="USD">285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_448"
      unitRef="USD">294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_449"
      unitRef="USD">303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_450"
      unitRef="USD">443000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_451"
      unitRef="USD">2165000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_452"
      unitRef="USD">566000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_453"
      unitRef="USD">1599000</us-gaap:OperatingLeaseLiability>
    <cvm:OperatingLeaseLiabilityCurrentPortion
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_454"
      unitRef="USD">-226000</cvm:OperatingLeaseLiabilityCurrentPortion>
    <cvm:OperatingLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_455"
      unitRef="USD">1373000</cvm:OperatingLeaseLiabilityNoncurrentPortion>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1186">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;G. &lt;span style="text-decoration:underline"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2024, the Company abandoned three patents which resulted in an impairment of $9,541 on patent costs. During the three months ended December 31, 2023, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;7&#160;years. For the three months ended December 31, 2024 and 2023, amortization of patent costs totaled approximately $8,000 and $9,000, respectively. The total estimated future amortization is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;32,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;148,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1260"
      unitRef="USD">9541</us-gaap:AssetImpairmentCharges>
    <cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod contextRef="From2024-10-01to2024-12-31" id="fid_1259">P7Y</cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_430"
      unitRef="USD">8000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_431"
      unitRef="USD">9000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1209">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;32,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;148,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_412"
      unitRef="USD">21000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_413"
      unitRef="USD">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_414"
      unitRef="USD">22000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_415"
      unitRef="USD">18000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_416"
      unitRef="USD">16000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_417"
      unitRef="USD">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_418"
      unitRef="USD">32000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_419"
      unitRef="USD">148000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1187">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;H. &lt;span style="text-decoration:underline"&gt;LOSS PER COMMON SHARE &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, common stock warrants, unvested common stock&#160;and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The calculation of basic and diluted net loss per share includes 8,577,500 of the pre-funded warrants that remain outstanding as of December 31, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Net loss available to common shareholders &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,073,062&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(6,709,524&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;65,325,855&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;48,470,600&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.11&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net loss per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,837,177&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,839,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;1,000,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;144,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;18,981,427&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,986,278&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31_cvm_PreFundedMember"
      decimals="0"
      id="fid_1267"
      unitRef="Shares">8577500</us-gaap:CommonStockSharesIssued>
    <cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1210">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Net loss available to common shareholders &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,073,062&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(6,709,524&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;65,325,855&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;48,470,600&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.11&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_406"
      unitRef="USD">-7073062</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_407"
      unitRef="USD">-6709524</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_408"
      unitRef="Shares">65325855</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_410"
      unitRef="Shares">48470600</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-10-01to2024-12-31"
      decimals="INF"
      id="fid_409"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-01to2023-12-31"
      decimals="INF"
      id="fid_411"
      unitRef="USDPShares">-0.14</us-gaap:EarningsPerShareDiluted>
    <cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1211">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,837,177&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,839,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;1,000,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;144,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;18,981,427&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,986,278&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2024-12-31_cvm_OptionsMember"
      decimals="0"
      id="fid_396"
      unitRef="Shares">17837177</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2023-12-31_cvm_OptionsMember"
      decimals="0"
      id="fid_397"
      unitRef="Shares">15839028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2024-12-31_cvm_UnvestedCommonStockMember"
      decimals="0"
      id="fid_1439"
      unitRef="Shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2024-12-31_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_398"
      unitRef="Shares">144250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2023-12-31_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_399"
      unitRef="Shares">147250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_401"
      unitRef="Shares">18981427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_402"
      unitRef="Shares">15986278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-10-01to2024-12-31" id="fid_1188">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;J. &lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
